nct_id,brief_title,search_condition,conditions,sponsor,sponsor_class,enrollment_count,num_arms,total_sites,num_countries,start_date,completion_date,has_participant_flow,total_started,total_completed,total_discontinued,dropout_rate,discontinuation_reasons,top_dropout_reason,top_dropout_reason_count,num_periods
NCT00359762,Exenatide Versus Glimepiride in Patients With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,1029,2,114,14,2006-09,2011-03,True,1029,0,426,100.0,Subject Decision (155); Adverse Event (83); Physician Decision (69); Protocol Violation (45); Lack of Efficacy (40); Lost to follow up (14); Entry Criteria Not Met (14); Death (6),Subject Decision,155.0,3
NCT01335399,"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma",cardiovascular disease,Multiple Myeloma,Bristol-Myers Squibb,INDUSTRY,748,2,235,20,2011-08-04,2021-09-03,True,748,0,748,100.0,Disease progression (262); Adverse event unrelated to study drug (184); Study drug toxicity (116); Other reasons (60); Participant request to discontinue (53); Administrative reasons by Sponsor (24); Consent withdrawal (20); Death (13); Poor/Non-compliance (7); Lost to Follow-up (4); Maximum clinical benefit (2); No longer meet study criteria (2); No longer meeting study criteria (1),Disease progression,262.0,2
NCT03868124,Clinical Study Comparing Two Models of a Travoprost Intraocular Implant,hypertension,"Glaucoma, Open-Angle; Ocular Hypertension",Glaukos Corporation,INDUSTRY,560,3,1,1,2018-09-17,2024-06-19,True,560,0,560,100.0,Ongoing in study (539); Withdrawal by Subject (5); Lost to Follow-up (4); Death (4); Adverse Event (3); Explanted (3); Physician Decision (2),Ongoing in study,539.0,1
NCT00424047,A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma,cardiovascular disease,Multiple Myeloma,Celgene,INDUSTRY,351,2,69,15,2003-01-01,2013-11-12,True,351,0,629,100.0,Progression of disease (409); Adverse Event (65); Withdrawal by Subject (65); Death (44); Other (28); Progression of Disease (10); Lack of therapeutic effect (4); Lack of Efficacy (4),Progression of disease,409.0,3
NCT00179647,Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma,cardiovascular disease,Multiple Myeloma,Celgene Corporation,INDUSTRY,1913,1,69,2,2005-09,2009-04,True,1913,0,1913,100.0,Other (960); Lack of Efficacy (478); Adverse Event (294); Death (94); Withdrawal by Subject (83); Lost to Follow-up (4),Other,960.0,1
NCT02136134,Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma,cardiovascular disease,Multiple Myeloma,"Janssen Research & Development, LLC",INDUSTRY,498,2,105,15,2014-08-15,2024-01-10,True,498,0,498,100.0,Death (318); Uspecified (145); Withdrawal by Subject (29); Lost to Follow-up (6),Death,318.0,1
NCT03053440,A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM),cardiovascular disease,Waldenström's Macroglobulinemia,BeiGene,INDUSTRY,201,2,58,12,2017-01-25,2022-06-21,True,201,0,201,100.0,Enrolled in Long-term Extension Study (114); Sponsor's Decision to End the Study (33); Death (32); Withdrawal by Subject (17); Physician Decision (3); Lost to Follow-up (1); Participant Randomized but died before dosing (1),Enrolled in Long-term Extension Study,114.0,1
NCT01239797,Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma,cardiovascular disease,Lymphoma; Multiple Myeloma,Bristol-Myers Squibb,INDUSTRY,646,2,216,23,2011-06-20,2021-04-21,True,646,0,646,100.0,Disease progression (370); Study drug toxicity (84); Adverse event unrelated to study drug (69); Participants request to discontinue study treatment (46); Other reasons (28); Participant withdrew consent (25); Administrative reason by sponsor (17); Participant no longer meets study criteria (4); Death (2); Poor/non-compliance (1),Disease progression,370.0,2
NCT01712789,Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma,cardiovascular disease,Multiple Myeloma,Celgene,INDUSTRY,682,1,112,20,2012-11-06,2019-12-11,True,682,0,682,100.0,Progressive Disease (504); Death (57); Adverse Event (52); Miscellaneous (31); Withdrawal by Subject (21); Transition to Commercial Treatment (8); Participants Did Not Receive Study Drug (6); Lack of Efficacy (2); Lost to Follow-up (1),Progressive Disease,504.0,1
NCT02990338,"Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients",cardiovascular disease,Plasma Cell Myeloma,Sanofi,INDUSTRY,307,2,111,24,2016-12-22,2023-11-01,True,307,0,307,100.0,Progressive disease (225); Adverse Event (45); Withdrawal by Subject (14); Physician's decision (8); Randomized and not treated (6); Treatment extension study (6); Poor compliance to protocol (1); Unconfirmed disease progression per investigator (1); Continue with therapy available commercially (1),Progressive disease,225.0,1
NCT02195479,A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma,cardiovascular disease,Multiple Myeloma,"Janssen Research & Development, LLC",INDUSTRY,706,2,160,24,2014-12-09,2024-08-07,True,706,0,706,100.0,Death (388); Discontinued at clinical cutoff (due to end of data collection period) (217); Withdrawal by Subject (60); Lost to Follow-up (33); Other (7); Physician Decision (1),Death,388.0,1
NCT01908816,An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.,cardiovascular disease,"Choroidal Neovascularization; Macular Edema; Glaucoma, Neovascular; Diabetic Retinopathy",Novartis Pharmaceuticals,INDUSTRY,270,1,39,1,2013-09-26,2016-01-08,True,270,0,270,100.0,Early termination (218); Unsatisfactory therapeutic effect (15); Lost to Follow-up (14); Death (9); Withdrawal by Subject (8); Protocol deviation (5); Subject's no longer requires study drug (1),Early termination,218.0,1
NCT03110562,"Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma",cardiovascular disease,Multiple Myeloma,Karyopharm Therapeutics Inc,INDUSTRY,402,4,157,21,2017-05-24,2022-05-12,True,402,0,482,100.0,Death (196); Participants withdrawn due to company goals (148); Withdrawal by Subject (94); Lost to Follow-up (22); Other (11); Disease Progression (3); Physician Decision (3); Randomized but never treated (3); Adverse Event (1); Protocol Deviation (1),Death,196.0,2
NCT02252172,"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma",cardiovascular disease,Multiple Myeloma,"Janssen Research & Development, LLC",INDUSTRY,737,2,206,13,2015-02-16,2024-10-02,True,737,0,737,100.0,Death (393); End of data collection (292); Withdrawal by Subject (35); Lost to Follow-up (15); Physician Decision (1); Site closure (1),Death,393.0,1
NCT02312258,A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT),cardiovascular disease,Multiple Myeloma,Takeda,INDUSTRY,706,2,275,35,2015-04-09,2022-08-26,True,706,0,706,100.0,Death (296); Reason not Specified (266); Withdrawal by Patient (125); Lost to Follow-up (16); Missing (3),Death,296.0,1
NCT02755597,A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,cardiovascular disease,Relapsed/Refractory Multiple Myeloma,AbbVie,INDUSTRY,291,2,97,16,2016-07-11,2022-08-15,True,291,0,291,100.0,"Death (114); Study terminated by Sponsor (114); Withdrew consent (38); Other, not specified (23); Lost to Follow-up (1); Participant missing reason for study discontinuation (1)",Death,114.0,1
NCT00056160,CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma,cardiovascular disease,Multiple Myeloma,Celgene,INDUSTRY,353,2,49,2,2003-01-01,2008-10-01,True,353,0,453,100.0,Progression of disease (268); Adverse Event (98); Other (36); Withdrawal by Subject (27); Lack of Efficacy (11); Death (8); Transferred into expanded access study. (3); Transferred into RevAssist Program (2),Progression of disease,268.0,3
NCT00622336,"A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma",cardiovascular disease,Multiple Myeloma,Celgene,INDUSTRY,330,1,7,2,2003-04-01,2013-11-25,True,330,0,330,100.0,Progression of Disease (181); Other (49); Adverse Event (48); Lack of therapeutic effect (15); Death (14); Withdrawal by Subject (14); Progressive Disease (6); Lost to Follow-up (3),Progression of Disease,181.0,2
NCT02076009,"A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma",cardiovascular disease,Multiple Myeloma,"Janssen Research & Development, LLC",INDUSTRY,569,2,145,18,2014-07-23,2024-11-21,True,569,0,569,100.0,Death (325); End of data collection (208); Withdrawal by Subject (28); Lost to Follow-up (6); Progressive Disease (1); Physician Decision (1),Death,325.0,1
NCT03277105,A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma,cardiovascular disease,Multiple Myeloma,"Janssen Research & Development, LLC",INDUSTRY,522,2,146,18,2017-10-27,2024-01-12,True,522,0,522,100.0,Death (253); Other (243); Withdrawal by Subject (20); Lost to Follow-up (6),Death,253.0,1
NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cardiovascular disease,Multiple Myeloma,"Janssen Research & Development, LLC",INDUSTRY,646,2,108,17,2004-12,2014-06,True,646,0,646,100.0,Death (510); Study closed by sponsor (71); Withdrawal by Subject (39); Lost to Follow-up (26),Death,510.0,1
NCT01734928,"Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",cardiovascular disease,Multiple Myeloma,Celgene,INDUSTRY,559,2,321,22,2013-01-07,2022-05-13,True,559,0,559,100.0,Progressive Disease (332); Adverse Event (91); Withdrawal of Consent (47); Other Reasons (46); Death (30); Withdrew informed consent (4); Lost to Follow-up (3); progressive disease (2); Physician Decision (1); clinical progression (1); Randomization error (1); Pregnancy (1),Progressive Disease,332.0,2
NCT03472040,A Long Term Safety Study of BCX7353 in Hereditary Angioedema,cardiovascular disease,Hereditary Angioedema; HAE; Prophylaxis,BioCryst Pharmaceuticals,INDUSTRY,387,1,87,20,2018-02-16,2022-04-27,True,387,1,386,99.7,"Berotralstat Provided by alternative Means (i.e., Early Access Program or Commercially Available) (221); Perceived Lack of Efficacy (59); Withdrawal by Subject (33); Lab Abnormality or Adverse Event (AE) (32); Other - Not Otherwise Specified (NOS) (23); Subject Non-compliance (7); Intercurrent Illness/Medical Condition (5); Physician Decision (3); Subsequent Ineligibility (2); Discontinuation due to Rash (1)","Berotralstat Provided by alternative Means (i.e., Early Access Program or Commercially Available)",221.0,1
NCT02307513,"A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease",cardiovascular disease,Behçet's Syndrome,Amgen,INDUSTRY,207,2,63,10,2014-12-30,2020-07-17,True,207,1,64,99.5,Withdrawal by Subject (23); Adverse Event (20); Lack of Efficacy (12); Lost to Follow-up (3); Protocol Violation (2); Non-Compliance with Study Drug (1); Miscellaneous (1); Pregnancy (1); Physician Decision (1),Withdrawal by Subject,23.0,3
NCT02104817,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,cardiovascular disease,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),AstraZeneca,INDUSTRY,13078,2,684,22,2014-10-30,2020-05-27,True,13078,172,12906,98.7,Study terminated by sponsor (11755); Death (693); Other reasons (263); Withdrawal by Subject (189); Lost to Follow-up (5); Protocol Violation (1),Study terminated by sponsor,11755.0,1
NCT01102426,Aplidin - Dexamethasone in Relapsed/Refractory Myeloma,cardiovascular disease,Relapsed/Refractory Multiple Myeloma,PharmaMar,INDUSTRY,255,2,82,19,2010-06,2017-11,True,255,9,246,96.5,Progressive Disease (129); Patient Refusal (36); Death (non-related to the study (27); Adverse Events (treatment-related) (23); Physician Decision (15); Adverse Events (unrelated to (10); Randomized but not treated (5); Death (due to adverse events (1),Progressive Disease,129.0,1
NCT01311687,"A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study",cardiovascular disease,Multiple Myeloma,Celgene,INDUSTRY,455,2,94,16,2011-03-11,2017-08-29,True,455,19,0,95.8,,,,2
NCT00855465,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.,cardiovascular disease,Pulmonary Hypertension,Bayer,INDUSTRY,262,2,89,26,2009-02-23,2012-06-27,True,262,11,29,95.8,Adverse Event (7); Withdrawal by Subject (6); Death (5); Lack of Efficacy (3); Lost to Follow-up (3); Protocol Violation (2); Non-compliance (1); Not treated (1); Missing (1),Adverse Event,7.0,2
NCT01968967,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,cardiovascular disease,Hyperlipidemia,Pfizer,INDUSTRY,2139,2,249,12,2013-10-29,2017-07-10,True,2139,98,287,95.4,Withdrawal by Subject (132); Lost to Follow-up (57); Other (44); Adverse Event (17); Death (11); Randomized Not Treated (11); Withdrew Consent (7); Did Not Meet Entrance Criteria (5); Protocol Violation (3),Withdrawal by Subject,132.0,2
NCT00773747,"Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)",cardiovascular disease,Multiple Myeloma,Merck Sharp & Dohme LLC,INDUSTRY,637,2,0,0,2008-12-01,2015-06-30,True,637,44,593,93.1,Lack of Efficacy (256); Withdrawal by Subject (150); Adverse Event (123); Physician Decision (44); Death (13); Protocol Violation (4); Not Treated (2); Lost to Follow-up (1),Lack of Efficacy,256.0,1
NCT00810693,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH),cardiovascular disease,Pulmonary Hypertension,Bayer,INDUSTRY,445,3,122,30,2008-12-17,2012-05-14,True,445,31,55,93.0,Adverse Event (21); Withdrawal by Subject (14); Death (6); Protocol Violation (6); Lost to Follow-up (4); Not treated (2); Lack of Efficacy (1); Non-compliance (1),Adverse Event,21.0,2
NCT01327846,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),cardiovascular disease,Atherosclerosis,Novartis Pharmaceuticals,INDUSTRY,10066,4,1131,40,2011-04-11,2019-04-14,True,10061,736,5160,92.7,Study terminated by sponsor (4924); Withdrawal by Subject (89); Subject decision (vital stat: alive) (80); Lost to Follow-up (33); Subject decision (vital stat: dead) (12); Technical Problems (10); Subject decision (vital status: missing) (6); Subject decision (vital stat: unkn) (6),Study terminated by sponsor,4924.0,2
NCT01568866,Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients,cardiovascular disease,Multiple Myeloma,Amgen,INDUSTRY,929,2,241,27,2012-06-20,2018-02-05,True,929,75,854,91.9,Disease Progression (391); Adverse Event (190); Patient Request (126); Physician Decision (72); Withdrawal by Subject (30); Death (28); Randomized but Not Dosed (10); Protocol Non-compliance (6); Lost to Follow-up (1),Disease Progression,391.0,1
NCT00097981,A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma,cardiovascular disease,Multiple Myeloma,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,225,2,58,1,2005-01,2009-10,True,225,19,206,91.6,Adverse Event (75); Transplant planned (55); Other (32); Withdrawal by Subject (18); Disease Progression (10); Physician Decision (8); Death (6); Protocol Violation (2),Adverse Event,75.0,1
NCT03988634,"Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)",heart failure,Heart Failure With Preserved Ejection Fraction (HFpEF),Novartis Pharmaceuticals,INDUSTRY,467,2,97,2,2019-06-29,2022-12-14,True,467,41,121,91.2,Death (44); Subject decision (37); Physician Decision (15); Lost to Follow-up (13); Adverse Event (11); Technical problems (1),Death,44.0,2
NCT04072835,Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303,cardiovascular disease,Paroxysmal Supraventricular Tachycardia,Milestone Pharmaceuticals Inc.,OTHER,1116,2,124,5,2019-09-23,2023-01-26,True,1116,103,1013,90.8,Overall trial ended (603); Ablation (97); Withdrawal of consent (66); Physician Decision (50); Lost to Follow-up (39); Participant no longer meets the inclusion/exclusion criteria (38); Participant wanted to try other therapy or treatment (34); Adverse Event (25); Participant non-compliance / Protocol violation(s) (25); Death (11); Participant felt the drug did not work (8); Participant tolerability (5); Missing (5); Participant withdrawn due to COVID-19 situation (4); Pregnancy (3),Overall trial ended,603.0,1
NCT00732641,Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7),cardiovascular disease,Multiple Myeloma,Merck Sharp & Dohme LLC,INDUSTRY,244,2,0,0,2000-12,2010-11,True,244,26,218,89.3,Relapse or Progressive Disease (166); Other (23); Serious Adverse Events (15); Physician Decision (6); Withdrawal by Subject (6); Unable to Complete (2),Relapse or Progressive Disease,166.0,1
NCT00683618,Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia,dyslipidemia,Hypercholesterolemia,AstraZeneca,INDUSTRY,934,3,6,1,2008-05,2009-07,True,436,56,17,87.2,Withdrawal by Subject (8); Adverse Event (5); Protocol Violation (2); Reason not provided (2),Withdrawal by Subject,8.0,2
NCT00591578,Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension,cardiovascular disease,Hypertension,Takeda,INDUSTRY,984,3,88,4,2007-12,2010-03,True,984,154,258,84.3,Adverse Event (73); Withdrawal by Subject (68); Lack of Efficacy (50); Lost to Follow-up (40); Other (18); Protocol Violation (8); Pregnancy (1),Adverse Event,73.0,2
NCT01182441,Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy,cardiovascular disease,Atrial Fibrillation; Stroke,Boston Scientific Corporation,INDUSTRY,407,2,41,1,2010-11,2017-11,True,407,68,339,83.3,Patient Still in Follow-up (224); Death (62); Withdrawal by Subject (19); Implant Attempt Unsuccessful (13); Lost to Follow-up (13); Implant Not Attempted (4); Adverse Event (2); Physician Decision (2),Patient Still in Follow-up,224.0,1
NCT02100514,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,cardiovascular disease,Hyperlipidemia,Pfizer,INDUSTRY,746,2,223,12,2014-10-28,2017-07-10,True,746,131,105,82.4,Withdrawal by Subject (49); Lost to Follow-up (22); Other (20); Adverse Event (5); Death (4); Protocol Violation (2); Withdrew consent (2); Did Not Meet Entrance Criteria (1),Withdrawal by Subject,49.0,2
NCT03325556,Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis,cardiovascular disease,Dementia-related Psychosis,ACADIA Pharmaceuticals Inc.,INDUSTRY,392,2,83,13,2017-09-27,2019-10-30,True,392,79,313,79.8,Administrative discont. at study termination (107); Lack of Response in OL period (70); Relapse (49); Adverse Event (31); Withdrawal by Subject (27); Not otherwise specified (14); Non-compliance with study drug (5); Protocol Violation (4); Use of prohibited medication (2); Death (1); Lost to Follow-up (1); Noncompliance with study drug (1); Physician Decision (1),Administrative discont. at study termination,107.0,2
NCT00330759,Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.,cardiovascular disease,Bone Metastases,Amgen,INDUSTRY,1779,2,0,0,2006-06-01,2011-10-01,True,1776,358,1418,79.8,Death (626); Withdrawal by Subject (267); Disease progression (230); Adverse Event (84); Other (80); Participant request (53); Lost to Follow-up (38); Noncompliance (32); Physician Decision (3); Ineligibility determined (3); Protocol deviation (2),Death,626.0,1
NCT00415532,Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura,cardiovascular disease,Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura,Amgen,INDUSTRY,234,2,0,0,2006-12-01,2009-05-11,True,234,52,53,77.8,Withdrawal by Subject (17); Adverse Event (9); Other (9); Death (6); Ineligibility determined (4); Noncompliance (3); Lost to Follow-up (2); Requirement for alternative therapy (2); Protocol Violation (1),Withdrawal by Subject,17.0,2
NCT03758638,Healthy Eating and Active Living Taught at Home (HEALTH) Dissemination & Implementation (D&I),obesity,Obesity,Washington University School of Medicine,OTHER,620,2,1,1,2019-01-25,2025-06-30,True,620,141,479,77.3,Providers not included in the primary outcome. (311); Lost to Follow-up (114); Pregnancy (42); Withdrawal by Subject (10); Protocol Violation (2),Providers not included in the primary outcome.,311.0,1
NCT00484315,TAXUS PERSEUS Workhorse,cardiovascular disease,Coronary Artery Disease,Boston Scientific Corporation,INDUSTRY,1264,2,90,4,2007-07,2013-10,True,1262,289,78,77.1,No 9-Month Angiography Performed (36); Missed 12-Month Visit (17); Death (8); Withdrawn at Investigator's discretion (5); Not Evaluable for Angiography Analysis (5); Withdrawal by Subject (4); Lost to Follow-up (3),No 9-Month Angiography Performed,36.0,2
NCT00121641,Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,diabetes type 2,"Diabetes Mellitus, Type 2",AstraZeneca,INDUSTRY,1035,5,134,6,2005-07,2010-02,True,467,107,537,77.1,Lack of Efficacy (230); Subject Withdrew Consent (142); Lost to Follow-up (64); Adverse Event (51); Poor / Non-compliance (18); Subject No Longer Meets Study Criteria (12); Other Reason (12); Administrative Reason by Sponsor (4); Pregnancy (2); Death (1); Missing (1),Lack of Efficacy,230.0,2
NCT01027949,An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension,hypertension,Pulmonary Arterial Hypertension,United Therapeutics,INDUSTRY,894,1,135,20,2007-01-16,2020-02-12,True,894,208,686,76.7,Death (174); Adverse Event (172); Progressive Disease (163); Withdrawal by Subject (113); Lost to Follow-up (17); Protocol Violation (13); PI Decision (8); Limited Study Drug Effectiveness (7); Non-compliance with Study Procedures (7); Lung Transplant (5); Unable to Tolerate Study Drug (2); Use of Excluded Medication (2); Patient Self-discontinuation (1); Pregnancy (1); Surgery (1),Death,174.0,1
NCT00386607,"A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.",cardiovascular disease,Hypertension,Novartis,INDUSTRY,601,2,4,4,2006-10,2008-07,True,601,145,132,75.9,Adverse Event (46); Lost to Follow-up (26); Unsatisfactory therapeutic effect (24); Patient withdrew consent (20); Protocol Deviation (6); Abnormal laboratory value(s) (4); Condition no longer requires study drug (4); Administrative problems (2),Adverse Event,46.0,2
NCT02741596,Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE,cardiovascular disease,Hereditary Angioedema (HAE),Shire,INDUSTRY,212,2,43,7,2016-05-26,2019-10-31,True,212,56,156,73.6,Subject withdrawn-to commercial product (117); Subject withdrawn-Other (21); Adverse Event (6); Pregnancy (4); Physician Decision (3); Other (Unspecified) (3); Lost to Follow-up (2),Subject withdrawn-to commercial product,117.0,1
NCT01023308,Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma,cardiovascular disease,Multiple Myeloma,Novartis Pharmaceuticals,INDUSTRY,767,2,210,34,2009-12-21,2015-07-30,True,768,204,564,73.4,Disease progression (235); Adverse Event (196); Withdrawal by Subject (52); Death (38); Abnormal test proceedure results (11); New Cancer therapy (11); Untreated (10); Protocol Violation (7); Administrative problems (3); Lost to Follow-up (1),Disease progression,235.0,1
NCT01345019,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma,cardiovascular disease,Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions,Amgen,INDUSTRY,1718,2,309,29,2012-05-17,2019-03-29,True,1718,460,1006,73.2,"Death (381); Withdrawal by Subject (311); Adverse Event (100); Administrative Decision (63); Disease Progression (57); Completed Survival Follow-up (30); Other, Not Specified (21); Noncompliance (17); Lost to Follow-up (12); Ineligibility Determined (7); Protocol Deviation (5); Pregnancy (1); Protocol Violation (1)",Death,381.0,2
NCT00507416,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",cardiovascular disease,Multiple Myeloma,"Millennium Pharmaceuticals, Inc.",INDUSTRY,502,3,235,2,2007-06,2013-03,True,502,145,357,71.1,Adverse Event (190); Progressive Disease (43); Patient declined further treatment (43); Other (40); Lack ofEfficacy / Physician Decision (22); Did not Receive Study Treatment (16); Protocol Violation (3),Adverse Event,190.0,1
NCT00368836,Breath Analysis Technique to Diagnose Pulmonary Embolism,cardiovascular disease,Pulmonary Embolism,Wake Forest University Health Sciences,OTHER,475,1,1,1,2006-01,2008-06,True,350,104,21,70.3,unable to collect blood and/or breath (17); Protocol Violation (2); Screen Failure (1); Withdrawal by Subject (1),unable to collect blood and/or breath,17.0,2
NCT00922480,Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients,cardiovascular disease,Hypertension,"Boryung Pharmaceutical Co., Ltd",INDUSTRY,506,2,0,0,2008-12,2009-09,True,505,150,74,70.3,Withdrawal by Subject (37); Adverse Event (15); Protocol Violation (12); Lost to Follow-up (5); Lack of Efficacy (3); Physician Decision (1); Others (1),Withdrawal by Subject,37.0,2
NCT01272219,Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes,obesity,Metabolism and Nutrition Disorder; Obesity,Novo Nordisk A/S,INDUSTRY,3731,5,226,29,2011-06-01,2015-03-02,True,3731,1110,2316,70.2,Withdrawal criteria (1192); Adverse Event (521); Unclassified (258); Protocol Violation (219); Lack of Efficacy (125); Missing reason (1),Withdrawal criteria,1192.0,3
NCT03180736,Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex,cardiovascular disease,Multiple Myeloma,Stichting European Myeloma Network,NETWORK,304,2,40,10,2017-06-14,2024-11-30,True,304,93,211,69.4,Lack of Efficacy (153); Death (17); Withdrawal by Subject (17); Physician Decision (11); Adverse Event (7); randomized but not treated (5); Lost to Follow-up (1),Lack of Efficacy,153.0,1
NCT04518306,Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension,cardiovascular disease,Hypertension,George Medicines PTY Limited,INDUSTRY,755,3,47,5,2021-06-14,2023-10-18,True,755,232,63,69.3,Participant moved to open-label extension (OLE) study (50); Lost to Follow-up (5); Adverse Event (4); Other (2); Run in failure (1); Missing (1),Participant moved to open-label extension (OLE) study,50.0,2
NCT00121667,Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone,diabetes type 2,"Diabetes Mellitus, Type 2",AstraZeneca,INDUSTRY,1462,4,152,9,2005-08,2010-02,True,743,229,714,69.2,Lack of Efficacy (330); Subject Withdrew Consent (164); Adverse Event (72); Lost to Follow-up (65); Subject No Longer Meets Study Criteria (27); Poor / Non-compliance (24); Other Reason (24); Death (4); Pregnancy (4),Lack of Efficacy,330.0,2
NCT00087516,Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021),diabetes type 2,"Diabetes Mellitus, Type 2",Merck Sharp & Dohme LLC,INDUSTRY,741,4,0,0,2004-06,2007-02,True,741,229,512,69.1,Lack of Efficacy (230); Protocol specified discontinuation (127); Withdrawal by Subject (66); Adverse Event (29); Lost to Follow-up (24); Protocol Violation (21); Patient moved (6); Patient was non-compliant (4); Site terminated (3); Recommendation of Primary Care Physician (1); Other (1),Lack of Efficacy,230.0,1
NCT04415658,Intravenous Thyroxine for Heart-Eligible Organ Donors,cardiovascular disease,Brain Death; Heart Failure,Washington University School of Medicine,OTHER,838,2,14,1,2020-12-01,2022-12-06,True,838,259,0,69.1,,,,2
NCT03725202,A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis,cardiovascular disease,Giant Cell Arteritis (GCA),AbbVie,INDUSTRY,438,8,172,24,2019-02-06,2025-02-24,True,429,136,168,68.3,"Ongoing in Period 2 (67); Adverse Event (51); Withdrew consent (25); Other, not specified (19); Failure to meet continuation criteria (3); COVID-19 logistical restrictions (1); Did not receive randomized study drug (1); Lost to Follow-up (1)",Ongoing in Period 2,67.0,2
NCT04429503,Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease,diabetes type 2,Diabetic Macular Edema; Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus,Regeneron Pharmaceuticals,INDUSTRY,660,3,138,8,2020-06-29,2024-06-18,True,660,210,181,68.2,Withdrawal by Subject (54); Lost to Follow-up (46); Death (43); Adverse Event (15); Decision by the investigator/sponsor (14); Decision by the Investigator/Sponsor (5); Non-compliance with protocol by the subject (3); Protocol Violation (1),Withdrawal by Subject,54.0,2
NCT03158688,"Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.",cardiovascular disease,Relapsed Multiple Myeloma; Refractory Multiple Myeloma,Amgen,INDUSTRY,466,2,113,19,2017-06-13,2022-04-15,True,466,151,315,67.6,Death (216); Decision by sponsor (50); Withdrawal by Subject (42); Lost to Follow-up (7),Death,216.0,1
NCT02073682,Cancer Venous Thromboembolism (VTE),cardiovascular disease,Venous Thromboembolism (VTE); Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Cancer,Daiichi Sankyo,INDUSTRY,1046,2,9,6,2015-07-16,2017-09-15,True,1046,354,692,66.2,"Death (186); Adverse Event (141); PD: Inconvenience of Dosing (99); Cancer Progression (86); ID: Benefit/Risk Judgment (78); Cancer Cured (25); No reason provided (20); ID: Palliative Treatment Only (17); Withdrawal by Subject (14); Start of New Chemotherapy Regimen (9); Surgery/Medical Procedure (4); Low Creatinine Clearance (3); ID: Patient Noncompliance (3); Platelet Count <50,000/mL (3); Lost to Follow-up (2); Prohibited Concomitant Medication Use (1); Protocol Violation (1)",Death,186.0,1
NCT00902538,Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension,cardiovascular disease,Essential Hypertension,Daiichi Sankyo,INDUSTRY,2204,6,117,14,2009-04,2010-10,True,2204,749,168,66.0,Adverse Event (68); Withdrawal by Subject (42); Protocol Violation (34); Other Reason (13); Lost to Follow-up (8); Other (3),Adverse Event,68.0,4
NCT01764386,Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects,cardiovascular disease,Obesity; Overweight,"Orexigen Therapeutics, Inc",INDUSTRY,242,2,15,1,2013-02,2014-09,True,242,83,158,65.7,"Adverse Event (50); Wk 16 Efficacy and BP Criteria (32); Lost to Follow-up (32); Wk 42 Efficacy and BP Criteria (26); Withdrawal of Consent,Protocol Deviation (18)",Adverse Event,50.0,2
NCT00395135,BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management,cardiovascular disease,Obesity,Eisai Inc.,INDUSTRY,3182,2,1,1,2006-11,2009-02,True,3182,1128,0,64.6,,,,2
NCT00523744,"Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension",cardiovascular disease,Hypertension,Novartis,INDUSTRY,257,1,2,2,2007-07,2007-12,True,257,91,9,64.6,Adverse Event (4); Lost to Follow-up (3); Withdrawal by Subject (1); Administrative problems (1),Adverse Event,4.0,3
NCT00568178,"An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))",hypertension,Proteinuria,Organon and Co,INDUSTRY,306,4,0,0,2007-06-01,2011-03-01,True,306,109,177,64.4,Termination of Trial (92); Adverse Event (24); Physician Decision (20); Lost to Follow-up (19); Withdrawal by Subject (10); Protocol Violation (6); Progressive Disease (5); Pregnancy (1),Termination of Trial,92.0,2
NCT00106704,Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035),diabetes type 2,"Diabetes Mellitus, Type 2",Merck Sharp & Dohme LLC,INDUSTRY,441,2,0,0,2005-03,2007-01,True,441,159,282,63.9,Lack of Efficacy (136); Patient Received Glycemic Medication (63); Withdrawal by Subject (35); Adverse Event (17); Protocol Violation (11); Lost to Follow-up (10); Death (3); Laboratory test (2); Pregnancy (1); Patient moved (1); Site terminated (1); Planned major surgery (1); Unable to re-enter US (1),Lack of Efficacy,136.0,1
NCT00575588,"52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period",diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,891,2,94,11,2007-12,2010-08,True,858,312,546,63.6,Study specific discontinuation criteria (421); Withdrawal by Subject (58); Adverse Event (24); Incorrect enrollment (12); Severe non-compliance to protocol (12); Death (6); Lost to Follow-up (4); Patient moved (4); Safety reasons (3); Elevated triglyceride (1); Impossible to determine HbA1c (1),Study specific discontinuation criteria,421.0,1
NCT01475825,A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol,dyslipidemia,Hypercholesterolemia; Heterozygous Familial,"Kastle Therapeutics, LLC",INDUSTRY,309,4,113,30,2011-12,2015-12-29,True,309,116,193,62.5,Adverse Event (94); Did not enter OLC (52); Withdrawal by Subject (29); Non-compliance with Study Drug (7); Lost to Follow-up (4); Death (2); Other: Not available (2); Lack of Efficacy (1); Protocol Violation (1); Physician Decision (1),Adverse Event,94.0,1
NCT02787551,"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",diabetes type 2,Type 2 Diabetes Mellitus,Sanofi,INDUSTRY,514,2,124,9,2016-07-06,2018-11-17,True,514,197,47,61.7,Withdrawal by Subject (18); Adverse Event (11); Other than specified (9); Poor compliance to protocol (5); Randomized but not treated (3); Lack of Efficacy (1),Withdrawal by Subject,18.0,2
NCT00075829,Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102),cardiovascular disease,Multiple Myeloma,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,710,3,36,1,2003-12,2013-03,True,710,276,0,61.1,,,,1
NCT00232180,A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines,cardiovascular disease,Heart Failure,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,2743,1,307,29,2006-03,2012-01,True,2743,1098,1294,60.0,Death (456); Withdrawal by Subject (316); Adverse Event (208); Other (161); Lost to Follow-up (67); Protocol Violation (52); Laboratory abnormality (23); Randomized but not treated (8); Study terminated by sponsor (3),Death,456.0,2
NCT00662831,Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients,cardiovascular disease,Diabetic Foot Ulcer,Pfizer,INDUSTRY,276,2,63,17,2008-04,2010-10,True,276,111,165,59.8,Other (93); Adverse Event (39); Lack of Efficacy (12); Protocol Violation (12); Death (5); Withdrawal by Subject (3); Lost to Follow-up (1),Other,93.0,1
NCT00308139,Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1),diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,303,2,25,2,2006-04,2014-08,True,303,122,181,59.7,Withdrawal of Consent (82); Adverse Event (34); Lost to Follow-up (21); Investigator Decision (21); Loss of Glucose Control (12); Protocol Violation (5); Administrative (5); Other (1),Withdrawal of Consent,82.0,1
NCT00496769,A Phase III Study of Apixaban in Patients With Atrial Fibrillation,cardiovascular disease,Atrial Fibrillation,Bristol-Myers Squibb,INDUSTRY,6421,2,503,36,2007-08-31,2017-05-25,True,5598,2264,2218,59.6,>=1 reason assigned per patient (2218),>=1 reason assigned per patient,2218.0,2
NCT00142584,Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension,cardiovascular disease,Hypertension,Mylan Bertek Pharmaceuticals,INDUSTRY,336,2,1,1,2005-08,2008-03,True,336,136,200,59.5,"Sponsor Termination of Study, etc. (88); Withdrawal by Subject (46); Lost to Follow-up (34); Adverse Event (19); Protocol Violation (11); Treatment Failure (2)","Sponsor Termination of Study, etc.",88.0,1
NCT00159861,The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH,cardiovascular disease,Pulmonary Hypertension,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,267,0,52,11,2003-07,2006-01,True,267,109,170,59.2,Death (55); Adverse Event (46); Reason Unspecified (39); Withdrawal by Subject (16); Lack of Efficacy (11); Randomized but not Treated (2); Subject Defaulted (1),Death,55.0,2
NCT00358215,RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial,cardiovascular disease,Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure,Amgen,INDUSTRY,2278,2,754,36,2006-06-01,2012-10-11,True,2278,947,1331,58.4,Death (546); Withdrawal by Subject (213); Adverse Event (148); Participant request (129); Protocol Violation (123); Physician Decision (86); Lost to Follow-up (38); Other (35); Ineligibility determined (7); Did not receive investigational product (5); Pregnancy (1),Death,546.0,1
NCT02505334,A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,635,2,47,1,2015-07-21,2017-11-09,True,466,194,72,58.4,Lack of Efficacy (28); Unclassified (17); Withdrawal by Subject (15); Adverse Event (11); Protocol Violation (1),Lack of Efficacy,28.0,2
NCT00103857,MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,1208,7,0,0,2005-03-17,2008-02-21,True,1208,517,510,57.2,Lack of Efficacy (159); Withdrawal by Subject (116); Adverse Event (66); Lost to Follow-up (58); protocol discontinuation criteria (43); Protocol Violation (28); patient moved (11); non-compliance with study procedures (8); Physician Decision (5); Pregnancy (5); Death (4); patient incarcerated (2); laboratory reporting error (1); site error (1); patient intolerance to rescue therapy (1); patient scheduled for elective surgery (1); reason unspecified (1),Lack of Efficacy,159.0,2
NCT03651765,Long Term Extension Trial of Setmelanotide,obesity,Obesity Associated With Defects in Leptin-melanocortin Pathway,"Rhythm Pharmaceuticals, Inc.",INDUSTRY,205,1,27,8,2018-07-15,2025-01-09,True,205,89,116,56.6,Discontinued by Sponsor (40); Withdrawal by Subject (24); Lack of Efficacy (18); Adverse Event (6); Physician Decision (6); Withdrawal by Parent/Guardian (6); Miscellaneous (6); Lost to Follow-up (5); Non-Compliance with Study Drug (4); Pregnancy (1),Discontinued by Sponsor,40.0,1
NCT00420849,"A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma",cardiovascular disease,Multiple Myeloma,Celgene Corporation,INDUSTRY,587,1,5,5,2006-11,2009-11,True,587,256,331,56.4,Lack of Efficacy (154); Adverse Event (107); Withdrawal by Subject (28); Death (18); Other (14); Transplant (8); Protocol Violation (1); Lost to Follow-up (1),Lack of Efficacy,154.0,1
NCT01560624,Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy,cardiovascular disease,Pulmonary Arterial Hypertension,United Therapeutics,INDUSTRY,690,2,155,23,2012-06-26,2018-06-24,True,690,303,0,56.1,,,,1
NCT01908699,Beraprost-314d Added-on to Tyvaso® (BEAT),hypertension,Pulmonary Arterial Hypertension,Lung Biotechnology PBC,INDUSTRY,273,2,75,2,2013-05-31,2019-02-19,True,273,120,153,56.0,Progressive Disease (59); Withdrawal by Subject (25); Death (21); Adverse Event (20); Physician Decision (16); Lost to Follow-up (6); Lack of Efficacy (4); Pregnancy (1); Randomized in Error (1),Progressive Disease,59.0,1
NCT00086515,Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED),diabetes type 2,"Diabetes Mellitus, Type II",Merck Sharp & Dohme LLC,INDUSTRY,701,2,0,0,2004-06-30,2007-02-02,True,701,310,391,55.8,Lack of Efficacy (137); Adverse Event (55); Protocol-Specific lab discon criteria (46); Withdrawal by Subject (41); Patient received Phase A rescue therapy (39); Lost to Follow-up (26); Patient Moved (9); Protocol-Spec lab discon criteria (9); Protocol-Specific discontinuation (8); Protocol Violation (6); Patient Died (4); Patient needed prohibited treatment (3); Physician Decision (3); Poor compliance (2); Personal Circumstance (2); Discontinued in error (1),Lack of Efficacy,137.0,3
NCT00094770,An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024),diabetes type 2,"Diabetes Mellitus, Type 2",Merck Sharp & Dohme LLC,INDUSTRY,1172,2,0,0,2004-09,2007-05,True,1172,519,1027,55.7,Lack of Efficacy (486); Adverse Event (122); Withdrawal by Subject (119); Protocol Specified Discontinuation (103); Lost to Follow-up (69); Other (59); Protocol Violation (45); Patient Moved (16); Site Terminated (8),Lack of Efficacy,486.0,2
NCT01154036,MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162),cardiovascular disease,Hypercholesterolemia,Organon and Co,INDUSTRY,1547,8,0,0,2010-07,2012-10,True,1547,689,116,55.5,Withdrawal by Subject (56); Adverse Event (28); Lost to Follow-up (15); Protocol Violation (15); Physician Decision (2),Withdrawal by Subject,56.0,2
NCT00414609,Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE),cardiovascular disease,Myocardial Infarction,Novartis,INDUSTRY,820,2,23,23,2006-12,2011-07,True,820,365,136,55.5,Death (38); Adverse Event (34); Patient withdrew consent (21); Lost to Follow-up (21); Withdrawal by Subject (13); Administrative problems (3); Abnormal test procedure results (2); Unsatisfactory therapeutic effect (2); Abnormal laboratory values (1); Protocol deviation (1),Death,38.0,2
NCT01776424,Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease,cardiovascular disease,Prevention & Control,Bayer,INDUSTRY,27395,3,565,33,2013-02-28,2021-06-15,True,27395,12745,282,53.5,Missing final visit (188); Lost to Follow-up (40); Withdrawal by Subject (36); Refused (18),Missing final visit,188.0,2
NCT04592419,"A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)",cardiovascular disease,Macular Edema; Retinal Vein Occlusion,Kodiak Sciences Inc,INDUSTRY,568,2,141,12,2020-09-25,2023-01-19,True,568,265,237,53.3,Sponsor Request (166); Withdrawal by Subject (32); Adverse Event (16); Lost to Follow-up (16); Non-compliance with Study Schedule (2); Progressive Disease (2); Participant left the country (2); Participant moved to another city with no available site (1),Sponsor Request,166.0,2
NCT01106014,Selexipag (ACT-293987) in Pulmonary Arterial Hypertension,hypertension,Pulmonary Arterial Hypertension,Actelion,INDUSTRY,1156,2,182,39,2009-12-01,2014-10-01,True,1156,541,615,53.2,Morbidity or Mortality primary endpoint (397); Adverse Event (120); Withdrawal by Subject (80); Administrative reason (13); Lost to Follow-up (5),Morbidity or Mortality primary endpoint,397.0,1
NCT00620542,CRESTOR Athero Imaging Head to Head IVUS Study,cardiovascular disease,Coronary Atherosclerosis,AstraZeneca,INDUSTRY,2333,4,195,14,2008-01,2011-06,True,2333,1093,1240,53.2,Protocol Violation (853); Withdrawal by Subject (192); Adverse Event (122); Lost to Follow-up (42); IVUS not available (13); Study specific discontinuation criteris (12); Safety reasons (6),Protocol Violation,853.0,2
NCT03459287,Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients,cardiovascular disease,Anemia,Cerus Corporation,INDUSTRY,581,2,18,1,2018-12-05,2024-03-05,True,581,272,0,53.2,,,,1
NCT02489968,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,880,4,83,1,2015-05-12,2017-06-16,True,879,423,456,51.9,Other than specified above (394); Adverse Event (38); Withdrawal by Subject (15); Protocol Violation (6); Lost to Follow-up (3),Other than specified above,394.0,2
NCT00318461,To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1091,5,190,20,2006-05,2008-11,True,1091,529,562,51.5,Lack of Efficacy (279); Adverse Event (105); Withdrawals between 6 and 24 months (93); Protocol Violation (44); Consent withdrawn (21); Subject decision/No wish to continue (5); FPG exceeds limits/too high (3); Hypoglycaemia/Hypoglycemia (2); Lost to follow up (1); Poor compliance/Non-compliance (1); Move (1); Tendency to low blood glucose levels (1); Work commitment (1); Investigator decision (1); Lack of time (1); Hyperglicaemia (1); metformin titrated <1500 mg or >2000 mg (1); Fear of experiencing AE again (1),Lack of Efficacy,279.0,2
NCT00532779,A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects,obesity,Obesity; Overweight,"Orexigen Therapeutics, Inc",INDUSTRY,1742,3,34,1,2007-10,2009-05,True,1742,870,872,50.1,"Adverse Event (290); Withdrawal by Subject (213); Lost to Follow-up (207); Drug noncompliance, moved, other (66); Lack of Efficacy (64); Protocol Violation (21); Pregnancy (10); Death (1)",Adverse Event,290.0,1
NCT00379769,RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",GlaxoSmithKline,INDUSTRY,4447,4,446,25,2001-04,2008-12,True,4447,2233,1111,49.8,Death (398); Withdrawal by Subject (268); Lost to Follow-up (161); Moved to survival status follow-up only (120); Entered into Another Clinical Trial (40); Adverse Event (35); Physician Decision (22); Site closed (20); Site Closed Early (13); Participant moved (11); Poor compliance (8); Prohibited glucose lowering medication (4); Entry criteria violation (2); Unknown; Reason Not Provided (2); Participant did not take study drug (1); Participant completed study at visit 27 (1); Personal reasons (1); Risk of heart failure (1); Investigator refused to log temperature (1); Reason unspecified (1); Participant Moved (1),Death,398.0,2
NCT00497146,The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4,cardiovascular disease,Chronic Kidney Disease; Left Ventricular Hypertrophy,"AbbVie (prior sponsor, Abbott)",INDUSTRY,227,2,71,12,2008-02,2012-03,True,227,116,69,48.9,Withdrawal by Subject (24); Adverse Event (12); Lost to Follow-up (10); Change in RAAS inhibitor therapy (7); Required dialysis (5); Unable to dose reduce per protocol (5); Other Reason (5); Other (1),Withdrawal by Subject,24.0,2
NCT01850524,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,cardiovascular disease,Multiple Myeloma,"Millennium Pharmaceuticals, Inc.",INDUSTRY,705,2,147,7,2013-04-29,2022-06-24,True,705,361,344,48.8,Reason not Specified (283); Withdrawal by Subject (46); Lost to Follow-up (15),Reason not Specified,283.0,1
NCT01734785,Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,607,3,90,11,2013-02-08,2015-03-23,True,606,314,292,48.2,Other Reasons (224); Lost to Follow-up (22); Protocol Violation (15); Adverse Event (14); Withdrawal by Subject (14); Lack of Efficacy (2); Not treated (1),Other Reasons,224.0,2
NCT00271817,To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED),dyslipidemia,Hypercholesterolemia,Organon and Co,INDUSTRY,1220,5,0,0,2005-12,2008-02,True,1220,635,566,48.0,Adverse Event (299); Withdrawal by Subject (100); Lost to Follow-up (62); LDL < 50 mg/dL (60); Protocol Violation (24); Patient Moved (14); Lack of Efficacy (7),Adverse Event,299.0,2
NCT00960661,"A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes",diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,1036,2,95,18,2009-09,2012-08,True,1036,539,497,48.0,Entry criteria not met (331); Withdrawal by Subject (94); Adverse Event (31); Physician Decision (16); Protocol Violation (9); Lost to Follow-up (6); Sponsor decision (3); entry criteria not met (3); Lack of Efficacy (2); Death (1); sponsor decision (1),Entry criteria not met,331.0,2
NCT00689936,"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma",cardiovascular disease,Multiple Myeloma,Celgene,INDUSTRY,1623,3,288,19,2008-08-21,2016-07-14,True,1623,845,2082,47.9,Disease Progression (974); Continue in Long Term Follow Up (459); Adverse Event (215); Miscellaneous (133); Death (125); Study Close Out (111); Withdrawal by Subject (53); Protocol Violation (8); Lost to Follow-up (4),Disease Progression,974.0,3
NCT00856284,Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Takeda,INDUSTRY,2639,3,261,32,2009-03,2012-10,True,2639,1392,1247,47.3,Hyperglycemic rescue (667); Adverse Event (216); Voluntary withdrawal (162); Lost to Follow-up (70); Major protocol deviation (55); Other (46); Investigator discretion (27); Pregnancy (3); Randomized in error (1),Hyperglycemic rescue,667.0,1
NCT00567255,A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects,obesity,Obesity; Overweight,"Orexigen Therapeutics, Inc",INDUSTRY,1496,2,36,1,2007-12,2009-06,True,1496,805,691,46.2,"Adverse Event (309); Withdrawal by Subject (131); Lost to Follow-up (125); Lack of Efficacy (52); Drug noncompliance,moved,other (40); Protocol Violation (28); Pregnancy (6)",Adverse Event,309.0,1
NCT00722566,A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma,cardiovascular disease,Multiple Myeloma,"Millennium Pharmaceuticals, Inc.",INDUSTRY,222,2,3,3,2008-07,2010-09,True,222,120,0,45.9,,,,1
NCT00614939,Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,572,2,74,14,2008-01,2010-03,True,170,92,78,45.9,Study specific discontinuation criteris (29); Withdrawal by Subject (27); Adverse Event (7); Death (7); Poor/non-compliance (4); Incorrect enrollment (3); Hospitalized due to kidney transplant (1),Study specific discontinuation criteris,29.0,1
NCT00474630,A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes,diabetes type 2,"Obesity; Overweight; Diabetes Mellitus, Type 2","Orexigen Therapeutics, Inc",INDUSTRY,505,2,53,1,2007-05,2009-06,True,505,275,230,45.5,"Adverse Event (124); Lost to Follow-up (37); Withdrawal by Subject (36); Drug noncompliance, other (15); Lack of Efficacy (11); Protocol Violation (7)",Adverse Event,124.0,1
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,1202,9,99,13,2008-08,2012-07,True,1202,657,545,45.3,"Adverse Event (241); Withdrawal by Subject (104); Sponsor Decision, Arm Discontinued (85); Lost to Follow-up (39); Physician Decision (34); Lack of Efficacy (14); Entry Criteria Not Met (11); Protocol Violation (11); Death (4); Sponsor Decision (2)",Adverse Event,241.0,1
NCT02943785,Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF),cardiovascular disease,Atrial Fibrillation,Daiichi Sankyo,INDUSTRY,1426,2,230,14,2017-03-21,2021-02-28,True,1426,781,645,45.2,Adverse Event (209); Withdrawal by Subject (189); Death (92); Physician Decision (70); Did not receive any study medication (49); Other (35); Lost to Follow-up (1),Adverse Event,209.0,1
NCT01101035,Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES),cardiovascular disease,Cardiovascular Disease,Takeda,INDUSTRY,6198,2,203,2,2010-04-23,2017-07-18,True,6198,3410,2788,45.0,Voluntary Withdrawal (1182); Reason not Specified (696); Lost to Follow-up (449); Adverse Event (363); Major Protocol Deviation (98),Voluntary Withdrawal,1182.0,1
NCT00286429,Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.,diabetes type 2,Diabetes Mellitus,Takeda,INDUSTRY,390,3,60,16,2006-02,2007-05,True,390,215,175,44.9,Lack of Efficacy (104); Physician Decision (24); Protocol Violation (12); Adverse Event (11); Withdrawal by Subject (11); Lost to Follow-up (9); Administrative Error (3); Administrative Decision (1),Lack of Efficacy,104.0,1
NCT02468232,Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction,heart failure,Heart Failure With Reduced Ejection Fraction (HF-rEF),Novartis Pharmaceuticals,INDUSTRY,225,2,49,1,2015-06-15,2021-02-18,True,225,124,66,44.9,Death (43); Adverse Event (10); Subject/Guardian decision (7); Physician Decision (4); Technical Problems (2),Death,43.0,2
NCT00603902,BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management,cardiovascular disease,Obesity,Eisai Inc.,INDUSTRY,4008,3,1,1,2008-01,2009-08,True,4008,2224,0,44.5,,,,1
NCT00023595,Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease,cardiovascular disease,"Cardiovascular Diseases; Coronary Disease; Heart Failure, Congestive; Heart Diseases",Duke University,OTHER,2136,4,1,1,2002-01,2015-11,True,2136,1187,40,44.4,Lost to Follow-up (40),Lost to Follow-up,40.0,2
NCT00695955,One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,cardiovascular disease,Hypertension,Takeda,INDUSTRY,669,1,41,3,2007-06,2010-05,True,362,203,206,43.9,Lost to Follow-up (68); Withdrawal by Subject (53); Adverse Event (50); Other (21); Protocol Violation (7); Lack of Efficacy (7),Lost to Follow-up,68.0,2
NCT01330628,Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis,cardiovascular disease,Peripheral Arterial Disease,Spectranetics Corporation,INDUSTRY,252,2,34,2,2011-06,2015-05,True,252,142,110,43.7,Adverse Event (69); Withdrawn (24); Lost to Follow-up (11); Death (5); Didn't receive study treatment (1),Adverse Event,69.0,1
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,cardiovascular disease,Hypertension,Novartis Pharmaceuticals,INDUSTRY,2694,9,18,18,2008-09,2009-05,True,2694,1539,1158,42.9,"Abnormal test procedure result(s) (810); Patient withdrew consent (116); Adverse Event (63); Unsatisfactory therapeutic effect (45); Abnormal laboratory value(s) (38); Protocol deviation (33); Lost to Follow-up (32); Administrative problems (13); Discont. single-blind, Mis- randomized (3); Abnormal laboratory values (2); Abnormal test procedure results (2); Patient no longer needs study drug (1)",Abnormal test procedure result(s),810.0,2
NCT05085275,Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease,cardiovascular disease,"Anemia, Iron Deficiency; Hyperphosphatemia; Renal Insufficiency, Chronic; Renal Anemia; Disease Progression; Cardiovascular; Iron",USRC Kidney Research,NETWORK,289,2,23,1,2022-03-30,2024-01-24,True,289,165,0,42.9,,,,1
NCT00700817,"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus",diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,665,5,166,15,2008-06,2010-06,True,665,381,210,42.7,Adverse Event (60); Withdrawal criteria (49); Unclassified (41); Protocol Violation (34); Lack of Efficacy (26),Adverse Event,60.0,3
NCT01560637,"An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension",hypertension,Pulmonary Arterial Hypertension,United Therapeutics,INDUSTRY,471,1,153,23,2013-09-11,2021-08-12,True,470,272,198,42.1,Death (69); Adverse Event (63); Withdrawal by Subject (24); Progressive Disease (20); Lost to Follow-up (8); Protocol Violation (8); Other Reason Not Specified (6),Death,69.0,1
NCT00456521,A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program,obesity,Obesity; Overweight,"Orexigen Therapeutics, Inc",INDUSTRY,793,2,9,1,2007-03,2008-12,True,793,460,333,42.0,"Adverse Event (175); Withdrawal by Subject (67); Lost to Follow-up (39); Drug non-compliance, moved, other (37); Lack of Efficacy (9); Protocol Violation (4); Pregnancy (2)",Adverse Event,175.0,1
NCT00377676,Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,VeroScience,INDUSTRY,3095,2,0,0,2004-07,2007-01,True,3070,1787,1283,41.8,Adverse Event (605); Withdrawal by Subject (259); Lost to Follow-up (176); Other (176); Protocol Violation (60); Death (7),Adverse Event,605.0,1
NCT00707993,Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics,diabetes type 2,Diabetes Mellitus,Takeda,INDUSTRY,441,2,80,11,2008-06,2010-08,True,441,258,183,41.5,Hyperglycemic Rescue (102); Adverse Event (36); Withdrawal by Subject (28); Protocol Violation (11); Lost to Follow-up (4); Other (2),Hyperglycemic Rescue,102.0,1
NCT00095238,Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve),cardiovascular disease,Congestive Heart Failure,Bristol-Myers Squibb,INDUSTRY,4128,2,229,25,2002-06,2008-07,True,4128,2419,1709,41.4,Adverse Event (618); Subject Withdrew Consent (431); Death (324); Other Reasons (175); Noncompliance (89); Lost to Follow-up (43); Lack of Efficacy (18); No longer met study criteria (9); Study terminated by sponsor (1); Missing (1),Adverse Event,618.0,1
NCT04518293,Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension,cardiovascular disease,Hypertension,George Medicines PTY Limited,INDUSTRY,1385,4,89,7,2021-07-09,2023-09-01,True,2244,1318,0,41.3,,,,2
NCT00826280,Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI),cardiovascular disease,Coronary Artery Disease (CAD),Astellas Pharma Inc,INDUSTRY,347,3,25,1,2009-03-24,2010-07-15,True,347,207,140,40.3,Reversible ischemic defect not present (127); Adverse Event (4); Randomized but drug not received (2); Machine Failure (2); One or more non-interpretable scan (2); Lost to Follow-up (1); Sponsor discontinued subject or study (1); Interpretation Failure (1),Reversible ischemic defect not present,127.0,1
NCT01818752,"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma",cardiovascular disease,Multiple Myeloma,Amgen,INDUSTRY,955,2,213,30,2013-07-08,2016-11-04,True,955,570,385,40.3,Adverse Event (138); Disease Progression (102); Non-compliance (36); Death (32); Withdrawal by Subject (29); Physician Decision (17); Other (15); Randomized but not Dosed (11); Continuing Treatment (5),Adverse Event,138.0,1
NCT00554216,Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults,obesity,Obesity,VIVUS LLC,INDUSTRY,1267,3,5,1,2007-11,2009-05,True,1267,759,508,40.1,Lost to Follow-up (186); Withdrawal by Subject (166); Adverse Event (68); Other (29); Non compliance (19); Lack of Efficacy (18); Pregnancy (17); Restricted med (5),Lost to Follow-up,186.0,1
NCT00306384,Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus,diabetes type 2,Diabetes Mellitus,Takeda,INDUSTRY,3323,2,114,12,2006-03,2011-11,True,3323,1996,1327,39.9,Voluntary withdrawal (477); Adverse Event (230); Other (182); Lost to Follow-up (133); Major protocol deviation (112); Lack of Efficacy (104); Investigator discretion (80); Pregnancy (5); Study termination (2); Site closure (2),Voluntary withdrawal,477.0,1
NCT00108082,The CLEVER Study - Coreg And Left Ventricular Mass Regression,cardiovascular disease,"Hypertrophy, Left Ventricular",GlaxoSmithKline,INDUSTRY,287,3,78,1,2005-01,2008-08,True,287,174,113,39.4,Adverse Event (43); Amendment 4: > Month 12 (17); Lost to Follow-up (16); Consent Withdrawn (11); Lack of Efficacy (6); Woman of Child-bearing Potential (4); Protocol Violation (3); Non-compliance (3); Incorrectly Randomized (2); Site Closed Study (2); Stopped Study Medication (1); Protocol Amendment (1); Study Medication Not Tapered (1); Subject Left Site Location (1); Investigator Not at Site (1); Blood Pressure Not Controlled (1),Adverse Event,43.0,1
NCT03888066,Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND),cardiovascular disease,Hyperkalemia,"Vifor Pharma, Inc.",INDUSTRY,1195,2,415,21,2019-04-24,2021-09-02,True,1195,727,468,39.2,"Study Terminated By Sponsor (71); Adverse Event (48); Consent withdrawn by subject (46); Withdrawal by Subject (43); Physician Decision (34); Sponsor Request (34); Not treated with Patiromer during Run-in (27); Randomization Criterion #1 (24); AE (Adverse Event) (17); Protocol Violation (14); Delayed visit and insufficient study (12); Randomization Criterion #3 (11); 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L (10); 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L (6); Randomization Criteria #1, #2 (5); Randomization Criterion #2 (5); Randomization Criterion #1; AE (4); Randomization Criteria #2, #4 (4); Randomization Criterion #4; AE (4); End of study visit not completed/delayed (4); Treatment discontinuation (4); Randomization Criterion #4 (3); AE; Withdrawal By Subject (3); Randomization Criterion #1; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L (2); Randomization Criteria #3, #4; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L (2); Randomization Criterion #4; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L (2); AE; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L (2); Non-Compliance With Study Drug (2); Exceeded 12 Weeks Of Run In (2); Randomization Criteria #1, #2 #4; AE; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L (1); Randomization Criteria #1, #3 (1); Randomization Criteria #1, #4 (1); Randomization Crit #1, #4; Withdraw By Subject; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L (1); Randomization Criteria #1, #4; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L (1); Randomization Criterion #1; AE; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L (1); Randomization Criteria #2, #3 (1); Randomization Criteria #2, #3, #4 (1); Randomization Criteria #3, #4 (1); Randomization Criterion #3; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L (1); Randomization Criterion #3; Physician Decision (1); Randomization Criterion #4; AE; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L (1); Randomization Criterion #3; Exceeded 12 Weeks Of Run In (1); Randomization Criterion #4; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L (1); AE; Withdrawal By Subject; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L (1); AE; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L (1); AE; Physician Decision (1); Withdrawal By Subject; Withdrawal Of Consent (1); Death (1); Withdrawal Of Consent (1); Lost to Follow-up (1); Early study termination (1); Sponsor's decision (1)",Study Terminated By Sponsor,71.0,2
NCT00549302,Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs,cardiovascular disease,"Hypertension, Pulmonary",Eli Lilly and Company,INDUSTRY,357,2,10,10,2005-12,2012-02,True,357,217,133,39.2,Death (51); Adverse Event (30); Withdrawal by Subject (17); Investigator Decision (11); New Drug Pulmonary Atrial Hypertension (11); Lost to Follow-up (5); Other (3); New condition or starts new therapy (2); New drug pulmonary atrial hypertension (2); Sponsor Decision (1),Death,51.0,2
NCT01760447,A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,223,4,0,0,2011-12-07,2019-09-17,True,222,135,24,39.2,Withdrawal by Subject (9); Consent withdrawn by Parent/Guardian (7); Lost to Follow-up (6); Randomized but not treated (2),Withdrawal by Subject,9.0,2
NCT03080883,Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy,cardiovascular disease,Cerebral Vein Thrombosis; Deep Vein Thrombosis; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Pulmonary Embolism; Splanchnic Vein Thrombosis,Academic and Community Cancer Research United,OTHER,370,2,32,1,2017-07-14,2025-05-09,True,360,220,140,38.9,Adverse Event (44); Death (37); Withdrawal by Subject (26); Other Complicating Disease (14); Disease Progression (10); Physician Decision (4); Alternative Therapy (3); Lost to Follow-up (2),Adverse Event,44.0,1
NCT00853827,Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients,cardiovascular disease,Coronary Artery Disease (CAD); Coronary Atherosclerosis,Novartis Pharmaceuticals,INDUSTRY,613,2,129,11,2009-03,2013-01,True,652,400,252,38.7,Administrative problems (101); Adverse Event (48); Withdrawal by Subject (46); Lost to Follow-up (19); Protocol Violation (15); Death (7); Other (4); Patient's no longer requires study drug (4); Abnormal laboratory value (3); Abnormal laboratory values (3); Abnormal test procedure result (1); Lack of Efficacy (1),Administrative problems,101.0,2
NCT01289990,Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,2705,13,243,19,2011-02,2013-05,True,2705,1659,1046,38.7,did not continue in extension (603); discontinued in preceding trial (241); Withdrawal by Subject (156); Lost to Follow-up (36); Death (5); Not treated (5),did not continue in extension,603.0,1
NCT01137812,The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial),diabetes type 2,"Diabetes Mellitus, Type 2","Janssen Research & Development, LLC",INDUSTRY,756,2,184,17,2010-07,2012-03,True,755,464,291,38.5,Patient met glycemic withdrawal criteria (125); Other (46); Physician Decision (42); Adverse Event (35); Withdrawal by Subject (18); Lost to Follow-up (14); Protocol Violation (9); Death (2),Patient met glycemic withdrawal criteria,125.0,1
NCT00528372,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,1067,9,78,4,2007-09,2010-07,True,558,343,210,38.5,Withdrawal by Subject (68); Lost to Follow-up (39); Lack of Efficacy (38); Adverse Event (30); Other (19); Poor compliance or noncompliance (4); Poor or noncompliance (3); Administration reason by sponsor (3); No longer met study criteria (3); Administrative reason by sponsor (3),Withdrawal by Subject,68.0,2
NCT01778049,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,708,8,114,11,2013-01,2015-03,True,709,436,273,38.5,Other reason not defined above (180); Adverse Event (34); Lost to Follow-up (19); Withdrawal by Subject (18); Protocol Violation (12); Not treated (7); Lack of Efficacy (3),Other reason not defined above,180.0,2
NCT00308737,Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes,diabetes type 2,"Diabetes, Type 1; Diabetes, Type 2",Mannkind Corporation,INDUSTRY,2053,3,176,8,2005-06,2008-10,True,2053,1264,789,38.4,Withdrawal by Subject (402); Lost to Follow-up (141); Adverse Event (113); Various (60); Protocol Violation (48); Physician Decision (18); Death (7),Withdrawal by Subject,402.0,1
NCT00782340,A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa,cardiovascular disease,Symptomatic Neurogenic Orthostatic Hypotension (NOH); Non-diabetic Neuropathy; Primary Autonomic Failure; Dopamine Beta Hydroxylase Deficiency,Chelsea Therapeutics,INDUSTRY,263,2,21,2,2008-09,2010-09,True,263,162,101,38.4,Treatment failure (50); Enrollment capped (16); Adverse Event (12); Randomized in error (6); Protocol Violation (5); Withdrawal by Subject (5); Lost to Follow-up (5); Did not meet responder criteria (2),Treatment failure,50.0,2
NCT00863681,BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension,cardiovascular disease,"Hypertension, Pulmonary",Bayer,INDUSTRY,396,1,99,27,2009-03-12,2019-08-19,True,396,244,152,38.4,Death (69); Adverse Event (44); Withdrawal by Subject (19); Lost to Follow-up (6); Lack of Efficacy (5); Non-compliance with study drug (4); Other (2); Protocol Violation (2); Missing (1),Death,69.0,1
NCT01243424,CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,6103,2,613,43,2010-11-11,2018-08-21,True,6042,3728,2562,38.3,Adverse Event (980); Withdrawal by Subject (637); Other than listed above (441); Lack of Efficacy (102); Protocol Violation (93); Consent Withdrawn (Status Alive) (86); LostToFollowUpfor3P-MACE(StatusAlive) (73); Lost to Follow-up (52); Site Closure (Status Alive) (37); Consent Withdrawn (Status Unknown) (26); Not treated (18); LostToFollowUpfor3P-MACE(StatusUnknown) (16); Site Closure (Status Unknown) (1),Adverse Event,980.0,2
NCT00305604,Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED),diabetes type 2,Type 2 Diabetes,Merck Sharp & Dohme LLC,INDUSTRY,206,2,0,0,2006-03-08,2008-03-12,True,206,127,79,38.3,Withdrawal by Subject (33); Lack of Efficacy (29); Adverse Event (9); Lost to Follow-up (4); Protocol Violation (3); Patient moved (1),Withdrawal by Subject,33.0,1
NCT00078286,Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure,cardiovascular disease,"Heart Failure, Congestive; Chronic Heart Failure; Depression",Duke University,OTHER,469,2,1,1,2003-11,2008-09,True,469,290,0,38.2,,,,1
NCT00617123,Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183),cardiovascular disease,Atherosclerosis; Ischemia; Myocardial Infarction; Cerebrovascular Accident,Merck Sharp & Dohme LLC,INDUSTRY,258,2,0,0,2008-07-01,2010-10-01,True,258,160,98,38.0,Did Not Meet Protocol Eligibility (62); Withdrawal by Subject (20); Adverse Event (11); Did Not Wish To Continue (4); Noncompliance with Protocol (1),Did Not Meet Protocol Eligibility,62.0,2
NCT00528879,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,915,4,75,5,2007-09,2010-05,True,546,339,207,37.9,Lack of Efficacy (73); Withdrawal by Subject (42); Lost to Follow-up (37); Adverse Event (28); Poor compliance/noncompliance (10); No longer meets study criteria (10); Administrative reason by author (3); Other (2); Death (1); Pregnancy (1),Lack of Efficacy,73.0,2
NCT01539083,Velcade (Bortezomib) Consolidation After Transplant,cardiovascular disease,Multiple Myeloma,"Janssen Scientific Affairs, LLC",INDUSTRY,256,3,23,3,2012-01-13,2018-01-09,True,256,159,97,37.9,Death (23); Progressive Disease (17); Adverse Event (16); Physician Decision (15); Withdrawal by Subject (13); Other (7); Lost to Follow-up (4); Protocol Violation (2),Death,23.0,2
NCT03275285,"Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients",cardiovascular disease,Plasma Cell Myeloma,Sanofi,INDUSTRY,302,2,70,16,2017-10-25,2025-01-03,True,302,188,114,37.7,Ongoing (114),Ongoing,114.0,1
NCT00129545,WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation,cardiovascular disease,Atrial Fibrillation; Stroke,Boston Scientific Corporation,INDUSTRY,800,3,62,3,2005-02,2014-05,True,800,499,301,37.6,Death (109); Device not implanted (77); Withdrawal by Subject (65); Lost to Follow-up (37); Physician Decision (13),Death,109.0,1
NCT02555878,A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants,cardiovascular disease,Neoplasms,"Janssen Research & Development, LLC",INDUSTRY,841,2,151,10,2015-09-11,2018-08-24,True,841,525,316,37.6,Death (133); Withdrawal by Subject (96); Other (34); Physician Decision (25); Adverse Event (20); Lost to Follow-up (5); Protocol Violation (3),Death,133.0,1
NCT00332488,Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Mannkind Corporation,INDUSTRY,547,3,120,11,2004-12,,True,528,330,149,37.5,Withdrawal by Subject (63); Various (29); Physician Decision (28); Adverse Event (19); Lost to Follow-up (5); Protocol Violation (5),Withdrawal by Subject,63.0,2
NCT00978627,Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 1",Novo Nordisk A/S,INDUSTRY,548,2,81,10,2009-08,2010-05,True,548,346,102,36.9,Unclassified (56); Protocol Violation (19); Withdrawal criteria (15); Adverse Event (10); Lack of Efficacy (2),Unclassified,56.0,2
NCT00316082,Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,diabetes type 2,Diabetes,AstraZeneca,INDUSTRY,365,5,74,4,2006-06,2008-11,True,365,231,134,36.7,Withdrawal of Consent by Subject (34); Lost to Follow-up (34); Lack of Efficacy (18); Poor/noncompliance (16); Adverse Event (15); Subject no longer meets study criteria (9); Physician Decision (6); Death (1); Administrative reason by sponsor (1),Withdrawal of Consent by Subject,34.0,1
NCT01028053,Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease,cardiovascular disease,Mild Cognitive Impairment; Alzheimer's Disease,GE Healthcare,INDUSTRY,365,1,1,1,2009-12,2014-01,True,365,232,133,36.4,Screen Failure (113); Patient Request (11); Various reasons (4); Physician Decision (2); Protocol Violation (1); Technical Problem (1); Terminated by Sponsor (1),Screen Failure,113.0,1
NCT00295633,A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone,diabetes type 2,"Diabetes Mellitus, Type 2",AstraZeneca,INDUSTRY,565,3,133,8,2006-03,2008-10,True,565,360,205,36.3,Withdrawal of consent by subject (58); Lack of Efficacy (42); Adverse Event (35); Physician Decision (27); Lost to Follow-up (24); Poor/Noncompliance (10); Subject No Longer Meets Study Criteria (6); Death (2); Administrative reason by sponsor (1),Withdrawal of consent by subject,58.0,1
NCT00542386,A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia,dyslipidemia,Chronic Kidney Disease; Dialysis; Hyperphosphatemia; Dyslipidemia,Tanabe Pharma Corporation,INDUSTRY,642,2,73,8,2007-12,2009-11,True,642,410,232,36.1,Lack of Efficacy (105); Withdrawal by Subject (56); Adverse Event (40); Other Reasons (18); Death (6); Protocol Violation (5); Physician Decision (2),Lack of Efficacy,105.0,1
NCT00982644,Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1030,2,187,15,2009-09,2010-12,True,1030,659,292,36.0,Unclassified (144); Protocol Violation (70); Adverse Event (42); Withdrawal criteria (23); Lack of Efficacy (13),Unclassified,144.0,2
NCT02229396,Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo,diabetes type 2,Diabetes Mellitus,AstraZeneca,INDUSTRY,695,3,133,6,2014-09-04,2017-12-28,True,695,445,250,36.0,Withdrawal by Subject (111); Lost to Follow-up (49); Other (43); Adverse Event (30); Death (6); Study-Specific Withdrawal Criteria (4); Protocol Violation (3); Withdrew; No Record on Termination Page (3); Patient Incorrectly Randomized (1),Withdrawal by Subject,111.0,1
NCT00518882,Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,467,2,125,16,2007-08,2009-04,True,467,299,168,36.0,Adverse Event (66); Completed extension 1 (weeks 26-40) (43); Protocol Violation (14); Lack of Efficacy (12); Lost to follow up (5); Subject decision (4); Withdrawal of consent (4); Hypoglycaemia (3); Withdrawel criteria (3); Consent withdrawn (3); Withdrawal criteria (2); Change in treatment (2); Exclusion criteria (2); Loss of trust (1); Fear of hypoglycaemia (1); Mutual consent (1); Creatine increased (1); Decreased kidney function (1),Adverse Event,66.0,2
NCT00082628,Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients,metabolic syndrome,HIV Infections; Lipodystrophy,EMD Serono,INDUSTRY,326,5,31,2,2004-05-28,2005-09-28,True,326,209,117,35.9,Subjects Did Not Complete Week 12 (48); Subjects Did Not Complete Week 36 (47); Did not continue to Period II (16); Subjects Without Post-Baseline Assessmen (3); Subjects Did Not Receive Study Drug (1); Lost to Follow-up (1); Withdrawal by Subject (1),Subjects Did Not Complete Week 12,48.0,2
NCT01237223,Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension,cardiovascular disease,Essential Hypertension,Novartis,INDUSTRY,1342,6,11,1,2010-10,2011-05,True,1342,867,475,35.4,Abnormal test procedure result(s) (308); Adverse Event (53); Unsatisfactory therapeutic effect (35); Subject withdrew consent (28); Abnormal laboratory value(s) (25); Protocol deviation(s) (14); Withdrawal by Subject (11); Administrative problems (1),Abnormal test procedure result(s),308.0,2
NCT02851407,Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients,cardiovascular disease,Veno-occlusive Disease,Jazz Pharmaceuticals,INDUSTRY,372,2,114,14,2016-09-01,2020-10-20,True,372,241,131,35.2,"Other Death (50); Disease relapse (15); Adverse event, serious fatal (14); Physician Decision (13); Adverse event, non-fatal (12); Withdrawal by parent/guardian (9); Consent withdrawn by participant (8); Screen failure (3); Lost to Follow-up (2); Protocol deviation (1); Transferred to another hospital to continue (1); Transferred to hospital closer to home (1); Enrolled in an investigational study (1); Early recovery (1)",Other Death,50.0,1
NCT00225277,Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,Diabetes Mellitus,Takeda,INDUSTRY,547,2,79,4,2003-07,2007-10,True,547,355,192,35.1,Withdrawal by Subject (74); Adverse Event (64); Other (16); Physician Decision (14); Lost to Follow-up (10); Protocol Violation (9); Lack of Efficacy (5),Withdrawal by Subject,74.0,1
NCT00403767,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,cardiovascular disease,Atrial Fibrillation; Stroke; Embolism,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,14269,2,932,44,2006-12,2010-09,True,14236,9248,4988,35.0,Adverse Event (1912); Consent withdrawn (1344); Clinical efficacy endpoint reached (632); Investigator dec./not protocol-related (369); Non-compliant with study medication (298); Protocol Violation (266); Study terminated by sponsor (151); Lost to Follow-up (14); Missing/incomplete data (2),Adverse Event,1912.0,1
NCT00482729,MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,1246,2,0,0,2007-06-19,2009-04-27,True,1250,815,435,34.8,Lost to Follow-up (152); Withdrawal by Subject (136); Adverse Event (62); Protocol Violation (28); Lack of Efficacy (20); Physician Decision (17); Hyperglycemia Criteria (12); Pregnancy (6); Creatinine/Creatinine Clearance Criteria (2),Lost to Follow-up,152.0,1
NCT00853658,Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure,heart failure,Chronic Heart Failure,Novartis Pharmaceuticals,INDUSTRY,7064,3,806,44,2009-03,2015-10,True,7064,4630,2434,34.5,Death (2234); H.A. Request (68); Patient's request (49); Lost to Follow-up (28); Vital Status at study end N/A (28); Missing study completion information (15); Vital Status known (alive) at study end (8); IRB request (2); Vital Status unknown at study end (2),Death,2234.0,1
NCT00432276,Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,Diabetes Mellitus,Takeda,INDUSTRY,803,2,86,1,2007-01,2009-06,True,803,526,277,34.5,Hyperglycemic Rescue (131); Protocol Violation (45); Withdrawal by Subject (45); Adverse Event (29); Physician Decision (14); Lost to Follow-up (8); Other (5),Hyperglycemic Rescue,131.0,1
NCT00249873,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A),cardiovascular disease,Atrial Fibrillation; Vascular Risk,Sanofi,INDUSTRY,7554,2,30,30,2003-06,2009-03,True,7554,4970,2584,34.2,Withdrawal by Subject (970); Oral anticoagulant required (316); Other non serious Adverse Event (220); Thromboembolic/outcome event (204); Other Serious Adverse Event (183); Minor bleeding (136); Physician withdrew consent (119); Serious haemorrhagic Adverse Event (104); Non-compliance (87); Open label clopidogrel required (73); Qualifying condition not present (43); Event related to cardiac condition (33); Surgery/ procedure (18); Significant thrombocytopenia (17); Not treated (15); Contraindication to oral anticoagulant (12); Lost to Follow-up (11); Severe allergic reaction (9); Patient not wish to continue after May08 (7); Study drug intolerance (5); Other contraindicated medication (1); Angiotensin II receptor blocker required (1),Withdrawal by Subject,970.0,1
NCT04520256,Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy,obesity,Overweight and Obesity,The Miriam Hospital,OTHER,384,32,1,1,2020-09-22,2023-05-18,True,384,253,131,34.1,Lost to Follow-up (131),Lost to Follow-up,131.0,1
NCT00715624,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin",diabetes type 2,"Diabetes Mellitus, Type 2",Sanofi,INDUSTRY,496,2,15,15,2008-07,2011-02,True,496,328,168,33.9,Adverse Event (49); Withdrawal by Subject (36); Familial and personal reasons (32); Lack of Efficacy (22); Poor compliance (19); Sponsor decision (4); Lost to Follow-up (3); Protocol Violation (1); Incorrect randomization (not treated) (1); Other (1),Adverse Event,49.0,1
NCT01106625,The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea),diabetes type 2,"Diabetes Mellitus, Type 2","Janssen Research & Development, LLC",INDUSTRY,469,3,76,12,2010-05,2012-04,True,469,310,152,33.9,"Other (33); Adverse Event (29); Withdrawal by Subject (28); Unable to take rescue therapy (28); Lost to Follow-up (15); Protocol Violation (7); Physician Decision (4); Creatinine or eGFR withdrawal criteria (4); Creatinine, or eGFR withdrawal criteria (2); Noncompliance with study drug (2)",Other,33.0,2
NCT00661999,Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer,cardiovascular disease,"Anemia; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific",Mayo Clinic,OTHER,502,3,2,1,2006-01,2009-03,True,490,324,166,33.9,Withdrawal by Subject (67); Other Reasons (40); Adverse Event (24); Death (17); Other Medical Problems (17); Alternative Treatment (1),Withdrawal by Subject,67.0,1
NCT00603291,BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus,diabetes type 2,Obesity,Eisai Inc.,INDUSTRY,604,3,1,1,2007-12,2010-10,True,604,401,0,33.6,,,,1
NCT03045406,Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer,cardiovascular disease,Venous Thromboembolism,"Fadoi Foundation, Italy",OTHER,1170,2,127,11,2017-04-13,2019-12-01,True,1170,781,0,33.2,,,,1
NCT03439254,Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis,NASH,Compensated Cirrhosis; Nonalcoholic Steatohepatitis,Intercept Pharmaceuticals,INDUSTRY,919,3,192,12,2017-08-30,2022-09-08,True,919,615,130,33.1,Adverse Event (58); Withdrawal by Subject (40); Lost to Follow-up (8); Death (5); Progressive Disease (4); Physician Decision (2); Bariatric Surgery (2); Covid-19 Non Adverse Event (AE) Related Issues (1); Non-Compliance With Study Drug (1); Participant moved to Kansas (1); Site cover and participant was not willing to be transferred (1); Stopped Investigational product (IP) due to an AE in Australia (1); Drug Holiday (1); Spouse underwent surgery and participant was unable to take IP regularly (1); Site closure (1); Covid-19 Non-AE Related Issues (1); Increase CR from Baseline (1); Medical reasons by Sponsor (1),Adverse Event,58.0,2
NCT01081834,The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial,diabetes type 2,"Diabetes Mellitus, Type 2","Janssen Research & Development, LLC",INDUSTRY,678,3,78,18,2010-03,2012-03,True,675,452,131,33.0,Withdrawal by Subject (34); Other (25); Lost to Follow-up (17); Adverse Event (13); Lack of efficacy on rescue therapy (12); Noncompliance with study drug (11); Protocol Violation (7); Creatinine or eGFR withdrawal criteria (5); Unable to take rescue therapy (3); Death (2); Pregnancy (1); Physician Decision (1),Withdrawal by Subject,34.0,2
NCT00093015,Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT),cardiovascular disease,Kidney Disease; Diabetes Mellitus; Anemia,Amgen,INDUSTRY,4038,2,0,0,2004-08-01,2009-07-01,True,4038,2709,1329,32.9,Death (760); Withdrawal by Subject (365); Lost to Follow-up (204),Death,760.0,1
NCT01001572,Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension,cardiovascular disease,Essential Hypertension,Novartis,INDUSTRY,932,3,2,1,2009-09,2010-05,True,932,625,307,32.9,Abnormal Test Procedure Result(s) (96); Administrative problems (82); Withdrawal by Subject (53); Condition no longer requires study drug (45); Adverse Event (15); Unsatisfactory therapeutic effect (8); Lost to Follow-up (5); Abnormal Laboratory Value (1); Abnormal test procedure result(s) (1); Protocol deviation (1),Abnormal Test Procedure Result(s),96.0,2
NCT00489736,Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation,cardiovascular disease,Atrial Fibrillation,Sanofi,INDUSTRY,504,2,23,23,2007-06,2008-10,True,504,339,165,32.7,Adverse Event (77); Lack of Efficacy (67); Not coded/ Not pre-specified (13); Poor compliance (8),Adverse Event,77.0,1
NCT01115855,Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure,cardiovascular disease,Heart Failure,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,221,2,54,1,2010-07,2015-09,True,221,149,72,32.6,Adverse Event (34); Other (14); Death (11); Withdrawal by Subject (10); Lab Abnormality (2); Protocol Violation (1),Adverse Event,34.0,1
NCT00696384,A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,cardiovascular disease,Hypertension,Takeda,INDUSTRY,418,3,45,3,2007-06,2009-04,True,418,282,136,32.5,Withdrawal by Subject (44); Adverse Event (31); Lost to Follow-up (27); Protocol Violation (18); Other (6); Physician Decision (6); Lack of Efficacy (4),Withdrawal by Subject,44.0,2
NCT00968812,CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride,diabetes type 2,"Diabetes Mellitus, Type 2","Janssen Research & Development, LLC",INDUSTRY,1452,3,138,20,2009-09,2013-01,True,1450,980,470,32.4,Adverse Event (109); Other (102); Withdrawal by Subject (65); Unable to take rescue therapy (41); Lost to Follow-up (40); Lack of Efficacy (32); Creatinine or eGFR withdrawal criteria (29); Physician Decision (22); Protocol Violation (14); Noncompliance with study drug (11); Death (5),Adverse Event,109.0,1
NCT00064753,Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT),cardiovascular disease,Chronic Kidney Disease; Cardiovascular Disease; Death,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,4110,2,30,3,2002-05,2011-10,True,4110,2788,1322,32.2,Death (493); Lost to Follow-up (460); Withdrawal by Subject (369),Death,493.0,1
NCT00856986,The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,987,5,233,10,2009-03,2010-11,True,988,670,318,32.2,Adverse Event (127); Unclassified (61); Protocol Violation (53); Withdrawal Criteria (34); Lost to Follow-up (22); Lack of Efficacy (21),Adverse Event,127.0,3
NCT00327015,A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,diabetes type 2,Diabetes,AstraZeneca,INDUSTRY,1306,4,211,13,2006-05,2008-12,True,1306,888,418,32.0,Lack of Efficacy (100); Withdrawal of Consent by Subject (97); Lost to Follow-up (96); Adverse Event (52); Poor/Noncompliance (28); Subject no longer meets study criteria (21); Death (8); Physician Decision (6); Administrative Reason by Sponsor (6); Pregnancy (4),Lack of Efficacy,100.0,1
NCT00616772,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",cardiovascular disease,Coronary Artery Disease; Coronary Heart Disease; Dyslipidemia,"AbbVie (prior sponsor, Abbott)",INDUSTRY,682,2,124,1,2008-02,2012-09,True,682,465,0,31.8,,,,1
NCT00309244,Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up,diabetes type 2,Diabetes Type 2,Mannkind Corporation,INDUSTRY,677,2,151,10,2006-02,2008-09,True,677,462,215,31.8,Withdrawal by Subject (82); Adverse Event (41); Lost to Follow-up (28); Randomized but not dosed (23); Various (14); Physician Decision (13); Protocol Violation (9); Death (5),Withdrawal by Subject,82.0,1
NCT00707031,"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",diabetes type 2,"Diabetes Mellitus, Type 2",Sanofi,INDUSTRY,639,2,18,18,2008-06,2010-11,True,639,436,203,31.8,Adverse Event (90); Familial or Personal Reasons (27); Lack of Efficacy (25); Poor Compliance to Protocol (20); Sponsor Decision (17); Withdrawal by Subject (15); Serious Noncompliance (5); Lost to Follow-up (3); Protocol Violation (1),Adverse Event,90.0,1
NCT03057951,EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved),cardiovascular disease,Heart Failure,Boehringer Ingelheim,INDUSTRY,5988,2,619,23,2017-03-02,2021-04-26,True,5988,4097,1891,31.6,"Adverse Event (1128); Patient refusal to continue, not due to AE (588); Protocol Violation (54); Other reason than stated above (52); Lost to Follow-up (22); Due to Covid-19 Pandemic (10); Medical advice (8); Study drug stopped, reason missing (7); Patient decision (7); Patient moved away (7); Not attending study visits (3); Not treated (3); Investigator decision (2)",Adverse Event,1128.0,1
NCT00300430,"Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.",cardiovascular disease,Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia,Abbott,INDUSTRY,1911,3,1,1,2006-09,,True,2201,1514,0,31.2,,,,1
NCT01598831,Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy,cardiovascular disease,Severe Sepsis; Coagulopathy,Asahi Kasei Pharma America Corporation,INDUSTRY,816,2,161,24,2012-10-29,2019-02-28,True,816,561,0,31.2,,,,1
NCT00434954,Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,494,2,39,1,2007-02,2009-06,True,494,341,153,31.0,Protocol Violation (63); Entry criteria not met (30); Subject decision (30); Adverse Event (19); Physician Decision (9); Lost to Follow-up (1); Sponsor decision (1),Protocol Violation,63.0,1
NCT02884206,Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction,cardiovascular disease,Chronic Heart Failure (CHF),Novartis Pharmaceuticals,INDUSTRY,592,2,135,20,2016-11-23,2022-05-16,True,706,488,218,30.9,Adverse Event (72); Death (70); Patient/guardian decision (48); Protocol deviation (10); Lost to Follow-up (9); Non-compliance with study treatment (5); Physician Decision (4),Adverse Event,72.0,3
NCT00249795,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I),cardiovascular disease,Atrial Fibrillation; Cardiovascular Disease,Sanofi,INDUSTRY,9016,2,30,30,2003-06,2009-08,True,9016,6232,2784,30.9,"Withdrawal by Subject (1420); Other adverse events (non-serious) (347); Symptomatic hypotension (191); Other Serious Adverse Event (177); Non-compliance (140); Physician withdrew consent (134); Angiotensin II receptor blocker required (93); Thromboembolic / outcome event (84); Qualifying condition not present (55); Event related to cardiac condition (33); Not treated (30); Lightheadedness / dizziness (26); Minor bleeding (e.g.,bruising,epistaxis) (10); Hypotension (non-symptomatic) (10); Patient not wish to continue after May08 (10); Surgery / procedure (9); Study drug intolerance (6); Oral anticoagulant required (2); Other contraindicated medication (2); Site not agree to continue after May08 (2); Lost to Follow-up (2); Missing (1)",Withdrawal by Subject,1420.0,1
NCT02801669,Study of DU-176b Aged 80 Years or Older,cardiovascular disease,Atrial Fibrillation,"Daiichi Sankyo Co., Ltd.",INDUSTRY,984,2,164,1,2016-08-05,2019-12-27,True,984,681,303,30.8,Withdrawal by Subject (158); Death (135); Other (10),Withdrawal by Subject,158.0,1
NCT00380068,Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension,cardiovascular disease,Pulmonary Hypertension,Gilead Sciences,INDUSTRY,224,1,39,3,2006-08,2009-05,True,224,155,69,30.8,Adverse Event (40); Withdrawal by Subject (10); Not compliant (6); Lack of Efficacy (5); Lung transplant (3); Physician Decision (2); Lost to Follow-up (1); Addition of other PAH therapeutic agent (1); Partipant moved away (1),Adverse Event,40.0,1
NCT00553787,Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions,diabetes type 2,Obesity; Type 2 Diabetes,VIVUS LLC,INDUSTRY,2487,3,6,1,2007-11,2009-06,True,2487,1723,764,30.7,Withdrawal by Subject (274); Lost to Follow-up (254); Adverse Event (122); Other (41); Lack of Efficacy (35); Requirement for restricted medication (20); non compliance (15); Pregnancy (3),Withdrawal by Subject,274.0,1
NCT02319005,ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC),cardiovascular disease,"Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC); Amyloidosis, Hereditary; Amyloid Neuropathies, Familial; Amyloid Neuropathies; Amyloidosis, Hereditary, Transthyretin-Related; Familial Transthyretin Cardiac Amyloidosis",Alnylam Pharmaceuticals,INDUSTRY,206,2,61,9,2014-12,2017-03-30,True,206,143,0,30.6,,,,1
NCT01426425,Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia,cardiovascular disease,AtrioVentricular Nodal Reentrant Tachycardia; Supraventricular Tachycardia; Heart Disease,Medtronic Cardiac Ablation Solutions,INDUSTRY,572,1,34,2,2012-05,2016-09,True,572,397,175,30.6,"Inclusion/exclusion criteria not met (151); Exited prior to EP study (22); Met inclusion/exclusion, not treated (2)",Inclusion/exclusion criteria not met,151.0,1
NCT00739674,SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335),cardiovascular disease,Hypertension,Organon and Co,INDUSTRY,992,2,0,0,2008-02-01,2010-01-01,True,992,689,303,30.5,Lost to Follow-up (82); No follow-up data (51); Screening failures (36); Adverse Event (35); Site 212 removal (32); Withdrawal by Subject (18); Dietician consultation >30 days (10); Protocol Violation (10); Clinic closed (10); Patient moved (5); Non compliant (4); Unable to attend visit (4); Reason missing (2); Death (1); Lack of Efficacy (1); Home monitoring off meds (1); Erectile dysfunction (1),Lost to Follow-up,82.0,1
NCT02398656,A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion,cardiovascular disease,"Stroke, Acute",University of Calgary,OTHER,1274,2,61,10,2015-04-01,2024-04-10,True,1274,886,0,30.5,,,,1
NCT00174785,A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation,cardiovascular disease,Atrial Fibrillation; Atrial Flutter,Sanofi,INDUSTRY,4628,2,37,37,2005-06,2008-03,True,4628,3216,1412,30.5,Adverse Event (484); Withdrawal by Subject (348); Atrial Fibrillation/Flutter recurrence (277); Prohibited antiarrhythmic medication (127); Not pre-specified/Not coded (126); Protocol Violation (28); Family request (14); Other prohibited medication (8),Adverse Event,484.0,1
NCT00781937,Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance,obesity,Metabolism and Nutrition Disorder; Obesity,Novo Nordisk A/S,INDUSTRY,422,2,37,2,2008-10-30,2010-09-01,True,422,294,128,30.3,Withdrawal by Subject (41); Adverse Event (36); Unclassified (34); Protocol Violation (15); Lack of Efficacy (2),Withdrawal by Subject,41.0,2
NCT00713830,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea",diabetes type 2,"Diabetes Mellitus, Type 2",Sanofi,INDUSTRY,859,2,16,16,2008-07,2011-01,True,859,600,259,30.2,Adverse Event (94); Familial and Personal Reasons (43); Lack of Efficacy (40); Withdrawal by Subject (36); Poor Compliance to Protocol (21); Sponsor Decision (14); Lost to Follow-up (11),Adverse Event,94.0,1
NCT00501059,A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease,cardiovascular disease,Moderate Risk of CVD,Bayer,INDUSTRY,12546,2,466,8,2007-07-05,2016-11-15,True,12546,8786,3760,30.0,Consent withdrawn by subject (1690); Other (475); Lost to Follow-up (408); Death (277); Adverse Event (251); Clinical endpoint reached (233); Missing end-of-study page (183); Protocol Violation (149); Not treated (42); Non-compliant with study treatment (39); Insufficient therapeutic effect (9); Reason not given (4),Consent withdrawn by subject,1690.0,1
NCT00311402,JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme,cardiovascular disease,Cerebrovascular Accident,Boehringer Ingelheim,INDUSTRY,1295,2,151,1,2006-04,,True,1294,907,387,29.9,Adverse Event (223); Lack of Efficacy (100); Withdrawal by Subject (35); Protocol Violation (13); IRB's rejection etc. (13); Lost to Follow-up (3),Adverse Event,223.0,1
NCT01709513,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",cardiovascular disease,Hypercholesterolemia,Regeneron Pharmaceuticals,INDUSTRY,314,3,70,8,2012-09-30,2017-05-31,True,314,220,94,29.9,Adverse Event (70); Other (21); Poor compliance to protocol (2); Randomized but not treated (1),Adverse Event,70.0,1
NCT03229057,Comparing the Effects of Oral Contraceptive Pills Versus Metformin,obesity,PCOS,Anuja Dokras,OTHER,240,3,2,1,2018-01-15,2024-07-15,True,240,169,0,29.6,,,,1
NCT00727857,Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.,diabetes type 2,Diabetes Mellitus,Takeda,INDUSTRY,600,3,77,4,2007-06,2008-08,True,600,424,0,29.3,,,,1
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks",diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,936,7,132,6,2010-08,2013-02,True,936,663,273,29.2,Reasons other than stated above (95); Withdrawal by Subject (66); Adverse Event (50); Lost to Follow-up (30); Protocol Violation (21); Lack of Efficacy (11),Reasons other than stated above,95.0,1
NCT00000125,Ocular Hypertension Treatment Study (OHTS),hypertension,Ocular Hypertension; Glaucoma,Washington University School of Medicine,OTHER,1636,2,0,0,1994-02,2019-06-30,True,1636,1159,0,29.2,,,,1
NCT01272232,Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes,diabetes type 2,Metabolism and Nutrition Disorder; Obesity,Novo Nordisk A/S,INDUSTRY,846,3,161,13,2011-06-01,2013-01-25,True,846,599,247,29.2,Withdrawal criteria (103); Adverse Event (66); Unclassified (39); Protocol Violation (35); Lack of Efficacy (4),Withdrawal criteria,103.0,2
NCT00508820,An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP,cardiovascular disease,Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenic Purpura,Amgen,INDUSTRY,407,1,0,0,2005-02-01,2011-03-01,True,407,288,119,29.2,Withdrawal by Subject (22); Requirement for alternative therapy (22); Adverse Event (16); Protocol-specified Criteria (15); Death (14); Other (13); Physician Decision (10); Lost to Follow-up (2); Pregnancy (2); Protocol Violation (2); Noncompliance (1),Withdrawal by Subject,22.0,1
NCT01755156,"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)",diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,402,2,0,0,2013-01-11,2016-03-16,True,402,285,116,29.1,Withdrawal by Subject (77); Lost to Follow-up (25); Adverse Event (5); Protocol Violation (2); Creatinine or eGFR Discon. Criteria (2); Need for Excluded Med. Discon. Criteria (2); Lack of Efficacy (1); Non-compliance with study drug (1); Physician Decision (1),Withdrawal by Subject,77.0,2
NCT00789737,Welchol as Monotherapy for Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Daiichi Sankyo,INDUSTRY,357,2,107,1,2009-01,2011-12,True,357,254,103,28.9,Withdrawal by Subject (35); Lost to Follow-up (24); Other (18); Adverse Event (16); hyperglycemia that met protocol-specifie (4); Protocol Violation (3); Lack of Efficacy (3),Withdrawal by Subject,35.0,1
NCT03691649,A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study,hypertension,Glaucoma and Ocular Hypertension,Santen Inc.,INDUSTRY,426,2,47,1,2018-09-14,2020-09-03,True,426,304,0,28.6,,,,2
NCT00044213,Trial to Assess Chelation Therapy (TACT),cardiovascular disease,Coronary Artery Disease,"Mt. Sinai Medical Center, Miami",OTHER,1708,4,86,2,2003-09,2012-08,True,1708,1222,486,28.5,Withdrawal by Subject (289); Death (175); Lost to Follow-up (22),Withdrawal by Subject,289.0,1
NCT00563368,A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults,obesity,Obesity,VIVUS LLC,INDUSTRY,756,7,2,1,2007-12,2008-09,True,756,541,215,28.4,Lost to Follow-up (72); Adverse Event (54); Withdrawal by Subject (46); Other (25); protocol non-compliance (9); Pregnancy (7); requirement for restricted medication (2),Lost to Follow-up,72.0,1
NCT00972283,Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1006,2,136,12,2009-09-01,2010-10-28,True,1006,722,212,28.2,Unclassified (105); Adverse Event (44); Protocol Violation (40); Withdrawal criteria (18); Lack of Efficacy (5),Unclassified,105.0,2
NCT00479882,MK-0524B Lipid Study (MK-0524B-063),dyslipidemia,Primary Hypercholesterolemia; Mixed Dyslipidemia,Merck Sharp & Dohme LLC,INDUSTRY,2414,4,0,0,2007-06-15,2008-06-16,True,2414,1733,681,28.2,Clinical Adverse Event (427); Withdrawal by Subject (122); Lost to Follow-up (46); Other (33); Protocol Violation (22); Laboratory Adverse Event (20); Participant moved (11),Clinical Adverse Event,427.0,2
NCT04844918,A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease,obesity,Obesity,Eli Lilly and Company,INDUSTRY,267,3,18,1,2021-05-10,2023-06-24,True,267,192,75,28.1,Participants Excluded Due to GCP Compliance Issue (42); Adverse Event (20); Withdrawal by Subject (12); Physician Decision (1),Participants Excluded Due to GCP Compliance Issue,42.0,1
NCT00763815,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone",diabetes type 2,Diabetes Mellitus Type 2,Sanofi,INDUSTRY,484,2,150,13,2008-09,2011-06,True,484,348,136,28.1,Adverse Event (43); Familial and Personal Reasons (25); Lack of Efficacy (21); Withdrawal by Subject (19); Poor Compliance to Protocol (12); Protocol Violation (7); Lost to Follow-up (6); Early Termination (1); Physician Decision (1); Sponsor's Decision (1),Adverse Event,43.0,1
NCT02733185,Trial to Assess Chelation Therapy 2,cardiovascular disease,Diabetes; Myocardial Infarction,"Mt. Sinai Medical Center, Miami",OTHER,1000,4,1,1,2016-10-01,2023-06-30,True,1000,720,280,28.0,Death (158); Lost to Follow-up (62); Withdrawal by Subject (60),Death,158.0,1
NCT00955747,Naturlose (D-Tagatose) Efficacy Evaluation Trial,diabetes type 2,Type 2 Diabetes,Robert Lodder,INDUSTRY,494,2,46,2,2007-04,2010-10,True,494,356,0,27.9,,,,1
NCT00094757,An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023),diabetes type 2,"Diabetes Mellitus, Type 2",Merck Sharp & Dohme LLC,INDUSTRY,521,3,0,0,2004-10-06,2006-04-28,True,521,376,145,27.8,Withdrawal by Subject (40); Lack of Efficacy (34); Adverse Event (26); Protocol Violation (16); Lost to Follow-up (14); Other (7); Patient Moved (4); Protocol specified discontinuation (4),Withdrawal by Subject,40.0,1
NCT00485758,Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069),diabetes type 2,Diabetes Mellitus Type 2,Merck Sharp & Dohme LLC,INDUSTRY,796,2,0,0,2007-07,2008-08,True,796,575,221,27.8,Adverse Event (133); Withdrawal by Subject (59); Protocol Violation (13); Lost to Follow-up (6); Physician Decision (6); Study Terminated by Sponsor (3); Death (1),Adverse Event,133.0,1
NCT03353350,Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise,diabetes type 2,Type 2 Diabetes Mellitus,Hanmi Pharmaceutical Company Limited,INDUSTRY,406,4,54,5,2017-12-05,2020-09-07,True,406,293,113,27.8,Withdrawal by Subject (89); Adverse Event (11); Other: Not related to COVID-19 (8); Protocol Violation (5),Withdrawal by Subject,89.0,2
NCT00790335,Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis,cardiovascular disease,Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome,Washington University School of Medicine,OTHER,692,2,56,1,2009-11,2017-01,True,692,500,0,27.7,,,,1
NCT01564537,A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma,cardiovascular disease,Relapsed Multiple Myeloma; Refractory Multiple Myeloma,Takeda,INDUSTRY,722,2,24,2,2012-08-01,2022-02-08,True,722,522,200,27.7,Reason not specified (163); Withdrawal by Subject (26); Lost to Follow-up (10); Site Terminated by Sponsor (1),Reason not specified,163.0,1
NCT00536744,Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers,cardiovascular disease,Diabetic Foot Ulcers,"SANUWAVE, Inc.",INDUSTRY,206,2,23,3,2007-10,2010-09,True,206,149,57,27.7,Adverse Event (23); Withdrawal by Subject (15); Lost to Follow-up (8); Physician Decision (4); PI tried alternative treatment (4); Death (3),Adverse Event,23.0,1
NCT00273052,COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension,cardiovascular disease,Hypertension,GlaxoSmithKline,INDUSTRY,514,2,120,3,2006-01-05,2007-12-28,True,568,411,157,27.6,Adverse Event (40); Withdrawal by Subject (35); Protocol Violation (32); Lost to Follow-up (32); Lack of Efficacy (10); Non-Compliance (4); Other (2); Worsening serum lipid levels (2),Adverse Event,40.0,1
NCT00313313,A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas,diabetes type 2,Diabetes,AstraZeneca,INDUSTRY,768,3,115,13,2006-04,2008-09,True,768,557,211,27.5,Withdrawal of consent by subject (66); Lack of Efficacy (43); Adverse Event (43); Lost to Follow-up (26); Physician Decision (12); Poor/Noncompliance (11); Subject No Longer Meets Study Criteria (5); Pregnancy (3); Death (2),Withdrawal of consent by subject,66.0,1
NCT00794573,Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial,cardiovascular disease,Acute Coronary Syndrome,Mark Eisenberg,OTHER,302,2,4,1,2009-09,2015-12,True,302,219,83,27.5,Lost to Follow-up (59); Withdrawal by Subject (21); Death (3),Lost to Follow-up,59.0,1
NCT00286468,Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.,diabetes type 2,Diabetes Mellitus,Takeda,INDUSTRY,500,3,68,15,2006-04,2007-06,True,500,363,137,27.4,Hyperglycemic Rescue (89); Withdrawal by Subject (22); Adverse Event (12); Physician Decision (6); Protocol Violation (4); Lost to Follow-up (4),Hyperglycemic Rescue,89.0,1
NCT01644188,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),cardiovascular disease,Hypercholesterolemia,Sanofi,INDUSTRY,720,2,126,10,2012-08,2015-07,True,720,523,197,27.4,Adverse Event (64); Poor compliance to protocol (40); Last visit outside protocol visit window (30); Consent withdrawn by participant (21); Other than specified above (13); Participant moved (9); Death (7); Physician Decision (4); Related to auto-injector administration (4); Selection criteria finally not met (2); Site closure (2); Lost to Follow-up (1),Adverse Event,64.0,1
NCT01106651,A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2","Janssen Research & Development, LLC",INDUSTRY,716,3,86,17,2010-06,2013-05,True,714,520,194,27.2,Other (86); Adverse Event (49); Withdrawal by Subject (25); Lost to Follow-up (16); Physician Decision (8); Protocol Violation (4); Noncompliance with study drug (3); Death (3),Other,86.0,1
NCT01336023,"Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes",diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1663,3,302,20,2011-05-23,2012-11-22,True,1663,1211,319,27.2,Withdrawal Criteria (192); Unclassified (70); Adverse Event (50); Protocol Violation (6); Lack of Efficacy (1),Withdrawal Criteria,192.0,2
NCT00729430,Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging,cardiovascular disease,"Myocardial Infarction; Death, Sudden, Cardiac",Brigham and Women's Hospital,OTHER,358,2,1,1,2008-08,2014-07,True,358,261,0,27.1,,,,1
NCT01652716,Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",AstraZeneca,INDUSTRY,377,2,58,1,2013-01,2014-08,True,377,275,102,27.1,Withdrawal by Subject (51); Lost to Follow-up (23); Adverse Event (17); Investigator decision (5); Protocol Violation (3); Administrative (2); Loss of glucose control (1),Withdrawal by Subject,51.0,1
NCT02924064,Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Tanabe Pharma Corporation,INDUSTRY,247,2,1,1,2016-09,,True,247,180,67,27.1,Other (46); Withdrawal by Subject (9); Adverse Event (4); Protocol Violation (4); Lost to Follow-up (2); Physician Decision (2),Other,46.0,1
NCT01507831,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),cardiovascular disease,Hypercholesterolemia,Sanofi,INDUSTRY,2341,2,320,27,2012-01,2014-11,True,2341,1708,633,27.0,Last visit outside protocol visit window (194); Adverse Event (161); Consent withdrawn by participant (106); Poor compliance to protocol (98); Participant moved (24); Related to study drug administration (19); Other (9); Death (8); Physician Decision (4); Randomized but not treated (3); Site closure (3); Potential lost to follow-up (3); Selection criteria finally not met (1),Last visit outside protocol visit window,194.0,1
NCT00051168,A Long-term Safety Study of Once-daily Travatan,hypertension,"Glaucoma, Open-angle; Ocular Hypertension",Alcon Research,INDUSTRY,502,1,1,1,2006-01,,True,502,367,0,26.9,,,,1
NCT01644175,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I),cardiovascular disease,Hypercholesterolemia,Sanofi,INDUSTRY,316,2,76,1,2012-07,2014-04,True,316,231,85,26.9,Adverse Event (21); Poor compliance to protocol (19); Last visit outside protocol visit window (15); Consent withdrawn by participant (7); Site closure (4); Death (3); Physician Decision (3); Participant Moved (3); Related to Autoinjector Administration (3); Other than specified above (3); Randomized But Not Treated (2); Selection criteria finally not met (1); Lost to Follow-up (1),Adverse Event,21.0,1
NCT01194830,Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,234,2,93,1,2010-09,2011-10,True,234,171,63,26.9,Other Reason (20); Lost to Follow-up (16); Protocol Violation (9); Non-compliance issues (8); Adverse Event (5); Withdrawal by Subject (3); Lack of Efficacy (2),Other Reason,20.0,1
NCT01313676,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,cardiovascular disease,"Pulmonary Disease, Chronic Obstructive",GlaxoSmithKline,INDUSTRY,16568,4,1611,44,2011-01-25,2015-07-15,True,16568,12123,4445,26.8,Decision by Participant or Proxy (2177); Adverse Event (1465); Lack of Efficacy (299); Physician Decision (227); Protocol Violation (171); Investigator Site Closed (48); Study Closed/terminated (31); Met Protocol-Defined Stopping Critera (20); Sponsor Terminated Study Treatment (3); Missing (3); Lost to Follow-up (1),Decision by Participant or Proxy,2177.0,1
NCT01045707,"Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes",diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,530,2,92,9,2010-01,2010-10,True,530,388,104,26.8,Withdrawal Criteria (33); Unclassified (32); Protocol Violation (16); Adverse Event (14); Lack of Efficacy (6); Withdrawal criteria (3),Withdrawal Criteria,33.0,2
NCT03037931,Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study,cardiovascular disease,Heart Failure; Iron-deficiency,"American Regent, Inc.",INDUSTRY,3065,2,345,13,2017-03-15,2023-02-02,True,3065,2244,821,26.8,Death (721); Withdrawal by Subject (89); Lost to Follow-up (11),Death,721.0,1
NCT00220961,Actos Now for Prevention of Diabetes (ACT NOW),diabetes type 2,Impaired Glucose Tolerance; Type 2 Diabetes,The University of Texas Health Science Center at San Antonio,OTHER,602,2,8,1,2004-01,2010-04,True,602,441,0,26.7,,,,1
NCT02929329,Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction,cardiovascular disease,Heart Failure,Cytokinetics,INDUSTRY,8256,2,1033,36,2017-01-06,2020-09-14,True,8232,6036,2196,26.7,Death (2105); Lost to Follow-up (46); Withdrawal by Subject (45),Death,2105.0,1
NCT00830960,A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome,cardiovascular disease,Acute Coronary Syndrome,Eli Lilly and Company,INDUSTRY,720,6,19,4,2009-02,2010-06,True,719,528,191,26.6,Withdrawal by Subject (116); No study drug received (28); Sponsor Decision (22); Death (21); Lost to Follow-up (4),Withdrawal by Subject,116.0,1
NCT00412984,Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation,cardiovascular disease,Atrial Fibrillation; Atrial Flutter,Bristol-Myers Squibb,INDUSTRY,20976,2,1111,41,2006-12-31,2011-05-25,True,18201,13398,4803,26.4,Withdrawal by Subject (1910); Adverse Event (1417); Death (680); Subject No Longer Meets Study Criteria (187); Other Reason (172); Physician Refused to Continue Treatment (170); Poor/Noncompliance (134); Lost to Follow-up (90); Not Reported (23); Administrative Reason by Sponsor (19); Pregnancy (1),Withdrawal by Subject,1910.0,1
NCT00996281,Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension,cardiovascular disease,Essential Hypertension,Takeda,INDUSTRY,837,2,26,5,2009-10,2011-11,True,837,617,220,26.3,Adverse Event (112); Withdrawal by Subject (51); Lost to Follow-up (30); Major Protocol Deviation (13); Other (12); Lack of Efficacy (2),Adverse Event,112.0,1
NCT03689374,"A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes",diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,2274,2,210,21,2018-10-01,2021-02-22,True,2274,1681,593,26.1,Run-in failure (526); Withdrawal by Subject (48); Death (12); Lost to Follow-up (7),Run-in failure,526.0,2
NCT03064126,RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty,cardiovascular disease,"Peripheral Artery Disease; Atherosclerosis; Artery Diseases, Peripheral; Plaque, Atherosclerotic; Occlusive Arterial Disease",Boston Scientific Corporation,INDUSTRY,440,2,67,6,2017-03-02,2023-10-25,True,440,326,114,25.9,Death (62); Withdrawal by Subject (28); Lost to Follow-up (10); Other reason for early termination (5); Missed Visit (4); Physician Decision (3); Adverse Event (2),Death,62.0,1
NCT01676220,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy,diabetes type 2,Type 2 Diabetes Mellitus,Sanofi,INDUSTRY,878,2,217,16,2012-08,2014-03,True,878,651,227,25.9,Personal Reason (79); Received Rescue Therapy (36); Lost to Follow-up (29); Protocol Violation (23); Adverse Event (18); Selection Criterion/Protocol Violation (18); Lack of Efficacy (7); Randomized But Not Treated (5); Site Closure/Site Withdrawal (5); Perceived Lack of Efficacy (4); Non Serious Hypoglycemia (2); No More Need of Insulin (1),Personal Reason,79.0,1
NCT00902174,Imatinib (QTI571) in Pulmonary Arterial Hypertension,cardiovascular disease,Pulmonary Arterial Hypertension,Novartis Pharmaceuticals,INDUSTRY,202,2,95,14,2009-09,2011-05,True,202,150,52,25.7,Adverse Event (34); Lack of Efficacy (6); Death (4); Withdrawal by Subject (3); Abnormal labs (2); Protocol Violation (2); Administration problem (1),Adverse Event,34.0,1
NCT03814187,Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C,cardiovascular disease,ASCVD; Elevated Cholesterol; Heterozygous Familial Hypercholesterolemia; Homozygous Familial Hypercholesterolemia,Novartis Pharmaceuticals,INDUSTRY,3275,1,238,13,2019-04-16,2023-02-13,True,3275,2446,829,25.3,Sponsor's Administrative Decision (272); Death (165); Withdrew Consent (157); Lost to Follow-up (100); Other reasons (76); Adverse Event (45); Physician Decision (13); Initiation Of Protocol-Prohibited Approved PCSK9 Inhibitor (1),Sponsor's Administrative Decision,272.0,1
NCT00910429,BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension,cardiovascular disease,Pulmonary Hypertension,Bayer,INDUSTRY,237,1,73,26,2009-07-01,2019-08-19,True,237,177,60,25.3,Death (30); Adverse Event (15); Withdrawal by Subject (5); Lack of Efficacy (5); Lost to Follow-up (3); Protocol Violation (1); Drug non-compliance (1),Death,30.0,1
NCT00722371,MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,1615,7,0,0,2008-09-05,2011-03-25,True,1615,1207,408,25.3,Withdrawal by Subject (150); Lost to Follow-up (96); Adverse Event (56); Lack of Efficacy (27); Physician Decision (23); Hyperglycemia (21); Protocol Violation (15); Creatinine / Creatinine clearance (12); Excluded medication (3); Pregnancy (3); Contraindication (1); Hypoglycemia (1),Withdrawal by Subject,150.0,1
NCT01178073,A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH),cardiovascular disease,"Hypertension, Pulmonary",GlaxoSmithKline,INDUSTRY,610,3,143,14,2010-10-01,2014-07-31,True,605,453,152,25.1,Adverse Event (85); Physician Decision (34); Withdrawal by Subject (24); Lost to Follow-up (5); Protocol Violation (3); Missing Completion Status (1),Adverse Event,85.0,1
NCT00168298,A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion,cardiovascular disease,Macular Edema; Retinal Vein Occlusion,Allergan,INDUSTRY,668,3,13,13,2004-11-01,2008-09-05,True,668,500,0,25.1,,,,2
NCT00604383,Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study,diabetes type 2,Diabetic Retinopathy,"Chromaderm, Inc.",INDUSTRY,685,2,1,1,2001-03,2005-06,True,685,514,171,25.0,Withdrawal by Subject (64); Lost to Follow-up (43); Death (36); Adverse Event (25); Physician Decision (3),Withdrawal by Subject,64.0,1
NCT00712673,"GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",diabetes type 2,"Diabetes Mellitus, Type 2",Sanofi,INDUSTRY,680,4,16,16,2008-06,2011-03,True,680,511,169,24.9,Adverse Event (53); Withdrawal by Subject (48); Poor Compliance to Protocol (26); Lack of Efficacy (24); Familial and Personal Reasons (12); Lost to Follow-up (3); Protocol Violation (2); Investigator's Decision (1),Adverse Event,53.0,1
NCT02849080,Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,504,2,83,10,2016-09-20,2019-03-27,True,504,379,23,24.8,Lost to Follow-up (13); Withdrawal by Subject (7); Death (2); Other (1),Lost to Follow-up,13.0,2
NCT01620489,Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,279,2,97,6,2012-06-14,2013-08-20,True,279,210,69,24.7,Withdrawal Criteria (42); Adverse Event (21); Protocol Violation (3); Unclassified (3),Withdrawal Criteria,42.0,1
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,cardiovascular disease,Atrial Fibrillation; Percutaneous Coronary Intervention,"Janssen Scientific Affairs, LLC",INDUSTRY,2124,3,348,25,2013-05-10,2016-07-28,True,2124,1599,525,24.7,Adverse Event (244); Subject Decision (97); Other (66); Death (64); Physician Decision (28); Protocol Violation (17); Withdrawal by consent (9),Adverse Event,244.0,1
NCT00368277,"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly",cardiovascular disease,Hypertension,Novartis Pharmaceuticals,INDUSTRY,901,2,1,1,2006-09,2008-02,True,901,680,221,24.5,Adverse Event (82); Patient withdrew consent (60); Unsatisfactory therapeutic effect (55); Lost to Follow-up (14); Protocol deviation (7); Death (3),Adverse Event,82.0,1
NCT00624923,Targeting Inflammation Using Salsalate in CardioVascular Disease,cardiovascular disease,Coronary Artery Disease; Overweight,Joslin Diabetes Center,OTHER,340,2,5,1,2008-09,2016-07,True,251,190,0,24.3,,,,1
NCT00202878,IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103),cardiovascular disease,Hypercholesterolemia; Myocardial Infarction,Organon and Co,INDUSTRY,18144,2,0,0,2005-10-17,2014-09-18,True,18144,13728,4416,24.3,Death (1932); Withdrawal by Subject (1603); Only Vital Status Known (713); Lost to Follow-up (93); Site Closure (75),Death,1932.0,1
NCT00283686,HALT Progression of Polycystic Kidney Disease Study A,cardiovascular disease,"Kidney, Polycystic",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,558,4,7,1,2006-01,2014-06,True,558,423,135,24.2,Lost to Follow-up (98); Less than full participation (34); Death (3),Lost to Follow-up,98.0,1
NCT01999218,Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,1326,3,0,0,2013-12-16,2017-04-18,True,1326,1006,320,24.1,Withdrawal by Subject (91); Lost to Follow-up (57); Hyperglycemia (52); Study Terminated By Sponsor (24); Adverse Event (23); Protocol Violation (13); Non-Compliance With Study Drug (11); Physician Decision (11); Participant moves (10); Death (10); Treated but excluded at 1 trial site (10); Excluded Medication (4); Lack of Efficacy (2); Screen failure (1); Creatinine/eGFR (1),Withdrawal by Subject,91.0,1
NCT00571649,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,cardiovascular disease,Venous Thromboembolism,Bayer,INDUSTRY,8101,2,676,53,2007-12,2010-11,True,8101,6145,3169,24.1,Adverse Event (909); Withdrawal by Subject (774); Death (400); Patient convenience (281); Lost to Follow-up (271); Protocol Violation (199); Non-compliant with study medication (177); Clinical endpoint reached (113); Physician Decision (37); Technical problems (8),Adverse Event,909.0,2
NCT00457002,Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness,cardiovascular disease,Venous Thrombosis; Pulmonary Embolism,Bristol-Myers Squibb,INDUSTRY,6758,2,296,35,2007-06,2011-05,True,6528,4958,1570,24.1,Withdrawal by Subject (570); Adverse Event (544); Lost to Follow-up (143); Death (87); Poor/Non-compliance (79); No longer met criteria (78); non-specified (67); Administrative reason by Sponsor (1); treated for 1 day; missing status/reason (1),Withdrawal by Subject,570.0,1
NCT01098539,A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.,diabetes type 2,"Diabetes Mellitus, Type 2",GlaxoSmithKline,INDUSTRY,507,2,218,15,2010-05,2012-11,True,495,376,119,24.0,Adverse Event (52); Withdrawal by Subject (38); Noncompliance (8); Lost to Follow-up (8); Physician Decision (8); Protocol Violation (5),Adverse Event,52.0,1
NCT00827606,Atorvastatin Three Year Pediatric Study,dyslipidemia,Familial Hypercholesterolemia,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,272,1,40,15,2009-03,2013-10,True,271,206,65,24.0,Other (18); LDL below 2.59 mmol/L (16); Withdrawal by Subject (13); Protocol Violation (7); Adverse Event (6); Lost to Follow-up (4); Pregnancy (1),Other,18.0,1
NCT01046110,Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,458,2,93,7,2010-01,2010-11,True,458,348,110,24.0,Unclassified (71); Protocol Violation (19); Adverse Event (11); Withdrawal Criteria (8); Lack of Efficacy (1),Unclassified,71.0,1
NCT00094302,Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function,cardiovascular disease,"Cardiovascular Diseases; Heart Diseases; Heart Failure, Congestive",Carelon Research,OTHER,3445,2,270,6,2006-08,2013-06,True,3445,2622,823,23.9,Death (512); Withdrawal by Subject (214); Lost to Follow-up (84); Physician Decision (13),Death,512.0,1
NCT01396083,Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO),cardiovascular disease,Visual Impairment; Macular Edema; Central Retinal Vein Occlusion,Novartis Pharmaceuticals,INDUSTRY,243,2,64,4,2011-08,2014-01,True,243,185,58,23.9,Adverse Event (30); Unsatisfactory therapeutic effect (15); Consent withdrawn (9); Protocol deviation(s) (1); Abnormal laboratory value(s) (1); Administrative problems (1); Lost to Follow-up (1),Adverse Event,30.0,1
NCT02419612,"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone",diabetes type 2,Diabetes,AstraZeneca,INDUSTRY,444,2,84,10,2015-08-14,2019-09-18,True,444,338,84,23.9,Withdrawal by Subject (28); Lost to Follow-up (22); Other (8); Adverse Event (7); Subject Decision (6); Non-compliance with Study Drug (4); Death (3); Subject Request To Discontinue Treatment (2); Lack of Efficacy (2); Worsening of liver function (1); Subject moved out of state (1),Withdrawal by Subject,28.0,2
NCT03199053,Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old,diabetes type 2,"Diabetes Mellitus, Type 2",AstraZeneca,INDUSTRY,256,5,122,23,2017-10-11,2024-01-03,True,245,187,53,23.7,Withdrawal by Subject (22); Lost to Follow-up (17); Withdrawal by parent/guardian (11); Miscellaneous (3),Withdrawal by Subject,22.0,3
NCT02023879,Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II),dyslipidemia,Hypercholesterolemia,Sanofi,INDUSTRY,233,3,43,8,2013-12-16,2017-06-30,True,233,178,49,23.6,Adverse Event (20); Other than specified above (16); Poor compliance to protocol (5); Participant moved (3); Consent withdrawn by participant (2); Randomized but not treated (2); Physician Decision (1),Adverse Event,20.0,2
NCT00839527,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",GlaxoSmithKline,INDUSTRY,685,3,358,9,2009-02,2013-04,True,663,507,443,23.5,Withdrawal by Subject (194); Lost to Follow-up (79); Adverse Event (66); Noncompliance (33); Termination of Study by Sponsor (18); Termination of Site by Sponsor (16); Protocol Violation (12); Physician Decision (9); Site Closed (4); Pregnancy (2); Site Closing and Withdrew Consent (2); Missing Follow-up Status (2); Missing (1); Persistant Elevated HbA1c Results (1); Sponsor Decision on Blinding (1); Informed Consent Recalled by Participant (1); Investigator Closed Study at Site (1); Unable to Complete Follow-up (1),Withdrawal by Subject,194.0,2
NCT01078675,An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia,dyslipidemia,Familial Hypercholesterolaemia,AstraZeneca,INDUSTRY,315,1,15,5,2010-02,2013-02,True,315,241,74,23.5,Protocol Violation (56); Withdrawal by Subject (10); Provided in CRF for specific reasons (5); Adverse Event (3),Protocol Violation,56.0,1
NCT00719563,American Ginseng in Treating Patients With Fatigue Caused by Cancer,cardiovascular disease,"Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific",Alliance for Clinical Trials in Oncology,OTHER,364,2,326,1,2008-10,2013-08,True,341,261,80,23.5,Adverse Event (29); Personal reasons (13); Lack of Efficacy (10); Unknown reasons (10); Medical condition changed (8); Lost to Follow-up (8); Noncompliant (2),Adverse Event,29.0,1
NCT04660643,A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss,diabetes type 2,Obesity; Overweight,Eli Lilly and Company,INDUSTRY,783,3,70,5,2021-03-29,2023-05-18,True,783,600,182,23.4,Withdrawal by Subject (67); Adverse Event (50); Lost to Follow-up (32); Protocol deviation (13); Other - as reported by the investigator (10); Pregnancy (4); Death (3); Physician Decision (1); Covid-19 (1); Perceived excessive weight loss (1),Withdrawal by Subject,67.0,2
NCT00286455,Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes,diabetes type 2,Diabetes Mellitus,Takeda,INDUSTRY,329,3,67,18,2006-02,2007-07,True,329,252,77,23.4,Hyperglycemia rescue (42); Withdrawal by Subject (15); Adverse Event (6); Lost to Follow-up (6); Physician Decision (5); Protocol Violation (2); Participant Non-compliance (1),Hyperglycemia rescue,42.0,1
NCT00168324,A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion,cardiovascular disease,Macular Edema; Retinal Vein Occlusion,Allergan,INDUSTRY,599,3,13,13,2004-10-01,2008-10-01,True,599,459,0,23.4,,,,2
NCT00618956,A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring,cardiovascular disease,Fibromyalgia,Forest Laboratories,INDUSTRY,321,2,38,1,2007-10,,True,321,246,75,23.4,"Adverse Event (44); Withdrawal by Subject (12); Lost to Follow-up (9); Protocol Violation (4); Lack of Efficacy (3); did not meet criteria, non-compliance (3)",Adverse Event,44.0,1
NCT00961636,A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102),dyslipidemia,Dyslipidemia,Merck Sharp & Dohme LLC,INDUSTRY,1152,3,0,0,2009-10,2011-01,True,1152,882,270,23.4,Adverse Event (102); Flushing Symptoms (78); Withdrawal by Subject (64); Protocol Violation (15); Lost to Follow-up (6); Physician Decision (5),Adverse Event,102.0,1
NCT03860935,Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy,cardiovascular disease,Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis; Cardiomyopathies; Heart Diseases,"Eidos Therapeutics, a BridgeBio company",INDUSTRY,632,2,104,18,2019-03-19,2023-05-11,True,632,485,147,23.3,Death (126); Withdrawal of Consent (21),Death,126.0,1
NCT00413413,Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension,cardiovascular disease,Hypertension,Novartis Pharmaceuticals,INDUSTRY,1134,3,19,1,2007-01,2007-11,True,1134,871,263,23.2,Subject no longer requires study drug (151); Withdrawal by Subject (27); Adverse Event (20); Subject withdrew consent (19); Lost to Follow-up (17); Protocol Violation (16); Lack of Efficacy (5); Unsatisfactory therapeutic effect (4); Protocol deviation (4),Subject no longer requires study drug,151.0,2
NCT00622284,Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,1560,2,221,16,2008-02,,True,1551,1191,360,23.2,Adverse Event (151); Lack of Efficacy (60); Other reason (not specified) (57); Withdrawal by Subject (51); Lost to Follow-up (24); Protocol Violation (17),Adverse Event,151.0,1
NCT02546323,A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis,cardiovascular disease,Atherosclerosis,AstraZeneca,INDUSTRY,543,2,24,1,2015-09-17,2019-01-29,True,543,417,126,23.2,Withdrawal by Subject (69); Adverse Event (28); Met Withdrawal Criteria (16); Lost to Follow-up (5); Non-compliance with Study Drug (4); Patient Specific Reasons (3); Eligibility Criteria not Fulfilled (1),Withdrawal by Subject,69.0,1
NCT02648347,Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease,cardiovascular disease,Anemia; Non-Dialysis-Dependent Chronic Kidney Disease,Akebia Therapeutics,INDUSTRY,1751,2,439,20,2015-12,2020-07-31,True,1751,1345,406,23.2,Death (341); Lost to Follow-up (39); Withdrawal by Subject (25); Missing (1),Death,341.0,1
NCT01087502,Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,241,3,52,9,2010-03,,True,241,185,73,23.2,Adverse Event (36); Other reason not described above (12); Withdrawal by Subject (7); Protocol Violation (6); Study site excluded from analysis (6); Lack of Efficacy (4); Lost to Follow-up (2),Adverse Event,36.0,2
NCT00143598,The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome,cardiovascular disease,Deep Venous Thrombosis,Sir Mortimer B. Davis - Jewish General Hospital,OTHER,806,2,25,2,2004-06,2012-02,True,806,620,186,23.1,Death (72); Withdrawal by Subject (70); Lost to Follow-up (44),Death,72.0,1
NCT03785405,Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF,cardiovascular disease,Heart Failure,Novartis Pharmaceuticals,INDUSTRY,216,1,79,27,2019-05-02,2023-12-29,True,216,166,50,23.1,Adverse Event (17); Physician Decision (13); Death (10); Guardian decision (5); Participant decision (2); Lost to Follow-up (1); Other (1); No treatment was received (1),Adverse Event,17.0,1
NCT01557166,Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea,obesity,Metabolism and Nutrition Disorder; Obesity; Obstructive Sleep Apnoea,Novo Nordisk A/S,INDUSTRY,359,2,42,2,2012-06-07,2013-06-17,True,359,276,83,23.1,Withdrawn consent (32); Adverse Event (26); Protocol Violation (13); Unclassified (7); Lack of Efficacy (3); Target dose not tolerated (1); Psychiatric disorder (1),Withdrawn consent,32.0,1
NCT01106690,The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone),diabetes type 2,"Diabetes Mellitus, Type 2","Janssen Research & Development, LLC",INDUSTRY,344,3,83,11,2010-06,2012-07,True,342,263,72,23.1,Other (33); Adverse Event (13); Withdrawal by Subject (6); Lost to Follow-up (5); Creatinine or eGFR withdrawal criteria (4); Physician Decision (4); Unable to take rescue therapy (3); Noncompliance with study drug (2); Protocol Violation (1); Lack of efficacy on rescue therapy (1),Other,33.0,2
NCT02963935,Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting,obesity,Metabolism and Nutrition Disorder; Obesity,Novo Nordisk A/S,INDUSTRY,282,2,10,1,2017-02-06,2018-06-19,True,282,217,65,23.0,Unclassified (35); Adverse Event (18); Lost to Follow-up (7); Protocol Violation (3); Lack of Efficacy (2),Unclassified,35.0,1
NCT02541383,A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma,cardiovascular disease,Multiple Myeloma,Intergroupe Francophone du Myelome,NETWORK,1085,4,107,3,2015-09,2023-09-01,True,1085,835,250,23.0,Death (222); Lost to Follow-up (13); Consent withdrawn (13); Sponsor's decision (2),Death,222.0,1
NCT01064414,"An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment",diabetes type 2,"Diabetes Mellitus, Type 2; Renal Insufficiency","Janssen Research & Development, LLC",INDUSTRY,272,3,106,18,2010-06,2012-08,True,269,207,57,23.0,Other (21); Adverse Event (15); Withdrawal by Subject (10); Protocol Violation (5); Death (2); Noncompliance with study drug (2); Lost to Follow-up (1); Physician Decision (1),Other,21.0,2
NCT02861534,A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001),cardiovascular disease,Heart Failure; Chronic Heart Failure With Reduced Ejection Fraction,Merck Sharp & Dohme LLC,INDUSTRY,5050,2,0,0,2016-09-20,2019-09-02,True,5050,3889,1161,23.0,Death (1093); Withdrawal by Subject (33); Lost to Follow-up (28); Site Terminated by Sponsor (7),Death,1093.0,1
NCT04184622,A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight,diabetes type 2,Overweight; Obesity,Eli Lilly and Company,INDUSTRY,2539,4,118,10,2019-12-04,2024-07-06,True,2539,1961,578,22.8,Withdrawal by Subject (243); Lost to Follow-up (131); Other - as reported by the investigator (81); Adverse Event (67); Pregnancy (23); Death (13); Missing Weight at Week 176 (9); Physician Decision (7); Protocol deviation (2); Site closed (2),Withdrawal by Subject,243.0,3
NCT01370616,Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061),cardiovascular disease,Infection; Diabetic Foot,Merck Sharp & Dohme LLC,INDUSTRY,565,2,0,0,2011-09-02,2013-12-18,True,565,436,129,22.8,Withdrawal by Subject (68); Adverse Event (27); Physician Decision (12); Lack of Efficacy (8); Technical Problems (8); Lost to Follow-up (3); Death (1); Progressive Disease (1); Recovery (1),Withdrawal by Subject,68.0,1
NCT01964326,Actual Use Trial of Atorvastatin Calcium 10 mg,dyslipidemia,Hypercholesterolemia,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,1311,1,37,1,2013-10,2014-12,True,1311,1014,297,22.7,Lost to Follow-up (88); Withdrawal by Subject (87); Physician Decision (55); Adverse Event (48); Other (9); Protocol Violation (4); Death (2); Pregnancy (1); No Longer Meets Eligibility Criteria (1); Investigator Discretion (1); Did not meet eligibility criteria (1),Lost to Follow-up,88.0,1
NCT00849017,Safety and Efficacy Study of Albiglutide in Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",GlaxoSmithKline,INDUSTRY,309,3,262,3,2009-01,2013-02,True,301,233,186,22.6,Lost to Follow-up (66); Withdrawal by Subject (52); Adverse Event (27); Noncompliance (13); Termination of Study/ Site by GSK (10); Did Not Enter Follow-up Period (6); Physician Decision (5); Pregnancy (2); Increased Calcitonin (1); Physician Discontinued-Thrombocytopenia (1); Participant Moved to Africa (1); Participant Decided to Move Out of State (1); Participant Relocating to Africa (1),Lost to Follow-up,66.0,2
NCT01167881,Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,1549,2,182,23,2010-08,2015-08,True,1549,1199,350,22.6,"Adverse Event (98); Other not defined above (86); Patient refusal to cont., not due to AE (85); Lost to Follow-up (39); Non compliant with protocol (27); Lack of Efficacy (11); Not treated (4)",Adverse Event,98.0,1
NCT01623115,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy,dyslipidemia,Hypercholesterolemia,Sanofi,INDUSTRY,486,2,91,14,2012-07,2014-12,True,486,376,110,22.6,Last visit outside protocol visit window (40); Adverse Event (23); Poor compliance to protocol (14); Consent withdrawn by participant (8); Site closure (8); Participants moved (6); Death (4); Other than specified above (3); Related to study drug administration (2); Randomized but not treated (1); Physician Decision (1),Last visit outside protocol visit window,40.0,1
NCT04157751,A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure,cardiovascular disease,Heart Failure,Boehringer Ingelheim,INDUSTRY,530,2,118,15,2020-05-18,2021-06-02,True,530,410,120,22.6,Adverse Event (57); Withdrawal by Subject (29); Other reason not stated above (20); Lost to Follow-up (8); Not treated (6),Adverse Event,57.0,1
NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,cardiovascular disease,Myocardial Infarction,"Cardiovascular Research Foundation, New York",OTHER,3602,2,1,1,2005-03,2010-11,True,3602,2790,556,22.5,Lost to Follow-up (360); Withdrawal by Subject (139); Not true myocardial infarction (57),Lost to Follow-up,360.0,2
NCT00484198,Study of Rivoglitazone in Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Daiichi Sankyo,INDUSTRY,1912,4,183,18,2007-04-23,2009-02-12,True,1912,1482,430,22.5,Participant Withdrew Consent (139); Hyperglycemia Meeting Discontinuation Criteria (100); Adverse Event (77); Other (76); Therapeutic failure/ lack of efficacy (19); Protocol Violation (19),Participant Withdrew Consent,139.0,1
NCT01499095,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy,diabetes type 2,Type 2 Diabetes Mellitus,Sanofi,INDUSTRY,811,2,213,13,2011-12,2013-11,True,811,629,182,22.4,Received Rescue Therapy (72); Diverse Reasons (47); Adverse Event (19); Protocol Violation (13); Lost to Follow-up (10); Insulin Dropped Below Authorized Dose (5); Hypoglycemia (4); Lack of Efficacy (3); Diagnosed With Type 1 Diabetes Mellitus (3); Randomized But Not Treated (2); Change in Injection Schedule (2); Perceived Lack of Efficacy (2),Received Rescue Therapy,72.0,1
NCT04509674,EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction),cardiovascular disease,Myocardial Infarction,Boehringer Ingelheim,INDUSTRY,6522,2,439,22,2020-12-16,2023-11-05,True,6522,5063,1459,22.4,"Patient refusal to continue, not due to adverse event (870); Adverse event, non-fatal event (225); Other reason than listed (201); Lost to Follow-up (70); Not treated (59); Protocol Violation (19); Adverse event, serious fatal event (15)","Patient refusal to continue, not due to adverse event",870.0,1
NCT01023581,Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Takeda,INDUSTRY,784,7,201,13,2009-11,2011-06,True,784,609,175,22.3,Withdrawal by Subject (66); Adverse Event (36); Lost to Follow-up (30); Lack of Efficacy (24); Physician Decision (8); Major protocol deviation (5); Pregnancy (3); Other (3),Withdrawal by Subject,66.0,1
NCT02427802,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,cardiovascular disease,"Foot Ulcer, Diabetic; Infection",Innocoll,INDUSTRY,612,3,86,1,2015-05,2016-10,True,612,476,136,22.2,protocol specific treatment unrelated (40); Lost to Follow-up (29); Withdrawal by Subject (26); Adverse Event (21); Physician Decision (10); Death (5); Protocol Violation (5),protocol specific treatment unrelated,40.0,1
NCT00689611,Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial,cardiovascular disease,Acute Coronary Syndrome; Myocardial Infarction; Smoking,Mark Eisenberg,OTHER,392,2,38,7,2005-12,2010-06,True,392,305,87,22.2,Lost to Follow-up (55); Withdrawal by Subject (17); Death (15),Lost to Follow-up,55.0,1
NCT00797862,Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension,cardiovascular disease,Hypertension,Novartis,INDUSTRY,1254,3,10,10,2008-11,2010-11,True,1254,976,278,22.2,Adverse Event (188); Withdrawal by Subject (28); Protocol Violation (18); Lost to Follow-up (16); Lack of Efficacy (14); Mis-randomized (7); Administrative Problem (4); Abnormal Test Procedure Result (2); No longer required study medication (1),Adverse Event,188.0,1
NCT00286494,Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,Diabetes Mellitus,Takeda,INDUSTRY,493,3,77,14,2006-02,2007-08,True,493,384,109,22.1,Hyperglycemic rescue (49); Withdrawal by Subject (21); Adverse Event (17); Physician Decision (11); Lost to Follow-up (7); Protocol Violation (4),Hyperglycemic rescue,49.0,1
NCT01442038,Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI),cardiovascular disease,Coronary Artery Disease; Angina Pectoris,Gilead Sciences,INDUSTRY,2651,2,218,15,2011-10,2015-02,True,2651,2069,582,22.0,Participant Withdrew Consent (239); Lost to Follow-up (88); Investigator-Initiated Early Closure (87); Death (64); Adverse Event (41); Protocol Deviation (29); Investigator's Discretion (29); Study Terminated By Sponsor (5),Participant Withdrew Consent,239.0,1
NCT00740051,"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate",diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,227,3,53,7,2008-08,,True,227,177,50,22.0,Withdrawal by Subject (14); Lost to Follow-up (11); Protocol Violation (8); Lack of Efficacy (7); Adverse Event (5); Other reason (not specified) (5),Withdrawal by Subject,14.0,1
NCT03096314,Vitamin D to Improve Outcomes by Leveraging Early Treatment,metabolic syndrome,Acute Respiratory Distress Syndrome; Vitamin D Deficiency; Critical Illness,Massachusetts General Hospital,OTHER,1358,2,47,1,2017-04-27,2018-12-11,True,1358,1059,21,22.0,Lost to Follow-up (21),Lost to Follow-up,21.0,2
NCT00660907,Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,1217,2,76,10,2008-03,2013-01,True,814,636,178,21.9,Withdrawal by Subject (55); Adverse Event (52); Subject No Longer Meets Study Criteria (33); Various (19); Lost to Follow-up (6); Poor/Non-Compliance (6); Death (4); Incorrect Enrollment (2); Safety (1),Withdrawal by Subject,55.0,1
NCT00637273,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,514,3,62,3,2008-01,2009-07,True,514,402,112,21.8,Withdrawal of Consent (42); Lost to Follow-up (30); Adverse Event (23); Protocol Violation (7); Investigator Decision (5); Loss of Glucose Control (3); Administrative (2),Withdrawal of Consent,42.0,1
NCT00116831,Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes,diabetes type 2,Atherosclerosis,GlaxoSmithKline,INDUSTRY,672,2,156,20,2005-01,2008-08,True,668,523,145,21.7,Withdrawal by Subject (64); Adverse Event (30); Baseline IVUS determined unevaluable (23); Lost to Follow-up (14); Protocol Violation (9); Hypoglycaemic events (1); Low haemoglobin on screening (1); Withdrawn investigational product (1); Insufficient therapeutic effect (1); Missing data for participant (1),Withdrawal by Subject,64.0,1
NCT00763451,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",diabetes type 2,"Diabetes Mellitus, Type 2",Sanofi,INDUSTRY,484,4,15,15,2008-09,2011-01,True,484,379,105,21.7,Adverse Event (43); Withdrawal by Subject (23); Familial and Personal Reasons (17); Lack of Efficacy (10); Poor Compliance to Protocol (6); Study Site Reason (3); Randomized but not Treated (2); Protocol Violation (1),Adverse Event,43.0,1
NCT00286442,Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus,diabetes type 2,Diabetes Mellitus,Takeda,INDUSTRY,527,3,56,17,2006-03,2007-06,True,527,413,114,21.6,Hyperglycemic Rescue (61); Withdrawal by Subject (18); Adverse Event (14); Protocol Violation (8); Lost to Follow-up (8); Physician Decision (3); Administrative Error (2),Hyperglycemic Rescue,61.0,1
NCT00395512,Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,Diabetes Mellitus,Takeda,INDUSTRY,655,4,161,23,2006-11,2008-02,True,655,514,141,21.5,Hyperglycemic Rescue (38); Withdrawal by Subject (28); Adverse Event (23); Protocol Violation (18); Lost to Follow-up (18); Physician Decision (14); Other (2),Hyperglycemic Rescue,38.0,1
NCT00894387,"Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure",cardiovascular disease,Acute Decompensated Heart Failure; Congestive Heart Failure,Novartis Pharmaceuticals,INDUSTRY,1639,2,308,24,2009-05,2012-08,True,1639,1289,350,21.4,Death (153); Adverse Event (89); Patient's request (55); Mis-randomized (22); Lost to Follow-up (8); Other (Missing) (8); Abnormal Laboratory values (4); Administrative problems (4); Protocol Deviation (4); GCP non-compliance (2); Unsatisfactory therapeutic effect (1),Death,153.0,1
NCT02558374,Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension,hypertension,Open-angle Glaucoma; Ocular Hypertension,Aerie Pharmaceuticals,INDUSTRY,708,2,1,1,2015-09,2016-12,True,708,557,0,21.3,,,,1
NCT00541450,A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,492,2,0,0,2008-01-15,2010-01-16,True,492,387,105,21.3,Withdrawal by Subject (28); Hyperglycemia (20); Lost to Follow-up (20); Adverse Event (15); Protocol Violation (11); Physician Decision (8); Creatinine/CrCl -Increase in creatinine (2); Pregnancy (1),Withdrawal by Subject,28.0,2
NCT00789750,Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Daiichi Sankyo,INDUSTRY,562,2,141,1,2009-04,2012-07,True,562,443,0,21.2,,,,1
NCT01791153,An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA),cardiovascular disease,Giant Cell Arteritis,Hoffmann-La Roche,INDUSTRY,251,5,78,14,2013-07-22,2018-06-04,True,250,197,52,21.2,Withdrawal by Subject (18); Adverse Event (16); Lack of Efficacy (9); Physician Decision (3); Death (3); Non-Compliance (1); Protocol Violation (1); Lost to Follow-up (1),Withdrawal by Subject,18.0,2
NCT00321919,A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia,cardiovascular disease,Anemia,Hoffmann-La Roche,INDUSTRY,605,2,93,22,2000-07,2004-12,True,603,476,127,21.1,Death (38); Refused Treatment (37); Adverse Event (27); Other withdrawal reason (13); Other Protocol Violation (5); Failure to Return (4); Violation of Selection Criteria at Entry (2); Insufficient Therapeutic Response (1),Death,38.0,1
NCT00509262,Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1),diabetes type 2,"Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic",Merck Sharp & Dohme LLC,INDUSTRY,426,2,0,0,2007-10-09,2011-03-16,True,423,334,89,21.0,Withdrawal by Subject (35); Adverse Event (34); Lost to Follow-up (7); Other (4); Physician Decision (4); Protocol Violation (4); Lack of Efficacy (1),Withdrawal by Subject,35.0,1
NCT03541174,A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety,hypertension,Resistant Hypertension,Idorsia Pharmaceuticals Ltd.,INDUSTRY,730,6,159,20,2018-06-18,2022-04-25,True,730,577,154,21.0,"Other reasons (55); Adverse Event (53); Withdrawal by Subject (29); Lost to Follow-up (9); Death (5); Lack of Efficacy (1); Pregnancy (1); Re-randomized in part 3, however no drug dispensed (1)",Other reasons,55.0,3
NCT00838903,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",GlaxoSmithKline,INDUSTRY,1049,4,386,11,2009-02,2013-04,True,1012,799,597,21.0,Withdrawal by Subject (184); Lost to Follow-up (128); Adverse Event (64); Noncompliance (60); Subject Withdrawn from Follow-up (49); Termination of Study/Site by GSK (34); Did Not Enter Follow-up Period (31); Protocol Violation (18); Physician Decision (10); Missing (5); Subject Migrated to Other Country (2); Severe or Repeated Hypoglycaemia (1); Patient and PI Decision to Discontinue (1); Poor Glycemic Control (1); Poor Therapeutic Response (1); Pregnancy (1); PI Decided for Safety Purpose (1); Site closed (1); Site Closed and Subject Withdrew Consent (1); Missing Active Treatment Status (1); ICF Withdrawn (1); Investigator Stopped Study at Site (1); Subject Moved out of Town (1),Withdrawal by Subject,184.0,2
NCT01890122,Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes,diabetes type 2,Diabetes Mellitus,Takeda,INDUSTRY,647,4,45,4,2013-09,2015-10,True,647,511,136,21.0,Lack of Efficacy (86); Voluntary Withdrawal (29); Adverse Event (5); Major Protocol Deviation (5); Lost to Follow-up (5); Reason not Specified (4); Randomized but not Treated (2),Lack of Efficacy,86.0,1
NCT00660179,Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension,hypertension,Pulmonary Arterial Hypertension,Actelion,INDUSTRY,742,3,153,38,2008-05,2012-04,True,742,587,155,20.9,Death (125); Withdrawal of consent (14); Lost to Follow-up (14); Administrative reason (1); Incorrect randomization (1),Death,125.0,1
NCT02630316,Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE,cardiovascular disease,Pulmonary Hypertension; Interstitial Lung Disease; Combined Pulmonary Fibrosis and Emphysema,United Therapeutics,INDUSTRY,326,2,97,2,2017-02-03,2019-12-26,True,326,258,0,20.9,,,,1
NCT03354273,An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD),cardiovascular disease,Coronary Artery Disease (CAD),GE Healthcare,INDUSTRY,730,1,53,7,2018-06-05,2022-05-05,True,730,578,152,20.8,Withdrawal by Subject (34); Technical Problems (30); Screen Failure (21); Investigational Medicinal Product (IMP) Supply Issues (21); Issues With Performing Invasive Coronary Angiography (ICA) (20); COVID-19 Restrictions (9); Adverse Event (5); Other (5); Lost to Follow-up (4); Investigator Decision (3),Withdrawal by Subject,34.0,1
NCT03514641,An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension,cardiovascular disease,Essential Hypertension,Theracos,INDUSTRY,673,4,87,1,2017-10-18,2018-11-30,True,673,533,76,20.8,Lost to Follow-up (31); Withdrawal by Subject (17); Adverse Event (11); Protocol Violation (8); 24 hr ABPM not enough readings (7); Physician Decision (1); Lack of Efficacy (1),Lost to Follow-up,31.0,2
NCT00131664,Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study),diabetes type 2,Type 2 Diabetes Mellitus,Canadian Heart Research Centre,OTHER,391,3,1,1,2005-09,2008-01,True,391,310,81,20.7,Lost to Follow-up (21); Adverse Event (20); Withdrawal by Subject (14); Administrative reasons (14); Protocol Violation (7); Clinically significant lab abnormalities (4); Death (1),Lost to Follow-up,21.0,2
NCT00328627,Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.,diabetes type 2,Type 2 Diabetes Mellitus,Takeda,INDUSTRY,1554,12,90,19,2006-05,2008-03,True,1554,1232,322,20.7,Hyperglycemic Rescue (146); Withdrawal by Subject (53); Protocol Violation (45); Adverse Event (31); Lost to Follow-up (23); Physician Decision (19); Other (4); Pregnancy (1),Hyperglycemic Rescue,146.0,1
NCT01076075,A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,427,2,0,0,2010-06-03,2012-01-19,True,427,339,88,20.6,other (28); Withdrawal by Subject (27); Adverse Event (12); Lost to Follow-up (11); Lack of Efficacy (9); Protocol Violation (1),other,28.0,1
NCT02866175,Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention,cardiovascular disease,Atrial Fibrillation,"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company",INDUSTRY,1506,2,200,18,2017-02-24,2019-06-06,True,1506,1196,310,20.6,Adverse Event (110); Withdrawal by Subject (83); Death (53); Other (21); Did not receive treatment (20); Physician Decision (18); Progressive disease (2); Lost to Follow-up (2); Lack of Efficacy (1),Adverse Event,110.0,1
NCT02558231,The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension,hypertension,Pulmonary Arterial Hypertension,Actelion,INDUSTRY,247,2,58,15,2016-05-01,2020-04-20,True,247,196,51,20.6,Death (16); Physician Decision (12); Lost to Follow-up (11); Withdrawal by Subject (11); Sponsor Decision (1),Death,16.0,1
NCT01297920,Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%,hypertension,Open-Angle Glaucoma; Ocular Hypertension,Alcon Research,INDUSTRY,1062,3,0,0,2011-03,2012-06,True,690,548,142,20.6,Adverse Event (90); Inadequate Control of IOP (33); Patient Decision Unrelated to AE (13); Protocol Violation (4); Noncompliance (1); Patient Did Not Meet Entrance Criteria (1),Adverse Event,90.0,1
NCT01406717,Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Sun Pharmaceutical Industries Limited,INDUSTRY,360,2,34,1,2013-03-01,2015-11-04,True,360,286,74,20.6,Withdrawal by Subject (34); Lost to Follow-up (22); Subject non-compliance (7); Protocol Violation (6); Adverse Event (3); Lack of Efficacy (1); Non-completion of visit activity (1),Withdrawal by Subject,34.0,1
NCT01106677,The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial),diabetes type 2,"Diabetes Mellitus, Type 2","Janssen Research & Development, LLC",INDUSTRY,1284,4,125,22,2010-05,2012-05,True,1284,1020,248,20.6,Other (77); Adverse Event (55); Withdrawal by Subject (36); Lost to Follow-up (19); Creatinine or eGFR withdrawal criteria (19); Physician Decision (17); Lack of Efficacy (7); Protocol Violation (5); Noncompliance with study drug (4); Study terminated by sponsor (3); Death (2); Product quality complaint (2); Pregnancy (1); Unable to take rescue therapy (1),Other,77.0,2
NCT00234832,A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients,cardiovascular disease,Obesity,Abbott,INDUSTRY,10777,3,1,1,2003-01,2009-11,True,9804,7792,0,20.5,,,,1
NCT02017171,A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes,cardiovascular disease,Diabetic Nephropathies; Coronary Artery Disease,Alessandro Doria,OTHER,530,2,30,3,2014-02,2019-08-31,True,530,422,108,20.4,Lost to Follow-up (41); Withdrawal by Subject (40); Death (14); ESKD (8); Miscellaneous (5),Lost to Follow-up,41.0,1
NCT00440193,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study,cardiovascular disease,Venous Thrombosis,Bayer,INDUSTRY,3449,2,324,34,2007-03,2010-04,True,3449,2749,739,20.3,Study terminated by sponsor (196); Adverse Event (145); Withdrawal by Subject (132); Death (76); Clinical endpoint reached (54); Lost to Follow-up (50); Protocol Violation (36); Participant did not receive treatment (20); Physician Decision (10); Participant convenience (9); Protocol driven decision point (4); Switch to commercial drug (2); Technical problems (2); Site closed by investigator (2); Lack of Efficacy (1),Study terminated by sponsor,196.0,2
NCT00139659,A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma,diabetes type 2,Asthma; Diabetes Mellitus,Pfizer,INDUSTRY,288,2,102,5,2003-01,2008-10,True,287,229,58,20.2,Withdrawal by Subject (24); Adverse Event (13); Lost to Follow-up (10); Reason not Specified (9); Lack of Efficacy (2),Withdrawal by Subject,24.0,1
NCT00151775,Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure,cardiovascular disease,Hypertension,Daiichi Sankyo,INDUSTRY,362,3,65,11,2005-05,2008-09,True,362,289,72,20.2,Lost to Follow-up (28); Withdrawal by Subject (8); Non-compliance with protocol (8); Adverse Event (7); Other (7); Protocol Violation (6); Physician Decision (3); Increased blood pressure (2); non-compliance (1); The blood pressure goal was met (1); Met blood pressure goal (1),Lost to Follow-up,28.0,3
NCT01698775,A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,213,2,0,0,2012-10-02,2016-01-19,True,213,170,43,20.2,Withdrawal by Subject (15); Adverse Event (12); Lost to Follow-up (4); Death (3); Protocol Violation (3); Lack of Efficacy (2); Physician Decision (2); Kidney [transplant] (1); Hyperglycemia Discontinuation Criteria (1),Withdrawal by Subject,15.0,2
NCT00090519,Reduction in the Occurrence of Center-Involved Diabetic Macular Edema,cardiovascular disease,Diabetic Retinopathy,"Chromaderm, Inc.",INDUSTRY,731,2,84,17,2004-02,2010-04,True,731,583,148,20.2,Withdrawal by Subject (57); Lost to Follow-up (55); Death (18); Adverse Event (9); Physician Decision (5); Sponsor Decision (4),Withdrawal by Subject,57.0,1
NCT00770653,Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.,diabetes type 2,Diabetes Mellitus; Dyslipidemias,Takeda,INDUSTRY,305,2,64,1,2007-04,2009-05,True,305,244,61,20.0,Adverse Event (18); Protocol Violation (14); Withdrawal by Subject (11); Lack of Compliance (5); Worsening of Glycosolated Hemoglobin (4); Fasting Glucose > 240 mg/dL (3); Lost to Follow-up (3); > Three Moderate Hypoglycemic Episodes (2); Physician Decision (1),Adverse Event,18.0,1
NCT02892149,Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD),cardiovascular disease,Anemia; Dialysis-Dependent Chronic Kidney Disease,Akebia Therapeutics,INDUSTRY,3554,2,278,18,2016-08,2020-03-30,True,3554,2846,708,19.9,Death (540); Withdrawal by Subject (100); Lost to Follow-up (68),Death,540.0,1
NCT00532935,MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,517,2,0,0,2008-01-26,2009-10-23,True,517,414,103,19.9,Protocol Specific Criteria (26); Adverse Event (23); Withdrawal by Subject (19); Lost to Follow-up (16); Physician Decision (9); Protocol Violation (6); Lack of Efficacy (3); Pregnancy (1),Protocol Specific Criteria,26.0,1
NCT01813435,GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation,cardiovascular disease,Coronary Artery Disease (CAD),ECRI bv,INDUSTRY,15991,2,130,18,2013-07-01,2018-04-26,True,15968,12791,3177,19.9,did not finish experimental regimen (2672); Lost to Follow-up (505),did not finish experimental regimen,2672.0,1
NCT00325403,FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH),cardiovascular disease,Pulmonary Hypertension,United Therapeutics,INDUSTRY,349,2,77,13,2006-10,2011-04,True,349,280,0,19.8,,,,1
NCT01841762,Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument,hypertension,Pulmonary Arterial Hypertension,Actelion,INDUSTRY,284,1,81,1,2013-04-01,2015-11-01,True,335,269,98,19.7,"Other, 2 PAH-SYMPACT cycles not complete (51); Adverse Event (16); Withdrawal by Subject (14); Lost to Follow-up (7); Other, including non-compliance (5); Death (2); Physician Decision (2); Other, administrative error (1)","Other, 2 PAH-SYMPACT cycles not complete",51.0,3
NCT00838916,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",GlaxoSmithKline,INDUSTRY,779,2,337,4,2009-02,2013-05,True,745,598,420,19.7,Withdrawal by Subject (112); Lost to Follow-up (97); Adverse Event (76); Noncompliance (46); Withdrawn from Follow-up Participation (38); Protocol Violation (15); Did not Enter Follow-up Period (14); Physician Decision (9); Missing (7); Termination of Study/Site by GSK (3); Pregnancy (2); Severe or Repeated Hypoglycaemia (1),Withdrawal by Subject,112.0,2
NCT00366249,Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.,cardiovascular disease,Bacterial Infections; Diabetic Foot; Osteomyelitis,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,1061,2,211,39,2007-01,2009-03,True,1061,852,209,19.7,Adverse Event (81); Most due to osteomylitis status (51); Lack of Efficacy (42); Withdrawal by Subject (22); Physician Decision (7); Protocol Violation (3); Lost to Follow-up (2); Death (1),Adverse Event,81.0,1
NCT01730053,Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II),dyslipidemia,Hypercholesterolemia,Regeneron Pharmaceuticals,INDUSTRY,305,6,93,9,2012-11-30,2014-05-31,True,305,245,60,19.7,Other than specified (33); Adverse Event (18); Poor compliance to protocol (7); Participant moved (1); Physician Decision (1),Other than specified,33.0,1
NCT00877890,"A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)",diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,254,2,41,1,2009-03,2010-01,True,254,204,50,19.7,Withdrawal of Consent (18); Adverse Event (12); Lost to Follow-up (10); Loss of Glucose Control (7); Investigator Decision (2); Protocol Violation (1),Withdrawal of Consent,18.0,1
NCT00113087,Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart Network,cardiovascular disease,"Heart Defects, Congenital; Heart Failure, Congestive","National Heart, Lung, and Blood Institute (NHLBI)",NIH,230,2,9,2,2003-08,2008-07,True,230,185,45,19.6,Death or Transplant (30); Family or MD withdrew subject (15),Death or Transplant,30.0,1
NCT02030600,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes",diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,721,2,166,2,2014-01-06,2015-12-04,True,721,580,141,19.6,Withdrawal by Subject (52); Protocol Violation (42); Adverse Event (20); Lost to Follow-up (20); Lack of Efficacy (4); Unclassified (2); Casebook Unsigned (1),Withdrawal by Subject,52.0,2
NCT00915772,Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,567,3,112,14,2009-06,,True,566,455,111,19.6,Adverse Event (36); Lack of Efficacy (27); Refused to continue trial medication (18); Any other reason (18); Protocol Violation (7); Lost to Follow-up (5),Adverse Event,36.0,1
NCT00329238,Secondary Prevention of Venous Thrombo Embolism (VTE).,cardiovascular disease,Thromboembolism,Boehringer Ingelheim,INDUSTRY,2867,2,275,33,2006-05,,True,2856,2299,557,19.5,Adverse Event (276); Withdrawal by Subject (122); Other reason (not specified) (94); Protocol Violation (57); Lost to Follow-up (8),Adverse Event,276.0,1
NCT02181413,A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant,cardiovascular disease,Multiple Myeloma; Autologous Stem Cell Transplant,Takeda,INDUSTRY,656,2,227,33,2014-07-16,2023-09-08,True,656,528,128,19.5,Withdrawal by Subject (106); Lost to Follow-up (15); Reason Not Specified (7),Withdrawal by Subject,106.0,1
NCT00289887,Obese Hypertension Study (0954-315),cardiovascular disease,Hypertension,Organon and Co,INDUSTRY,261,2,0,0,2006-02,2007-03,True,261,210,51,19.5,Lack of Efficacy (14); Withdrawal by Subject (11); Other (10); Adverse Event (6); Lost to Follow-up (6); Protocol Violation (4),Lack of Efficacy,14.0,1
NCT00708435,Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy,cardiovascular disease,Blood Coagulation Disorders; Acute Major Bleeding,CSL Behring,INDUSTRY,216,2,69,6,2008-06,2010-11,True,216,174,42,19.4,Death / Serious Adverse Event (15); Lost to Follow-up (13); Withdrawal by Subject (10); Adverse Event (1); Protocol Violation (1); Intervention by primary care physician (1); Refused hospitalization (1),Death / Serious Adverse Event,15.0,1
NCT01730040,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),dyslipidemia,Hypercholesterolemia,Regeneron Pharmaceuticals,INDUSTRY,355,7,97,9,2012-10,2014-05,True,355,286,69,19.4,Other than specified (38); Adverse Event (19); Poor compliance to protocol (7); Subject moved (2); Physician Decision (2); Randomized but not treated (1),Other than specified,38.0,1
NCT01788358,Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension,cardiovascular disease,Hypertension,Bayer,INDUSTRY,508,1,82,6,2013-02-14,2014-05-01,True,508,410,98,19.3,Adverse Event (51); Withdrawal by Subject (26); Other (11); Lost to Follow-up (5); Protocol Violation (3); Logistical difficulties (1); Lack of Efficacy (1),Adverse Event,51.0,1
NCT01126580,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3),diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,807,3,91,19,2010-05,2012-06,True,807,651,156,19.3,Withdrawal by Subject (44); Lost to Follow-up (37); Adverse Event (34); Sponsor Decision (16); Lack of Efficacy (9); Treatment Non-compliance (5); Physician Decision (4); Entry Criteria Not Met (4); Protocol Violation (3),Withdrawal by Subject,44.0,1
NCT01617434,The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,451,2,86,9,2012-09,2013-10,True,451,365,86,19.1,Withdrawal Criteria (49); Adverse Event (15); Protocol Violation (15); Unclassified (7),Withdrawal Criteria,49.0,1
NCT00545584,Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078),diabetes type 2,"Diabetes Mellitus, Non-Insulin-Dependent",Merck Sharp & Dohme LLC,INDUSTRY,1512,3,0,0,2007-04-01,2009-11-19,True,1132,917,215,19.0,Only one reason for discontinuation (171); Two or more reasons for discontinuation (44),Only one reason for discontinuation,171.0,1
NCT01663402,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,cardiovascular disease,Atherosclerotic Cardiovascular Disease,Sanofi,INDUSTRY,18924,2,1388,57,2012-10,2018-01-23,True,18924,15325,3599,19.0,Poor compliance to protocol (983); Two consecutive LDL-C <15 mg/dL (730); Adverse Event (709); Other than specified above (319); Participant moved (243); Withdrawal by Subject (209); Related to study drug administration (201); Physician Decision (139); Lost to Follow-up (32); Randomized but not treated (30); Site terminated by sponsor (4),Poor compliance to protocol,983.0,1
NCT00663260,Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment,diabetes type 2,"Diabetes Mellitus, Type 2",AstraZeneca,INDUSTRY,631,3,96,13,2008-06,2011-06,True,252,204,48,19.0,"Adverse Event (25); Withdrawal by Subject (10); non-compliance, not met criteria, etc. (8); Lack of Efficacy (2); Death (2); Lost to Follow-up (1)",Adverse Event,25.0,1
NCT00323037,A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure,cardiovascular disease,Congestive Heart Failure,"CTI-1, LLC",INDUSTRY,318,2,75,1,2006-03,2008-06,True,318,258,0,18.9,,,,1
NCT02926950,Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin,diabetes type 2,Type 2 Diabetes Mellitus,Lexicon Pharmaceuticals,INDUSTRY,518,2,93,4,2016-11,2019-03-22,True,518,421,97,18.7,At the participant's own request (46); Reason not Specified (26); Lost to Follow-up (15); Adverse Event (10),At the participant's own request,46.0,1
NCT01926782,Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1),dyslipidemia,Hypercholesterolemia,Regeneron Pharmaceuticals,INDUSTRY,803,3,83,8,2013-09,2015-04,True,803,653,150,18.7,Adverse Event (55); Other than specified (37); Poor compliance to protocol (23); Withdrawal by Subject (21); Participant moved (7); Physician Decision (4); Related to study drug administration (2); Randomized and not treated (1),Adverse Event,55.0,1
NCT01191268,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4),diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,884,3,101,16,2010-11,2012-09,True,884,719,165,18.7,Withdrawal by Subject (65); Adverse Event (42); Physician Decision (23); Lost to Follow-up (22); Entry Criteria Not Met (5); Death (4); Protocol Violation (2); Sponsor Decision (2),Withdrawal by Subject,65.0,1
NCT00402103,An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure,cardiovascular disease,Hypertension,Novartis,INDUSTRY,556,2,8,8,2006-11,2008-04,True,556,452,104,18.7,Adverse Event (67); Patient withdrew consent (13); Lost to Follow-up (9); Protocol Deviation (8); Unsatisfactory therapeutic effect (3); Condition no longer requires study drug (2); Administrative problems (2),Adverse Event,67.0,1
NCT02432209,Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility,obesity,"Infertility, Female",Yale University,OTHER,379,2,10,1,2015-08,2020-05,True,379,308,0,18.7,,,,1
NCT01682759,A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,751,2,0,0,2012-09-10,2015-01-26,True,751,612,139,18.5,Withdrawal by Subject (111); Lost to Follow-up (23); Death (3); Physician Decision (2),Withdrawal by Subject,111.0,1
NCT00757588,Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,455,2,80,10,2008-11,2010-04,True,455,371,84,18.5,Withdrawal by Subject (24); No longer meets study criteria (14); Adverse Event (13); Lost to Follow-up (10); Poor or noncompliance (7); Lack of Efficacy (6); Poor compliance or noncompliance (6); Other (2); Death (1); Pregnancy (1),Withdrawal by Subject,24.0,2
NCT01485614,Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083),diabetes type 2,Diabetes Mellitus; Type 2 Diabetes,Merck Sharp & Dohme LLC,INDUSTRY,200,4,0,0,2012-02-10,2019-10-09,True,200,163,37,18.5,Withdrawal by Subject (14); Withdrawal by Parent/Guardian (12); Lost to Follow-up (10); Not Treated (1),Withdrawal by Subject,14.0,3
NCT03436693,Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy,diabetes type 2,Diabetic Nephropathy,Tanabe Pharma Corporation,INDUSTRY,308,2,26,1,2018-02-15,2021-01-21,True,308,251,57,18.5,Adverse Event (32); Withdrawal by Subject (17); Physician Decision (6); Progressive Disease (2),Adverse Event,32.0,1
NCT01296412,Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403),diabetes type 2,"Diabetes Mellitus, Type 2",Merck Sharp & Dohme LLC,INDUSTRY,653,2,0,0,2011-03-11,2012-02-29,True,653,532,121,18.5,Adverse Event (37); Other reason not specified (35); Withdrawal by Subject (23); Lost to Follow-up (17); Physician Decision (4); Non-compliance with study drug (3); Lack of Efficacy (1); Pregnancy (1),Adverse Event,37.0,1
NCT00184600,"Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes",diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,708,3,63,2,2004-11,2009-08,True,708,578,130,18.4,Withdrawal by Subject (60); Death (19); Adverse Event (14); Unclassified (12); Lost to Follow-up (11); Lack of Efficacy (7); Protocol Violation (7),Withdrawal by Subject,60.0,1
NCT00765817,Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,261,2,59,6,2008-10,2010-01,True,261,213,48,18.4,Subject decision (18); Adverse Event (14); Entry criteria not met (4); Lost to Follow-up (4); Physician Decision (3); Loss of glucose control (2); Protocol Violation (2); Death (1),Subject decision,18.0,1
NCT00608023,TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy,metabolic syndrome,Lipodystrophy; HIV Infections,Theratechnologies,INDUSTRY,263,3,47,6,2007-08,2008-10,True,263,215,48,18.3,Withdrawal by Subject (25); Adverse Event (10); Lost to Follow-up (5); Protocol Violation (5); Unknown reason (3),Withdrawal by Subject,25.0,1
NCT00849056,Safety and Efficacy of Albiglutide in Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",GlaxoSmithKline,INDUSTRY,310,2,331,6,2009-01,2013-01,True,301,246,165,18.3,Withdrawal by Subject (65); Lost to Follow-up (35); Adverse Event (28); Termination of Study/Site by GSK (10); Protocol Violation (9); Physician Decision (8); Noncompliance (7); Calcitonin Out of Range (1); Pregnancy (1); Early Termination (1),Withdrawal by Subject,65.0,2
NCT02441218,Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study,heart failure,Chronic Heart Failure,Institut de Recherches Internationales Servier,OTHER,6505,2,2,2,2006-09,2010-04,True,6505,5315,1190,18.3,Death (1056); Withdrawal by Subject (131); Lost to Follow-up (3),Death,1056.0,1
NCT00799643,Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II,diabetes type 2,Type 2 Diabetes Mellitus,Joslin Diabetes Center,OTHER,638,2,21,1,2008-11,,True,286,234,0,18.2,,,,1
NCT01717313,A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,329,2,0,0,2012-12-05,2015-06-19,True,329,269,60,18.2,Withdrawal by Subject (34); Lost to Follow-up (8); Study Terminated by Sponsor (8); Adverse Event (6); Non-Compliance with Study Drug (2); Death (1); Completed Phase A Did Not Enter Phase B (1),Withdrawal by Subject,34.0,3
NCT01451398,Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes,Mannkind Corporation,INDUSTRY,353,2,76,4,2011-11,2013-07,True,353,289,64,18.1,Withdrawal by Subject (24); Adverse Event (16); Lost to Follow-up (10); Non-compliance with study drug (4); Protocol Violation (3); Physician Decision (2); Non-compliance with protocol (2); Moved out of country (1); Adverse Event + Elevated Fasting Glucose (1); Lack of Efficacy (1),Withdrawal by Subject,24.0,1
NCT02916706,Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Tanabe Pharma Corporation,INDUSTRY,254,2,1,1,2016-09,,True,254,208,46,18.1,Other (24); Withdrawal by Subject (15); Protocol Violation (4); Adverse Event (1); Lost to Follow-up (1); Physician Decision (1),Other,24.0,1
NCT03481634,Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema,cardiovascular disease,Diabetic Macular Edema,Novartis Pharmaceuticals,INDUSTRY,566,3,116,14,2018-07-23,2021-10-18,True,566,464,102,18.0,Withdrawal by Subject (49); Death (19); Adverse Event (16); Lost to Follow-up (11); Physician Decision (4); Protocol Violation (2); Progressive disease (1),Withdrawal by Subject,49.0,1
NCT02680574,Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD),cardiovascular disease,Anemia; Non-Dialysis-Dependent Chronic Kidney Disease,Akebia Therapeutics,INDUSTRY,1725,2,503,30,2016-02,2020-07-31,True,1725,1415,310,18.0,Death (274); Withdrawal by Subject (26); Lost to Follow-up (10),Death,274.0,1
NCT00626392,Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia,dyslipidemia,Dyslipidemia,Abbott,INDUSTRY,277,6,26,1,2008-02,2008-04,True,267,219,48,18.0,Adverse Event (24); Withdrawal by Subject (11); Other (8); Protocol Violation (3); Noncompliance (2),Adverse Event,24.0,2
NCT02284893,Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,461,2,79,6,2014-09-09,2016-09-20,True,461,378,74,18.0,Withrawal of the consent by the subject (27); Adverse Event (14); Subject no longer meets study criteria (14); Lost to Follow-up (8); Non-Compliance (5); Discontinuation by the subject (4); Other (2),Withrawal of the consent by the subject,27.0,2
NCT04404166,Phone-based Intervention Under Nurse Guidance After Stroke 2,cardiovascular disease,Blood Pressure; Stroke; Cardiovascular Diseases,Northern California Institute of Research and Education,OTHER,500,2,10,1,2020-10-23,2024-04-05,True,500,410,0,18.0,,,,1
NCT02634333,Anti-VEGF Treatment for Prevention of PDR/DME,cardiovascular disease,Diabetic Retinopathy; Diabetic Macular Edema,Jaeb Center for Health Research,OTHER,399,2,85,2,2016-01,2022-05-11,True,399,327,72,18.0,Withdrawal by Subject (22); Lost to Follow-up (19); Death (19); Missed Visit (7); Completed out of Window (5),Withdrawal by Subject,22.0,1
NCT03548987,Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity,obesity,Metabolism and Nutrition Disorder; Obesity,Novo Nordisk A/S,INDUSTRY,902,2,72,10,2018-06-04,2020-03-20,True,902,741,161,17.8,Adverse Event (67); other (35); Run-in failure (19); Withdrawal by Subject (13); Lost to Follow-up (11); Other (9); Pregnancy (3); Safety concern as judged by investigator (2); Protocol Violation (2),Adverse Event,67.0,2
NCT00542178,Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study),diabetes type 2,Diabetic Retinopathy,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,3472,6,7,2,2003-10,2009-12,True,3472,2856,616,17.7,did not complete year 4 follow-up (616),did not complete year 4 follow-up,616.0,1
NCT04807400,Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support,cardiovascular disease,Atherosclerotic Cardiovascular Disease; Atherosclerotic Cardiovascular Disease Risk Equivelents; Elevated Low Density Lipoprotein Cholesterol,Novartis Pharmaceuticals,INDUSTRY,892,3,17,1,2021-07-07,2023-01-13,True,892,734,158,17.7,Participant Decision (65); Withdrawal by Subject (42); Lost to Follow-up (20); Protocol Violation (14); Adverse Event (8); Non-Compliance With Study Drug (5); Death (2); Physician Decision (1); Mis-randomized (1),Participant Decision,65.0,1
NCT02344290,Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults,cardiovascular disease,HIV; Cardiovascular Diseases,National Institute of Allergy and Infectious Diseases (NIAID),NIH,7769,2,137,13,2015-03-26,2023-08-21,True,7769,6402,1367,17.6,Withdrawal by Subject (639); Lost to Follow-up (507); Unable to get to clinic (129); Physician Decision (50); Site Closure (34); Other (8),Withdrawal by Subject,639.0,1
NCT00065806,Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE),cardiovascular disease,"Lupus Erythematosus, Systemic",Laura Schanberg,OTHER,221,2,1,1,2003-09,2009-12,True,221,182,0,17.6,,,,1
NCT00166205,Safety and Effectiveness Study of The Swedish Adjustable Gastric Band (SAGB) in the Treatment of Morbid Obesity,obesity,"Obesity, Morbid",Ethicon Endo-Surgery,INDUSTRY,276,1,12,1,2003-06,2006-12,True,276,228,0,17.4,,,,1
NCT00633893,Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism,cardiovascular disease,Venous Thrombosis,Bristol-Myers Squibb,INDUSTRY,2711,3,428,29,2008-05,2012-08,True,2482,2051,431,17.4,Adverse Event (249); Other (92); Withdrawal by Subject (25); Poor/non-compliance (20); Lost to Follow-up (14); Not meet/no longer meets criteria (14); Death (13); Pregnancy (4),Adverse Event,249.0,1
NCT01363440,Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema,cardiovascular disease,Diabetic Macular Edema,Regeneron Pharmaceuticals,INDUSTRY,466,3,51,1,2011-05,2014-11,True,466,385,81,17.4,Withdrawal by Subject (31); Death (15); Adverse Event (13); Lost to Follow-up (11); Other (11),Withdrawal by Subject,31.0,1
NCT04657016,A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program,diabetes type 2,Obesity; Overweight,Eli Lilly and Company,INDUSTRY,579,2,65,4,2021-03-29,2023-05-12,True,579,479,100,17.3,Withdrawal by Subject (42); Lost to Follow-up (36); Adverse Event (6); Other - as reported by the investigator (6); Pregnancy (4); Physician Decision (3); Death (2); Protocol Deviation (1),Withdrawal by Subject,42.0,1
NCT03611582,Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program,obesity,Overweight; Obesity,Novo Nordisk A/S,INDUSTRY,611,2,41,1,2018-08-01,2020-04-28,True,611,505,106,17.3,other (33); Adverse Event (32); Lost to Follow-up (25); Withdrawal by Subject (7); Pregnancy (3); Safety concern as judged by the investigator (3); Protocol Violation (1); Lack of Efficacy (1); At the discretion of the investigator (1),other,33.0,1
NCT03332771,Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy,diabetes type 2,Type 2 Diabetes Mellitus,Lexicon Pharmaceuticals,INDUSTRY,954,4,142,4,2017-12-01,2019-09-06,True,954,789,165,17.3,At the Participant's own request (83); Reason Not Specified (59); Adverse Event (14); Lost to Follow-up (7); Poor Compliance to Protocol (2),At the Participant's own request,83.0,1
NCT00858637,Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis,dyslipidemia,Chronic Kidney Disease,Tanabe Pharma Corporation,INDUSTRY,260,4,39,13,2009-03,2010-03,True,260,215,45,17.3,Adverse Event (23); Withdrawal by Subject (14); Death (4); Physician Decision (2); Other Reasons (2),Adverse Event,23.0,2
NCT00536510,Effect of MK0524A on Cholesterol Levels (0524A-048),dyslipidemia,Hypercholesterolemia; Hyperlipidemia,Merck Sharp & Dohme LLC,INDUSTRY,646,2,0,0,2007-04,2008-03,True,646,535,111,17.2,Adverse Event (31); Withdrawal by Subject (25); Flushing with Product (20); Lost to Follow-up (19); Protocol Violation (9); Patient Discontinued for Other Reasons (4); Laboratory Adverse Event (3),Adverse Event,31.0,1
NCT00289848,MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,530,2,0,0,2006-03,2007-03,True,530,439,91,17.2,Lack of Efficacy (44); Withdrawal by Subject (16); Adverse Event (10); Patient Moved (8); Protocol Violation (7); Lost to Follow-up (4); Death (1); Open-Label AHA Treatment Requested (1),Lack of Efficacy,44.0,1
NCT00103662,Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients,cardiovascular disease,Multiple Myeloma,"Genzyme, a Sanofi Company",INDUSTRY,302,2,39,3,2005-01,2008-01,True,302,250,52,17.2,Other (15); Death (14); Elective Withdrawal (10); Entered Rescue Procedure (7); Failed mobilization (4); Lost to Follow-up (1); Intercurrent illness (1),Other,15.0,1
NCT02867813,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension,cardiovascular disease,Dyslipidemia,Amgen,INDUSTRY,5035,1,198,7,2016-09-02,2022-03-21,True,5035,4174,861,17.1,Death (562); Lost to Follow-up (169); Withdrawal by Subject (113); Decision by Sponsor (14); Missing (3),Death,562.0,1
NCT05412004,Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea,obesity,Obstructive Sleep Apnea; Obesity,Eli Lilly and Company,INDUSTRY,469,4,58,10,2022-06-21,2024-03-29,True,469,389,80,17.1,Withdrawal by Subject (41); Assigned Treatment by Mistake (22); Adverse Event (8); Lost to Follow-up (3); Patient could not travel to site (1); Physician Decision (1); Pregnancy (1); Protocol Violation (1); Screen Failure (1); The participant quit treatment and study due to their schedule and the final V801 was done remotely (1),Withdrawal by Subject,41.0,1
NCT00917267,A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects,diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,691,2,42,5,2009-07,2011-04,True,691,573,118,17.1,Adverse Event (51); Protocol Violation (27); Withdrawal by Subject (17); Sponsor Decision (10); Physician Decision (6); Lack of Efficacy-Loss of Glucose Control (4); Lost to follow up (2); Entry Criteria Not Met (1),Adverse Event,51.0,1
NCT01508910,Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina,cardiovascular disease,Chronic Myocardial Ischemia; Refractory Angina Pectoris; Advanced Coronary Heart Disease,"Lisata Therapeutics, Inc.",INDUSTRY,291,3,41,1,2012-04,2015-11,True,112,93,19,17.0,Withdrawal by Subject (8); Death (7); Lost to Follow-up (3); Sponsor Decision (1),Withdrawal by Subject,8.0,2
NCT01555164,A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone,diabetes type 2,Type 2 Diabetes Mellitus,Gilead Sciences,INDUSTRY,442,2,146,11,2012-06,2013-10,True,442,367,75,17.0,Subject Non-compliance (20); Subject Withdrew Consent (17); Protocol Violation (14); Adverse Event (12); Lost to Follow-up (7); Investigator's Discretion (4); Hyperglycemia (1),Subject Non-compliance,20.0,1
NCT00808067,RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial,cardiovascular disease,Atrial Fibrillation,Boehringer Ingelheim,INDUSTRY,5897,2,567,35,2008-11,2012-12,True,5883,4884,999,17.0,Adverse Event (232); Patient refused to take study medication (141); Reduced creatinine clearance (108); Physician Decision (85); Hospitalization due to surgery (77); Major/minor bleed (74); Outcome event - other (58); Withdrawal by Subject (46); Site closed for cause (38); Hospitalization (not including surgery) (35); Excluded from analysis (32); Patient elected (16); Protocol Violation (14); Procedure (13); Elevated LFT results (10); Other reason not defined above (10); Site closed (7); Death (2); Missing (1),Adverse Event,232.0,1
NCT00479388,Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067),dyslipidemia,Primary Hypercholesterolemia; Mixed Dyslipidemia,Merck Sharp & Dohme LLC,INDUSTRY,1216,2,0,0,2007-07,2008-10,True,1216,1011,205,16.9,Adverse Event (135); Withdrawal by Subject (49); Protocol Violation (19); Lost to Follow-up (2),Adverse Event,135.0,1
NCT01618162,The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,435,2,87,8,2012-08-29,2013-10-23,True,435,362,73,16.8,Unclassified (27); Protocol Violation (23); Withdrawal Criteria (12); Adverse Event (11),Unclassified,27.0,1
NCT01710007,Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia,dyslipidemia,Hypercholesterolemia,"Orient Pharma Co., Ltd.",INDUSTRY,202,2,8,1,2011-11,2012-11,True,202,168,0,16.8,,,,1
NCT01621178,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),diabetes type 2,Type 2 Diabetes; Chronic Kidney Disease,Eli Lilly and Company,INDUSTRY,577,3,89,9,2012-07,2016-12,True,577,480,97,16.8,Withdrawal by Subject (49); Adverse Event (15); Death (15); Physician Decision (14); Lost to Follow-up (4),Withdrawal by Subject,49.0,1
NCT01033071,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.,cardiovascular disease,Essential Hypertension,Takeda,INDUSTRY,1071,3,94,2,2010-01,2010-11,True,1071,892,179,16.7,Adverse Event (105); Withdrawal by Subject (42); Lost to Follow-up (14); Other (13); Protocol Violation (3); Lack of Efficacy (2),Adverse Event,105.0,1
NCT00323284,A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma,hypertension,Open-Angle Glaucoma,Glaukos Corporation,INDUSTRY,240,2,31,1,2005-06,2010-03,True,239,199,0,16.7,,,,2
NCT00124072,Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine,cardiovascular disease,Cardiovascular Disease,University of Oxford,OTHER,12064,4,1,1,1998-07,2008-05,True,12064,10046,2018,16.7,Death (1934); Lost to Follow-up for Morbidity (77); Lost to Follow-up for Mortality (7),Death,1934.0,1
NCT03242018,"A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control",diabetes type 2,Type 2 Diabetes Mellitus; Chronic Kidney Disease Stage 4,Lexicon Pharmaceuticals,INDUSTRY,277,3,106,15,2017-08-16,2019-12-11,True,277,231,46,16.6,Adverse Event (20); At the Participant's Own Request (10); Reason Not Specified (8); Lost to Follow-up (6); Study Terminated by Sponsor (2),Adverse Event,20.0,1
NCT01599650,Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion,cardiovascular disease,Branch Retinal Vein Occlusion,Novartis Pharmaceuticals,INDUSTRY,455,3,82,17,2012-05,2015-05,True,455,380,75,16.5,Withdrawal by Subject (32); Adverse Event (15); Physician Decision (9); Lost to Follow-up (9); Death (5); Protocol Violation (3); Administrative issue (2),Withdrawal by Subject,32.0,1
NCT00289900,Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024),dyslipidemia,Mixed Hyperlipidemia,Merck Sharp & Dohme LLC,INDUSTRY,2340,6,0,0,2006-01-24,2010-08-06,True,2340,1954,386,16.5,Adverse Event (153); Withdrawal by Subject (80); Participant had flushing (67); Lost to Follow-up (42); Protocol Violation (31); Other (6); Participant moved (4); site terminated (2); Not treated (1),Adverse Event,153.0,1
NCT00082407,Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin,diabetes type 2,"Diabetes Mellitus, Type 2",AstraZeneca,INDUSTRY,505,2,69,12,2003-11,2008-07,True,505,422,83,16.4,Protocol Violation (26); Adverse Event (20); Patient Decision (19); Physician Decision (8); Loss of Glucose Control (4); Death (3); Lost to Follow-up (3),Protocol Violation,26.0,1
NCT00300274,Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection,cardiovascular disease,Graft Rejection,Novartis Pharmaceuticals,INDUSTRY,721,3,64,15,2006-01,2011-07,True,721,603,118,16.4,Death (76); Withdrawal by Subject (29); Lost to Follow-up (12); Re-transplant (1),Death,76.0,1
NCT00350779,Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,262,2,0,0,2006-06-12,2008-06-11,True,262,219,43,16.4,Withdrawal by Subject (17); Adverse Event (6); Physician Decision (6); Lack of Efficacy (4); Protocol Violation (4); Patient Moved (3); Lost to Follow-up (2); Non-compliance with study procedures (1),Withdrawal by Subject,17.0,1
NCT01958671,"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)",diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,461,3,0,0,2013-10-09,2016-07-28,True,461,386,75,16.3,Withdrawal by Subject (31); Lost to Follow-up (25); Adverse Event (7); Non-compliance with study drug (3); Hyperglycemia (2); Study site terminated by sponsor (2); Death (1); Excluded medication (1); Pregnancy (1); Protocol Violation (1); Participant moved (1),Withdrawal by Subject,31.0,1
NCT01435616,A Study in Patients With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,1538,2,167,23,2011-11,2014-01,True,1538,1287,251,16.3,Withdrawal by Subject (90); Adverse Event (60); Lost to Follow-up (35); Protocol Violation (29); Physician Decision (27); Death (9); Sponsor Decision (1),Withdrawal by Subject,90.0,1
NCT00630877,Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin,dyslipidemia,Dyslipidemia,Abbott,INDUSTRY,276,3,40,1,2008-02,2008-06,True,271,227,44,16.2,Adverse Event (26); Withdrawal by Subject (7); Noncompliance (6); Lost to Follow-up (2); Protocol violation (2); Personal reasons (1),Adverse Event,26.0,1
NCT02507687,Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension,hypertension,"Glaucoma, Open-Angle; Ocular Hypertension",AbbVie,INDUSTRY,240,4,95,12,2015-08-27,2023-05-31,True,240,201,39,16.2,"Withdrawal by Subject (17); Adverse Event (9); Other, Not Specified (6); Protocol Violation (3); Lost to Follow-up (3); Screen Failure (1)",Withdrawal by Subject,17.0,1
NCT02226120,Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction,cardiovascular disease,Chronic Heart Failure With Reduced Ejection Fraction,Novartis Pharmaceuticals,INDUSTRY,1980,1,394,41,2014-10-16,2017-12-28,True,1980,1660,320,16.2,Death (172); Adverse Event (60); Withdrawal by parent/guardian (36); Physician Decision (21); Lost to Follow-up (13); Non-compliance with study drug (10); Technical problems (4); missing treatment disposition pages (2); Study terminated by sponsor (1); Protocol deviation (1),Death,172.0,1
NCT02769481,Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects,diabetes type 2,Type 2 Diabetes Mellitus,Theracos,INDUSTRY,426,2,45,4,2016-08-15,2019-06-14,True,426,357,69,16.2,Withdrawal by Subject (30); Lost to Follow-up (18); Adverse Event (9); Undefined (5); Entry Criteria Not Met (3); Protocol Violation (1); Physician Decision (1); Terminated by Sponsor (1); Death (1),Withdrawal by Subject,30.0,1
NCT00393718,Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,400,2,1,1,2006-11,2008-05,True,400,335,65,16.2,Adverse Event (28); Lack of Efficacy (19); Hypoglycaemia (5); Subject decision (5); Protocol Violation (3); Withdrawal of consent (3); Missed measurement (1); Move (1),Adverse Event,28.0,1
NCT01392573,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,413,2,86,7,2011-11-28,2012-10-04,True,413,346,67,16.2,Withdrawal Criteria (28); Site closure (15); Unclassified (15); Adverse Event (4); Lack of Efficacy (3); Protocol Violation (2),Withdrawal Criteria,28.0,1
NCT01713530,A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,274,2,51,5,2013-02-21,2014-01-09,True,274,230,44,16.1,Withdrawal criteria (33); Unclassified (6); Adverse Event (5),Withdrawal criteria,33.0,1
NCT03214380,A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,933,4,141,16,2017-07-14,2019-03-13,True,933,783,150,16.1,Withdrawal by Subject (91); Lost to Follow-up (14); Protocol Deviation (10); Natural Disaster (9); Adverse Event (7); Physician Decision (6); Eligibility Criteria (3); Death (3); Participant Schedule (2); Family Emergency (1); Non Compliance (1); Non-Compliance with Study Drug (1); Participant schedule (1); Treatment Interruption (1),Withdrawal by Subject,91.0,2
NCT00614120,Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,929,4,50,3,2008-01,2009-02,True,929,779,150,16.1,"Adverse Event (64); Withdrawal by Subject (38); Protocol Violation (11); Lack of Efficacy (10); Lost to Follow-up (10); Lack of trial product (8); Did not meet trial criteria (3); Taken inhibition medication eg Prandin (2); Withdrawal criteria (1); hCG positive (not pregnant) (1); Hypoglycaemia (1); Late syphilis, latent (1)",Adverse Event,64.0,1
NCT01294462,Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS),cardiovascular disease,Acute Coronary Syndrome; Percutaneous Coronary Intervention,AstraZeneca,INDUSTRY,801,2,87,3,2011-02,2012-07,True,801,672,129,16.1,Withdrawal by Subject (128); Lost to Follow-up (1),Withdrawal by Subject,128.0,1
NCT01624142,Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders,dyslipidemia,Severe Familial Hypercholesterolemia,Amgen,INDUSTRY,300,1,44,18,2012-06-01,2018-05-11,True,300,252,48,16.0,Withdrawal by Subject (18); Study Closure (18); Death (9); Lost to Follow-up (2); Other (1),Withdrawal by Subject,18.0,1
NCT00890409,Safety and Efficacy of Hypothermia to Treat Neonatal Hypoxic-Ischemic Encephalopathy,cardiovascular disease,Hypoxic-Ischemic Encephalopathy,Fudan University,OTHER,256,2,1,1,2002-05,2005-08,True,256,215,41,16.0,Lost to Follow-up (41),Lost to Follow-up,41.0,1
NCT01664247,The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,346,2,132,11,2012-10-01,2013-12-31,True,346,291,55,15.9,Unclassified (34); Adverse Event (8); Protocol Violation (8); Withdrawal Criteria (5),Unclassified,34.0,1
NCT00282984,Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking,cardiovascular disease,Smoking Cessation,Pfizer,INDUSTRY,714,2,39,15,2006-02,2008-08,True,703,591,112,15.9,Withdrawal by Participant (56); Lost to Follow-up (24); Adverse Event (13); Death (7); Participant stopped study medication (4); Lack of Efficacy (2); Protocol Violation (2); Participant only allowed phone follow-up (1); Participant used antipsychosis meds (1); lack of motivation (1); in prison (1),Withdrawal by Participant,56.0,1
NCT02250651,Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension,hypertension,"Glaucoma, Open-Angle; Ocular Hypertension",Allergan,INDUSTRY,528,3,113,15,2014-12-15,2020-07-22,True,528,444,56,15.9,Personal Reasons (21); Adverse Event (15); Lost to Follow-up (8); Reason not Specified (6); Randomized but not Treated (4); Protocol Deviation (2),Personal Reasons,21.0,3
NCT00818883,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension,cardiovascular disease,Essential Hypertension,Takeda,INDUSTRY,609,2,53,2,2009-02,2009-11,True,609,512,97,15.9,Adverse Event (47); Withdrawal by Subject (30); Other (9); Lost to Follow-up (5); Protocol Violation (4); Lack of Efficacy (2),Adverse Event,47.0,1
NCT01189890,Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,480,2,0,0,2010-08-16,2012-10-31,True,480,404,76,15.8,Withdrawal by Subject (26); Hyperglycemia Discontinuation Criteria (10); Lack of Efficacy (9); Physician Decision (9); Lost to Follow-up (8); Adverse Event (7); Protocol Violation (6); Non Compliance (1),Withdrawal by Subject,26.0,1
NCT03284853,Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension,hypertension,Open Angle Glaucoma; Ocular Hypertension,Aerie Pharmaceuticals,INDUSTRY,436,2,68,11,2017-09-05,2020-11-06,True,430,362,68,15.8,Adverse Event (44); Other - Reason not reported in CSR (7); Withdrawal by Subject (6); Protocol Violation (6); Disallowed Concurrent Medication (2); Lost to Follow-up (1); Lack of Efficacy (1); Death (1),Adverse Event,44.0,1
NCT01320722,Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function,obesity,Renal Function; Endothelial Function; Blood Pressure; Overweight; Obesity,Brigham and Women's Hospital,OTHER,242,5,1,1,2011-03,2015-06,True,242,204,38,15.7,Did not Receive Intervention (9); Adverse Event (9); Lost to Follow-up (5); Participant Developed a Rash (4); Not Compliant with Study Procedures (4); Not Available for the 8 Week Visit (3); Non-compliant with Medication (1); Pregnancy (1); Started an Exclusionary Medication (1); Withdrew due to Health Condition (1),Did not Receive Intervention,9.0,1
NCT01898923,Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers,cardiovascular disease,Diabetic Foot,"Oneness Biotech Co., Ltd.",INDUSTRY,236,2,21,3,2012-11-23,2020-05-11,True,236,199,37,15.7,Lack of Efficacy (11); Withdrawal by Subject (11); Physician Decision (7); Adverse Event (4); One of the subjects IS NO LONGER USING AQUACEL STANDARD OF CARE AND WAS REMOVED FROM THE STUDY (3); Lost to Follow-up (1),Lack of Efficacy,11.0,1
NCT02963922,Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin,diabetes type 2,Metabolism and Nutrition Disorder; Obesity,Novo Nordisk A/S,INDUSTRY,396,2,54,7,2017-02-06,2018-09-25,True,396,334,62,15.7,Other (22); Adverse Event (21); Protocol deviation (12); Lost to Follow-up (5); Lack of Efficacy (2),Other,22.0,1
NCT01814072,Opt-IN: Optimization of Remotely Delivered Intensive Lifestyle Treatment for Obesity,obesity,Weight Loss,Northwestern University,OTHER,562,32,1,1,2013-09,2017-09-20,True,562,474,88,15.7,Lost to Follow-up (62); Withdrawal by Subject (26),Lost to Follow-up,62.0,1
NCT00347360,The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial,cardiovascular disease,Hypertension,GlaxoSmithKline,INDUSTRY,654,2,151,1,2006-07,2008-04,True,654,551,103,15.7,"Adverse Event (28); Withdrawal by Subject (24); Protocol Violation (15); Lost to Follow-up (9); Lack of Efficacy (9); Subject did not meet end of study ABPM (4); Reason not listed/blank (3); Per sponsors instruction (1); P.I. recommended due to blood pressure (1); Abnormal lab values (1); PI recommended early withdrawal (1); Did not meet criteria before ABPM (1); Randomized in error (1); Failed inclusion criteria #4 (1); Prolonged duration between visits (1); Subject left town, ran out of study drug (1); Subject refuse to sign updated consent (1); Visits conflicted with new job (1)",Adverse Event,28.0,1
NCT00954447,Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,1263,2,169,19,2009-08,,True,1261,1063,198,15.7,Adverse Event (58); Withdrawal by Subject (47); Other (39); Lost to Follow-up (22); Lack of Efficacy (20); Protocol Violation (12),Adverse Event,58.0,1
NCT04264819,Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration,cardiovascular disease,Neovascular Age-Related Macular Degeneration,Novartis Pharmaceuticals,INDUSTRY,295,1,51,1,2020-12-14,2023-05-10,True,295,249,46,15.6,Physician Decision (19); Adverse Event (12); Withdrawal by Subject (11); Lost to Follow-up (2); Death (2),Physician Decision,19.0,1
NCT00252694,DIabetic Retinopathy Candesartan Trials,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,4717,2,0,0,2001-08,2008-04,True,1905,1607,298,15.6,Withdrawal by Subject (174); Death (70); Patient Moving (33); Mostly Lost to Follow Up (21),Withdrawal by Subject,174.0,1
NCT00330876,Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia,dyslipidemia,Hypercholesterolemia; Dyslipidemias,Kowa Research Europe,INDUSTRY,545,2,59,5,2006-06,2007-12,True,539,455,0,15.6,,,,1
NCT01128894,A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.,diabetes type 2,"Diabetes Mellitus, Type 2",GlaxoSmithKline,INDUSTRY,841,2,173,8,2010-05,2011-09,True,812,686,126,15.5,Adverse Event (72); Withdrawal by Subject (22); Lost to Follow-up (16); Noncompliance (9); Protocol Violation (3); Physician Decision (3); Conflicting HbA1c Results at Screening (1),Adverse Event,72.0,1
NCT01307033,A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351),cardiovascular disease,Hypertension,Organon and Co,INDUSTRY,278,2,0,0,2011-03-29,2012-12-04,True,278,235,43,15.5,Potassium Withdrawal Criteria Met (22); Withdrawal by Subject (8); Adverse Event (5); Blood Pressure Withdrawal Criteria Met (5); Lack of Efficacy (1); Physician Decision (1); Death (1),Potassium Withdrawal Criteria Met,22.0,2
NCT01603615,BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity,cardiovascular disease,Pediatrics; Muscle Spasticity; Cerebral Palsy; Stroke,Allergan,INDUSTRY,220,1,48,9,2012-10-30,2018-09-03,True,220,186,34,15.5,Personal Reasons (17); Lost to Follow-up (9); Did not Receive Treatment (7); Other Miscellaneous (1),Personal Reasons,17.0,1
NCT00809965,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,cardiovascular disease,Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia; Unstable Angina,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,15526,3,556,43,2008-11,2011-09,True,15526,13124,2402,15.5,Withdrawal by Subject (1294); Death (537); Other Reason (526); Lost to Follow-up (45),Withdrawal by Subject,1294.0,1
NCT01299376,MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356),cardiovascular disease,Hypertension,Merck Sharp & Dohme LLC,INDUSTRY,286,2,0,0,2011-01-24,2012-09-20,True,286,242,44,15.4,Blood Pressure/Potassium Criteria Met (24); Adverse Event (8); Withdrawal by Subject (5); Lost to Follow-up (4); Lack of Efficacy (1); Protocol Violation (1); Physician Decision (1),Blood Pressure/Potassium Criteria Met,24.0,2
NCT02324569,"A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes",diabetes type 2,Type 2 Diabetes Mellitus,Takeda,INDUSTRY,240,2,65,1,2014-12-27,2016-12-28,True,240,203,37,15.4,Pretreatment Event/Adverse Event (19); Voluntary Withdrawal (9); Lack of Efficacy (5); Change Insulin Dosage Exceeding Criteria (2); Inconvenient Schedule (2),Pretreatment Event/Adverse Event,19.0,1
NCT01920711,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",cardiovascular disease,Heart Failure With Preserved Ejection Fraction,Novartis Pharmaceuticals,INDUSTRY,4822,2,715,43,2014-07-18,2019-06-07,True,4822,4085,737,15.3,Death (703); Lost to Follow-up (27); Withdrawal by Subject (7),Death,703.0,1
NCT03451591,LACunar Intervention (LACI-2) Trial-2,cardiovascular disease,"Cerebral Small Vessel Diseases; Stroke, Lacunar",University of Edinburgh,OTHER,363,4,1,1,2018-01-08,2022-08-11,True,363,308,0,15.2,,,,3
NCT02513303,Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes,cardiovascular disease,Complication of Renal Dialysis; End Stage Renal Disease; End Stage Kidney Disease; ESRD; Chronic Kidney Failure; Complication of Hemodialysis; Vascular Access Complication; Arteriovenous Fistula,"Vascular Therapies, Inc.",INDUSTRY,269,2,4,1,2015-11,2021-06,True,269,228,41,15.2,Withdrawal by Subject (18); Death (14); Lost to Follow-up (6); Physician Decision (2); Adverse Event (1),Withdrawal by Subject,18.0,1
NCT00649389,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,cardiovascular disease,Hypertension,Daiichi Sankyo,INDUSTRY,2500,4,232,2,2008-05,2009-12,True,2492,2116,376,15.1,Adverse Event (154); Withdrawal by Subject (83); Lost to Follow-up (79); Protocol Violation (41); Other (19),Adverse Event,154.0,1
NCT00796367,A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787),obesity,Obesity,VIVUS LLC,INDUSTRY,676,3,0,0,2008-12,2010-07,True,676,574,102,15.1,Withdrawal by Subject (32); Lost to Follow-up (30); Adverse Event (17); other (9); non compliance (5); Requirement for restricted medication (4); Lack of Efficacy (3); Pregnancy (2),Withdrawal by Subject,32.0,1
NCT00676338,"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,820,4,106,22,2008-11,2011-01,True,820,696,124,15.1,Withdrawal by Subject (44); Protocol Violation (21); Adverse Event (18); Lack of Efficacy-Loss of Glucose Control (14); Lost to Follow-up (12); Physician Decision (11); Entry Criteria Not Met (4),Withdrawal by Subject,44.0,1
NCT05822830,A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities,obesity,Obesity; Overweight,Eli Lilly and Company,INDUSTRY,751,2,32,2,2023-04-21,2024-11-13,True,751,638,113,15.0,Withdrawal by Subject (53); Lost to Follow-up (34); Adverse Event (12); Assigned Treatment by Mistake (8); Pregnancy (3); Non-Compliance With Study Drug (2); Participant was Out of the Country (1),Withdrawal by Subject,53.0,1
NCT01375647,Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh,metabolic syndrome,Rotavirus Diarrhea; Vaccine Virus Shedding; Tropical Enteropathy,University of Vermont,OTHER,700,4,1,1,2011-05,2014-11,True,700,595,105,15.0,Withdrawal by Subject (77); Lost to Follow-up (23); Death (4); Physician Decision (1),Withdrawal by Subject,77.0,1
NCT00494013,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY),diabetes type 2,Diabetes Mellitus Type 2,Eli Lilly and Company,INDUSTRY,442,2,56,9,2007-08,2008-09,True,442,376,66,14.9,Withdrawal by Subject (27); Protocol Violation (13); Lost to Follow-up (11); Physician Decision (8); Entry Criteria Not Met (5); Adverse Event (1); Sponsor Decision (1),Withdrawal by Subject,27.0,1
NCT00300469,Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,cardiovascular disease,Mixed Dyslipidemia; Coronary Heart Disease; Dyslipidemia,Abbott,INDUSTRY,613,6,1,1,2006-03,,True,609,518,0,14.9,,,,1
NCT00789191,Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,222,2,51,8,2008-11,2009-08,True,222,189,33,14.9,Protocol Violation (8); Unclassified (8); Adverse Event (6); Withdrawal Criteria (6); Lack of Efficacy (5),Protocol Violation,8.0,1
NCT00475852,A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure,cardiovascular disease,Heart Decompensation,"Scios, Inc.",INDUSTRY,7141,2,328,28,2007-05,2011-03,True,7141,6076,1065,14.9,Death (900); Lost to Follow-up (122); Withdrawal by Subject (43),Death,900.0,1
NCT02798471,Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE),cardiovascular disease,Venous Thromboembolism (VTE); Pulmonary Embolism; Deep Vein Thrombosis (DVT),Daiichi Sankyo,INDUSTRY,290,2,140,34,2017-03-27,2022-05-24,True,290,247,43,14.8,"Physician Decision (10); Adverse Event (9); Other (8); Subject withdrew consent (6); Death (5); Data entry error (reported as study completion and study discontinuation) (2); Randomized, but not treated (2); Lost to Follow-up (1)",Physician Decision,10.0,1
NCT01652729,"Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus",diabetes type 2,Diabetes Type 2,AstraZeneca,INDUSTRY,365,3,60,1,2013-02,2014-04,True,365,311,54,14.8,Withdrawal by Subject (28); Lost to Follow-up (15); Adverse Event (7); Physician Decision (2); Protocol Violation (1); Administrative (1),Withdrawal by Subject,28.0,1
NCT01215253,Ranolazine Implantable Cardioverter-Defibrillator Trial,cardiovascular disease,Ischemic Cardiomyopathy; Nonischemic Cardiomyopathy; Heart Failure,University of Rochester,OTHER,1012,2,90,2,2011-09,2017-02-28,True,1012,863,149,14.7,Withdrawal by Subject (92); Other (26); Physician Decision (21); Lost to Follow-up (10),Withdrawal by Subject,92.0,1
NCT00487240,Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 1",Eli Lilly and Company,INDUSTRY,387,2,28,9,2007-06,2008-08,True,387,330,57,14.7,Withdrawal by Subject (18); Lost to Follow-up (13); Protocol Violation (10); Entry Criteria Not Met (7); Adverse Event (4); Sponsor Decision (3); Physician Decision (2),Withdrawal by Subject,18.0,1
NCT00082381,Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin,diabetes type 2,"Diabetes Mellitus, Type 2",AstraZeneca,INDUSTRY,551,2,91,13,2003-06,2008-07,True,551,470,81,14.7,Adverse Event (29); Protocol Violation (21); Lost to Follow-up (12); Patient Decision (12); Loss of Glucose Control (4); Physician Decision (3),Adverse Event,29.0,1
NCT00300456,Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,cardiovascular disease,Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia,Abbott,INDUSTRY,657,6,1,1,2006-03,,True,650,555,0,14.6,,,,1
NCT01472185,Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Gilead Sciences,INDUSTRY,465,2,159,10,2011-11,2013-10,True,465,397,68,14.6,Subject Noncompliance (23); Adverse Event Other than Hyperglycemia (13); Subject Withdrew Consent (9); Hyperglycemia (7); Protocol Violation (6); Lost to Follow-up (5); Investigator's Discretion (4); Randomized but Not Treated (1),Subject Noncompliance,23.0,1
NCT03859427,A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma,cardiovascular disease,Relapsed or Refractory Multiple Myeloma,Amgen,INDUSTRY,454,2,108,17,2019-05-08,2023-03-31,True,454,388,66,14.5,Death (47); Withdrawal by Subject (11); Lost to Follow-up (5); Decision by sponsor (3),Death,47.0,1
NCT02414841,A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2),cardiovascular disease,Chronic Kidney Disease,Proteon Therapeutics,INDUSTRY,696,2,41,2,2015-08,2019-05-01,True,613,524,89,14.5,Death (31); Lost to Follow-up (19); Received a Kidney Transplant (17); Withdrawal by Subject (12); Randomized But Not Treated (10),Death,31.0,1
NCT05093933,A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035),heart failure,Chronic Heart Failure With Reduced Ejection Fraction,Merck Sharp & Dohme LLC,INDUSTRY,6106,2,519,36,2021-11-02,2025-02-05,True,6105,5219,886,14.5,Death (806); Withdrawal by Subject (43); Lost to Follow-up (29); Sponsor Decision (4); Physician Decision (2); Withdrawal by Guardian (2),Death,806.0,1
NCT00032487,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),diabetes type 2,Type 2 Diabetes Mellitus,VA Office of Research and Development,FED,1791,2,21,2,2000-12-01,2008-05-30,True,1791,1532,259,14.5,Lost to Follow-up (115); Withdrawal by Subject (110); Had other reason (24); Adverse Event (10),Lost to Follow-up,115.0,1
NCT02235909,An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension,cardiovascular disease,Hypertension,"Arbor Pharmaceuticals, Inc.",INDUSTRY,377,13,69,12,2015-03-30,2019-11-11,True,215,184,0,14.4,,,,3
NCT01524289,Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020),dyslipidemia,"Hyperlipoproteinemia Type II; Hypercholesterolemia, Familial",Merck Sharp & Dohme LLC,INDUSTRY,306,2,0,0,2012-02-03,2018-11-13,True,306,262,44,14.4,Withdrawal by Subject (18); Adverse Event (17); Protocol Violation (6); Lost to Follow-up (1); Physician Decision (1); Did not take study medication (1),Withdrawal by Subject,18.0,1
NCT00266695,Treatment for Completers of the Study B7A-MC-MBCM,cardiovascular disease,Diabetic Retinopathy,"Chromaderm, Inc.",INDUSTRY,203,1,29,1,2006-01,2008-08,True,203,174,29,14.3,Withdrawal by Subject (15); Death (9); Lost to Follow-up (3); Adverse Event (1); Physician Decision (1),Withdrawal by Subject,15.0,1
NCT02833948,"Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)",cardiovascular disease,Aortic Valve Stenosis; Cardiovascular Diseases; Heart Valve Diseases; Ventricular Outflow Obstruction; Thrombosis,ECRI bv,INDUSTRY,231,2,25,7,2016-05,2019-03-06,True,231,198,33,14.3,were not scanned (21); scans could not be evaluated (7); Death (5),were not scanned,21.0,1
NCT02918279,Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity,obesity,Metabolism and Nutrition Disorder; Obesity,Novo Nordisk A/S,INDUSTRY,251,2,33,5,2016-09-29,2019-08-08,True,251,215,36,14.3,Withdrawal by Subject (20); Lost to Follow-up (9); Other (4); Withdrawal by parent/guardian (3),Withdrawal by Subject,20.0,1
NCT00847626,Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension,cardiovascular disease,Hypertension,Takeda,INDUSTRY,1711,11,99,5,2009-01,2010-07,True,1715,1470,245,14.3,Adverse Event (103); Withdrawal by Subject (65); Lack of Efficacy (28); Other (25); Protocol Violation (12); Lost to Follow-up (12),Adverse Event,103.0,1
NCT00397631,Initial Combination With Pioglitazone Study (0431-064),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,520,2,0,0,2006-12-19,2008-06-28,True,520,446,74,14.2,Withdrawal by Subject (21); Lack of Efficacy (17); Lost to Follow-up (17); Adverse Event (11); protocol discontinuation criteria (5); Physician Decision (2); Protocol Violation (1),Withdrawal by Subject,21.0,1
NCT02110901,A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1),cardiovascular disease,Chronic Kidney Disease,Proteon Therapeutics,INDUSTRY,349,2,35,1,2014-07,2018-12,True,311,267,44,14.1,Lost to Follow-up (20); Withdrawal by Subject (10); Death (9); received a kidney transplant (5),Lost to Follow-up,20.0,1
NCT01729871,A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy,cardiovascular disease,Atrial Fibrillation,"Janssen Scientific Affairs, LLC",INDUSTRY,253,2,44,5,2013-02,2014-10,True,248,213,35,14.1,Adverse Event (14); Other (13); Withdrawal by Subject (3); Physician Decision (2); Death (1); Lack of Efficacy (1); Protocol Violation (1),Adverse Event,14.0,1
NCT01535261,Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion,cardiovascular disease,Macular Edema; Central Retinal Vein Occlusion,Novartis Pharmaceuticals,INDUSTRY,357,1,78,18,2012-02,2015-03,True,357,307,50,14.0,Withdrawal by Subject (14); Adverse Event (12); Physician Decision (8); Lost to Follow-up (8); Death (5); Protocol Violation (3),Withdrawal by Subject,14.0,1
NCT01003184,Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,222,2,34,2,2009-10,2011-12,True,222,191,31,14.0,Adverse Event (17); Withdrawal by Subject (7); Protocol Violation (3); Loss of glucose control (2); Lost to Follow-up (1); Physician Decision (1),Adverse Event,17.0,1
NCT01680341,Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,272,2,45,5,2012-08-31,2013-08-22,True,272,234,38,14.0,Unclassified (33); Adverse Event (5),Unclassified,33.0,1
NCT02440022,Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae,cardiovascular disease,Arteriovenous Fistula,C. R. Bard,INDUSTRY,285,2,23,1,2015-06,2018-06,True,285,245,0,14.0,,,,1
NCT01009580,Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,447,2,53,10,2009-11-05,2010-08-23,True,447,385,62,13.9,Unclassified (38); Withdrawal Criteria (10); Adverse Event (8); Protocol Violation (5); Lack of Efficacy (1),Unclassified,38.0,1
NCT02229227,Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2",GlaxoSmithKline,INDUSTRY,814,2,157,14,2014-11-21,2017-07-24,True,814,701,113,13.9,Adverse Event (23); Study terminated by sponsor (22); Withdrawal by Subject (20); Physician Decision (17); Protocol Violation (14); Lack of Efficacy (6); Lost to Follow-up (6); Protocol defined stopping criteria (4); Other (1),Adverse Event,23.0,1
NCT03683030,Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation,cardiovascular disease,Atrial Fibrillation,"Biosense Webster, Inc.",INDUSTRY,397,1,41,3,2018-10-22,2022-02-18,True,397,342,55,13.9,Enrolled but no catheter inserted (24); Enrolled but screen failures (19); Lost to Follow-up (6); Withdrawal by Subject (2); Death (2); Early termination by subject (1); Catheter inserted but did not undergo ablation (1),Enrolled but no catheter inserted,24.0,1
NCT01582854,Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI),cardiovascular disease,Post-Stroke Cognitive Impairment (PSCI),Takeda,INDUSTRY,503,2,14,3,2012-06,2014-11,True,503,433,70,13.9,Recurrent Stroke (21); Withdrawal by Participant (19); Death (13); Adverse Event (5); Disallowed Concomitant Medication (5); Lost to Follow-up (3); Physician Decision (1); Carotid or Neurosurgery (1); General Anaesthesia (1); Other Miscellaneous Reason (1),Recurrent Stroke,21.0,1
NCT00570739,"Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.",diabetes type 2,Type 2 Diabetes Mellitus; Hypercholesterolemia; Pre-diabetes,Daiichi Sankyo,INDUSTRY,502,4,31,4,2007-11,2009-05,True,502,432,70,13.9,Withdrawal by Subject (22); Adverse Event (18); Lost to Follow-up (14); Other (10); Met discontinuation criteria (3); Physician Decision (2); Required restricted medication (1),Withdrawal by Subject,22.0,1
NCT01306214,Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2; Obesity",Boehringer Ingelheim,INDUSTRY,566,3,103,14,2011-02,2013-04,True,566,488,78,13.8,Withdrawal by Subject (62); Lost to Follow-up (12); Not treated (3); Death (1),Withdrawal by Subject,62.0,1
NCT01310777,Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension,hypertension,Open-Angle Glaucoma; Ocular Hypertension,Alcon Research,INDUSTRY,771,3,0,0,2011-05,2013-01,True,560,483,77,13.8,Adverse Event (39); Inadequate Control of IOP (22); Other (7); Lost to Follow-up (5); Patient's Decision Unrelated to AE (4),Adverse Event,39.0,1
NCT01045447,"Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes",diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,465,2,65,9,2010-01,2010-10,True,465,401,64,13.8,Unclassified (30); Withdrawal Criteria (20); Protocol Violation (9); Lack of Efficacy (4); Adverse Event (1),Unclassified,30.0,1
NCT02064439,Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism),cardiovascular disease,Pulmonary Embolism; Thromboembolism; Thrombosis; Venous Thrombosis; Venous Thromboembolism,Bayer,INDUSTRY,3365,3,266,31,2014-03-05,2016-11-04,True,3365,2902,463,13.8,Adverse Event (144); Efficacy outcome reached (91); Withdrawal by Subject (73); Non-compliance with study medication (63); Safety outcome reached (42); Logistical difficulties (13); Protocol Violation (11); Other (11); Lost to Follow-up (8); Death (5); Physician Decision (2),Adverse Event,144.0,1
NCT02161562,OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients,cardiovascular disease,Chronic Spontaneous Urticaria,Novartis Pharmaceuticals,INDUSTRY,314,2,35,8,2014-08-01,2016-11-03,True,314,271,43,13.7,Withdrawal by Subject (13); Protocol Violation (13); Lack of Efficacy (5); Lost to Follow-up (4); Pregnancy (3); Adverse Event (2); Participant moved back to home country (1); Withdrew due to being out of the country (1); Participant moved out of province (1),Withdrawal by Subject,13.0,1
NCT00276380,A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke,cardiovascular disease,"Stroke, Acute; Neurological Impairment",Ipsen,INDUSTRY,204,2,10,4,2003-02,2009-03,True,204,176,28,13.7,Withdrawal by Subject (9); Adverse Event (8); Death (8); Lost to Follow-up (2); Abnormal aPPT Levels (1),Withdrawal by Subject,9.0,1
NCT00395746,Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,264,4,1,1,2006-10,2008-05,True,264,228,36,13.6,Lack of Efficacy (19); Adverse Event (9); Hypoglycaemia (3); Protocol Violation (1); Subject decision (1); Withdrawal of consent (1); Difficultulty in use of device (1); Unable to visit site on schedule (1),Lack of Efficacy,19.0,1
NCT00360334,A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,235,2,31,1,2006-06,2008-04,True,235,203,32,13.6,Adverse Event (11); Subject decision (10); Physician Decision (5); Entry criterion not met (3); Protocol Violation (2); Lack of Efficacy (1),Adverse Event,11.0,1
NCT02558296,Bexagliflozin Efficacy and Safety Trial,diabetes type 2,Type 2 Diabetes Mellitus,Theracos,INDUSTRY,1700,2,157,10,2015-10,2019-10-23,True,1700,1469,300,13.6,"Withdrawal by Subject (114); Death (78); Lost to Follow-up (63); Adverse Event (31); Physician Decision (7); Protocol Violation (5); The subject was randomized, but did not take any investigational product (2)",Withdrawal by Subject,114.0,2
NCT01191450,Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension,cardiovascular disease,Arterial Hypertension,Eurofarma Laboratorios S.A.,INDUSTRY,246,2,10,1,2011-08,2013-08,True,243,210,0,13.6,,,,1
NCT00300482,Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood,cardiovascular disease,Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia,Abbott,INDUSTRY,1445,6,1,1,2006-03,,True,1439,1243,0,13.6,,,,1
NCT02277691,A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension,cardiovascular disease,Essential Hypertension,Takeda,INDUSTRY,341,1,38,1,2014-11-07,2016-04-25,True,341,295,46,13.5,Pretreatment Event/Adverse Event (33); Voluntary Withdrawal (7); Lack of Efficacy (5); Used Other Antihypertensive Drug (1),Pretreatment Event/Adverse Event,33.0,1
NCT01068678,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,460,2,99,8,2010-02,2010-11,True,460,398,62,13.5,Unclassified (33); Withdrawal criteria (18); Protocol Violation (6); Lack of Efficacy (5),Unclassified,33.0,1
NCT00859898,Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,1093,3,123,6,2009-04,2010-05,True,638,552,86,13.5,Withdrawal by Subject (30); Lost to Follow-up (26); Adverse Event (21); non-specified (3); Lack of Efficacy (2); poor/non-compliance (2); Death (1); No longer meets criteria (1),Withdrawal by Subject,30.0,1
NCT01294436,Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus,diabetes type 2,Type2 Diabetes; High Blood Sugar,AstraZeneca,INDUSTRY,728,1,38,1,2011-02,2012-09,True,728,630,98,13.5,Withdrawal by Subject (39); Adverse Event (27); subject no longer meets study criteria (25); poor/non-compliance (7),Withdrawal by Subject,39.0,1
NCT01181102,"A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty",cardiovascular disease,Venous Thromboembolism,"Daiichi Sankyo Co., Ltd.",INDUSTRY,716,2,3,2,2009-03,2010-02,True,716,619,97,13.5,Adverse Event (54); Withdrawal by Subject (22); Protocol Violation (11); Lack of Efficacy (4); Physician Decision (4); Lost to Follow-up (2),Adverse Event,54.0,1
NCT00643851,An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,994,3,99,7,2008-06,2009-08,True,598,518,80,13.4,"Withdrawal by Subject (32); Lost to Follow-up (19); Adverse Event (14); Non-compl., not met criteria, etc. (13); Death (1); Lack of Efficacy (1)",Withdrawal by Subject,32.0,1
NCT01076088,Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,744,6,0,0,2010-11-15,2012-12-24,True,744,644,100,13.4,Withdrawal by Subject (68); Adverse Event (18); Lost to Follow-up (6); Physician Decision (6); Non-compliance with study drug (1); Other protocol specified criteria (1),Withdrawal by Subject,68.0,1
NCT01370603,A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1),dyslipidemia,Hypercholesterolemia,Organon and Co,INDUSTRY,328,2,0,0,2011-09,2012-05,True,328,284,44,13.4,Adverse Event (16); Withdrawal by Subject (16); Lost to Follow-up (5); Protocol Violation (5); Non-compliance with Study Drug (2),Adverse Event,16.0,3
NCT00798161,"Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design",diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,857,6,138,14,2008-12,,True,857,743,114,13.3,Other reason (incl. lack of efficacy) (31); Adverse Event (30); Withdrawal by Subject (24); Lost to Follow-up (15); Protocol Violation (14),Other reason (incl. lack of efficacy),31.0,1
NCT00996658,Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,278,2,52,4,2009-10,,True,278,241,37,13.3,Other (16); Adverse Event (7); Lost to Follow-up (7); Non-compliance issues (6); Protocol Violation (1),Other,16.0,1
NCT01517412,Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin,diabetes type 2,Type 2 Diabetes Mellitus,Sanofi,INDUSTRY,451,2,82,10,2012-02,2013-05,True,451,391,60,13.3,Adverse Event (21); Lack of Efficacy (15); Other than specified above (13); Poor compliance to protocol (11),Adverse Event,21.0,1
NCT02270736,Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability,cardiovascular disease,Chronic Troublesome Sialorrhea; Cerebral Palsy; Stroke; Traumatic Brain Injury; Intellectual Disability,Merz Pharmaceuticals GmbH,INDUSTRY,256,5,31,6,2015-02-09,2019-05-07,True,256,222,31,13.3,"Withdrawal by Subject (19); Adverse Event (5); Lost to Follow-up (3); Lack of Efficacy (2); Randomized, not Treated (1); Physician Decision (1)",Withdrawal by Subject,19.0,2
NCT01029886,Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,912,2,108,21,2010-01,2011-04,True,912,791,121,13.3,Adverse Event (37); Withdrawal by Subject (26); Protocol Violation (22); Entry Criteria Not Met (18); Physician Decision (8); Loss Glucose Control (8); Lost to Follow-up (1); Sponsor Decision (1),Adverse Event,37.0,1
NCT01648582,A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,774,3,30,4,2012-07,2014-12,True,774,672,102,13.2,Withdrawal by Subject (49); Lost to Follow-up (23); Adverse Event (19); Protocol Violation (4); Physician Decision (4); Sponsor Decision (2); Death (1),Withdrawal by Subject,49.0,1
NCT01779362,RISE Adult Medication Study,diabetes type 2,Prediabetes; Type 2 Diabetes,RISE Study Group,NETWORK,267,4,4,1,2013-04,2019-08,True,267,232,0,13.1,,,,1
NCT00546052,"A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)",cardiovascular disease,Hypertension; Metabolic Disorder,Organon and Co,INDUSTRY,1738,1,0,0,2005-09-01,2008-01-01,True,1738,1511,227,13.1,Lost to Follow-up (144); Adverse Event (47); Withdrawal by Subject (20); Protocol Violation (9); Non Compliance (7),Lost to Follow-up,144.0,1
NCT02561078,An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,420,2,57,2,2015-10-20,2017-05-09,True,420,365,55,13.1,Withdrawal by Subject (23); Non-Compliance with Study Drug (9); Lost to Follow-up (8); Adverse Event (7); Physician Decision (5); Death (3),Withdrawal by Subject,23.0,1
NCT00449930,Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,1050,2,0,0,2007-03-01,2008-07-25,True,1050,914,136,13.0,Withdrawal by Subject (39); Protocol Violation (29); Adverse Event (28); Lost to Follow-up (23); Lack of Efficacy (11); Physician Decision (3); Glycemic discontinuation criteria (2); Trial Terminated ( Site Closed) (1),Withdrawal by Subject,39.0,1
NCT00086502,Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2",Merck Sharp & Dohme LLC,INDUSTRY,353,2,0,0,2004-06,2005-11,True,353,307,46,13.0,Adverse Event (13); Withdrawal by Subject (11); Protocol Violation (6); Lost to Follow-up (4); Protocol Discontinuation Criteria (4); Lack of Efficacy (2); Physician Decision (2); Patient Moved (2); Pregnancy (1); Patient Accidentally Unblinded (1),Adverse Event,13.0,1
NCT04588259,"Research Study to Compare a New Medicine ""Fast-acting Insulin Aspart"" to Another Medicine ""Insulin Aspart"" in Chinese People With Diabetes",diabetes type 2,"Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,331,2,40,2,2020-10-09,2022-08-05,True,331,288,43,13.0,Run-in failure (23); Withdrawal by Subject (12); Withdrawn before randomisation (8),Run-in failure,23.0,2
NCT00097786,Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications,diabetes type 2,"Diabetes Mellitus, Type 2",Novartis Pharmaceuticals,INDUSTRY,9306,4,38,38,2002-01,2009-10,True,9306,8095,1211,13.0,lost to follow-up for all-cause death (1211),lost to follow-up for all-cause death,1211.0,1
NCT01494987,Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Gilead Sciences,INDUSTRY,431,2,140,12,2012-01,2013-08,True,431,375,56,13.0,Subject Non-Compliance (19); Adverse Event (11); Hyperglycemia (10); Protocol Violation (6); Subject Withdrew Consent (5); Investigator's Discretion (3); Lost to Follow-up (2),Subject Non-Compliance,19.0,1
NCT00887978,Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension,cardiovascular disease,Pulmonary Hypertension,United Therapeutics,INDUSTRY,310,2,62,12,2009-06,2011-07,True,310,270,40,12.9,Adverse Event (23); Clinical Worsening (8); Death (5); Withdrawal by Subject (3); Lost to Follow-up (1),Adverse Event,23.0,1
NCT03551496,The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia,cardiovascular disease,Critical Limb Ischemia,Boston Scientific Corporation,INDUSTRY,201,2,42,5,2018-08-31,2023-12-20,True,201,175,26,12.9,Death (18); Withdrawal by Subject (7); Other Reasons (1),Death,18.0,1
NCT02681094,"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes",diabetes type 2,Type 2 Diabetes Mellitus; Inadequate Glycaemic Control,AstraZeneca,INDUSTRY,905,3,110,6,2016-02-26,2017-07-15,True,883,770,264,12.8,Participant decision (52); Study specific discontinuation criteria (50); Study-specific discontinuation criteria (44); Lack of therapeutic response (40); Other (38); Adverse Event (30); Severe non-compliance to protocol (6); No treatment given (4),Participant decision,52.0,2
NCT01068665,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,460,2,116,8,2010-03,2010-11,True,460,401,59,12.8,Other (29); Withdrawal Criteria (12); Adverse Event (9); Protocol Violation (7); Lack of Efficacy (2),Other,29.0,1
NCT01421459,A Study in Adults With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,759,2,62,12,2011-09,2012-09,True,759,662,97,12.8,Withdrawal by Subject (28); Physician Decision (18); Lost to Follow-up (17); Adverse Event (16); Protocol Violation (13); Lack of Efficacy (3); Death (2),Withdrawal by Subject,28.0,1
NCT01164501,Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment,diabetes type 2,"Diabetes Mellitus, Type 2; Renal Insufficiency",Boehringer Ingelheim,INDUSTRY,741,3,127,15,2010-07,2012-07,True,741,646,95,12.8,"Adverse Event (43); Patient refusal to continue,not due toAE (22); Other reason not defined above (14); Non compliant with protocol (6); Lost to Follow-up (6); Not treated (3); Lack of Efficacy (1)",Adverse Event,43.0,1
NCT02033889,A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).,diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,621,3,0,0,2013-12-13,2017-08-03,True,621,542,79,12.7,Withdrawal by Subject (41); Lost to Follow-up (19); Adverse Event (7); Death (6); Excluded Medication (2); Physician Decision (2); Non-Compliance With Study Drug (1); Participant moved (1),Withdrawal by Subject,41.0,1
NCT00437645,Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension,cardiovascular disease,Essential Hypertension,Novartis Pharmaceuticals,INDUSTRY,1183,2,12,12,2007-01,2007-11,True,1183,1033,150,12.7,Adverse Event (99); Withdrawal by Subject (32); Protocol Violation (6); Lost to Follow-up (5); Administrative problems (3); Lack of Efficacy (3); Condition no longer requires study drug (2),Adverse Event,99.0,1
NCT00558259,Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE,cardiovascular disease,Venous Thromboembolism,Boehringer Ingelheim,INDUSTRY,1353,2,147,21,2007-11,,True,1343,1173,170,12.7,Adverse Event (131); Withdrawal by Subject (25); Protocol Violation (14),Adverse Event,131.0,1
NCT01095653,A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,1179,3,39,4,2010-06,2012-03,True,393,343,50,12.7,"non-compliance, not met criteria, etc. (21); Withdrawal by Subject (12); Adverse Event (9); Lost to Follow-up (5); Lack of Efficacy (3)","non-compliance, not met criteria, etc.",21.0,1
NCT00256867,A Study In Patients With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2",GlaxoSmithKline,INDUSTRY,369,0,85,6,2005-08-18,2006-10-31,True,369,322,47,12.7,Lost to Follow-up (14); Adverse Event (12); Withdrawal by Subject (11); Protocol Violation (3); Fasting plasma glucose >240 mg/dL (1); Glycemia over 13.3 millimole per litre (1); Investigator's Decision (1); Non-compliance with study medication (1); Participant travelled Overseas (1); Participant out of assessment window (1); Withdrawal by participant (1),Lost to Follow-up,14.0,1
NCT00489541,TAXUS PERSEUS Small Vessel,cardiovascular disease,Coronary Artery Disease,Boston Scientific Corporation,INDUSTRY,224,1,28,1,2007-07,2013-10,True,349,305,58,12.6,No 9-Month Angiography Performed (35); Not Evaluable for 9-Month Angiography (9); Withdrawal by Subject (5); Death (5); Lost to Follow-up (2); Missed 12-Month Visit (2),No 9-Month Angiography Performed,35.0,2
NCT00667719,A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension,cardiovascular disease,Essential Hypertension,Novartis,INDUSTRY,564,1,8,8,2008-06-05,2009-10-05,True,564,493,71,12.6,Adverse Event (39); Withdrawal by Subject (17); Lost to Follow-up (8); Unsatisfactory Therapeutic Effect (3); Protocol Violation (3); Abnormal Test Procedure (1),Adverse Event,39.0,1
NCT04252287,"A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure",cardiovascular disease,Heart Failure,"Janssen Research & Development, LLC",INDUSTRY,476,2,18,1,2020-03-10,2021-11-09,True,476,416,60,12.6,Withdrawal by Subject (35); Lost to Follow-up (10); Death (8); Protocol Violation (7),Withdrawal by Subject,35.0,1
NCT00683878,Add-on to Thiazolidinedione (TZD) Failures,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,972,3,89,9,2008-07,2010-06,True,420,367,53,12.6,"Withdrawal by Subject (23); Adverse Event (10); Lost to Follow-up (10); Non-compliance, not met criteria etc. (5); Lack of Efficacy (4); Death (1)",Withdrawal by Subject,23.0,1
NCT00846365,Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension,cardiovascular disease,Essential Hypertension,Takeda,INDUSTRY,1085,3,80,3,2009-03,2010-06,True,1085,948,137,12.6,Adverse Event (61); Withdrawal by Subject (31); Other (16); Lost to Follow-up (15); Protocol Violation (9); Lack of Efficacy (4); Pregnancy (1),Adverse Event,61.0,1
NCT01151410,"An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age",cardiovascular disease,Hypertension,Novartis Pharmaceuticals,INDUSTRY,208,2,36,7,2010-08,2015-08,True,208,182,26,12.5,Withdrawal by Subject (8); Lost to Follow-up (7); Adverse Event (3); Protocol deviation (3); Administrative problems (2); Unsatisfactory therapeutic effect (2); Abnormal laboratory value(s) (1),Withdrawal by Subject,8.0,1
NCT01059812,A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,424,2,46,5,2010-02-01,2010-12-23,True,424,371,53,12.5,Unclassified (18); Adverse Event (14); Withdrawal Criteria (13); Lack of Efficacy (4); Protocol Violation (4),Unclassified,18.0,1
NCT01031680,"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension",diabetes type 2,Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control,AstraZeneca,INDUSTRY,922,2,140,9,2010-02,2012-12,True,922,807,115,12.5,Subject No Longer Meets Study Criteria (43); Withdrawal by Subject (28); Lost to Follow-up (12); Adverse Event (11); Poor/Non-compliance (11); Death (3); Incorrect Enrolment (3); Various (2); Safety (1); Administrative Reason by Sponsor (1),Subject No Longer Meets Study Criteria,43.0,1
NCT00463606,A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia,dyslipidemia,Hypercholesterolemia; Dyslipidemia,AstraZeneca,INDUSTRY,760,3,168,1,2007-04,2008-02,True,758,663,95,12.5,Adverse Event (50); Withdrawal by Subject (27); Lost to Follow-up (7); Subject noncompliance (2); Exclusion criteria violation (2); Subject moved out of town (1); Physician Decision (1); Sponsor request (1); Coordinator error (1); Patient randomized in error (1); Participation in another ABT-335 trial (1); Protocol Violation (1),Adverse Event,50.0,1
NCT02314637,Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients,diabetes type 2,Type 2 Diabetes Mellitus,Tanabe Pharma Corporation,INDUSTRY,240,2,1,1,2009-08,2011-07,True,240,210,30,12.5,Adverse Event (12); Withdrawal by Subject (9); Physician Decision (7); Lack of Efficacy (1); Other Reason (1),Adverse Event,12.0,1
NCT02227875,Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2),diabetes type 2,Type 2 Diabetes,Mylan Inc.,INDUSTRY,560,2,120,6,2014-08,2015-12,True,560,490,70,12.5,Withdrawal by Subject (25); Lost to Follow-up (20); Protocol Violation (17); Other (4); Adverse Event (3); Physician Decision (1),Withdrawal by Subject,25.0,1
NCT01986881,"Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)",diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,8246,3,0,0,2013-11-04,2019-12-27,True,8246,7212,1034,12.5,Death (708); Lost to Follow-up (150); Withdrawal by Subject (146); Physician Decision (17); Study Site Terminated by Sponsor (7); Other (5); Subject Moved (1),Death,708.0,1
NCT00888355,MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension,cardiovascular disease,Hypertension,Merck Sharp & Dohme LLC,INDUSTRY,428,4,0,0,1992-05,1993-02,True,428,375,53,12.4,Lack of Efficacy (18); Adverse Event (16); Protocol Violation (8); Withdrawal by Subject (7); Lost to Follow-up (4),Lack of Efficacy,18.0,1
NCT03952143,A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,628,2,41,3,2019-05-27,2021-01-20,True,628,550,78,12.4,Withdrawal by Subject (50); Physician Decision (7); Due to COVID 19 restrictions (7); Protocol Violation (6); Adverse Event (3); Lack of Efficacy (2); Lost to Follow-up (2); Participant had taken prohibited concomitant medication (1),Withdrawal by Subject,50.0,2
NCT01026194,Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,Tanabe Pharma Corporation,INDUSTRY,204,2,1,1,2009-12,2011-06,True,204,179,25,12.3,Adverse Event (12); Physician Decision (8); Withdrawal by Subject (4); Lack of Efficacy (1),Adverse Event,12.0,2
NCT00546754,BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333),cardiovascular disease,Hypertension,Organon and Co,INDUSTRY,808,2,0,0,2007-05-01,2009-05-01,True,808,709,99,12.3,"Adverse Event (27); Lost to Follow-up (24); Missing (21); Withdrawal by Subject (13); Protocol Violation (3); Serious Adverse Event (2); Lack of Efficacy (2); Dyspnea (1); Per Data Query, Less Than 4 Wks Coversyl (1); Hip Replacement (1); Suicide (1); Missing Cooperation (1); Elevated Creatinine and Potassium levels (1); Patient's Decision (1)",Adverse Event,27.0,1
NCT00143507,The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction,cardiovascular disease,"Coronary Disease; Ventricular Dysfunction, Left",Institut de Recherches Internationales Servier,OTHER,10917,2,1,1,2004-12,2008-02,True,10917,9578,1339,12.3,Death (1119); Withdrawal by Subject (216); Withdrawn by sponsor's decision (3); Lost to Follow-up (1),Death,1119.0,1
NCT01885559,HALT Progression of Polycystic Kidney Disease Study B,cardiovascular disease,"Kidney, Polycystic",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,486,2,7,1,2006-01,2014-06,True,486,426,60,12.3,Lost to Follow-up (31); Less than full participation (28); Protocol Violation (1),Lost to Follow-up,31.0,1
NCT01646320,Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,320,2,66,8,2012-09,2015-02,True,320,281,32,12.2,Lost to Follow-up (10); Adverse Event (9); Not reported (4); Withdrawal by Subject (4); Subject no longer meets study criteria (2); No longer meets study criteria (1); Other (1); Lack of Efficacy (1),Lost to Follow-up,10.0,2
NCT02447172,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,cardiovascular disease,"Foot Ulcer, Diabetic; Infection",Innocoll,INDUSTRY,524,3,91,16,2015-06,2016-09,True,524,460,64,12.2,Adverse Event (26); Lost to Follow-up (15); Withdrawal by Subject (9); Protocol Violation (5); protocol specific treatment unrelated (5); Death (4),Adverse Event,26.0,1
NCT01064687,A Study in Participants With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,978,4,89,4,2010-02,2012-05,True,978,860,118,12.1,Lost to Follow-up (35); Withdrawal by Subject (33); Adverse Event (26); Lack of Efficacy (6); Physician Decision (4); Entry Criteria Not Met (3); Protocol Violation (3); Sponsor Decision (3); Treatment Noncompliance (3); Death (2),Lost to Follow-up,35.0,1
NCT01128153,Saxagliptin Triple Oral Therapy,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,257,2,33,6,2010-06,2011-06,True,257,226,31,12.1,Condition under investigation worsened (15); Withdrawal by Subject (5); Adverse Event (4); Incorrect enrolment to study (3); Protocol Violation (2); Developed discontinuation criteria (2),Condition under investigation worsened,15.0,1
NCT00661362,Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,570,2,30,3,2008-06,2009-09,True,570,501,69,12.1,Withdrawal by Subject (36); Study specific discontinuation criteria (15); Adverse Event (9); Lost to Follow-up (4); Incorrect enrollment (2); Severe non-compliance to protocol (1); Safety reasons (1); Metformin dose haven't decreasd to 2.5 g (1),Withdrawal by Subject,36.0,1
NCT00168818,Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery,cardiovascular disease,"Thromboembolism; Arthroplasty, Replacement, Hip",Boehringer Ingelheim,INDUSTRY,3494,3,116,16,2004-11,,True,3463,3046,767,12.0,Adverse Event (317); Withdrawal by Subject (188); Other (159); Protocol Violation (68); Lost to Follow-up (35),Adverse Event,317.0,2
NCT00395343,Sitagliptin Added-on to Insulin Study (0431-051),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,641,2,0,0,2006-12-11,2008-10-13,True,641,564,77,12.0,Withdrawal by Subject (23); Adverse Event (18); Protocol Violation (14); Lost to Follow-up (8); Other (7); Physician Decision (6); Lack of Efficacy (1),Withdrawal by Subject,23.0,1
NCT00687882,Evaluation of the Duration of Therapy for Thrombosis in Children,cardiovascular disease,Venous Thrombosis,Johns Hopkins All Children's Hospital,OTHER,532,4,63,6,2008-03,2022-02-15,True,532,468,0,12.0,,,,1
NCT00591253,Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension,cardiovascular disease,Hypertension,Takeda,INDUSTRY,413,3,64,2,2007-10,2009-04,True,415,365,50,12.0,Withdrawal by Subject (14); Other (13); Adverse Event (7); Protocol Violation (6); Lost to Follow-up (6); Lack of Efficacy (4),Withdrawal by Subject,14.0,1
NCT02476006,"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)",cardiovascular disease,Hypercholesterolemia,Sanofi,INDUSTRY,998,1,153,16,2015-06-23,2019-04-12,True,998,878,120,12.0,Adverse Event (41); Participant did not wish to continue (39); Sponsor decision (6); Lost to Follow-up (5); Physician Decision (5); Death (4); Study ended treatment not available (4); Switched to commercial drug (4); Enrolled but not treated (4); Poor compliance to study protocol (3); Lack of treatment efficacy (2); Pregnancy (1); Excluded from study (1); Protocol Violation (1),Adverse Event,41.0,1
NCT01819129,Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,881,2,144,10,2013-09-09,2015-01-22,True,689,606,83,12.0,"Withdrawal Criteria (35); Withdrawal by Subject (30); Lost to Follow-up (7); Adverse Event (5); Death (2); Other, Subject wanted HbA1c to be > 7% (1); Other, weight gain, hypoglycaemic events (1); Other, Subject moved out of the country (1); Lack of Efficacy (1)",Withdrawal Criteria,35.0,1
NCT01798706,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients,diabetes type 2,Type 2 Diabetes,Sanofi,INDUSTRY,350,2,83,13,2013-06,2015-02,True,350,308,42,12.0,Adverse Event (25); Other than specified above (14); Lack of Efficacy (2); Poor compliance to protocol (1),Adverse Event,25.0,1
NCT00000620,Action to Control Cardiovascular Risk in Diabetes (ACCORD),diabetes type 2,"Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia; Hypertension; Diabetes Mellitus, Type 2; Diabetes Mellitus; Coronary Disease","National Heart, Lung, and Blood Institute (NHLBI)",NIH,10251,6,7,2,1999-09,2012-12,True,10251,9023,1228,12.0,Death (718); Withdrawal by Subject (237); missed closeout visit (160); Lost to Follow-up (113),Death,718.0,1
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,1405,5,211,22,2011-08,2013-09,True,1363,1201,226,11.9,Consent withdrawn (136); Lost to Follow-up (82); Death (8),Consent withdrawn,136.0,2
NCT01396057,Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO),cardiovascular disease,Visual Impairment; Macular Edema; Branch Retinal Vein Occlusion,Novartis Pharmaceuticals,INDUSTRY,244,2,66,5,2011-07,2013-06,True,244,215,29,11.9,Adverse Event (8); Unsatisfactory therapeutic effect (8); Protocol deviation (8); Consent withdrawn (5),Adverse Event,8.0,1
NCT00402363,"Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation",cardiovascular disease,"Fibrillation, Atrial",GlaxoSmithKline,INDUSTRY,663,2,178,1,2006-11,2010-01,True,663,584,79,11.9,"Adverse Event (27); Withdrew Consent (18); Captured as ""Other"" (12); Protocol Violation (11); Lost to Follow-up (11)",Adverse Event,27.0,1
NCT00654381,Japanese P III vs Voglibose and Placebo,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,561,4,47,1,2008-04,,True,561,494,67,11.9,Adverse Event (52); Withdrawal by Subject (8); Investigator's decision (3); Closure of the trial site (2); Protocol Violation (1); Lack of Efficacy (1),Adverse Event,52.0,3
NCT02809131,Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.,cardiovascular disease,Sick Sinus Syndrome; Complete Heart Block; Syncope; Chronic Systolic Heart Failure,Vanderbilt University Medical Center,OTHER,1010,2,1,1,2016-04-01,2021-09-30,True,1010,890,0,11.9,,,,1
NCT00529451,"Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg",cardiovascular disease,Hypertension,Novartis,INDUSTRY,1613,4,3,3,2007-09,2008-07,True,1316,1160,156,11.9,Subject withdrew consent (62); Adverse Event (47); Lost to Follow-up (19); Unsatisfactory therapeutic response (17); Protocol deviation (7); Administrative problems (4),Subject withdrew consent,62.0,1
NCT02865850,Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD),cardiovascular disease,Anemia; Dialysis-Dependent Chronic Kidney Disease,Akebia Therapeutics,INDUSTRY,369,2,118,11,2016-07,2020-03-30,True,369,325,44,11.9,Death (34); Withdrawal by Subject (5); Lost to Follow-up (5),Death,34.0,1
NCT00673231,"Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin",diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,1240,4,92,13,2008-04,2011-01,True,807,712,95,11.8,"Withdrawal by Subject (38); Adverse Event (26); Study criteria,compliance,safety, other (24); Lost to Follow-up (6); Death (1)",Withdrawal by Subject,38.0,1
NCT01318135,Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan,diabetes type 2,Type 2 Diabetes Mellitus,Takeda,INDUSTRY,576,4,0,0,2009-01,2010-04,True,576,508,64,11.8,Adverse Event (26); Lack of Efficacy (23); Withdrawal by Subject (10); Protocol Violation (3); Treatment Complications (1); Use of Excluded Medications (1),Adverse Event,26.0,2
NCT01703221,Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,414,3,0,0,2012-10-24,2014-04-25,True,414,365,49,11.8,Lack of Efficacy (28); Adverse Event (13); Withdrawal by Subject (6); Physician Decision (1); Protocol Violation (1),Lack of Efficacy,28.0,2
NCT00887250,A Study to Investigate the Antihypertensive Efficacy of MK0954,cardiovascular disease,Hypertension,Merck Sharp & Dohme LLC,INDUSTRY,366,3,0,0,1991-12,1992-11,True,366,323,43,11.7,Lack of Efficacy (16); Adverse Event (10); Lost to Follow-up (6); Protocol Violation (5); Withdrawal by Subject (5); Patient uncooperative (1),Lack of Efficacy,16.0,1
NCT00781391,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,cardiovascular disease,Stroke; Atrial Fibrillation; Embolism,Daiichi Sankyo,INDUSTRY,21105,3,1009,46,2008-11,2013-05,True,21105,18635,2470,11.7,Death (2225); Withdrawal by Subject (109); never received study drug (79); Protocol Violation (56); Lost to Follow-up (1),Death,2225.0,1
NCT02273050,Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control,diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,1136,3,17,1,2014-12,2016-08,True,640,565,75,11.7,Withdrawal by Subject (47); Adverse Event (10); Protocol Violation (8); Lost to Follow-up (5); Dev. of study spec. withdrawal criteria (2); Lack of Efficacy (2); Death (1),Withdrawal by Subject,47.0,1
NCT03211858,Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine,diabetes type 2,Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus,Sanofi,INDUSTRY,597,2,82,7,2017-08-02,2019-01-12,True,597,527,70,11.7,Other than specified above (43); Adverse Event (14); Poor compliance to protocol (8); Lack of Efficacy (4); Non-serious Hypoglycemia (1),Other than specified above,43.0,1
NCT00286741,Can Group Visits Improve Outcomes of Veterans With Diabetes,cardiovascular disease,Diabetes; Hypertension,US Department of Veterans Affairs,FED,239,2,2,1,2006-06,2009-01,True,239,211,0,11.7,,,,1
NCT00960076,An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,282,2,35,5,2009-08,2010-10,True,282,249,33,11.7,Adverse Event (8); No longer met study criteria (6); Lost to Follow-up (6); Hyperglycemia (6); Withdrawal by Subject (3); Severe non-compliance to protocol (3); Did not attend the termination visit (1),Adverse Event,8.0,1
NCT01968954,Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events,cardiovascular disease,Hyperlipidemia,Pfizer,INDUSTRY,711,2,103,9,2013-10,2016-04,True,711,628,83,11.7,Withdrawal by Subject (43); Other (15); Lost to Follow-up (10); Adverse Event (9); Death (3); Did not met inclusion criteria (2); Protocol Violation (1),Withdrawal by Subject,43.0,1
NCT01590771,A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,498,2,0,0,2012-07-09,2014-06-24,True,498,440,58,11.6,Withdrawal by Subject (23); Other Protocol Specified Criteria (19); Adverse Event (10); Protocol Violation (3); Lost to Follow-up (2); Lack of Efficacy (1),Withdrawal by Subject,23.0,1
NCT03242252,"Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control",diabetes type 2,Type 2 Diabetes Mellitus; Chronic Kidney Disease Stage 3,Lexicon Pharmaceuticals,INDUSTRY,787,3,170,16,2017-08-16,2019-10-25,True,787,696,91,11.6,At the Participant's own Request (43); Adverse Event (23); Lost to Follow-up (10); Reason not Specified (9); Poor Compliance to Protocol (5); Study Terminated by Sponsor (1),At the Participant's own Request,43.0,1
NCT00641056,Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3),diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,467,2,75,16,2008-04,2009-11,True,467,413,54,11.6,Subject Decision (25); Adverse Event (14); Physician Decision (4); Lost to Follow-up (3); Entry Criteria Not Met (3); Sponsor Decision (3); Protocol Violation (2),Subject Decision,25.0,1
NCT04740905,A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion,cardiovascular disease,Macular Edema; Branch Retinal Vein Occlusion,Hoffmann-La Roche,INDUSTRY,553,2,150,22,2021-03-02,2023-06-12,True,553,489,64,11.6,Withdrawal by Subject (26); Lost to Follow-up (15); Adverse Event (5); Death (4); Physician Decision (4); Protocol Violation (3); Non-Compliance With Study Drug (3); Patient Missed Week 72 Visit Due to SAE (2); Patient Could Not Return to Hospital Due to COVID-19 Epidemic (1); Patient Refused to Continue Study (1),Withdrawal by Subject,26.0,2
NCT02942576,Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation,cardiovascular disease,Atrial Fibrillation,"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company",INDUSTRY,632,2,75,11,2017-03-21,2018-09-24,True,602,533,69,11.5,Adverse Event (34); Other (18); Withdrawal by Subject (12); Physician Decision (5),Adverse Event,34.0,1
NCT01499082,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin,diabetes type 2,Type 2 Diabetes Mellitus,Sanofi,INDUSTRY,807,2,193,13,2011-12,2013-09,True,807,714,93,11.5,Diverse Reasons (32); Adverse Event (28); Protocol Violation (14); Site Closure for Noncompliance (7); Hypoglycemia (5); Lost to Follow-up (4); Lack of Efficacy (2); Randomized but not Treated (1),Diverse Reasons,32.0,1
NCT00760214,Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension,cardiovascular disease,Hypertension,Takeda,INDUSTRY,885,3,72,10,2008-01,2009-04,True,885,784,101,11.4,Withdrawal by Subject (39); Adverse Event (29); Other (13); Lack of Efficacy (9); Protocol Violation (6); Physician Decision (3); Lost to Follow-up (1); Pregnancy (1),Withdrawal by Subject,39.0,1
NCT01413204,Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,Tanabe Pharma Corporation,INDUSTRY,272,3,5,1,2011-07,2012-08,True,272,241,31,11.4,Fasting plasma glucose level increased (11); Withdrawal by Subject (9); Adverse Event (5); Physician Decision (5); Clearly not eligible for the study (1),Fasting plasma glucose level increased,11.0,1
NCT01012674,Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF),cardiovascular disease,Cerebral Arterial Diseases,Guerbet,INDUSTRY,211,1,1,1,2009-10,2010-12,True,211,187,0,11.4,,,,1
NCT03259789,Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects,diabetes type 2,Type2 Diabetes Mellitus,Theracos,INDUSTRY,351,3,43,2,2017-11-28,2019-01-23,True,351,311,40,11.4,Lost to Follow-up (18); Withdrawal by Subject (15); Adverse Event (6); Physician Decision (1),Lost to Follow-up,18.0,1
NCT00968708,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,diabetes type 2,"Diabetes Mellitus, Type 2; Acute Coronary Syndrome",Takeda,INDUSTRY,5380,2,908,50,2009-09,2013-06,True,5380,4764,616,11.4,Adverse Event (319); Voluntary Withdrawal (205); Other (60); Lost to Follow-up (30); Major Protocol Deviation (1); Investigator Discretion (1),Adverse Event,319.0,1
NCT00325780,Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia,dyslipidemia,Hypercholesterolemia; Dyslipidemia,Kowa Research Europe,INDUSTRY,1355,1,186,13,2006-07,2007-11,True,1355,1200,0,11.4,,,,1
NCT00736099,Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,2122,2,232,32,2008-08,,True,2121,1880,241,11.4,Adverse Event (79); Withdrawal by Subject (55); Other reason (53); Lack of Efficacy (23); Lost to Follow-up (17); Protocol Violation (14),Adverse Event,79.0,1
NCT00105027,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study,cardiovascular disease,"Macular Edema, Cystoid; Retinal Vein Occlusion","The Emmes Company, LLC",INDUSTRY,682,6,1,1,2004-10,2009-02,True,682,605,0,11.3,,,,1
NCT02926937,Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy,diabetes type 2,Type 2 Diabetes Mellitus,Lexicon Pharmaceuticals,INDUSTRY,399,3,70,3,2016-11-11,2019-05-17,True,399,354,45,11.3,At the Participant's own Request (24); Lost to Follow-up (9); Reason not Specified (9); Adverse Event (2); Poor Compliance to Protocol (1),At the Participant's own Request,24.0,1
NCT01326026,Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,222,2,45,4,2011-03,2011-12,True,222,197,25,11.3,Withdrawal Criteria (12); Adverse Event (7); Other (6),Withdrawal Criteria,12.0,1
NCT00243919,Locomotor Experience Applied Post Stroke Trial,cardiovascular disease,Stroke,Duke University,OTHER,408,3,8,1,2006-04,2012-06,True,408,362,46,11.3,Lost to Follow-up (16); Withdrawal by Subject (14); Death (13); Physician Decision (2); Administrative Error (1),Lost to Follow-up,16.0,1
NCT01582451,A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,466,2,61,9,2012-05,2013-12,True,466,414,52,11.2,Withdrawal by Subject (22); Protocol Violation (14); Death (6); Adverse Event (4); Physician Decision (3); Lost to Follow-up (2); Sponsor Decision (1),Withdrawal by Subject,22.0,1
NCT01006291,Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,687,3,72,14,2009-11,2010-09,True,687,610,77,11.2,Other (45); Withdrawal criteria (13); Protocol Violation (9); Adverse Event (5); Lack of Efficacy (5),Other,45.0,1
NCT02234843,EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis,cardiovascular disease,Venous Thromboembolism,Bayer,INDUSTRY,500,2,109,28,2014-11-13,2019-01-30,True,500,444,56,11.2,Withdrawal by Subject (14); Adverse Event (14); Physician Decision (7); Other (5); Efficacy outcome reached (4); Patient convenience (3); Non-compliance with study drug (3); Protocol Violation (2); Lost to Follow-up (2); Death (1); Recovery (1),Withdrawal by Subject,14.0,1
NCT04093752,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo),diabetes type 2,Type 2 Diabetes,Eli Lilly and Company,INDUSTRY,917,4,67,4,2019-12-09,2021-11-24,True,917,815,102,11.1,Adverse Event (48); Withdrawal by Subject (40); Lost to Follow-up (5); Death (3); Participant Could Not Continue Due to Work Related Reasons (2); Covid 19 (1); Participant Thought there were Too Many Adverse Events (1); Participant was Reluctant to Follow-up (1); Participant Did Not Come for the Visit (1),Adverse Event,48.0,1
NCT01619059,Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,315,2,83,9,2012-06,2015-01,True,315,280,34,11.1,"Withdrawal by Subject (12); Lost to Follow-up (10); Adverse Event (6); Non-compliance, not Met Study Criteria (3); Lack of Efficacy (1); Death (1); Not Met Study Criteria (1)",Withdrawal by Subject,12.0,2
NCT00976391,A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine,diabetes type 2,"Diabetes Mellitus, Type 2",GlaxoSmithKline,INDUSTRY,586,2,209,14,2009-09,2012-05,True,566,503,144,11.1,Lost to Follow-up (44); Withdrawal by Subject (39); Adverse Event (22); Did not Entered Follow-up (14); Noncompliance (12); Termination of Study/Site by GSK (8); Protocol Violation (2); Physician Decision (2); Pregnancy (1),Lost to Follow-up,44.0,2
NCT03285594,Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents,diabetes type 2,Type 2 Diabetes Mellitus,Lexicon Pharmaceuticals,INDUSTRY,571,3,106,8,2017-09-15,2019-09-27,True,571,508,63,11.0,At the Participant's Own Request (36); Reason Not Specified (15); Adverse Event (10); Poor Compliance to Protocol (1); Lost to Follow-up (1),At the Participant's Own Request,36.0,1
NCT00309751,Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia,diabetes type 2,Type II Diabetes Mellitus; Dyslipidemia,Kowa Research Europe,INDUSTRY,418,2,35,6,2005-12,2007-06,True,418,372,0,11.0,,,,1
NCT01854918,Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia,dyslipidemia,Hyperlipidemia and Mixed Dyslipidemia,Amgen,INDUSTRY,3681,2,363,25,2013-04-23,2018-05-31,True,3681,3275,406,11.0,Withdrawal by Subject (264); Lost to Follow-up (89); Death (31); Decision by Sponsor (22),Withdrawal by Subject,264.0,2
NCT04873934,Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome,cardiovascular disease,Acute Coronary Syndrome,Novartis Pharmaceuticals,INDUSTRY,400,2,88,1,2021-06-24,2024-08-07,True,400,356,44,11.0,Lost to Follow-up (22); Subject decision (9); Withdrew consent (4); Protocol deviation (3); Death (2); Physician Decision (2); Adverse Event (1); Missing (1),Lost to Follow-up,22.0,1
NCT00866658,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)",diabetes type 2,"Diabetes Mellitus, Type 2",Sanofi,INDUSTRY,311,2,4,4,2009-03,2010-06,True,311,277,34,10.9,Adverse Event (19); Familial and Personal Reasons (9); Lack of Efficacy (3); Protocol Violation (2); Withdrawal by Subject (1),Adverse Event,19.0,1
NCT03066830,Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin,diabetes type 2,Type 2 Diabetes Mellitus,Lexicon Pharmaceuticals,INDUSTRY,507,2,76,10,2017-02-24,2019-04-30,True,507,452,55,10.8,At the Participant's own Request (33); Lost to Follow-up (14); Adverse Event (4); Other (3); Poor Compliance to Protocol (1),At the Participant's own Request,33.0,1
NCT00841672,Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension,cardiovascular disease,Moderate to Severe Hypertension,Novartis,INDUSTRY,485,2,6,6,2009-01,2009-09,True,485,433,52,10.7,Adverse Event (23); Administrative problems (18); Subject withdrew consent (6); Lost to Follow-up (2); Abnormal test procedure result(s) (1); Misrandomized (1); Protocol Deviation (1),Adverse Event,23.0,1
NCT00984308,Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease,cardiovascular disease,Obstructive Sleep Apnea; Stroke; Transient Ischemic Attack; Hypertension,VA Office of Research and Development,FED,225,2,2,1,2008-12-23,2011-09-30,True,225,201,0,10.7,,,,1
NCT00429364,Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome,cardiovascular disease,Marfan Syndrome,Carelon Research,OTHER,608,2,26,3,2007-01,2014-02,True,608,543,65,10.7,Underwent aortic root surgery (28); Withdrawal by Subject (16); Lost to Follow-up (13); Physician Decision (6); Death (1); Pregnancy (1),Underwent aortic root surgery,28.0,1
NCT01075282,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2),diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,810,3,78,20,2010-02,2012-11,True,810,723,87,10.7,Withdrawal by Subject (29); Adverse Event (22); Lost to Follow-up (9); Physician Decision (9); Entry Criteria Not Met (5); Treatment Non-compliance (5); Protocol Violation (3); Death (3); Lack of Efficacy (2),Withdrawal by Subject,29.0,1
NCT01076647,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,467,2,105,7,2010-03,2010-12,True,467,417,50,10.7,Unclassified (24); Protocol Violation (16); Adverse Event (5); Withdrawal criteria (4); Lack of Efficacy (1),Unclassified,24.0,1
NCT02099110,"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)",diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,1233,5,0,0,2014-04-22,2016-05-26,True,1233,1101,132,10.7,Withdrawal by Subject (53); Lost to Follow-up (40); Adverse Event (15); Protocol Violation (7); Physician Decision (7); Participant moved (5); Non-compliance with study drug (3); Death (1); Screen failure (1),Withdrawal by Subject,53.0,1
NCT02207491,Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,hypertension,Ocular Hypertension; Open-angle Glaucoma,Aerie Pharmaceuticals,INDUSTRY,411,2,1,1,2014-07,2015-03,True,411,367,44,10.7,Adverse Event (24); Protocol Violation (8); Withdrawal by Subject (5); Lack of Efficacy (3); Physician Decision (2); Non-compliant (1); Lost to Follow-up (1),Adverse Event,24.0,1
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,986,5,124,9,2010-07,,True,986,881,105,10.6,Withdrawal by Subject (33); Lost to Follow-up (26); Adverse Event (23); Other reason not defined above (14); Protocol Violation (8); Lack of Efficacy (1),Withdrawal by Subject,33.0,1
NCT01492361,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin,cardiovascular disease,Cardiovascular Diseases,Amarin Pharma Inc.,INDUSTRY,8179,2,410,11,2011-11,2018-05,True,8179,7314,865,10.6,Withdrawal by Subject (578); Other than specified above (244); Physician Decision (24); Lost to Follow-up (19),Withdrawal by Subject,578.0,1
NCT00435045,"Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia",dyslipidemia,Hypertriglyceridemia,GlaxoSmithKline,INDUSTRY,245,2,0,0,2007-02,2007-10,True,245,219,26,10.6,Adverse Event (14); Withdrawal by Subject (5); Lost to Follow-up (4); Family Crisis - could not participate (1); Requirement for Excluded Medications (1); Per Sponsors Request (1),Adverse Event,14.0,3
NCT00439777,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study,cardiovascular disease,Pulmonary Embolism,Bayer,INDUSTRY,4833,2,305,39,2007-03,2011-12,True,4833,4321,960,10.6,Study terminated by sponsor (261); Adverse Event (203); Withdrawal by Subject (198); Death (97); Protocol Violation (55); Clinical endpoint reached (39); Lost to Follow-up (30); Physician Decision (25); Participant convenience (20); Did not take study treatment (15); Lack of Efficacy (6); Protocol driven decision point (5); Technical problems (5); Site closed by investigator (1),Study terminated by sponsor,261.0,2
NCT03954834,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,478,4,53,5,2019-06-03,2020-10-28,True,478,428,50,10.5,Withdrawal by Subject (24); Lost to Follow-up (13); Adverse Event (6); Physician Decision (3); Protocol Violation (2); Death (1); Participant left the country (1),Withdrawal by Subject,24.0,1
NCT02460978,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,diabetes type 2,Type 1 Diabetes Mellitus,AstraZeneca,INDUSTRY,815,3,136,13,2015-07-08,2018-04-18,True,813,728,85,10.5,Adverse Event (39); Withdrawal by Subject (24); Discontinued due to DKA/hypoglycemia (11); Lost to Follow-up (6); Protocol Violation (3); Pregnancy (2),Adverse Event,39.0,1
NCT02164864,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),cardiovascular disease,Atrial Fibrillation; Percutaneous Coronary Intervention,Boehringer Ingelheim,INDUSTRY,2725,3,421,41,2014-07-22,2017-06-05,True,2725,2438,287,10.5,"Other Adverse Event (AE) (133); Consent withdrawn, not due to AE (85); Other than stated (21); Other pre-existing disease worsening (19); Trial disease worsening (13); Lost to Follow-up (9); Protocol Violation (7)",Other Adverse Event (AE),133.0,1
NCT02586155,Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD,diabetes type 2,"Diabetes Mellitus, Type 2; Coronary Artery Disease",Resverlogix Corp,INDUSTRY,2425,2,214,15,2015-11,2021-06-21,True,2425,2171,254,10.5,Death (133); Withdrawal by Subject (55); Other reasons (41); Lost to Follow-up (20); Adverse Event (5),Death,133.0,1
NCT01177384,Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,380,2,0,0,2011-01-25,2013-03-25,True,381,341,40,10.5,Withdrawal by Subject (17); Adverse Event (10); Lost to Follow-up (7); Physician Decision (3); Protocol Violation (2); Lack of Efficacy (1),Withdrawal by Subject,17.0,1
NCT02715258,Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,Theracos,INDUSTRY,210,2,23,2,2016-03,2017-04,True,210,188,22,10.5,Lost to Follow-up (8); Withdrawal by Subject (7); GCP violation (3); Subject non-compliant (2); Terminated by Sponsor (1); Death (1),Lost to Follow-up,8.0,1
NCT00129402,Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579),dyslipidemia,Hypercholesterolemia,Organon and Co,INDUSTRY,248,2,0,0,2005-08,2007-06,True,248,222,26,10.5,Withdrawal by Subject (9); Adverse Event (5); Protocol Violation (4); Laboratory Adverse Event (4); Lost to Follow-up (3); Subject moved (1),Withdrawal by Subject,9.0,3
NCT00257686,Study to Compare the Efficacy and Safety of Pitavastatin and Pravastatin in Elderly Patients,dyslipidemia,Hypercholesterolemia or Combined Dyslipidemia,Kowa Research Europe,INDUSTRY,962,6,62,5,2005-09,2006-05,True,962,862,0,10.4,,,,1
NCT00680017,30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease,dyslipidemia,Dyslipidemia; Kidney Disease,AstraZeneca,INDUSTRY,280,2,114,2,2008-06,2011-04,True,280,251,29,10.4,Adverse Event (20); Withdrawal by Subject (7); Lost to Follow-up (2),Adverse Event,20.0,1
NCT03011450,Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment,dyslipidemia,Severe Hypertriglyceridemia,"Kowa Research Institute, Inc.",INDUSTRY,471,2,241,9,2016-11-26,2019-07-05,True,470,421,0,10.4,,,,2
NCT01217463,The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study,cardiovascular disease,Diabetic Foot Ulcer of Neuropathic Origin,Olympus Biotech Corporation,INDUSTRY,201,2,24,4,2010-11,2013-02,True,201,180,21,10.4,Adverse Event (13); Withdrawal by Subject (3); Other (2); Physician Decision (1); Surgery on the Target Limb (1); Patient Non-compliant (1),Adverse Event,13.0,1
NCT01134393,TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch,cardiovascular disease,Hypertension,Boehringer Ingelheim,INDUSTRY,502,1,47,5,2010-05,,True,501,449,52,10.4,Adverse Event (18); Protocol Violation (12); Withdrawal by Subject (11); Other (6); Lost to Follow-up (3); Lack of Efficacy (2),Adverse Event,18.0,1
NCT01318122,Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan,diabetes type 2,Type 2 Diabetes Mellitus,Takeda,INDUSTRY,336,2,0,0,2008-05,2009-08,True,326,292,34,10.4,Adverse Event (21); Withdrawal by Subject (6); Lack of Efficacy (5); Other (1); Lost to Follow-up (1),Adverse Event,21.0,2
NCT02551874,"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin",diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,650,2,40,10,2015-10-20,2017-11-10,True,650,583,67,10.3,Did not enter long-term study (43); Reason not reported (14); Did not receive randomized treatment (7); Lost to Follow-up (2); Pregnancy (1),Did not enter long-term study,43.0,1
NCT01976312,Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO),cardiovascular disease,Central Retinal Vein Occlusion,Novartis Pharmaceuticals,INDUSTRY,252,2,34,7,2013-11-12,2016-03-14,True,252,226,26,10.3,Adverse Event (12); Withdrawal by Subject (9); Lost to Follow-up (2); Protocol Violation (2); Pregnancy (1),Adverse Event,12.0,1
NCT01676116,The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,438,2,109,5,2012-08-29,2014-03-11,True,438,393,45,10.3,Withdrawal criteria (16); Unclassified (14); Protocol Violation (12); Adverse Event (3),Withdrawal criteria,16.0,1
NCT01556997,Perindopril Amlodipine for the Treatment of Hypertension,cardiovascular disease,Essential Hypertension,Symplmed Pharmaceuticals LLC,INDUSTRY,837,3,48,1,2012-02,2013-02,True,837,751,86,10.3,Adverse Event (34); Withdrawal by Subject (21); Lost to Follow-up (16); Other (12); Physician Decision (3),Adverse Event,34.0,1
NCT01370590,A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1),dyslipidemia,Hypercholesterolemia,Organon and Co,INDUSTRY,406,2,0,0,2011-09,2012-04,True,406,364,42,10.3,Adverse Event (18); Withdrawal by Subject (12); Lost to Follow-up (6); Protocol Violation (4); Could not access randomization system (1); Non-compliance with Study Drug (1),Adverse Event,18.0,3
NCT00639158,Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood,cardiovascular disease,Dyslipidemias; Coronary Heart Disease; Combined (Atherogenic) Dyslipidemia; Mixed Dyslipidemia,Abbott,INDUSTRY,543,2,118,1,2008-02,,True,542,486,0,10.3,,,,1
NCT00219141,Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension,cardiovascular disease,Hypertension; Left Ventricular Hypertrophy; Overweight,Novartis Pharmaceuticals,INDUSTRY,460,3,9,9,2005-10,2007-11,True,460,413,47,10.2,Adverse Event (19); Withdrawal by Subject (9); Lost to Follow-up (7); Lack of Efficacy (5); Protocol Violation (5); Administrative problems (1); Condition no longer requires study drug (1),Adverse Event,19.0,1
NCT03682185,The Healthy Patterns Sleep Study,cardiovascular disease,Dementia; Alzheimer Disease; Circadian Rhythm Disorders; Circadian Rhythm Sleep Disorder; Insomnia; Hypersomnia; Cognitive Impairment; Cognitive Decline; Mild Cognitive Impairment; Frontotemporal Dementia; Neurocognitive Disorders; Vascular Dementia; Sleep Disorder; Memory Impairment,University of Pennsylvania,OTHER,421,2,1,1,2016-05-01,2021-05-31,True,421,378,43,10.2,Lost to Follow-up (23); Withdrawal by Subject (20),Lost to Follow-up,23.0,1
NCT00698932,Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,568,2,30,4,2008-06,2009-10,True,568,510,58,10.2,Withdrawal by Subject (34); Study specific discontinuation criteria (7); Lost to Follow-up (7); Severe non-compliance to protocol (3); Adverse Event (2); Incorrect enrollment (2); Safety reasons (2); Death (1),Withdrawal by Subject,34.0,1
NCT01624259,A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes,diabetes type 2,Type 2 Diabetes,Eli Lilly and Company,INDUSTRY,599,2,57,10,2012-06,2013-11,True,599,538,61,10.2,Adverse Event (36); Withdrawal by Subject (12); Lost to Follow-up (5); Protocol Violation (3); Abnormal laboratory measure (3); Physician Decision (2),Adverse Event,36.0,1
NCT00591773,Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension,cardiovascular disease,Hypertension,Takeda,INDUSTRY,551,3,46,1,2007-09,2009-03,True,551,495,56,10.2,Adverse Event (24); Withdrawal by Subject (10); Lost to Follow-up (6); Other (6); Protocol Violation (5); Lack of Efficacy (5),Adverse Event,24.0,1
NCT01733758,A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM),diabetes type 2,"Diabetes Mellitus, Type 2",GlaxoSmithKline,INDUSTRY,494,4,74,1,2013-02,2015-02,True,490,440,50,10.2,"Adverse Event (21); Withdrawal by Subject (10); Persistent Hyperglycemia (5); Protocol Violation (5); Intro of New Anti-Diabetic Medication (5); Inv Decision, HbA1c not controlled (3); Non-compliance (1)",Adverse Event,21.0,1
NCT00063622,Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS),NASH,Liver Diseases,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,247,3,8,1,2005-01,2009-09,True,247,222,0,10.1,,,,1
NCT00221104,Japan Statin Treatment Against Recurrent Stroke (J-STARS),cardiovascular disease,Ischemic Stroke,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",OTHER,1578,2,1,1,2004-03-01,,True,1578,1419,159,10.1,Others (84); Withdrawal by Subject (71); Protocol Violation (2); Adverse Event (1); Physician Decision (1),Others,84.0,1
NCT00657150,Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty,cardiovascular disease,Venous Thromboembolism,Boehringer Ingelheim,INDUSTRY,2055,2,108,19,2008-03,,True,2013,1809,412,10.1,Adverse Event (142); Withdrawal by Subject (130); Other (104); Non-compliant with protocol (33); Lost to Follow-up (3),Adverse Event,142.0,2
NCT00705575,Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension,cardiovascular disease,Hypertension,Novartis,INDUSTRY,688,2,8,8,2008-06,2009-04,True,688,619,69,10.0,Adverse Event (26); Withdrawal by Subject (15); Abnormal test procedure result(s) (14); Lost to Follow-up (7); Protocol Violation (4); Abnormal laboratory value(s) (3),Adverse Event,26.0,1
NCT00624065,Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure,cardiovascular disease,Hypertension,GlaxoSmithKline,INDUSTRY,348,2,76,1,2008-03,2008-08,True,432,389,43,10.0,Met protocol-defined stopping criteria (13); Adverse Event (11); Consent withdrawn (11); Lost to Follow-up (5); Lack of Efficacy (3),Met protocol-defined stopping criteria,13.0,1
NCT04740931,A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion,cardiovascular disease,Macular Edema; Central Retinal Vein Occlusion; Hemiretinal Vein Occlusion,Hoffmann-La Roche,INDUSTRY,729,2,194,22,2021-03-02,2023-07-12,True,729,656,73,10.0,Withdrawal by Subject (26); Lost to Follow-up (13); Adverse Event (12); Death (8); Physician Decision (4); Other (4); Non-compliance with study drug (3); Reason Not Specified (2); Protocol Violation (1),Withdrawal by Subject,26.0,2
NCT01120405,"Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery",cardiovascular disease,Elevated Cardiac Risk; Coronary Arteries Disease Risk,Air Liquide Santé International,INDUSTRY,600,2,13,1,2010-05,2012-07,True,600,540,0,10.0,,,,1
NCT00560417,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide,diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,339,2,52,2,2007-11,2009-12,True,339,305,34,10.0,Protocol Violation (11); Physician Decision (8); Withdrawal by Subject (6); Adverse Event (5); Sponsor Decision (2); Entry Criteria Not Met (1); Lost to Follow-up (1),Protocol Violation,11.0,1
NCT01214239,"Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control",diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,300,2,19,3,2010-10,,True,299,269,30,10.0,Withdrawal by Subject (13); Adverse Event (7); Protocol Violation (3); Lack of Efficacy (3); Lost to Follow-up (2); patient's private reason (2),Withdrawal by Subject,13.0,1
NCT03730662,A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,2002,4,216,15,2018-11-20,2021-04-22,True,2002,1801,201,10.0,Death (60); Withdrawal by Subject (57); Lost to Follow-up (37); Adverse Event (18); Personal Reason (15); Physician Decision (8); Protocol Violation (5); Screen Failure (1),Death,60.0,2
NCT00446511,"Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension",cardiovascular disease,Hypertension,Novartis Pharmaceuticals,INDUSTRY,250,4,9,9,2007-06,2009-06,True,250,225,25,10.0,Adverse Event (13); Administrative Problems (8); Withdrawal by Subject (3); Protocol Violation (1),Adverse Event,13.0,1
NCT00813995,A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,395,2,0,0,2008-12-09,2010-08-09,True,395,356,39,9.9,Clinical adverse event (12); Lost to Follow-up (6); Protocol Violation (5); Withdrawal by Subject (5); Other reason (4); Subject moved (4); Laboratory adverse event (2); Lack of Efficacy (1),Clinical adverse event,12.0,1
NCT01010932,Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF),cardiovascular disease,Cerebral Arterial Diseases,Guerbet,INDUSTRY,222,1,1,1,2009-10,2010-12,True,222,200,0,9.9,,,,1
NCT04576988,A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR),cardiovascular disease,Pulmonary Arterial Hypertension,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",INDUSTRY,324,2,120,21,2021-01-25,2022-12-06,True,323,291,26,9.9,Withdrawal by Subject (8); Death (8); Adverse Event (4); Protocol Violation (3); Clinical worsening event (2); Sponsor decision (1),Withdrawal by Subject,8.0,2
NCT01042977,Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease,diabetes type 2,Type 2 Diabetes Mellitus; Cardiovascular Disease; Inadequate Glycaemic Control,AstraZeneca,INDUSTRY,964,2,135,10,2010-03,2012-12,True,965,869,96,9.9,Subject no longer meets study criteria (28); Withdrawal by Subject (24); Adverse Event (16); Incorrect enrollment (10); Poor/non-compliance (7); Death (3); Various (3); Lost to Follow-up (2); Safety (2); Administrative reason by sponsor (1),Subject no longer meets study criteria,28.0,1
NCT01809327,"A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise",diabetes type 2,"Diabetes Mellitus, Type 2","Janssen Research & Development, LLC",INDUSTRY,1186,5,129,13,2013-06-04,2014-12-02,True,1186,1069,117,9.9,Other (49); Adverse Event (26); Withdrawal by Subject (21); Lost to Follow-up (16); Physician Decision (2); Death (1); Protocol Violation (1); Pregnancy (1),Other,49.0,1
NCT03759392,Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure,heart failure,Heart Failure With Reduced Ejection Fraction,Cytokinetics,INDUSTRY,276,2,81,9,2019-04-09,2022-01-06,True,276,249,27,9.8,Adverse Event (16); Death (3); Withdrawal by Subject (2); Protocol Violation (2); Physician Decision (1); Consistently forgot to bring study drug kits to site visits (for compliance check) (1); No longer able to take medicines (1); Stopped taking study drug (1),Adverse Event,16.0,1
NCT00147199,Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH),cardiovascular disease,Pulmonary Hypertension,United Therapeutics,INDUSTRY,235,2,30,10,2005-06,2007-10,True,235,212,0,9.8,,,,1
NCT02188784,Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure,heart failure,Chronic Heart Failure,Adrian Hernandez,OTHER,225,2,17,1,2014-09-03,2016-04-06,True,225,203,22,9.8,Withdrawal by Subject (12); Physician Decision (5); Death (4); Lost to Follow-up (1),Withdrawal by Subject,12.0,1
NCT00426751,Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI),cardiovascular disease,"Infarction, Myocardial",GlaxoSmithKline,INDUSTRY,429,2,24,2,2006-10,2007-12,True,429,387,42,9.8,Other Reasons (19); Lost to Follow-up (13); Adverse Event (9); Consent Withdrawn (1),Other Reasons,19.0,1
NCT01387737,Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Tanabe Pharma Corporation,INDUSTRY,1299,2,7,1,2011-05,2012-12,True,1299,1173,126,9.7,Withdrawal by Subject (58); Adverse Event (50); Physician Decision (13); Clearly not eligible for the study (4); Lack of Efficacy (1),Withdrawal by Subject,58.0,1
NCT00069784,The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention),diabetes type 2,"Diabetes Mellitus, Non-Insulin-Dependent",Sanofi,INDUSTRY,12537,4,40,40,2003-08,2011-12,True,12537,11325,1212,9.7,Withdrawal by Subject (1090); Adverse Event (105); Other (17),Withdrawal by Subject,1090.0,1
NCT01769378,Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8),diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,300,2,31,8,2013-01,2014-12,True,300,271,29,9.7,Withdrawal by Subject (13); Adverse Event (10); Protocol Violation (2); Lost to Follow-up (2); Entry criteria not met (1); Sponsor Decision (1),Withdrawal by Subject,13.0,1
NCT02683746,Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2",GlaxoSmithKline,INDUSTRY,308,2,70,1,2016-03-16,2017-05-15,True,308,278,30,9.7,Lost to Follow-up (11); Withdrawal by Subject (11); Adverse Event (5); Physician Decision (3),Lost to Follow-up,11.0,1
NCT00525824,"12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe",cardiovascular disease,Hypercholesterolemia; Coronary Heart Disease; Atherosclerosis,AstraZeneca,INDUSTRY,1743,0,9,9,2007-08,2008-09,True,833,752,81,9.7,Adverse Event (31); Withdrawal by Subject (21); Lost to Follow-up (10); Other (8); Incorrect enrolment/mis-randomisation (6); Severe non-compliance (3); Safety reasons (2),Adverse Event,31.0,1
NCT03917472,Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema,cardiovascular disease,Diabetic Macular Edema,Novartis Pharmaceuticals,INDUSTRY,517,2,92,5,2019-07-17,2021-03-24,True,517,467,50,9.7,Withdrawal by Subject (15); Lost to Follow-up (15); Death (12); Physician Decision (4); Adverse Event (4),Withdrawal by Subject,15.0,1
NCT03495102,A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,1842,3,208,16,2018-04-05,2019-10-10,True,1842,1665,177,9.6,Withdrawal by Subject (79); Lost to Follow-up (48); Adverse Event (22); Death (11); Site Closure (6); Physician Decision (4); Protocol Violation (2); Non-compliance (1); Participant Duplicated at Another Site (1); Primary Care Physician Recommendation (1); Relocated to Another Country (1); Participant was in Rehabilitation (1),Withdrawal by Subject,79.0,1
NCT04929249,"A Randomized Study to Evaluate the Effect of an ""Inclisiran First"" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)",cardiovascular disease,Atherosclerotic Cardiovascular Disease,Novartis Pharmaceuticals,INDUSTRY,450,2,43,1,2021-06-25,2023-09-15,True,450,407,43,9.6,Lost to Follow-up (14); Subject decision (14); Withdrew consent (8); Adverse Event (3); Death (3); Technical problems (1),Lost to Follow-up,14.0,1
NCT01898221,Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation,cardiovascular disease,Ventricular Tachycardia; Atrial Fibrillation,The Methodist Hospital Research Institute,OTHER,343,2,12,1,2013-10,2019-12,True,343,310,0,9.6,,,,1
NCT04915729,A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity,cardiovascular disease,Stroke,Boehringer Ingelheim,INDUSTRY,1489,2,55,1,2021-06-22,2023-10-08,True,1489,1346,143,9.6,Death (78); Lost to Follow-up (30); Withdrawal by Subject (17); not treated (9); refuse of hospital visit (4); Investigator removed subject (3); questionnaire result not evaluated (1); Subject withdrew (1),Death,78.0,1
NCT00701090,A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED),diabetes type 2,"Type 2 Diabetes Mellitus, Non Insulin Dependent; Diabetes Mellitus, Non-Insulin-Dependent",Merck Sharp & Dohme LLC,INDUSTRY,1035,2,0,0,2008-05,2009-10,True,1035,936,99,9.6,Withdrawal by Subject (27); Other (19); Lost to Follow-up (18); Adverse Event (13); Lack of Efficacy (9); Physician Decision (7); Protocol Violation (5); Death (1),Withdrawal by Subject,27.0,1
NCT05064735,Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis,obesity,Obesity,Novo Nordisk A/S,INDUSTRY,407,2,122,11,2021-10-01,2023-09-08,True,407,368,39,9.6,Withdrawal by Subject (15); Lost to Follow-up (9); Site Closure (9); Physician Decision (3); Failing to Meet Randomization Requirements (3),Withdrawal by Subject,15.0,1
NCT01468987,A Study in Participants With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,1369,2,156,25,2011-12,2013-08,True,1369,1238,131,9.6,Withdrawal by Subject (56); Physician Decision (23); Adverse Event (21); Lost to Follow-up (15); Protocol Violation (10); Death (5); Sponsor Decision (1),Withdrawal by Subject,56.0,1
NCT03001817,Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function,dyslipidemia,Severe Hypertriglyceridemia,"Kowa Research Institute, Inc.",INDUSTRY,551,2,220,9,2016-11-28,2019-06-24,True,551,498,0,9.6,,,,2
NCT00362232,Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.,cardiovascular disease,Venous Thromboembolism,Bayer,INDUSTRY,3148,2,124,13,2006-06,2008-01,True,3148,2849,387,9.5,Adverse Event (123); Withdrawal by Subject (111); Lost to Follow-up (59); Protocol Violation (43); Clinical Endpoint Reached (28); Noncompliance to Study Drug (9); Physician Decision (7); Death (6); Technical Problems (1),Adverse Event,123.0,2
NCT00514735,Tailored Treatment of Permanent Atrial Fibrillation,cardiovascular disease,Atrial Fibrillation,Medtronic Cardiac Rhythm and Heart Failure,INDUSTRY,210,2,24,2,2007-05,2010-11,True,210,190,20,9.5,Withdrawal by Subject (18); Death (1); Lost to Follow-up (1),Withdrawal by Subject,18.0,1
NCT02271217,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.,cardiovascular disease,Post-Ischemic Stroke,Acorda Therapeutics,INDUSTRY,377,3,74,2,2014-12,2016-10,True,377,341,0,9.5,,,,1
NCT01708902,Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,876,5,56,4,2012-10,2014-04,True,873,791,82,9.4,Adverse Event (33); Refused to continue trial medication (24); Lost to Follow-up (8); Non compliance with protocol (6); Other Reason (6); Lack of Efficacy (5),Adverse Event,33.0,1
NCT00680186,Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE),cardiovascular disease,Thromboembolism,Boehringer Ingelheim,INDUSTRY,2589,2,220,31,2008-04,,True,2568,2327,241,9.4,Adverse Event (91); Withdrawal by Subject (71); Protocol Violation (57); Lost to Follow-up (17); Other (5),Adverse Event,91.0,1
NCT01364428,Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,373,2,45,1,2011-06,2012-01,True,373,338,35,9.4,Withdrawal Criteria (24); Other (6); Adverse Event (3); Protocol Violation (2),Withdrawal Criteria,24.0,1
NCT01462266,Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,660,2,0,0,2012-01-13,2013-06-07,True,660,598,62,9.4,"Adverse Event (13); Creatinine and eGFR, excluded medication (12); Withdrawal by Subject (9); Lost to Follow-up (7); Physician Decision (7); Protocol Violation (4); Death (3); Non-compliance with study drug (3); Lack of Efficacy (2); Screen failure (2)",Adverse Event,13.0,1
NCT03399370,Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol,cardiovascular disease,ASCVD; Elevated Cholesterol,The Medicines Company,INDUSTRY,1561,2,145,1,2017-12-21,2019-09-17,True,1561,1415,0,9.4,,,,1
NCT01059799,Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,435,2,53,6,2010-02-01,2010-12-16,True,435,394,41,9.4,Withdrawal criteria (15); Other (15); Adverse Event (5); Protocol Violation (5); Lack of Efficacy (1),Withdrawal criteria,15.0,1
NCT00240331,AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD),cardiovascular disease,Renal Failure,AstraZeneca,INDUSTRY,2776,2,239,25,2003-01,2008-10,True,2773,2513,260,9.4,Withdrawal by Subject (257); Option selected by investigator (3),Withdrawal by Subject,257.0,1
NCT00402727,Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection,cardiovascular disease,Abscess; Wound Infection; Diabetic Foot; Ulcer,Bayer,INDUSTRY,813,2,123,20,2006-09,2008-06,True,813,737,76,9.3,Lost to Follow-up (35); Adverse Event (16); Withdrawal by Subject (10); Lack of Efficacy (4); Protocol Violation (4); supply problems (3); Physician Decision (2); Death (1); non-compliance (1),Lost to Follow-up,35.0,1
NCT02585778,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),diabetes type 2,Hypercholesterolaemia,Sanofi,INDUSTRY,517,2,110,10,2015-10-23,2017-04-03,True,517,469,48,9.3,Adverse Event (21); Participant did not wish to continue (13); Other than specified above (8); Randomized but not treated (3); Poor compliance to study protocol (2); Death (1),Adverse Event,21.0,1
NCT00909870,Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers,cardiovascular disease,Venous Leg Ulcer,Organogenesis,INDUSTRY,537,2,70,8,2009-06,2011-08,True,537,487,50,9.3,Adverse Event (20); Withdrawal by Subject (13); Lost to Follow-up (6); Other (6); Protocol Violation (3); Physician Decision (2),Adverse Event,20.0,1
NCT02294474,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine,diabetes type 2,Type 2 Diabetes Mellitus,Sanofi,INDUSTRY,505,2,103,12,2015-01,2016-02,True,505,458,47,9.3,Other than specified above (24); Adverse Event (14); Protocol Violation (6); Lack of Efficacy (3),Other than specified above,24.0,1
NCT04847557,A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial,heart failure,Obesity; Heart Failure With Preserved Ejection Fraction (HFpEF),Eli Lilly and Company,INDUSTRY,731,2,146,10,2021-04-20,2024-07-02,True,731,663,68,9.3,Death (34); Withdrawal by Subject (22); Lost to Follow-up (9); Adverse Event (1); Physician Decision (1); Protocol Violation (1),Death,34.0,1
NCT01558271,A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,492,3,14,1,2012-03,2014-05,True,492,446,46,9.3,Withdrawal by Subject (28); Adverse Event (13); Physician Decision (3); Lost to Follow-up (1); Protocol Violation (1),Withdrawal by Subject,28.0,1
NCT00923091,"Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension",cardiovascular disease,Essential Hypertension,Daiichi Sankyo,INDUSTRY,2689,8,133,15,2009-06,2011-03,True,2689,2439,244,9.3,Adverse Event (105); Withdrawal by Subject (87); Protocol Violation (41); Lost to Follow-up (6); Other Reason (5),Adverse Event,105.0,5
NCT03448419,This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms,cardiovascular disease,Heart Failure,Boehringer Ingelheim,INDUSTRY,312,2,109,11,2018-03-20,2019-10-07,True,312,283,29,9.3,Adverse Event (19); Withdrawal by Subject (4); Lost to Follow-up (2); Patient did not attend all visits (2); Not treated (1); Withdrawn by Sponsor (1),Adverse Event,19.0,1
NCT02152371,A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,300,2,40,7,2014-05,2015-10,True,300,272,28,9.3,Withdrawal by Subject (10); Adverse Event (8); Protocol Violation (5); Physician Decision (2); Lost to Follow-up (1); Lack of Efficacy (1); Reason Not Given (1),Withdrawal by Subject,10.0,1
NCT01159600,Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,1504,4,148,12,2010-07,,True,1479,1342,137,9.3,"Adverse Event (41); Patient refusal to continue,not due toAE (33); Other reason not defined above (27); Lost to Follow-up (20); Non compliant with protocol (7); Not treated (6); Lack of Efficacy (3)",Adverse Event,41.0,1
NCT01195662,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,2245,2,298,16,2010-10,2013-02,True,582,528,54,9.3,Withdrawal by Subject (17); Lost to Follow-up (8); No Longer Meets Criteria (8); Adverse Event (7); Administrative reason (4); Non-specified (3); Requested discontinue treatment (2); Lack of Efficacy (2); Missing disposition information (2); non-specified (1),Withdrawal by Subject,17.0,2
NCT01627327,Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease,cardiovascular disease,"Pulmonary Disease, Chronic Obstructive",GlaxoSmithKline,INDUSTRY,623,2,54,6,2012-04-01,2012-12-21,True,623,565,58,9.3,Adverse Event (18); Protocol Violation (14); Lack of Efficacy-Sub-Reason Exacerbation (13); Withdrawal by Subject (6); Lost to Follow-up (4); Lack of Efficacy-No Sub-Reason (2); Physician Decision (1),Adverse Event,18.0,1
NCT03371108,Gan & Lee Insulin Glargine Target Type (2) Evaluating Research,diabetes type 2,"Diabetes Mellitus, Type 2","Gan and Lee Pharmaceuticals, USA",INDUSTRY,567,2,57,1,2017-10-31,2019-04-17,True,567,515,0,9.2,,,,2
NCT01388361,Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,413,3,124,12,2011-09,2012-07,True,413,375,38,9.2,Withdrawal criteria (29); Adverse Event (6); Protocol Violation (2); Unclassified (1),Withdrawal criteria,29.0,1
NCT00759681,"ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial",cardiovascular disease,Vascular Disease,"Tenaxis Medical, Inc.",INDUSTRY,217,2,1,1,2008-09,2010-03,True,217,197,20,9.2,Lost to Follow-up (13); Death (7),Lost to Follow-up,13.0,1
NCT00975286,24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine,diabetes type 2,Type 2 Diabetes Mellitus,Sanofi,INDUSTRY,446,2,140,26,2009-10,2011-08,True,446,405,41,9.2,Adverse Event (28); Familial and Personal Reasons (4); Protocol Violation (3); Withdrawal by Subject (2); Poor Compliance to Protocol (2); Sponsor Decision (2),Adverse Event,28.0,1
NCT01217476,The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study,cardiovascular disease,Diabetic Foot Ulcer of Neuropathic Origin,Olympus Biotech Corporation,INDUSTRY,207,2,37,10,2010-12,2013-03,True,207,188,19,9.2,Adverse Event (7); Withdrawal by Subject (6); Surgery on the Target Limb (2); Other (2); Physician Decision (1); Protocol Deviation (1),Adverse Event,7.0,1
NCT01719003,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2; Hyperglycemia",Boehringer Ingelheim,INDUSTRY,1413,9,190,21,2012-10,2014-12,True,1413,1284,129,9.1,"Refusal to continue, not due to AE (38); Adverse Event (36); Lost to Follow-up (29); Reason other than those specified (14); Non compliant with protocol (11); Lack of Efficacy (1)","Refusal to continue, not due to AE",38.0,1
NCT05662332,A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1),diabetes type 2,Type 2 Diabetes; T2D,Eli Lilly and Company,INDUSTRY,795,2,71,4,2023-01-14,2024-07-19,True,795,723,72,9.1,Withdrawal by Subject (28); Assigned Treatment by Mistake (12); Lost to Follow-up (11); Death (6); Non-compliance with study drug (5); Physician Decision (3); Protocol Deviation (3); Due to Bariatric surgery (1); Subject Moving out of State (1); Subject Missed the Schedule (1); The Patient Moved to Another City (1),Withdrawal by Subject,28.0,1
NCT01704261,Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,307,2,0,0,2012-10-18,2014-12-23,True,307,279,28,9.1,Withdrawal by Subject (27); Lost to Follow-up (1),Withdrawal by Subject,27.0,1
NCT02994927,A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis,cardiovascular disease,ANCA-Associated Vasculitis,Amgen,INDUSTRY,331,2,198,20,2017-03-15,2019-11-01,True,331,301,30,9.1,Withdrawal by Subject (9); Physician Decision (7); Death (6); Adverse Event (3); Lost to Follow-up (3); Withdrawal by parent/guardian (1); Did not meet eligibility criteria (1),Withdrawal by Subject,9.0,1
NCT02229383,Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus,diabetes type 2,Diabetes Mellitus,AstraZeneca,INDUSTRY,464,2,123,6,2014-09-06,2016-08-29,True,461,419,42,9.1,Adverse Event (11); Other (11); Withdrawal by Subject (10); Lost to Follow-up (8); Death (1); Did not receive treatment (1),Adverse Event,11.0,1
NCT00696436,An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.,cardiovascular disease,Hypertension,Takeda,INDUSTRY,1291,5,131,6,2008-04,2009-08,True,1291,1175,116,9.0,Adverse Event (34); Withdrawal by Subject (28); Lost to Follow-up (16); Lack of Efficacy (15); Protocol Violation (8); Participant Unavailability (5); Administrative Error (4); Participant Non-compliance (3); Missing (2); Administrative Decision (1),Adverse Event,34.0,1
NCT01181167,"A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty",cardiovascular disease,Prevention; Venous Thromboembolism,"Daiichi Sankyo Co., Ltd.",INDUSTRY,610,2,2,1,2009-05,2010-03,True,610,555,55,9.0,Adverse Event (32); Withdrawal by Subject (14); Physician Decision (5); Protocol Violation (3); Lost to Follow-up (1),Adverse Event,32.0,1
NCT00594399,Enhancing Fitness in Older Pre-diabetic Veterans,obesity,Impaired Glucose Tolerance; Obesity; Diabetes,US Department of Veterans Affairs,FED,302,2,1,1,2008-10,2011-06,True,302,275,27,8.9,Too busy (8); Lack of Interest (6); Death (3); Withdrawal by Subject (3); Personal issues (2); Pain (2); Not ready to exercise (1); Moved (1); Family illness (1),Too busy,8.0,2
NCT02463071,AZD0585 Phase III Long-term Study in Japan,dyslipidemia,Hypertriglyceridemia,AstraZeneca,INDUSTRY,383,3,26,1,2015-06-10,2017-03-11,True,383,349,34,8.9,Reason not specified (20); Adverse Event (9); Protocol Violation (2); Death (1); Eligibility criteria not fulfilled (1); Lost to Follow-up (1),Reason not specified,20.0,1
NCT00510952,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE),diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,471,2,17,4,2007-08,2008-10,True,471,429,42,8.9,Withdrawal by Subject (13); Protocol Violation (11); Lost to Follow-up (8); Entry Criteria Not Met (4); Physician Decision (2); Did Not Receive Study Drug (2); Adverse Event (1); Sponsor Decision (1),Withdrawal by Subject,13.0,1
NCT02059187,The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,531,2,0,0,2014-02-11,2015-03-11,True,531,484,47,8.9,Withdrawal by Subject (20); Lost to Follow-up (17); Adverse Event (3); Physician Decision (3); Death (2); Non-compliance with study drug (1); Protocol Violation (1),Withdrawal by Subject,20.0,1
NCT00984867,Dapagliflozin DPPIV Inhibitor add-on Study,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,833,2,88,6,2009-10,2011-09,True,451,411,40,8.9,Withdrawal by Subject (17); Adverse Event (10); Lost to Follow-up (7); Subject no longer meets study criteria (2); Death (1); Poor/non-compliance (1); site closing (1); lack of efficacy and subject compliance (1),Withdrawal by Subject,17.0,1
NCT00885352,Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,313,2,0,0,2009-04-15,2010-11-10,True,313,285,28,8.9,Withdrawal by Subject (6); Adverse Event (5); Lost to Follow-up (4); Excluded medication (4); Physician Decision (3); Protocol Violation (2); Contradiction to study medication (2); Lab abnormalities (2),Withdrawal by Subject,6.0,1
NCT00126425,Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease,cardiovascular disease,"Heart Failure, Congestive",GE Healthcare,INDUSTRY,587,1,1,1,2005-07,2008-12,True,587,535,52,8.9,Withdrawal by Subject (18); Protocol Violation (15); Lost to Follow-up (12); Other (5); Adverse Event (1); Failed Inclusion Exclusion Criteria (1),Withdrawal by Subject,18.0,1
NCT00452530,Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery,cardiovascular disease,Deep Vein Thrombosis; Pulmonary Embolism,Bristol-Myers Squibb,INDUSTRY,3221,2,122,27,2007-06,2009-01,True,3057,2785,272,8.9,Withdrawal by Subject (125); Adverse Event (84); No longer met study criteria (40); Other (18); Poor compliance/noncompliance (3); Death (1); Lost to Follow-up (1),Withdrawal by Subject,125.0,1
NCT01674647,Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion,cardiovascular disease,Atrial Fibrillation,Bayer,INDUSTRY,1504,2,178,17,2012-10,2014-01,True,1504,1370,357,8.9,Protocol Violation (153); Adverse Event (82); Withdrawal by Subject (50); Logistical difficulties (17); Lost to Follow-up (15); Treatment failure (14); Death (10); Switching to other therapy (7); Physician Decision (4); Non-compliance with study drug (4); Efficacy outcome reached (1),Protocol Violation,153.0,2
NCT03078478,A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1609,2,229,12,2017-03-13,2019-03-04,True,1609,1467,142,8.8,Withdrawal by Subject (103); Lost to Follow-up (20); Death (16); Not reconsenting (2); Subject withdrawal reason not collected (1),Withdrawal by Subject,103.0,3
NCT01242527,Epanova® for Lowering Very High Triglycerides,dyslipidemia,Severe Hypertriglyceridemia,AstraZeneca,INDUSTRY,399,4,68,7,2011-01,2012-04,True,399,364,0,8.8,,,,1
NCT02203916,Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension,cardiovascular disease,Hypertension,Takeda,INDUSTRY,328,3,15,1,2014-07,2016-02,True,328,299,29,8.8,Voluntary Withdrawal (14); Pretreatment Event/Adverse Event (6); Lack of Efficacy (3); Reason Not Specified (3); Major Protocol Deviation (2); Lost to Follow-up (1),Voluntary Withdrawal,14.0,1
NCT00004562,Occluded Artery Trial (OAT),cardiovascular disease,"Cardiovascular Diseases; Heart Diseases; Myocardial Infarction; Heart Failure, Congestive; Heart Failure",NYU Langone Health,OTHER,2201,2,1,1,1999-09,2011-06,True,2201,2008,193,8.8,Lost to Follow-up (193),Lost to Follow-up,193.0,1
NCT04760626,"A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before",diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1085,2,180,8,2021-03-01,2022-08-29,True,1085,990,95,8.8,Withdrawal by Subject (44); Lost to Follow-up (33); Death (9); Physician Decision (8); Site closure (1),Withdrawal by Subject,44.0,1
NCT00423319,Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3),cardiovascular disease,Deep Vein Thrombosis; Pulmonary Embolism,Bristol-Myers Squibb,INDUSTRY,5407,2,143,21,2007-03,2009-09,True,5407,4931,476,8.8,Adverse Event (205); Withdrawal by Subject (185); Other (45); No longer meets study criteria (30); Lost to Follow-up (7); Death (2); Poor compliance or noncompliance (2),Adverse Event,205.0,1
NCT01954394,Open Label Study of Long Term Safety Evaluation of Alirocumab,dyslipidemia,Hypercholesterolemia,Sanofi,INDUSTRY,986,1,177,24,2013-12-17,2017-06-30,True,986,899,87,8.8,Adverse Event (33); Other than specified above (31); Poor compliance to protocol (14); Participant Moved (4); Related to Study Drug administration (4); Enrolled but not treated (1),Adverse Event,33.0,1
NCT02674854,Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension,hypertension,Open-angle Glaucoma; Ocular Hypertension,Aerie Pharmaceuticals,INDUSTRY,750,3,1,1,2016-02,2017-03,True,750,685,65,8.7,Adverse Event (37); Withdrawal by Subject (10); Disallowed Concurrent Medication (4); Protocol Violation (4); Lost to Follow-up (3); Lack of Efficacy (3); No-compliant subject (2); Death (1); Subject missed V6.2 (1),Adverse Event,37.0,1
NCT01084005,Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,241,2,34,5,2010-03,,True,241,220,21,8.7,Protocol Violation (10); Adverse Event (9); Withdrawal by Subject (2),Protocol Violation,10.0,1
NCT04537923,A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin,diabetes type 2,Type 2 Diabetes,Eli Lilly and Company,INDUSTRY,1428,4,135,16,2020-10-19,2022-11-01,True,1428,1304,124,8.7,Withdrawal by Subject (70); Death (18); Lost to Follow-up (10); Adverse Event (9); Physician Decision (8); Missed study visits (5); Sponsor's decision (2); Pregnancy (1); Safety reasons (1),Withdrawal by Subject,70.0,1
NCT04058067,To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema,cardiovascular disease,Diabetic Macular Edema,Novartis Pharmaceuticals,INDUSTRY,266,2,24,1,2019-08-23,2023-01-31,True,263,240,23,8.7,Withdrawal by Subject (15); Physician Decision (4); Adverse Event (2); Death (1); Protocol Violation (1),Withdrawal by Subject,15.0,1
NCT00882440,A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011),cardiovascular disease,Hypertension,Merck Sharp & Dohme LLC,INDUSTRY,576,7,0,0,1990-12,1992-01,True,576,526,50,8.7,Adverse Event (14); Lack of Efficacy (13); Withdrawal by Subject (11); Lost to Follow-up (6); Protocol Violation (3); Patient Uncooperative (3),Adverse Event,14.0,1
NCT03355664,Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam,cardiovascular disease,"Malaria, Falciparum",University of Oxford,OTHER,310,2,4,2,2018-03-19,2020-03-04,True,310,283,27,8.7,Lost to Follow-up (18); Adverse Event (3); Protocol Violation (3); Withdrawal by Subject (3),Lost to Follow-up,18.0,1
NCT00641043,Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,389,2,43,7,2008-03,,True,389,355,34,8.7,Adverse Event (10); Withdrawal by Subject (8); Other incl. lack of efficacy (6); Protocol Violation (5); Lost to Follow-up (5),Adverse Event,10.0,1
NCT00325442,FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH),cardiovascular disease,Pulmonary Hypertension,United Therapeutics,INDUSTRY,354,2,72,14,2006-10,2010-12,True,350,320,0,8.6,,,,1
NCT02924727,Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI,cardiovascular disease,Acute Myocardial Infarction,Novartis Pharmaceuticals,INDUSTRY,5669,2,486,41,2016-12-09,2021-02-26,True,5669,5181,488,8.6,Death (468); Lost to Follow-up (7); Mis-randomized (one mis-randomized patient in the Ramipril group also died) (7); Withdrawal by Subject (6),Death,468.0,1
NCT01885208,Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,813,2,146,13,2013-12-02,2015-07-13,True,813,743,70,8.6,Unclassified (70),Unclassified,70.0,1
NCT00594100,GORE Embolic Protection With Reverse Flow,cardiovascular disease,Carotid Artery Stenosis,W.L.Gore & Associates,INDUSTRY,245,1,2,1,2006-07,2008-09,True,245,224,21,8.6,Technical Failure (9); Discontinued Prior to Visit (6); Missed Visit - Phone Contact Follow-up (4); Death / Reintervention / Medical Reasons (2),Technical Failure,9.0,2
NCT00434161,A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma,cardiovascular disease,Multiple Myeloma,Swedish Orphan Biovitrum,INDUSTRY,281,3,1,1,2006-12,2012-05,True,281,257,24,8.5,Adverse Event (10); Withdrawal by Subject (5); Logistical error study assessments (4); Death (2); Non-Compliance (2); Lost to Follow-up (1),Adverse Event,10.0,1
NCT00976937,24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years,diabetes type 2,Type 2 Diabetes Mellitus,Sanofi,INDUSTRY,319,2,92,13,2009-08,2011-03,True,319,292,27,8.5,Adverse Event (9); Withdrawal by Subject (8); Personal and Familial Reason (4); Lost to Follow-up (3); Poor compliance to protocol (3),Adverse Event,9.0,1
NCT03172494,"A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)",diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,720,3,36,1,2017-05-26,2019-07-13,True,720,659,61,8.5,Withdrawal by Subject (26); Adverse Event (21); Protocol Violation (6); Lack of Efficacy (4); Non-compliance towards treatment (2); Pregnancy (1); Severe hypoglycaemic episode (1),Withdrawal by Subject,26.0,1
NCT01215097,Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,306,2,19,3,2010-10,2012-04,True,305,279,26,8.5,Withdrawal by Subject (9); Adverse Event (4); patient's refusal to come (4); Lack of Efficacy (3); Protocol Violation (2); Lost to Follow-up (2); patient's private reason (2),Withdrawal by Subject,9.0,1
NCT01350999,Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia,dyslipidemia,Hypertriglyceridemia,Takeda,INDUSTRY,503,3,0,0,2009-11,2011-01,True,503,460,43,8.5,Adverse Event (23); Voluntary withdrawal (13); Difficulty Making it to Study Visit (7),Adverse Event,23.0,1
NCT00126438,Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease,cardiovascular disease,"Heart Failure, Congestive",GE Healthcare,INDUSTRY,515,1,1,1,2005-07,2008-09,True,515,471,44,8.5,Lost to Follow-up (22); Protocol Violation (16); Withdrawal by Subject (5); Withdrawal due to adverse event (1),Lost to Follow-up,22.0,1
NCT01512108,Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,363,2,36,1,2012-01-10,2013-04-26,True,363,332,31,8.5,Unclassified (14); Adverse Event (13); Protocol Violation (3); Withdrawal Criteria (1),Unclassified,14.0,1
NCT01210001,Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,499,3,68,7,2010-09,,True,499,457,42,8.4,"Adverse Event (11); Lost to Follow-up (9); Patient refusal to continue,not due toAE (9); Non compliant with protocol (7); Other reason not defined above (5); Not treated (1)",Adverse Event,11.0,1
NCT00344370,Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia,diabetes type 2,Type II Diabetes Mellitus; Dyslipidemia,Kowa Research Europe,INDUSTRY,214,2,35,6,2006-08,2008-04,True,214,196,0,8.4,,,,1
NCT00680745,Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,597,4,66,7,2008-04,2010-05,True,596,546,50,8.4,Withdrawal by Subject (21); Adverse Event (14); Subject No Longer Meets Study Criteria (4); False Treatment (4); Poor/Non-compliance (3); Lost to Follow-up (2); Death (2),Withdrawal by Subject,21.0,1
NCT02735044,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus,diabetes type 2,Type 1 Diabetes Mellitus,Sanofi,INDUSTRY,463,2,107,24,2016-04-14,2018-12-20,True,463,424,39,8.4,"Other, not specified above (16); Poor compliance to protocol (14); Adverse Event (6); Randomized and not treated (2); Lack of Efficacy (1)","Other, not specified above",16.0,1
NCT01294423,Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes; High Blood Sugar,AstraZeneca,INDUSTRY,261,3,26,1,2011-02,2012-03,True,261,239,22,8.4,subject no longer meets study criteria (9); Adverse Event (6); Withdrawal by Subject (5); poor/non-compliance (2),subject no longer meets study criteria,9.0,1
NCT00091949,Insulin Resistance Intervention After Stroke Trial,cardiovascular disease,Stroke; Myocardial Infarction; Diabetes,Yale University,OTHER,3876,2,183,8,2005-02,2015-11,True,3876,3550,326,8.4,Withdrawal by Subject (227); Lost to Follow-up (99),Withdrawal by Subject,227.0,1
NCT04657003,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight,diabetes type 2,Type 2 Diabetes; Overweight; Obesity,Eli Lilly and Company,INDUSTRY,938,3,75,8,2021-03-29,2023-04-10,True,938,859,79,8.4,Withdrawal by Subject (33); Lost to Follow-up (22); Adverse Event (11); Other - As Reported by Investigator (7); Pregnancy (4); Death (2),Withdrawal by Subject,33.0,1
NCT00417963,ViVEXX Carotid Revascularization Trial (VIVA),cardiovascular disease,Carotid Artery Stenosis,C. R. Bard,INDUSTRY,407,1,0,0,2005-10,2010-03,True,486,445,41,8.4,Withdrawal by Subject (18); Death (17); Lost to Follow-up (3); Study device could not be deployed (3),Withdrawal by Subject,18.0,1
NCT03768427,Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439),dyslipidemia,Hypercholesterolemia,Organon and Co,INDUSTRY,454,4,30,1,2019-05-27,2021-04-01,True,454,416,38,8.4,Withdrawal by Subject (22); Physician Decision (13); Lost to Follow-up (2); Death (1),Withdrawal by Subject,22.0,1
NCT02107898,Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN),cardiovascular disease,Hypercholesterolemia,Sanofi,INDUSTRY,216,2,32,1,2014-03,2015-09,True,216,198,18,8.3,Adverse Event (11); Consent withdrawn by participant (3); Participant moved (2); Poor compliance to protocol (1); Randomized but not treated (1),Adverse Event,11.0,1
NCT00773279,"Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics",diabetes type 2,"Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Delivery Systems",Novo Nordisk A/S,INDUSTRY,242,2,65,1,2008-09,2009-06,True,242,222,20,8.3,Unclassified (10); Adverse Event (4); Lack of Efficacy (3); Protocol Violation (3),Unclassified,10.0,2
NCT01644500,A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,737,3,30,3,2012-07,2014-08,True,737,676,61,8.3,Withdrawal by Subject (35); Lost to Follow-up (11); Adverse Event (9); Physician Decision (3); Protocol Violation (2); Death (1),Withdrawal by Subject,35.0,1
NCT01368081,Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,1162,3,87,1,2011-05,2013-04,True,1160,1064,96,8.3,Adverse Event (46); Withdrawal by Subject (33); Other reason not defined above (10); Lack of Efficacy (4); Protocol Violation (2); Lost to Follow-up (1),Adverse Event,46.0,1
NCT01976988,Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery,cardiovascular disease,Venous Thromboembolism,Cedars-Sinai Medical Center,OTHER,410,2,1,1,2013-09,2015-05,True,410,376,0,8.3,,,,1
NCT02480764,Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension,cardiovascular disease,Essential Hypertension,Takeda,INDUSTRY,612,3,30,1,2015-08-27,2017-10-13,True,612,561,51,8.3,Voluntary Withdrawal (21); Pretreatment Event/Adverse Event (12); Major Protocol Deviation (8); Lack of Efficacy (6); Lost to Follow-up (3); Reason not Specified (1),Voluntary Withdrawal,21.0,1
NCT01289119,Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Takeda,INDUSTRY,506,6,21,3,2010-12,2011-12,True,506,464,42,8.3,Withdrawal by Subject (15); Major Protocol Deviation (9); Adverse Event (6); Lack of Efficacy (5); Lost to Follow-up (4); Other (2); Pregnancy (1),Withdrawal by Subject,15.0,1
NCT01323153,A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE),cardiovascular disease,Coronary Heart Disease,Hoffmann-La Roche,INDUSTRY,300,2,33,4,2011-03,2012-03,True,300,275,0,8.3,,,,1
NCT00688701,GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy,diabetes type 2,"Diabetes Mellitus, Type 2",Sanofi,INDUSTRY,361,4,12,12,2008-05,2009-12,True,361,331,30,8.3,Withdrawal by Subject (18); Adverse Event (9); Poor compliance to protocol (2); Lack of Efficacy (1),Withdrawal by Subject,18.0,1
NCT01456195,Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Takeda,INDUSTRY,421,3,95,8,2011-11,2013-07,True,421,386,35,8.3,Voluntary Withdrawal (15); Lost to Follow-up (7); Pretreatment Event/Adverse Event (6); Other Reasons (6); Lack of Efficacy (1),Voluntary Withdrawal,15.0,1
NCT01656889,Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers,cardiovascular disease,Venous Leg Ulcers,Healthpoint,INDUSTRY,447,2,50,2,2012-08,2014-12,True,447,410,36,8.3,Adverse Event (14); Death (7); Withdrawal by Subject (6); Lost to Follow-up (5); Moved out of the area (2); Protocol Violation (1); Site Closure (1),Adverse Event,14.0,2
NCT03882970,A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,1444,4,122,13,2019-04-01,2021-01-04,True,1444,1325,119,8.2,Withdrawal by Subject (54); Lost to Follow-up (27); Adverse Event (16); Personal Reason (9); Physician Decision (6); Death (5); Protocol Violation (2),Withdrawal by Subject,54.0,1
NCT03772041,Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure,cardiovascular disease,Congestive Heart Failure,"Otsuka Pharmaceutical Co., Ltd.",INDUSTRY,294,2,1,1,2019-01-16,2020-07-29,True,294,270,24,8.2,Adverse Event (11); Protocol Violation (6); Physician Decision (5); Withdrawal by Subject (2),Adverse Event,11.0,1
NCT01674712,A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease,cardiovascular disease,Dyslipidemia,Abbott,INDUSTRY,575,5,69,7,2012-06,2013-10,True,575,528,47,8.2,Adverse Event (24); Withdrawal by Subject (16); Protocol Violation (2); Administrative (2); Lack of Efficacy (2); Lost to Follow-up (1),Adverse Event,24.0,1
NCT06437626,Efficacy and Safety of Mexidol® in Stroke Therapy,cardiovascular disease,Ischemic Stroke,Pharmasoft,INDUSTRY,304,2,17,3,2019-11-18,2023-08-18,True,304,279,0,8.2,,,,1
NCT01644331,Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure,cardiovascular disease,Heart Failure; Dyspnea,Duke University,OTHER,257,2,18,1,2012-10,2016-02,True,257,236,0,8.2,,,,1
NCT00152971,Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement,cardiovascular disease,"Arthroplasty, Replacement, Knee; Thromboembolism",Boehringer Ingelheim,INDUSTRY,2615,3,94,4,2004-11,,True,2596,2382,362,8.2,Adverse Event (174); Protocol Violation (53); Lost to Follow-up (48); Withdrawal by Subject (44); Other (43),Adverse Event,174.0,2
NCT01606007,Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,1282,3,139,8,2012-07,2014-01,True,534,490,44,8.2,Lost to Follow-up (19); Withdrawal by Subject (15); discontinue study treatment (3); Reason 'Other' in the protocol (2); Pregnancy (2); Adverse Event (2); Poor/Non-compliance (1),Lost to Follow-up,19.0,1
NCT01986855,A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,468,3,0,0,2013-12-02,2016-09-28,True,468,430,38,8.1,Withdrawal by Subject (20); Death (11); Lost to Follow-up (3); Participant Moved (2); Adverse Event (1); Screen Failure (1),Withdrawal by Subject,20.0,1
NCT03585270,"Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain",cardiovascular disease,Aneurysmal Subarachnoid Hemorrhage,Idorsia Pharmaceuticals Ltd.,INDUSTRY,409,2,80,15,2019-02-03,2022-11-18,True,409,376,33,8.1,Withdrawal by Subject (8); Death (8); Adverse Event (7); Lost to Follow-up (5); Other reasons (4); Withdrawal by proxy/legal representative (1),Withdrawal by Subject,8.0,1
NCT01301833,Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,Tanabe Pharma Corporation,INDUSTRY,462,4,1,1,2011-02,2012-09,True,462,425,37,8.0,Adverse Event (22); Withdrawal by Subject (7); Physician Decision (5); Lack of Efficacy (2); Personal matter (1),Adverse Event,22.0,1
NCT00666718,A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients,diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,374,2,50,10,2008-04,2010-02,True,374,344,30,8.0,Withdrawal by Subject (19); Protocol Violation (4); Entry Criteria Not Met (2); Physician Decision (2); Adverse Event (1); Death (1); Lost to Follow-up (1),Withdrawal by Subject,19.0,1
NCT00281580,Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension,cardiovascular disease,Hypertension,Boehringer Ingelheim,INDUSTRY,1461,16,136,5,2006-04,,True,1461,1344,117,8.0,Adverse Event (38); Withdrawal by Subject (27); Lack of Efficacy (16); Protocol Violation (13); Randomised in error; pregnancy; moving (13); Lost to Follow-up (10),Adverse Event,38.0,1
NCT00168805,RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery,cardiovascular disease,"Arthroplasty, Replacement, Knee; Thromboembolism",Boehringer Ingelheim,INDUSTRY,2101,3,105,15,2004-11,,True,2076,1909,394,8.0,Other (120); Adverse Event (117); Withdrawal by Subject (73); Protocol Violation (44); Lost to Follow-up (40),Other,120.0,2
NCT01777282,A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus,diabetes type 2,Diabetes Mellitus,GlaxoSmithKline,INDUSTRY,374,5,49,1,2013-02-23,2015-01-27,True,374,344,30,8.0,"Adverse Event (14); Withdrawal by Subject (7); Protocol Violation (5); Moved, transfer abroad, did not enter FU (2); Persistent Hyperglycemia (1); New Antidiabetic Medication (1)",Adverse Event,14.0,1
NCT01545388,Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,337,3,0,0,2012-02-23,2013-03-12,True,337,310,27,8.0,Lack of Efficacy (10); Adverse Event (7); Withdrawal by Subject (7); Other (2); Participant moved or relocated (1),Lack of Efficacy,10.0,1
NCT01028391,30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,317,2,0,0,2007-09-01,2009-01-01,True,317,292,25,7.9,Withdrawal by Subject (9); Lost to Follow-up (7); Adverse Event (4); Lack of Efficacy (2); Needed excluded medication (2); Physician Decision (1),Withdrawal by Subject,9.0,1
NCT00763867,Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study),cardiovascular disease,Heart Failure,Duke University,OTHER,216,2,10,2,2008-09,2012-09,True,216,199,0,7.9,,,,1
NCT00345839,E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events,cardiovascular disease,Secondary Hyperparathyroidism; Chronic Kidney Disease,Amgen,INDUSTRY,3883,2,0,0,2006-08-22,2012-04-10,True,3883,3575,308,7.9,Withdrawal by Subject (189); Lost to Follow-up (119),Withdrawal by Subject,189.0,1
NCT01095666,A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,1484,3,33,3,2010-06,2013-03,True,444,409,35,7.9,"Withdrawal by Subject (13); Non-compliance, not met criteria etc. (11); Adverse Event (6); Lost to Follow-up (4); Lack of Efficacy (1)",Withdrawal by Subject,13.0,1
NCT01749904,Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension,hypertension,Open-Angle Glaucoma; Ocular Hypertension,Bausch & Lomb Incorporated,INDUSTRY,420,2,1,1,2013-01-31,2015-09-30,True,420,387,0,7.9,,,,1
NCT00291330,Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism,cardiovascular disease,Thromboembolism,Boehringer Ingelheim,INDUSTRY,2564,2,250,29,2006-02,,True,2539,2341,198,7.8,Adverse Event (87); Withdrawal by Subject (47); Protocol Violation (33); Lost to Follow-up (27); Other (4),Adverse Event,87.0,1
NCT01631227,Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension,cardiovascular disease,Essential Hypertension,Abbott,INDUSTRY,665,2,38,3,2012-06,2013-04,True,665,613,52,7.8,withdrawn consent (48); administrative (3); Adverse Event (1),withdrawn consent,48.0,1
NCT01467466,Prevention of Serious Adverse Events Following Angiography,cardiovascular disease,Acute Renal Failure; Kidney Disease; Coronary Artery Disease,VA Office of Research and Development,FED,5177,4,54,4,2013-10-07,2017-10-17,True,5177,4772,405,7.8,No Endpoint Blood Draw (164); Procedure Cancelled (145); Withdrawal by Subject (57); Revoked Consent Prior To Procedure (39),No Endpoint Blood Draw,164.0,1
NCT00877929,Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus,diabetes type 2,Hypertension,Boehringer Ingelheim,INDUSTRY,706,2,65,9,2009-02,,True,706,651,55,7.8,Adverse Event (31); Withdrawal by Subject (8); Other reason (not specified) (8); Protocol Violation (6); Lost to Follow-up (1); Lack of Efficacy (1),Adverse Event,31.0,1
NCT00736879,Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,497,4,62,7,2008-09-22,2009-12-29,True,282,260,23,7.8,Withdrawal by Subject (10); non-specified (4); Lost to Follow-up (3); Adverse Event (2); Poor non-compliance (2); Lack of Efficacy (1); No longer met criteria (1),Withdrawal by Subject,10.0,2
NCT02525939,Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS,cardiovascular disease,Acute Coronary Syndrome,DalCor Pharmaceuticals,INDUSTRY,6147,2,557,32,2016-04,2021-10,True,6147,5673,474,7.7,Death (359); Withdrawal by Subject (63); Lost to Follow-up (51); Physician Decision (1),Death,359.0,1
NCT01032629,CANVAS - CANagliflozin cardioVascular Assessment Study,diabetes type 2,"Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors","Janssen Research & Development, LLC",INDUSTRY,4330,3,305,25,2009-12-09,2017-02-22,True,4330,3996,334,7.7,Lost to Follow-up (158); Withdrawal by Subject (121); Closed Site (55),Lost to Follow-up,158.0,1
NCT00778921,Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone,cardiovascular disease,Hypertension,Novartis,INDUSTRY,847,3,7,7,2008-10,2009-06,True,847,782,65,7.7,Adverse Event (33); Patient withdrew request (10); Protocol Violation (5); Not treated (4); Unsatisfactory therapeutic response (3); Lost to Follow-up (3); Administrative Problems (3); Abnormal Test Procedure Result(s) (2); Abnormal Laboratory Value(s) (1); Patient No Longer Requires Study Drug (1),Adverse Event,33.0,1
NCT00666458,18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D),diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,822,2,87,9,2008-04,2009-03,True,801,739,62,7.7,Study specific discontinuation criteria (21); Adverse Event (15); Withdrawal by Subject (9); Incorrect enrollment (8); Lost to Follow-up (3); Administrative reason by sponsor (2); Severe non-compliance to the protocol (2); Safety reasons (1); Medical history of anemia (1),Study specific discontinuation criteria,21.0,1
NCT00535405,A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128),dyslipidemia,Hypercholesterolemia,Organon and Co,INDUSTRY,1289,5,0,0,2007-11,2009-03,True,1289,1190,99,7.7,Withdrawal by Subject (44); Adverse Event (31); Lost to Follow-up (10); Physician Decision (7); Protocol Violation (7),Withdrawal by Subject,44.0,1
NCT02302716,A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,493,2,44,7,2014-12,2016-07,True,493,455,38,7.7,Withdrawal by Subject (20); Physician Decision (7); Lost to Follow-up (6); Adverse Event (2); Death (1); Lack of Efficacy (1); Protocol Violation (1),Withdrawal by Subject,20.0,1
NCT00935532,Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,427,2,22,1,2009-07,2011-07,True,427,394,33,7.7,Adverse Event (17); Loss Glucose Control (4); Physician Decision (3); Protocol Violation (3); Subject Decision (3); Death (1); Lost to Follow-up (1); Sponsor Decision (1),Adverse Event,17.0,1
NCT02398188,Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2),obesity,Central Abdominal Bulging,Evofem Inc.,INDUSTRY,793,2,35,1,2015-04-09,2015-10-29,True,793,732,61,7.7,Withdrawal by Subject (23); Protocol Violation (16); Non-compliance (8); Adverse Event (5); Lost to Follow-up (5); Sponsor Decision (3); Pregnancy (1),Withdrawal by Subject,23.0,1
NCT00690794,Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension,hypertension,Open-angle Glaucoma; Ocular Hypertension,Alcon Research,INDUSTRY,726,2,0,0,2008-07,2009-05,True,726,670,56,7.7,Adverse Event (22); Protocol Violation (13); Withdrawal by Subject (9); Lost to Follow-up (5); Other not specified (4); Noncompliance (3),Adverse Event,22.0,1
NCT03448406,This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.,cardiovascular disease,Heart Failure,Boehringer Ingelheim,INDUSTRY,315,2,108,11,2018-03-20,2019-10-09,True,315,291,24,7.6,Adverse Event (17); Noncompliance of scheduled visits (3); Withdrawal by Subject (3); Protocol Violation (1),Adverse Event,17.0,1
NCT00601250,Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,701,2,82,10,2008-01,,True,700,647,53,7.6,Withdrawal by Subject (17); Adverse Event (12); Other incl. lack of efficacy (11); Lost to Follow-up (8); Protocol Violation (5),Withdrawal by Subject,17.0,1
NCT03338010,A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes,Eli Lilly and Company,INDUSTRY,536,2,32,1,2018-03-22,2020-03-18,True,536,495,41,7.6,Withdrawal by Subject (22); Lost to Follow-up (6); Adverse Event (5); Physician Decision (4); Non-Compliance with Study Drug (3); Protocol Violation (1),Withdrawal by Subject,22.0,1
NCT01583218,Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study),cardiovascular disease,Venous Thromboembolism (VTE),Portola Pharmaceuticals,INDUSTRY,7513,2,462,34,2012-03,2016-01,True,7513,6941,572,7.6,Death (417); Withdrawal by Subject (72); Patient randomized but not dosed (33); Lost to Follow-up (28); Adverse event or serious adverse event (6); Patient /Family decision (3); Cannot contact patient directly (3); SOURCE DOCUMENT/COORDINATOR MISSING (2); Patient deemed ineligible after random (2); Patient did not wish to attend visits (1); Patient was assessed via phone in person (1); Patient was early terminated from study (1); Patient was randomized due to mistake (1); THE SUBJECT MOVED TO ANOTHER PROVINCE (1); Withdraw of consent on day of random (1),Death,417.0,1
NCT00371683,Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery,cardiovascular disease,Deep Vein Thrombosis; Pulmonary Embolism,Bristol-Myers Squibb,INDUSTRY,3608,2,107,13,2006-11,2008-05,True,3195,2953,330,7.6,Adverse Event (118); Withdrawal by Subject (91); Lost to Follow-up (78); non-specified (35); Death (4); No longer meets study criteria (3); Administrative reason by sponsor (1),Adverse Event,118.0,2
NCT02054897,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,388,4,86,9,2014-02-03,2015-05-08,True,388,359,29,7.5,Lost to Follow-up (13); Missing follow-up information (11); Withdrawal by Subject (4); Randomized but not exposed (1),Lost to Follow-up,13.0,1
NCT01217892,Evaluation of Dapagliflozin Taken Twice-daily,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,400,4,55,7,2010-11,2011-08,True,400,370,30,7.5,Subject no longer meets study criteria (19); Adverse Event (3); Withdrawal by Subject (3); Lab value (2); Incorrect enrollment (2); Poor/Non-Compliance (1),Subject no longer meets study criteria,19.0,1
NCT02104804,Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control,diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,953,2,11,1,2014-05-07,2016-02-26,True,466,431,35,7.5,Withdrawal by Subject (16); Study specific discontinuation criteria (7); Adverse Event (7); Other listed (3); Did not take study medication (1); Protocol Violation (1),Withdrawal by Subject,16.0,1
NCT00576693,Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis,cardiovascular disease,Ischemic Stroke,Medical University of South Carolina,OTHER,451,2,50,1,2008-10,2013-04,True,451,417,34,7.5,Lost to Follow-up (18); Withdrawal by Subject (16),Lost to Follow-up,18.0,1
NCT00696241,Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension,cardiovascular disease,Hypertension,Takeda,INDUSTRY,1275,5,85,3,2007-06,2008-10,True,1275,1179,96,7.5,Adverse Event (29); Withdrawal by Subject (19); Lack of Efficacy (18); Other (15); Lost to Follow-up (8); Protocol Violation (7),Adverse Event,29.0,1
NCT00602472,BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,1058,2,100,11,2008-02,,True,1055,976,79,7.5,Adverse Event (28); Protocol Violation (23); Withdrawal by Subject (22); Other incl. lack of efficacy (6),Adverse Event,28.0,1
NCT01952145,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,557,2,91,10,2013-09-20,2014-11-04,True,557,515,42,7.5,Withdrawal Criteria (27); Adverse Event (9); Protocol Violation (3); Unclassified (2); Death (1),Withdrawal Criteria,27.0,1
NCT00485836,A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE),cardiovascular disease,Macular Edema; Retinal Vein Occlusion,"Genentech, Inc.",INDUSTRY,392,3,0,0,2007-07,2009-12,True,392,363,0,7.4,,,,1
NCT01272193,Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,296,2,50,1,2011-01,2011-09,True,296,274,22,7.4,Unclassified (15); Lack of Efficacy (3); Adverse Event (2); Withdrawal Criteria (2),Unclassified,15.0,1
NCT01814748,A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028),diabetes type 2,Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,203,2,0,0,2013-05-03,2015-09-14,True,203,188,15,7.4,Withdrawal by Subject (10); Lost to Follow-up (3); Study site terminated by sponsor (2),Withdrawal by Subject,10.0,1
NCT00706134,"Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study",cardiovascular disease,Hypertension,Novartis,INDUSTRY,756,4,8,8,2008-05,2009-04,True,756,700,56,7.4,Adverse Event (20); Unsatisfactory therapeutic effect (20); Protocol Violation (9); Withdrawal by Subject (4); Did not meet study criteria (2); Lost to Follow-up (1),Adverse Event,20.0,1
NCT00491530,"A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia",dyslipidemia,Mixed Dyslipidemia,Abbott,INDUSTRY,310,3,1,1,2007-06,2008-11,True,310,287,23,7.4,Adverse Event (9); Lost to Follow-up (7); Withdrawal by Subject (3); Lack of Efficacy (1); Investigator Discretion (1); Patient Request (1); Use of Prohibited Medication (1),Adverse Event,9.0,1
NCT03061214,Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT),diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,868,4,67,7,2017-08-28,2019-04-15,True,868,805,63,7.3,Withdrawal by Subject (56); Lost to Follow-up (5); Death (2),Withdrawal by Subject,56.0,1
NCT00441350,Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension,cardiovascular disease,Hypertension,Menarini Group,INDUSTRY,1004,2,65,8,2007-07,2008-05,True,846,784,0,7.3,,,,2
NCT02058147,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,diabetes type 2,Type 2 Diabetes,Sanofi,INDUSTRY,1170,3,273,23,2014-02,2015-06,True,1170,1085,85,7.3,Adverse Event (42); Poor compliance to protocol (21); Other than specified (17); Lack of Efficacy (4); Randomized but not treated (1),Adverse Event,42.0,1
NCT01392677,Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea,diabetes type 2,Type 2 Diabetes Mellitus; High HbA1c Level; Inadequate Glycaemic Control,AstraZeneca,INDUSTRY,311,2,42,6,2011-10,2013-08,True,218,202,16,7.3,Incorrect enrollment (5); Other reason (5); Adverse Event (4); Withdrawal by Subject (2),Incorrect enrollment,5.0,1
NCT01615198,Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension,cardiovascular disease,Essential Hypertension,Novartis Pharmaceuticals,INDUSTRY,588,2,79,7,2012-08,2013-07,True,588,545,43,7.3,Adverse Event (16); Withdrawal by Subject (10); Lack of Efficacy (7); Physician Decision (6); Protocol deviation (2); Lost to Follow-up (2),Adverse Event,16.0,1
NCT02715726,Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia,cardiovascular disease,Hypercholesterolemia,Sanofi,INDUSTRY,615,2,62,3,2016-07-27,2018-08-06,True,615,570,45,7.3,Other than specified above (26); Adverse Event (8); Participant moved (4); Death (3); Randomized but not treated (3); Protocol Violation (1),Other than specified above,26.0,1
NCT05275400,A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin,diabetes type 2,Type 2 Diabetes,Eli Lilly and Company,INDUSTRY,986,2,127,10,2022-03-08,2024-05-15,True,986,914,96,7.3,Withdrawal by Subject (45); Assigned Treatment by Mistake (9); Death (9); Physician Decision (9); Adverse Event (8); Non-Compliance with Study Drug (6); Lost to Follow-up (6); Protocol Violation (2); Lack of Efficacy (1); Sponsor Decision (1),Withdrawal by Subject,45.0,2
NCT02446990,Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure,cardiovascular disease,Coronary Artery Disease,Institut de Recherches Internationales Servier,OTHER,19102,2,2,2,2009-09,2014-01,True,19102,17724,1378,7.2,Death (943); Withdrawal by Subject (430); Lost to Follow-up (4); Physician Decision (1),Death,943.0,1
NCT03693430,Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity,obesity,Overweight; Obesity,Novo Nordisk A/S,INDUSTRY,304,2,41,5,2018-10-05,2021-03-23,True,304,282,22,7.2,Lost to Follow-up (17); Withdrawal by Subject (4); Death (1),Lost to Follow-up,17.0,1
NCT05040971,Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes,obesity,Obesity,Novo Nordisk A/S,INDUSTRY,207,2,43,5,2021-09-06,2023-07-14,True,207,192,15,7.2,Lost to Follow-up (11); Withdrawal by Subject (2); Death (2),Lost to Follow-up,11.0,1
NCT01169779,Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin,diabetes type 2,Type 2 Diabetes Mellitus,Sanofi,INDUSTRY,391,2,35,4,2010-07,2011-12,True,391,363,28,7.2,Adverse Event (14); Familial and personal reasons (6); Withdrawal by Subject (5); Protocol Violation (2); Lack of Efficacy (1),Adverse Event,14.0,1
NCT01790438,A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,641,2,63,11,2013-03,2014-05,True,641,595,46,7.2,Withdrawal by Subject (15); Protocol Required Discontinuation (8); Lost to Follow-up (7); Adverse Event (5); Death (4); Physician Decision (4); Sponsor Decision (3),Withdrawal by Subject,15.0,1
NCT01590797,A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,467,2,0,0,2012-07-10,2014-06-25,True,467,434,33,7.1,Withdrawal by Subject (12); Adverse Event (7); Other Protocol Specified Criteria (6); Protocol Violation (5); Lack of Efficacy (2); Lost to Follow-up (1),Withdrawal by Subject,12.0,1
NCT00765674,Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension,cardiovascular disease,Hypertension,Novartis,INDUSTRY,1191,4,12,12,2008-09,2009-08,True,1191,1106,85,7.1,Adverse Event (28); Withdrawal by Subject (23); Lost to Follow-up (13); Lack of Efficacy (8); Abnormal Test Procedure Result(s) (7); Protocol Violation (3); Randomized in Error - No Study Drug (2); Abnormal Laboratory Value(s) (1),Adverse Event,28.0,1
NCT00413972,Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420),dyslipidemia,Hypercholesterolemia,Organon and Co,INDUSTRY,392,4,0,0,2006-04,2006-11,True,392,364,28,7.1,Withdrawal by Subject (18); Lost to Follow-up (4); Adverse Event (3); Protocol Violation (2); Other (1),Withdrawal by Subject,18.0,1
NCT02412878,Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma,cardiovascular disease,Multiple Myeloma,Amgen,INDUSTRY,478,2,140,20,2015-09-09,2019-01-07,True,478,444,34,7.1,Withdrawal by Subject (29); Lost to Follow-up (5),Withdrawal by Subject,29.0,1
NCT01468181,A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,394,5,14,1,2011-11,2013-12,True,394,366,28,7.1,Adverse Event (19); Protocol Violation (4); Physician Decision (2); Lost to Follow-up (2); Withdrawal by Subject (1),Adverse Event,19.0,1
NCT00860262,Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension,cardiovascular disease,Hypertension,Boehringer Ingelheim,INDUSTRY,858,3,137,11,2009-03,,True,858,798,60,7.0,Adverse Event (22); Withdrawal by Subject (18); Other (9); Lack of Efficacy (7); Lost to Follow-up (3); Protocol Violation (1),Adverse Event,22.0,1
NCT03735979,Multi-arm Optimization of Stroke Thrombolysis,cardiovascular disease,Acute Ischemic Stroke,Washington University School of Medicine,OTHER,514,3,61,1,2019-10-15,2024-10-31,True,514,478,36,7.0,Lost to Follow-up (27); Withdrawal by Subject (8); Not due to the above reasons (1),Lost to Follow-up,27.0,1
NCT01977794,Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension,cardiovascular disease,Hypertension,"Merck KGaA, Darmstadt, Germany",INDUSTRY,200,2,1,1,2014-03,2015-03,True,200,186,14,7.0,Adverse Event (4); Lost to Follow-up (3); Withdrew consent (3); Death (2); Protocol Violation (1); Other (1),Adverse Event,4.0,1
NCT00309738,Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin,dyslipidemia,Hypercholesterolemia; Dyslipidemia,Kowa Research Europe,INDUSTRY,355,2,35,4,2005-09,2006-10,True,355,330,0,7.0,,,,1
NCT00541775,Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,273,3,0,0,2006-06,2007-03,True,273,254,19,7.0,Withdrawal by Subject and Other (7); Adverse Event (6); Lack of Efficacy (3); Lost to Follow-up (2); Protocol Violation (1),Withdrawal by Subject and Other,7.0,1
NCT02453555,Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,275,6,40,1,2015-05-14,2017-03-27,True,275,256,19,6.9,Adverse Event (7); Withdrawal by Subject (7); Other than specified above (3); Lost to Follow-up (1); Protocol Violation (1),Adverse Event,7.0,2
NCT00819091,"Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug",diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,245,2,45,7,2008-12,,True,245,228,17,6.9,Adverse Event (8); Withdrawal by Subject (3); Other (3); Lost to Follow-up (2); Protocol Violation (1),Adverse Event,8.0,1
NCT01137474,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,2996,4,329,16,2010-07,2013-02,True,944,880,64,6.8,Withdrawal by Subject (24); Adverse Event (12); No longer met study criteria (12); Lost to Follow-up (8); Other (4); Lack of Efficacy (2); Pregnancy (1); Administrative reason by sponsor (1),Withdrawal by Subject,24.0,1
NCT00461630,Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE,cardiovascular disease,Cardiovascular Disease; Peripheral Arterial Disease; Diabetes Mellitus; Coronary Heart Disease,University of Oxford,OTHER,25673,2,1,1,2007-01,2012-10,True,25673,23940,1733,6.8,Death (1530); Lost to Follow-up (203),Death,1530.0,1
NCT00130208,Effect of Sulodexide in Early Diabetic Nephropathy,diabetes type 2,Diabetic Nephropathy,Keryx Biopharmaceuticals,INDUSTRY,1056,2,3,3,2005-08,2008-02,True,1056,984,72,6.8,Adverse Event (31); Withdrawal by Subject (25); Lost to Follow-up (10); Other (4); Physician Decision (2),Adverse Event,31.0,2
NCT01307046,MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352),cardiovascular disease,Hypertension,Organon and Co,INDUSTRY,336,2,0,0,2011-03-29,2012-02-07,True,336,313,23,6.8,Adverse Event (6); Serum Potassium Withdrawal Criteria Met (6); Blood Pressure Withdrawal Criteria Met (5); Lack of Efficacy (2); Physician Decision (2); Withdrawal by Subject (2),Adverse Event,6.0,1
NCT01456169,A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone,cardiovascular disease,Essential Hypertension,Takeda,INDUSTRY,507,3,108,14,2011-10,2013-01,True,395,368,27,6.8,Adverse Event (10); Major Protocol Deviation (8); Voluntary Withdrawal (5); Lack of Efficacy (2); Other (2),Adverse Event,10.0,1
NCT03087773,Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction,cardiovascular disease,Acute Myocardial Infarction,Medical University of Graz,OTHER,476,2,11,1,2017-05-11,2022-05-17,True,476,444,32,6.7,Lost to Follow-up (20); Withdrawal by Subject (12),Lost to Follow-up,20.0,1
NCT02036515,Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,464,3,0,0,2014-03-12,2016-06-06,True,464,433,31,6.7,Withdrawal by Subject (20); Adverse Event (4); Lost to Follow-up (2); Non-compliance with study drug (2); Screen failure (2); Hyperglycemia (1),Withdrawal by Subject,20.0,1
NCT01768559,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,diabetes type 2,Type 2 Diabetes,Sanofi,INDUSTRY,894,3,199,18,2013-01,2014-12,True,894,834,60,6.7,Adverse Event (22); Other than specified (22); Lack of Efficacy (10); Poor compliance to protocol (5); Randomized but not treated (1),Adverse Event,22.0,1
NCT01849289,A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,833,2,81,7,2013-06-02,2014-05-15,True,833,777,56,6.7,Unclassified (43); Adverse Event (6); Protocol Violation (6); Withdrawal criteria (1),Unclassified,43.0,1
NCT00621140,Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,503,2,69,11,2008-02,,True,503,470,33,6.6,Other incl. lack of efficacy (11); Withdrawal by Subject (10); Adverse Event (9); Lost to Follow-up (3),Other incl. lack of efficacy,11.0,1
NCT02607306,"A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.",diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,819,3,76,1,2015-11-18,2017-12-22,True,819,765,54,6.6,Adverse Event (20); Withdrawal by Subject (20); Protocol Violation (7); Unclassified (5); Lack of Efficacy (2),Adverse Event,20.0,1
NCT00523978,A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation,cardiovascular disease,Paroxysmal Atrial Fibrillation,Medtronic Cardiac Rhythm and Heart Failure,INDUSTRY,245,2,26,2,2006-10,2011-07,True,258,241,17,6.6,Withdrawal by Subject (10); Screen Failures (6); Death (1),Withdrawal by Subject,10.0,1
NCT05691712,A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes,diabetes type 2,Diabetes Type 2; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Disease; Endocrine System Diseases,Eli Lilly and Company,INDUSTRY,257,4,25,1,2023-02-05,2024-07-01,True,257,240,17,6.6,Withdrawal by Subject (9); Adverse Event (4); Assigned Treatment by Mistake (2); Death (1); Pregnancy (1),Withdrawal by Subject,9.0,1
NCT01355159,High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention,hypertension,Pregnancy Complications; Preeclampsia,Ottawa Hospital Research Institute,OTHER,2464,2,72,5,2011-04,2016-09,True,2464,2301,163,6.6,Withdrew consent (86); Spontaneous abortion (<20 weeks) (37); No primary outcome data (28); Early intrauterine fetal death (12),Withdrew consent,86.0,1
NCT01594333,Cardiovascular Inflammation Reduction Trial,diabetes type 2,Cardiovascular Disease,Brigham and Women's Hospital,OTHER,4786,2,470,3,2013-04,2019-10-30,True,4786,4474,312,6.5,Death (179); Withdrawal by Subject (123); Lost to Follow-up (10),Death,179.0,1
NCT04707469,Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1606,3,228,15,2021-01-15,2023-03-08,True,1606,1502,104,6.5,Withdrawal by Subject (45); Lost to Follow-up (42); Death (9); Physician Decision (6); Site closure (2),Withdrawal by Subject,45.0,1
NCT00812955,"Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (""Bad Cholesterol"") and Triglycerides",dyslipidemia,"Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia",AstraZeneca,INDUSTRY,474,4,129,1,2008-11,2009-06,True,474,443,31,6.5,Adverse Event (20); Lost to Follow-up (6); Withdrawal by Subject (4); randomized in error (1),Adverse Event,20.0,1
NCT02072434,Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF),cardiovascular disease,Atrial Fibrillation,Daiichi Sankyo,INDUSTRY,2199,2,228,19,2014-03-25,2016-02-03,True,2199,2055,144,6.5,"Withdrawal by Subject (46); Other (43); Protocol Violation (19); Physician Decision (15); Adverse Event (13); Adverse event, serious fatal (7); Lost to Follow-up (1)",Withdrawal by Subject,46.0,1
NCT01365507,Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,276,2,42,7,2011-06,2012-04,True,276,258,18,6.5,Withdrawal Criteria (13); Unclassified (5),Withdrawal Criteria,13.0,1
NCT04944290,To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes,hypertension,"Glaucoma, Open-Angle; Ocular Hypertension",Padagis LLC,INDUSTRY,447,2,1,1,2021-05-28,2022-06-21,True,447,418,0,6.5,,,,1
NCT00309777,Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin,dyslipidemia,Hypercholesterolemia; Dyslipidemia,Kowa Research Europe,INDUSTRY,857,4,42,5,2005-09,2006-10,True,857,802,55,6.4,Adverse Event (24); Withdrawal by Subject (20); Protocol Violation (9); Lost to Follow-up (1); Death (1),Adverse Event,24.0,1
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,cardiovascular disease,Diabetic Retinopathy; Diabetic Macular Edema,Jaeb Center for Health Research,OTHER,691,4,50,1,2007-03,2014-02,True,854,799,55,6.4,Dropped (36); Death (17); Missed visit (2),Dropped,36.0,1
NCT03376789,Mylan Insulin Glargine Study,diabetes type 2,"Diabetes Mellitus, Type 1",Mylan Inc.,INDUSTRY,219,2,38,1,2017-11-29,2019-01-10,True,219,205,14,6.4,Withdrawal by Subject (8); Lost to Follow-up (2); Protocol Violation (1); Adverse Event (1); Per sponsor due to noncompliance (1); Subject off study medication (1),Withdrawal by Subject,8.0,1
NCT00970489,Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation,cardiovascular disease,Atrial Fibrillation,Brigham and Women's Hospital,OTHER,1516,2,1,1,2010-08,2012-06,True,1516,1421,95,6.3,Death/Withdrew/Criteria Violation (95),Death/Withdrew/Criteria Violation,95.0,1
NCT01204294,Comprehensive Add on Study in Japan,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,574,7,43,1,2010-09,2012-01,True,574,538,36,6.3,Adverse Event (20); Withdrawal by Subject (9); Protocol Violation (4); Lack of Efficacy (2); Other (house moving) (1),Adverse Event,20.0,1
NCT00433836,Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure,cardiovascular disease,Hypertension,Novartis Pharmaceuticals,INDUSTRY,300,6,11,11,2007-01,2009-02,True,300,281,19,6.3,Adverse Event (7); Lost to Follow-up (3); Withdrawal by Subject (3); Unsatisfactory therapeutic effect (2); Protocol Violation (2); Condition no longer requires study drug (1); Abnormal laboratory values (1),Adverse Event,7.0,1
NCT00439725,Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study,cardiovascular disease,Venous Thromboembolism,Bayer,INDUSTRY,1197,2,322,33,2007-02,2009-09,True,1197,1122,497,6.3,Study terminated by sponsor (304); Clinical endpoint reached (60); Adverse Event (57); Withdrawal by Subject (45); Participant did not receive treatment (8); Death (4); Site closed by investigator (3); Protocol Violation (3); Lost to Follow-up (3); Physician Decision (2); Technical problems (2); Participant convenience (2); Protocol driven decision point (2); Study termination by sponsor (2),Study terminated by sponsor,304.0,2
NCT05963022,A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO),diabetes type 2,Type 2 Diabetes,Eli Lilly and Company,INDUSTRY,206,4,28,1,2023-08-21,2024-10-09,True,206,193,13,6.3,Protocol Violation (3); Pregnancy (3); Withdrawal by Subject (3); Adverse Event (2); Lost to Follow-up (1); Subject Required long-term Initiation of Rescue Antihyperglycemic Medication (1),Protocol Violation,3.0,1
NCT03136484,Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,788,2,119,12,2017-03-15,2018-11-16,True,788,739,49,6.2,Withdrawal by Subject (33); Lost to Follow-up (15); Death (1),Withdrawal by Subject,33.0,1
NCT03067441,Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE),cardiovascular disease,Hypercholesterolemia; Atherosclerotic Cardiovascular Disease,"Esperion Therapeutics, Inc.",INDUSTRY,1462,1,3,1,2017-02-03,2019-11-05,True,1462,1372,90,6.2,Withdrawal by Subject (50); Adverse Event (21); Lost to Follow-up (12); Physician Decision (4); Other (2); Study Terminated by Sponsor or Investigator (1),Withdrawal by Subject,50.0,1
NCT02906917,A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,532,2,71,7,2016-09-20,2017-12-24,True,532,499,33,6.2,Withdrawal by Subject (12); Unclassified (9); Lost to Follow-up (9); Adverse Event (3),Withdrawal by Subject,12.0,2
NCT00699998,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,cardiovascular disease,Acute Coronary Syndrome,Eli Lilly and Company,INDUSTRY,9326,2,688,53,2008-06,2012-04,True,9326,8753,573,6.1,Withdrawal by Subject (559); Physician Decision (7); Lost to Follow-up (7),Withdrawal by Subject,559.0,1
NCT02058160,Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes,Sanofi,INDUSTRY,736,2,236,18,2014-01,2015-07,True,736,691,45,6.1,Other than specified above (18); Adverse Event (15); Randomized but not treated (6); Poor compliance to protocol (5); Lost to Follow-up (1),Other than specified above,18.0,1
NCT02132767,Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation,cardiovascular disease,Postoperative Atrial Fibrillation,Icahn School of Medicine at Mount Sinai,OTHER,523,2,23,2,2014-05,2015-09,True,523,491,32,6.1,Withdrawal by Subject (19); Lost to Follow-up (8); Death (5),Withdrawal by Subject,19.0,1
NCT01263483,Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan,diabetes type 2,Type 2 Diabetes Mellitus,Takeda,INDUSTRY,230,3,0,0,2007-01,2008-04,True,230,216,14,6.1,Adverse Event (7); Lack of Efficacy (2); Protocol Violation (2); Participant Unavailability (2); Withdrawal by Subject (1),Adverse Event,7.0,1
NCT02197416,Safety of Dabigatran Etexilate in Blood Clot Prevention in Children,cardiovascular disease,Venous Thromboembolism; Secondary Prevention,Boehringer Ingelheim,INDUSTRY,214,1,62,22,2014-09-29,2019-11-19,True,213,200,13,6.1,Other reasons (7); Withdrawal by Subject (3); Protocol Violation (2); Adverse Event (1),Other reasons,7.0,1
NCT01047683,Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL,dyslipidemia,Hypertriglyceridemia,Amarin Pharma Inc.,INDUSTRY,229,3,60,11,2009-12,2011-07,True,229,215,14,6.1,Withdrew Consent (7); Adverse Event (4); Triglycerides >2000 mg/dL (2); Lost to Follow-up (1),Withdrew Consent,7.0,1
NCT00591266,"Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension",cardiovascular disease,Hypertension,Takeda,INDUSTRY,566,3,50,1,2007-10,2009-04,True,566,532,34,6.0,Withdrawal by Subject (13); Other (10); Adverse Event (7); Lack of Efficacy (2); Lost to Follow-up (1); Protocol Violation (1),Withdrawal by Subject,13.0,1
NCT02551094,Colchicine Cardiovascular Outcomes Trial (COLCOT),cardiovascular disease,Coronary Artery Disease; Myocardial Infarction,Montreal Heart Institute,OTHER,4745,2,1,1,2015-12-04,2019-07-17,True,4745,4458,0,6.0,,,,1
NCT01976338,Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO),cardiovascular disease,Macular Edema Secondary to Branch Retinal Vein Occlusion,Novartis Pharmaceuticals,INDUSTRY,283,2,33,6,2013-11-12,2016-03-28,True,283,266,17,6.0,Withdrawal by Subject (7); Adverse Event (6); Lost to Follow-up (3); Physician Decision (1),Withdrawal by Subject,7.0,1
NCT00413049,Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension,cardiovascular disease,Hypertension,Novartis,INDUSTRY,698,2,12,1,2007-01,2007-11,True,698,656,42,6.0,Adverse Event (18); Withdrawal by Subject (12); Lost to Follow-up (5); Protocol Violation (4); Subject no longer requires study drug (1); Abnormal laboratory value(s) (1); Lack of Efficacy (1),Adverse Event,18.0,1
NCT02320721,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications,diabetes type 2,Type 2 Diabetes Mellitus,Sanofi,INDUSTRY,1014,2,162,18,2015-01,2016-05,True,1014,953,61,6.0,Other than specified above (35); Adverse Event (12); Poor compliance to protocol (10); Lack of Efficacy (2); Randomized but not treated (1); Hypoglycemia (1),Other than specified above,35.0,1
NCT01872611,Nepafenac Once Daily for Macular Edema - Study 2,diabetes type 2,Non-Proliferative Diabetic Retinopathy; Cataract,Alcon Research,INDUSTRY,819,2,0,0,2013-06,2015-05,True,605,569,36,6.0,"Reason not provided (12); Lost to Follow-up (9); Withdrawal by Subject (7); Adverse Event (4); Adverse Event, prior to treatment (1); Death (1); Death, prior to treatment (1); Physician Decision (1)",Reason not provided,12.0,1
NCT02648204,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1201,4,209,17,2016-01-06,2017-05-19,True,1201,1129,72,6.0,Withdrawal by Subject (28); Lost to Follow-up (23); Missing follow-up information (14); Death (6); Adverse Event (1),Withdrawal by Subject,28.0,1
NCT02298192,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,420,2,84,9,2014-11-21,2015-12-23,True,420,395,25,6.0,Adverse Event (8); Withdrawal by Subject (7); Unclassified (5); Lost to Follow-up (3); Withdrawal criteria (2),Adverse Event,8.0,1
NCT03861039,A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,443,3,34,1,2019-03-30,2021-02-16,True,443,417,26,5.9,Adverse Event (18); Withdrawal by Subject (8),Adverse Event,18.0,1
NCT02128932,Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1089,3,231,15,2014-08-04,2015-09-03,True,1082,1018,64,5.9,No reason for withdrawal (30); Withdrawal by Subject (26); Death (4); Lost to Follow-up (4),No reason for withdrawal,30.0,1
NCT04560998,A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2; Peripheral Arterial Disease",Novo Nordisk A/S,INDUSTRY,792,2,194,21,2020-10-01,2024-07-12,True,792,745,47,5.9,Withdrawal by Subject (30); Lost to Follow-up (13); Physician Decision (4),Withdrawal by Subject,30.0,1
NCT01841697,Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026),diabetes type 2,Type 2 Diabetes,Merck Sharp & Dohme LLC,INDUSTRY,642,2,0,0,2013-06-13,2014-11-17,True,642,604,38,5.9,Withdrawal by Subject (32); Lost to Follow-up (5); Death (1),Withdrawal by Subject,32.0,1
NCT01850615,"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes",diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,323,2,58,6,2013-09-23,2014-11-17,True,236,222,14,5.9,Protocol Violation (5); Withdrawal by Subject (4); Adverse Event (3); Lost to Follow-up (1); Unclassified (1),Protocol Violation,5.0,1
NCT01876368,Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan,cardiovascular disease,Hypertension,Novartis Pharmaceuticals,INDUSTRY,376,2,51,7,2013-09,2014-08,True,376,354,22,5.9,Adverse Event (7); Protocol deviation (6); Subject/guardian decision (4); Physician Decision (2); Lack of Efficacy (1); Lost to Follow-up (1); Non-compliance with study treatment (1),Adverse Event,7.0,1
NCT00097591,A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention,cardiovascular disease,Coronary Arteriosclerosis; Acute Coronary Syndromes,Eli Lilly and Company,INDUSTRY,13619,2,1,1,2004-11,2007-07,True,13608,12804,804,5.9,Withdrawal of consent (665); Unable to attend termination visit (104); Less than 6 months on study drug (16); Lost to follow up (16); Other (3),Withdrawal of consent,665.0,1
NCT04880850,"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)",diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,582,2,116,9,2021-05-14,2022-06-16,True,582,548,34,5.8,Withdrawal by Subject (19); Lost to Follow-up (9); Death (3); Physician Decision (3),Withdrawal by Subject,19.0,1
NCT01357616,Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension,hypertension,Open-Angle Glaucoma; Ocular Hypertension,Alcon Research,INDUSTRY,328,2,0,0,2010-11,2013-01,True,328,309,19,5.8,Lost to Follow-up (7); Decision Unrelated to Adverse Event (4); Inadequate Control of IOP (3); Adverse Event (2); Protocol Violation (2); Withdrawal by Subject (1),Lost to Follow-up,7.0,1
NCT01513590,A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,394,2,49,10,2012-01-16,2012-11-19,True,394,371,23,5.8,Unclassified (15); Adverse Event (5); Withdrawal Criteria (3),Unclassified,15.0,1
NCT00980174,Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis,metabolic syndrome,Low Bone Mass; Low Bone Mineral Density; Males With Osteoporosis; Osteopenia; Osteoporosis,Amgen,INDUSTRY,242,2,0,0,2009-10-01,2012-05-23,True,242,228,14,5.8,Withdrawal by Subject (5); Adverse Event (3); Ineligibility determined (3); Death (2); Other (1),Withdrawal by Subject,5.0,1
NCT01786993,MultiPoint Pacing IDE Study,cardiovascular disease,Heart Failure,Abbott Medical Devices,INDUSTRY,506,2,49,1,2013-04,2016-06,True,381,359,22,5.8,Death (13); Withdrawal by Subject (5); Lost to Follow-up (1); Subject Non-Compliance (1); System Explant (1); Hospice Admission (1),Death,13.0,1
NCT01722604,Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt,hypertension,Glaucoma; Open Angle or Ocular Hypertension,Bausch & Lomb Incorporated,INDUSTRY,258,2,1,1,2012-01,2012-09,True,258,243,0,5.8,,,,1
NCT02774265,A Different Approach to Preventing Thrombosis,cardiovascular disease,Venous Thromboembolism; Pulmonary Embolism,"University of Maryland, Baltimore",OTHER,329,2,1,1,2016-01,2017-09,True,329,310,0,5.8,,,,1
NCT00141778,"Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)",cardiovascular disease,Atrial Fibrillation,Vanderbilt University,OTHER,455,3,1,1,2005-04,2010-08,True,458,432,26,5.7,Withdrawal by Subject (15); Met safety criteria for discontinuation (9); Difficulty Swallowing (1); Chest Discomfort (1),Withdrawal by Subject,15.0,2
NCT02607865,Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1864,4,242,15,2016-02-15,2018-03-28,True,1864,1758,106,5.7,Withdrawal by Subject (61); Lost to Follow-up (28); Death (13); Unclassified (4),Withdrawal by Subject,61.0,1
NCT03548935,STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity,obesity,Metabolism and Nutrition Disorder; Overweight or Obesity,Novo Nordisk A/S,INDUSTRY,1961,2,128,17,2018-06-04,2021-03-05,True,1961,1849,112,5.7,Lost to Follow-up (67); Withdrawal by Subject (43); Death (2),Lost to Follow-up,67.0,1
NCT01763918,Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2,dyslipidemia,Hyperlipidemia,Amgen,INDUSTRY,331,4,39,14,2013-02-07,2013-12-19,True,331,312,19,5.7,Sponsor Decision (13); Withdrawal by Subject (6),Sponsor Decision,13.0,1
NCT02648217,"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan",diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,263,2,32,6,2016-01-04,2016-09-05,True,263,248,15,5.7,Withdrawal by Subject (7); Unclassified (5); Lost to Follow-up (2); Adverse Event (1),Withdrawal by Subject,7.0,1
NCT02906930,Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,703,4,105,11,2016-09-20,2017-12-08,True,703,663,40,5.7,Lost to Follow-up (19); Withdrawal by Subject (14); Other (6); Death (1),Lost to Follow-up,19.0,1
NCT02371759,Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2,diabetes type 2,Diabetes Mellitus; Local Anesthesia,University of Belgrade,OTHER,256,8,1,1,2013-06,2016-01,True,233,220,13,5.6,Protocol Violation (12); Withdrawal by Subject (1),Protocol Violation,12.0,1
NCT00918879,Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,213,2,9,1,2009-05,2010-07,True,213,201,12,5.6,Withdrawal by Subject (8); Lost to Follow-up (2); Severe non-compliance to protocol (2),Withdrawal by Subject,8.0,1
NCT01047501,Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL),dyslipidemia,Hypertriglyceridemia,Amarin Pharma Inc.,INDUSTRY,702,3,80,1,2009-12,2011-02,True,702,663,39,5.6,Adverse Event (20); Withdrew Consent (12); Lost to Follow-up (2); Other discontinuation (2); Triglycerides >800 mg/dL (1); Death (1); Investigator judgement (1),Adverse Event,20.0,1
NCT04074161,Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity,obesity,Overweight; Obesity,Novo Nordisk A/S,INDUSTRY,338,4,19,1,2019-09-11,2021-05-11,True,338,319,19,5.6,Lost to Follow-up (12); Withdrawal by Subject (7),Lost to Follow-up,12.0,1
NCT00600483,Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection,obesity,Cardiac Surgery; Sternal Wound Infection,Innocoll,INDUSTRY,1502,2,43,1,2007-12,2010-09,True,1502,1419,83,5.5,Lost to Follow-up (73); Randomized but not treated (10),Lost to Follow-up,73.0,1
NCT01763905,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2,dyslipidemia,Hyperlipidemia,Amgen,INDUSTRY,307,4,58,14,2013-01-24,2013-11-19,True,307,290,17,5.5,Decision by sponsor (13); Withdrawal by Subject (3); Lost to Follow-up (1),Decision by sponsor,13.0,1
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,cardiovascular disease,Proliferative Diabetic Retinopathy; Diabetic Macular Edema,Jaeb Center for Health Research,OTHER,333,3,56,1,2007-03,2010-07,True,345,326,19,5.5,Missed Visit (9); Dropped (6); Death (4),Missed Visit,9.0,1
NCT01516879,Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study,dyslipidemia,Hypercholesterolemia,Amgen,INDUSTRY,905,2,96,9,2012-01-05,2013-10-14,True,905,855,50,5.5,Withdrawal by Subject (20); Other (15); Lost to Follow-up (13); Death (2),Withdrawal by Subject,20.0,1
NCT04986202,Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%,cardiovascular disease,Heart Failure With Preserved Ejection Fraction,AstraZeneca,INDUSTRY,711,5,171,18,2021-06-30,2024-03-27,True,711,672,39,5.5,Death (23); Withdrawal by Subject (10); Physician Decision (6),Death,23.0,1
NCT00790205,Sitagliptin Cardiovascular Outcomes Study (MK-0431-082),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,14671,2,0,0,2008-12-10,2015-03-30,True,14671,13877,794,5.4,Withdrawal by Subject (662); Lost to Follow-up (132),Withdrawal by Subject,662.0,1
NCT01853072,Nepafenac Once Daily for Macular Edema - Study 1,diabetes type 2,Non-Proliferative Diabetic Retinopathy; Cataract,Alcon Research,INDUSTRY,881,2,0,0,2013-06,2015-05,True,615,582,33,5.4,Reason not specified (15); Death (5); Adverse Event (3); Lost to Follow-up (3); Withdrawal by Subject (3); Physician Decision (2); Adverse event prior to treatment (1); Non-compliance with study drug (1),Reason not specified,15.0,1
NCT02666664,Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony),cardiovascular disease,Hypercholesterolemia; Atherosclerotic Cardiovascular Diseases,"Esperion Therapeutics, Inc.",INDUSTRY,2230,2,104,6,2016-01-21,2018-03-28,True,2230,2110,120,5.4,Withdrawal by participant (63); Adverse Event (49); Lost to Follow-up (3); Protocol Violation (2); Physician Decision (1); Other (1); Sponsor decision (1),Withdrawal by participant,63.0,1
NCT03175120,A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD),diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,453,2,37,2,2017-05-26,2019-04-04,True,453,429,24,5.3,Protocol Violation (7); Withdrawal by Subject (7); Other (5); Adverse Event (4); Lost to Follow-up (1),Protocol Violation,7.0,1
NCT00411554,A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED),diabetes type 2,"Diabetes Mellitus, Non-Insulin-Dependent",Merck Sharp & Dohme LLC,INDUSTRY,319,2,0,0,2007-01,2007-08,True,319,302,17,5.3,Lack of Efficacy (7); Adverse Event (6); Withdrawal by Subject (3); Patient Moved (1),Lack of Efficacy,7.0,1
NCT05352815,"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec",diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1291,2,281,22,2022-06-01,2024-04-23,True,1291,1222,69,5.3,Withdrawal by Subject (52); Lost to Follow-up (11); Death (5); Site closure (1),Withdrawal by Subject,52.0,1
NCT00486018,A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO),cardiovascular disease,Macular Edema; Retinal Vein Occlusion,"Genentech, Inc.",INDUSTRY,397,3,0,0,2007-07,2009-11,True,397,376,0,5.3,,,,1
NCT02897349,Linagliptin Add-on to Insulin Background Therapy,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,206,2,25,1,2016-09-30,2019-01-18,True,206,195,11,5.3,Adverse Event (6); Lost to Follow-up (4); Other than listed above (1),Adverse Event,6.0,1
NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,cardiovascular disease,Venous Thrombosis,Bristol-Myers Squibb,INDUSTRY,5614,2,381,31,2008-07,2013-03,True,5395,5107,939,5.3,Adverse Event (332); Other (214); Withdrawal by Subject (150); Death (108); Lost to Follow-up (62); Poor or non-compliance (43); Fails to meet inclusion/exclusion (22); Pregnancy (5); Administrative reason (2); non-specified (1),Adverse Event,332.0,2
NCT05142722,Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies,cardiovascular disease,Dyslipidemias; High Cholesterol; Hypercholesterolemia; Familial Hypercholesterolemia; Atherosclerotic Cardiovascular Disease,NewAmsterdam Pharma,INDUSTRY,2530,2,181,8,2021-12-15,2024-09-26,True,2530,2395,135,5.3,Lost to Follow-up (54); Withdrawal by Subject (47); Death (28); Adverse Event (3); Participant Moved Away (2); Physician Decision (1),Lost to Follow-up,54.0,1
NCT05362058,A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time,diabetes type 2,Diabetes; Type 2 Diabetes,Eli Lilly and Company,INDUSTRY,928,2,113,11,2022-06-03,2024-04-10,True,928,880,57,5.2,Withdrawal by Subject (24); Lost to Follow-up (12); Assigned treatment by mistake (7); Adverse Event (6); Death (3); Protocol deviation (3); Non-compliance with study drug (1); Physician Decision (1),Withdrawal by Subject,24.0,2
NCT00002850,Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy,cardiovascular disease,Infection; Multiple Myeloma,Gary Morrow,OTHER,212,3,45,3,1997-03,2012-01,True,212,201,11,5.2,Death (8); Protocol Violation (2); Withdrawal by Subject (1),Death,8.0,1
NCT00777946,Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone,cardiovascular disease,Hypertension,Novartis,INDUSTRY,818,3,9,9,2008-10,2009-05,True,820,777,43,5.2,Adverse Event (15); Lack of Efficacy (9); Patient withdrew consent (8); Lost to Follow-up (4); Protocol deviation (4); Randomized in error (2); Condition no longer required study drug (1),Adverse Event,15.0,1
NCT00249249,Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels,dyslipidemia,Primary Hypercholesterolemia; Dyslipidemia,Kowa Research Europe,INDUSTRY,830,0,192,13,2005-10,2006-11,True,830,787,0,5.2,,,,1
NCT02185417,Diuretic Comparison Project,cardiovascular disease,Hypertension,VA Office of Research and Development,FED,20723,3,70,2,2016-06-15,2022-12-29,True,17651,16738,913,5.2,Death (894); Withdrawal by Subject (19),Death,894.0,1
NCT01894568,A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,388,2,31,3,2013-07,2015-04,True,388,368,20,5.2,Withdrawal by Subject (10); Adverse Event (5); Protocol required discontinuation (3); Physician Decision (1); Lost to Follow-up (1),Withdrawal by Subject,10.0,1
NCT02988115,Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant,cardiovascular disease,Hypercholesterolemia; Atherosclerotic Cardiovascular Disease; Statin Adverse Reaction,"Esperion Therapeutics, Inc.",INDUSTRY,345,2,67,2,2016-11-16,2018-03-16,True,345,327,18,5.2,Adverse Event (7); Sponsor Decision (7); Withdrawal by Subject (2); Withdrawn by Mistake (1); Lost to Follow-up (1),Adverse Event,7.0,1
NCT04591626,A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,291,2,27,1,2020-12-07,2022-04-28,True,291,276,15,5.2,Withdrawal by Subject (8); Adverse Event (4); Physician Decision (1); Death (1); Non-Compliance with Study Drug (1),Withdrawal by Subject,8.0,1
NCT01895777,Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE),cardiovascular disease,Venous Thromboembolism,Boehringer Ingelheim,INDUSTRY,267,2,65,26,2013-09-25,2019-11-14,True,267,253,14,5.2,Other reasons (5); Adverse Event (3); Non-compliance with the CTP (3); Lost to Follow-up (2); Not treated (1),Other reasons,5.0,1
NCT04039503,A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin,diabetes type 2,Type 2 Diabetes,Eli Lilly and Company,INDUSTRY,475,4,48,8,2019-08-30,2021-01-13,True,475,451,24,5.1,Withdrawal by Subject (14); Adverse Event (5); Protocol Violation (4); Lost to Follow-up (1),Withdrawal by Subject,14.0,1
NCT01930188,Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1231,4,141,18,2013-12-02,2015-10-12,True,1225,1163,62,5.1,Withdrawal by Subject (28); unclassified (12); Lost to Follow-up (9); Missing follow-up information (7); Death (6),Withdrawal by Subject,28.0,1
NCT02738879,Randomized Sitagliptin Withdrawal Study (MK-0431-845),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,746,2,0,0,2016-05-09,2018-01-30,True,746,708,38,5.1,Withdrawal by Subject (12); Physician Decision (7); Lost to Follow-up (6); Protocol Violation (4); Screen Failure (3); Adverse Event (2); Death (2); Pregnancy (1); Site Discontinued Study Participation (1),Withdrawal by Subject,12.0,1
NCT03987919,A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes,Eli Lilly and Company,INDUSTRY,1879,4,127,9,2019-07-30,2021-02-15,True,1879,1783,96,5.1,Lost to Follow-up (31); Withdrawal by Subject (26); Death (13); Adverse Event (9); Physician Decision (6); Other - as reported by the investigator (6); Pregnancy (3); Protocol Violation (1); Site terminated by Sponsor (1),Lost to Follow-up,31.0,1
NCT01697592,Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,585,10,0,0,2012-10-24,2014-05-08,True,585,555,30,5.1,Adverse Event (17); Withdrawal by Subject (8); Physician Decision (3); Lost to Follow-up (1); Protocol Violation (1),Adverse Event,17.0,2
NCT01499953,Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux,cardiovascular disease,Superficial Vein Thrombosis,GWT-TUD GmbH,OTHER,472,2,23,1,2012-04,2016-05,True,472,448,0,5.1,,,,1
NCT05425745,Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.,dyslipidemia,"Dyslipidemias; High Cholesterol; Hypercholesterolemia; Familial Hypercholesterolemia; Lipid Metabolism Disorder; Metabolic Disease; Lipid Metabolism, Inborn Errors; Genetic Disease, Inborn; Hyperlipoproteinemias",NewAmsterdam Pharma,INDUSTRY,354,2,96,10,2022-07-25,2024-05-28,True,354,336,18,5.1,Withdrawal of Consent (6); Death (5); Lost to Follow-up (3); Adverse Event (1); Did not return for end of study visit (1); End of study visit completed by phone (1); Subject decision (1),Withdrawal of Consent,6.0,1
NCT02836873,Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment,diabetes type 2,Type 2 Diabetes Mellitus,Theracos,INDUSTRY,312,2,56,4,2016-09-23,2018-01-11,True,312,296,16,5.1,Adverse Event (5); Withdrawal by Subject (4); Lost to Follow-up (4); Protocol Violation (1); Physician Decision (1); Other (1),Adverse Event,5.0,1
NCT02630706,A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,506,3,0,0,2015-12-16,2017-12-27,True,506,480,26,5.1,Withdrawal by Subject (16); Adverse Event (4); Lost to Follow-up (3); Physician Decision (2); Pregnancy (1),Withdrawal by Subject,16.0,1
NCT01422304,Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038),cardiovascular disease,"Neuromuscular Blockade; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Coagulation; Antithrombotic Agents",Merck Sharp & Dohme LLC,INDUSTRY,1198,2,0,0,2011-10-12,2012-09-26,True,1198,1137,61,5.1,Lost to Follow-up (34); Not Treated (14); Withdrawal by Subject (6); Never Entered Follow-up (3); Did Not Meet Protocol Eligibility (2); Adverse Event (1); Protocol Violation (1),Lost to Follow-up,34.0,1
NCT02991118,Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk,cardiovascular disease,Hypercholesterolemia; Atherosclerotic Cardiovascular Disease,"Esperion Therapeutics, Inc.",INDUSTRY,779,2,2,1,2016-11-18,2018-08-22,True,779,740,39,5.0,Death (11); Lost to Follow-up (10); Withdrawal by Subject (8); Adverse Event (4); Protocol Violation (3); Physician Decision (1); Moved out of the country (1); Could not attend study visits (1),Death,11.0,1
NCT01618669,A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT),cardiovascular disease,Coronary Artery Disease (CAD),"Astellas Pharma Global Development, Inc.",INDUSTRY,1147,2,69,4,2012-06,2014-12,True,1147,1090,57,5.0,Adverse Event (23); Withdrawal by Subject (18); Protocol Violation (8); Randomized but Never Received Study Drug (5); Lost to Follow-up (2); Miscellaneous Reason (1),Adverse Event,23.0,1
NCT03337308,"A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy",cardiovascular disease,Hyperlipidemias,"Esperion Therapeutics, Inc.",INDUSTRY,382,4,5,1,2017-10-23,2018-07-18,True,382,363,19,5.0,Adverse Event (9); Withdrawal by Subject (6); Lost to Follow-up (3); Protocol Violation (1),Adverse Event,9.0,1
NCT03444324,Adjusted Fibrinogen Replacement Strategy,cardiovascular disease,Bleeding Disorder; Hypofibrinogenemia; Acquired,Biotest,INDUSTRY,222,2,19,7,2018-04-03,2023-11-21,True,222,211,11,5.0,Lost to Follow-up (6); Lack of Trial Compliance (2); Withdrawal by Subject (1); Protocol Violation (1); Physical disability to come to the site for the closing visit (1),Lost to Follow-up,6.0,1
NCT03961360,Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida,cardiovascular disease,Pre-Eclampsia; Hypertension in Pregnancy; Obesity,"The University of Texas Health Science Center, Houston",OTHER,220,2,1,1,2019-05-06,2023-04-10,True,220,209,0,5.0,,,,1
NCT04445519,Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension,hypertension,Open Angle Glaucoma; Ocular Hypertension,"Nicox Ophthalmics, Inc.",INDUSTRY,691,5,1,1,2020-06-01,2022-09-16,True,691,657,34,4.9,Adverse Event (14); Withdrawal by Subject (6); Lost to Follow-up (5); Due to adaptive design (3); Sponsor or IRB Decision (3); Other Reason (2); Protocol Violation (1),Adverse Event,14.0,1
NCT02512042,Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes,hypertension,Glaucoma,Actavis Inc.,INDUSTRY,973,2,10,1,2015-04,2016-05,True,973,925,48,4.9,Other (22); Withdrawal by Subject (12); Lost to Follow-up (7); Adverse Event (4); Non-compliance with study drug (3),Other,22.0,1
NCT00449956,MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED),hypertension,Glaucoma,Merck Sharp & Dohme LLC,INDUSTRY,474,3,0,0,2007-03-12,2008-02-16,True,474,451,23,4.9,Adverse Event (14); Physician Decision (4); Protocol Violation (3); Lack of Efficacy (1); Withdrawal by Subject (1),Adverse Event,14.0,1
NCT01302691,MK-0954E Study in Participants With Hypertension (MK-0954E-357),cardiovascular disease,Hypertension,Merck Sharp & Dohme LLC,INDUSTRY,327,2,0,0,2011-01-01,2012-04-01,True,327,311,16,4.9,Blood Pressure/Potassium Criteria Met (10); Adverse Event (2); Death (1); Lost to Follow-up (1); Physician Decision (1); Protocol Violation (1),Blood Pressure/Potassium Criteria Met,10.0,1
NCT00998881,Monotherapy Study of MP-513 in Patients With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,Tanabe Pharma Corporation,INDUSTRY,203,2,1,1,2009-09,2010-06,True,203,193,10,4.9,Adverse Event (4); Physician Decision (3); Lack of Efficacy (1); Withdrawal by Subject (1); Personal matter (1),Adverse Event,4.0,1
NCT03351478,Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin,diabetes type 2,Type 2 Diabetes Mellitus,Lexicon Pharmaceuticals,INDUSTRY,770,3,160,12,2017-11-27,2019-05-16,True,770,732,38,4.9,At the subject's own request (28); Adverse Event (4); Reason not Specified (4); Poor compliance to protocol (1); Lost to Follow-up (1),At the subject's own request,28.0,1
NCT00699192,"Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension",cardiovascular disease,Hypertension,Novartis Pharmaceuticals,INDUSTRY,965,3,18,10,2008-05,2009-05,True,819,780,39,4.8,Adverse Event (16); Withdrawal by Subject (9); Administrative problems (5); Protocol Violation (4); Missing (3); Abnormal test procedure result(s) (1); Lack of Efficacy (1),Adverse Event,16.0,1
NCT04017832,A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1441,4,93,9,2019-07-29,2021-10-27,True,1441,1372,69,4.8,Withdrawal by Subject (53); Lost to Follow-up (7); Death (5); Physician Decision (4),Withdrawal by Subject,53.0,1
NCT00947661,Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension,hypertension,Open Angle Glaucoma; Ocular Hypertension,Sun Pharma Advanced Research Company Limited,INDUSTRY,578,2,1,1,2010-07,2012-05,True,578,550,0,4.8,,,,1
NCT00627445,Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,441,2,1,1,2008-02,2009-01,True,441,420,21,4.8,Other (14); Adverse Event (6); Lack of Efficacy (1),Other,14.0,1
NCT01599104,Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension,cardiovascular disease,Essential Hypertension,Novartis Pharmaceuticals,INDUSTRY,1161,3,61,1,2012-06,2013-04,True,1161,1105,56,4.8,Adverse Event (25); Lack of Efficacy (18); Physician Decision (7); Withdrawal by Subject (4); Technical Problems (1); Non-compliance with study treatment (1),Adverse Event,25.0,1
NCT00766493,GORE® Embolic Filter in Carotid Stenting for High Risk Surgical Subjects (EMBOLDEN),cardiovascular disease,Carotid Artery Stenosis,W.L.Gore & Associates,INDUSTRY,250,1,0,0,2009-01,2010-07,True,250,238,12,4.8,Discontinued (7); Missed Visit - Phone Contact f/u (4); Missed Visit - No Phone Contact (1),Discontinued,7.0,2
NCT00986154,Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).,cardiovascular disease,Venous Thromboembolism; Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Thromboembolism; Venous Thrombosis,Daiichi Sankyo,INDUSTRY,8292,2,454,38,2009-10,2013-04,True,8292,7892,400,4.8,Death (263); Withdrawal by Subject (65); never received study drug (52); Lost to Follow-up (11); investigator/subject decide not continue (9),Death,263.0,1
NCT00614380,Open Label Study Telmisartan and Amlodipine in Hypertension,cardiovascular disease,Hypertension,Boehringer Ingelheim,INDUSTRY,976,0,122,12,2008-01,,True,976,930,46,4.7,Adverse Event (18); Non compliant with the protocol (17); Lost to Follow-up (7); Consent withdrawn (4),Adverse Event,18.0,1
NCT02993406,"Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo",cardiovascular disease,Cardiovascular Diseases; Statin Adverse Reaction,"Esperion Therapeutics, Inc.",INDUSTRY,13970,2,1319,32,2016-12-22,2022-11-07,True,13970,13317,653,4.7,Withdrawal by Subject (366); Unclassifiable Response (244); Lost to Follow-up (25); Sponsor decision (9); Physician Decision (8); Administrative decision (1),Withdrawal by Subject,366.0,1
NCT03021187,Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,731,4,118,10,2017-02-02,2018-08-22,True,731,697,34,4.7,Lost to Follow-up (18); Withdrawal by Subject (13); Death (3),Lost to Follow-up,18.0,1
NCT04848480,"A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)",diabetes type 2,"Diabetes Mellitus, Type 1",Novo Nordisk A/S,INDUSTRY,582,2,130,12,2021-04-30,2022-12-02,True,582,555,27,4.6,Withdrawal by Subject (22); Lost to Follow-up (3); Death (1); Physician Decision (1),Withdrawal by Subject,22.0,2
NCT03400800,Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol,cardiovascular disease,"ASCVD; Risk Factor, Cardiovascular; Elevated Cholesterol",The Medicines Company,INDUSTRY,1617,2,70,7,2017-11-01,2019-08-27,True,1617,1542,0,4.6,,,,1
NCT00425373,Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension,cardiovascular disease,Essential Hypertension,Novartis Pharmaceuticals,INDUSTRY,1474,9,1,1,2006-11,2008-03,True,1468,1401,67,4.6,Adverse Event (28); Withdrawal by Subject (15); Lack of Efficacy (12); Protocol Violation (10); Lost to Follow-up (2),Adverse Event,28.0,1
NCT01984424,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3,dyslipidemia,Hyperlipidemia,Amgen,INDUSTRY,511,5,58,13,2013-12-10,2017-11-21,True,218,208,10,4.6,Withdrawal by Subject (8); Sponsor Decision (1); Lost to Follow-up (1),Withdrawal by Subject,8.0,1
NCT02501161,A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1012,2,143,16,2016-01-31,2018-10-03,True,1012,965,47,4.6,Withdrawal by Subject (25); Lost to Follow-up (11); Adverse Event (8); Other (3),Withdrawal by Subject,25.0,1
NCT01370005,12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2; Hypertension",Boehringer Ingelheim,INDUSTRY,825,3,120,12,2011-06,2012-07,True,825,787,38,4.6,"Adverse Event (16); Patient refusal to continue,not due toAE (9); Other reason not defined above (5); Non compliant with protocol (3); Lost to Follow-up (3); Not treated (1); Lack of Efficacy (1)",Adverse Event,16.0,1
NCT00558428,Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension,cardiovascular disease,Hypertension,Boehringer Ingelheim,INDUSTRY,1098,0,129,12,2007-10,,True,1097,1046,51,4.6,Adverse Event (35); Non compliant with protocol (4); Consent withdrawn (4); Other (4); Lack of Efficacy (3); Lost to Follow-up (1),Adverse Event,35.0,1
NCT05763875,Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.,dyslipidemia,Hypercholesterolemia,Novartis Pharmaceuticals,INDUSTRY,350,3,42,5,2023-03-15,2024-06-20,True,350,334,16,4.6,Subject decision (8); Lost to Follow-up (7); Adverse Event (1),Subject decision,8.0,1
NCT02762578,Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,543,2,42,1,2016-05-03,2017-06-19,True,543,518,25,4.6,Adverse Event (7); Protocol Violation (6); Withdrawal by Subject (6); Unclassified (6),Adverse Event,7.0,1
NCT03001076,Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility),cardiovascular disease,Hypercholesterolemia; Atherosclerosis; Statin Adverse Reaction,"Esperion Therapeutics, Inc.",INDUSTRY,269,2,1,1,2016-11-29,2018-02-12,True,269,257,12,4.5,Adverse Event (6); Withdrawal by patient (2); Lost to Follow-up (2); Other (1); Sponsor decision (1),Adverse Event,6.0,1
NCT01150357,Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age,cardiovascular disease,Hypertension,Novartis Pharmaceuticals,INDUSTRY,267,3,48,9,2010-06,2014-08,True,267,255,12,4.5,Adverse Event (3); Withdrawal by Participants (3); Protocol Violation (2); Withdrawal by Subject (2); Unsatisfactory therapeutic effect (1); Lost to Follow-up (1),Adverse Event,3.0,2
NCT01785472,Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension,cardiovascular disease,Essential Hypertension,Novartis Pharmaceuticals,INDUSTRY,1438,3,50,7,2013-04,2014-08,True,1438,1373,65,4.5,Subject/guardian decision (36); Adverse Event (15); Protocol deviation (4); Lack of Efficacy (3); Lost to Follow-up (3); Physician Decision (3); Technical problems (1),Subject/guardian decision,36.0,1
NCT02096705,Phase III Insulin Add-On Asia Regional Program - ST,diabetes type 2,Diabetes,AstraZeneca,INDUSTRY,477,2,29,3,2014-03-31,2016-01-28,True,272,260,22,4.4,Adverse Event (13); Subjects not reporting status (3); Subject request to discontinue treatment (2); Withdrawal by Subject (2); Other (2),Adverse Event,13.0,2
NCT00823212,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions,cardiovascular disease,Coronary Artery Disease,Boston Scientific Corporation,INDUSTRY,1530,2,133,17,2009-01,2014-12,True,1530,1462,68,4.4,Missed 12-month visit (42); Death (18); Withdrawal by Subject (7); Incarcerated (1),Missed 12-month visit,42.0,1
NCT00553267,Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension,cardiovascular disease,Hypertension,Boehringer Ingelheim,INDUSTRY,947,0,97,14,2007-11,,True,947,905,42,4.4,Adverse Event (23); Non compliant with protocol (8); Consent withdrawn (6); Specified category (4); Lost to Follow-up (1),Adverse Event,23.0,1
NCT00091507,"IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.",cardiovascular disease,"Angina, Unstable; Cardiovascular Diseases; Heart Diseases; Coronary Disease; Myocardial Infarction; Heart Failure, Congestive",Tufts Medical Center,OTHER,911,2,13,1,2006-11,2012-08,True,911,871,0,4.4,,,,1
NCT03115112,Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects,diabetes type 2,Type 2 Diabetes Mellitus,Theracos,INDUSTRY,386,2,56,6,2017-10-12,2018-10-31,True,386,369,17,4.4,Adverse Event (6); Withdrawal by Subject (6); Site closure (2); Lost to Follow-up (1); Death (1); Pregnancy (1),Adverse Event,6.0,1
NCT00234533,Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq,cardiovascular disease,"Turner Syndrome; Renal Insufficiency, Chronic; Pituitary Diseases; Dwarfism",Ipsen,INDUSTRY,251,1,45,14,2004-06,2008-07,True,251,240,11,4.4,Withdrawal by Subject (6); Enrolled but not treated (3); Adverse Event (2),Withdrawal by Subject,6.0,1
NCT01381900,"A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea",diabetes type 2,"Diabetes Mellitus, Type 2","Janssen Research & Development, LLC",INDUSTRY,678,3,25,3,2011-08,2012-11,True,676,646,30,4.4,Adverse Event (17); Early withdraw (5); Subject meets glycemic withdrawal crit. (2); Physician Decision (2); Protocol Violation (2); Noncompliance with study drug (1); Withdrawal by Subject (1),Adverse Event,17.0,1
NCT00624052,26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension,cardiovascular disease,Hypertension,Boehringer Ingelheim,INDUSTRY,838,0,92,12,2008-03,,True,838,802,36,4.3,Adverse Event (16); Lost to Follow-up (6); Non compliant with the protocol (5); Consent withdrawn (5); Lack of Efficacy (2); Changed job/ran out if meds (2),Adverse Event,16.0,1
NCT00462748,A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121),dyslipidemia,Hypercholesterolemia,Organon and Co,INDUSTRY,786,3,0,0,2007-03,2008-06,True,786,752,34,4.3,Adverse Event (21); Withdrew consent (6); Protocol Violation (3); Lost to Follow-up (3); Discontinued after 41 days Rx (1),Adverse Event,21.0,1
NCT00496730,"A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)",dyslipidemia,Hypercholesterolemia,Organon and Co,INDUSTRY,256,2,0,0,2007-07,2008-08,True,256,245,11,4.3,Lost to Follow-up (7); Withdrawal by Subject (4),Lost to Follow-up,7.0,1
NCT02305381,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,397,4,99,6,2014-12-01,2015-11-21,True,397,380,17,4.3,Unclassified (17),Unclassified,17.0,1
NCT02585713,Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism,cardiovascular disease,Cerebral Vein Thrombosis; Deep Vein Thrombosis; Gonadal Thrombosis; Hepatic Thrombosis; Malignant Neoplasm; Mesenteric Thrombosis; Metastatic Malignant Neoplasm; Portal Vein Thrombosis; Pulmonary Embolism; Renal Vein Thrombosis; Splenic Thrombosis; Venous Thromboembolism,Academic and Community Cancer Research United,OTHER,300,2,18,1,2015-11-20,2019-12-24,True,300,287,13,4.3,Withdrew prior to treatment (9); Other (4),Withdrew prior to treatment,9.0,1
NCT00628498,Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study,cardiovascular disease,Hepatic Veno-Occlusive Disease,Jazz Pharmaceuticals,INDUSTRY,1206,1,125,1,2007-12,2016-09,True,1206,1154,0,4.3,,,,1
NCT05024032,A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN),diabetes type 2,Obesity; Overweight; Metabolism and Nutrition Disorder,Eli Lilly and Company,INDUSTRY,210,3,29,1,2021-09-01,2022-12-27,True,210,201,9,4.3,Withdrawal by Subject (7); Adverse Event (1); Protocol Deviation (1),Withdrawal by Subject,7.0,1
NCT02068443,Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy,diabetes type 2,Type 2 Diabetes Mellitus,Takeda,INDUSTRY,374,3,27,1,2014-02,2015-02,True,374,358,16,4.3,Pretreatment Event/Adverse Event (7); Voluntary Withdrawal (5); Lack of Efficacy (3); Other Reason Not Specified (1),Pretreatment Event/Adverse Event,7.0,1
NCT01572740,Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,257,2,23,1,2012-04-05,2013-03-27,True,257,246,11,4.3,unclassified (7); Adverse Event (2); Withdrawal by Subject (2),unclassified,7.0,1
NCT01890434,Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD),cardiovascular disease,Coronary Artery Disease,Bayer,INDUSTRY,478,1,24,4,2013-08-26,2016-11-10,True,478,458,20,4.2,Adverse Event (8); Withdrawal by PI for ICA not performed (2); PCI at external hospital (1); Assessment discrepancy (1); CRC didn't contact participant for FU (1); Could not get whole set of images (1); Decline to return for GSPECT (1); GSPECT at rest was not done (1); Participant didn't complete MRI (1); Uncontactable by phone (1); Moved out of position (1); Unable to contact (1),Adverse Event,8.0,1
NCT00262600,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,cardiovascular disease,Atrial Fibrillation; Stroke,Boehringer Ingelheim,INDUSTRY,18113,3,984,44,2005-12,,True,18113,17360,753,4.2,Withdrawal by Subject (412); Other (179); Lost to Follow-up (89); Not Treated (73),Withdrawal by Subject,412.0,1
NCT00494871,Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation,cardiovascular disease,Atrial Fibrillation,Bayer,INDUSTRY,1280,2,165,1,2007-06,2010-01,True,1280,1226,384,4.2,Adverse Event (145); Withdrawal by Subject (71); Clinical Endpoint Reached (51); Death (36); Protocol Driven Decision Point (20); Protocol Violation (19); Physician Decision (18); Lost to Follow-up (13); Non-compliant with Study Medication (4); Site Closed by Investigator (3); Site Closed by Sponsor (2); Drop out before Treatment Start (2),Adverse Event,145.0,2
NCT01318083,Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan,diabetes type 2,Type 2 Diabetes Mellitus,Takeda,INDUSTRY,312,3,0,0,2008-08,2009-04,True,312,299,13,4.2,Adverse Event (7); Withdrawal by Subject (3); Lack of Efficacy (1); Treatment Complications (1); Lack of Study Medication Compliance (1),Adverse Event,7.0,1
NCT00032630,Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass,cardiovascular disease,Ischemic Heart Disease,US Department of Veterans Affairs,FED,2203,2,17,1,2002-04,2008-04,True,2203,2111,0,4.2,,,,1
NCT00786474,Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study),cardiovascular disease,Arterial Thromboembolic Events; Atrial Fibrillation,Duke University,OTHER,1884,2,1,1,2009-07,2015-02,True,1884,1804,80,4.2,Withdrawal by Subject (54); Death (9); Other (8); Lost to Follow-up (6); Physician Decision (3),Withdrawal by Subject,54.0,1
NCT01792518,"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin",diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,360,2,74,12,2013-02,2015-12,True,360,345,15,4.2,Adverse Event (7); Lost to Follow-up (4); Withdrawal by Subject (2); Protocol Violation (1); Other Reason (1),Adverse Event,7.0,1
NCT00418834,Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112),dyslipidemia,Hypercholesterolemia,Organon and Co,INDUSTRY,1053,2,0,0,2007-01,2008-10,True,1053,1010,43,4.1,Adverse Event (25); Withdrawal by Subject (10); Protocol Violation (7); Lost to Follow-up (1),Adverse Event,25.0,1
NCT00409773,Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED),dyslipidemia,Hypercholesterolemia; Metabolic Syndrome,Organon and Co,INDUSTRY,1143,5,0,0,2007-01,2008-07,True,1143,1096,47,4.1,Adverse Event (19); Lost to Follow-up (13); Protocol Violation (9); Withdrawal by Subject (3); Physician Decision (2); Lack of Eligibility (1),Adverse Event,19.0,1
NCT02320669,Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass,cardiovascular disease,Congenital Heart Defects,Seattle Children's Hospital,OTHER,220,2,3,1,2014-11,2019-10,True,220,211,0,4.1,,,,1
NCT05413369,iGlarLixi vs IDegAsp in Chinese Participants After OAD(s),diabetes type 2,Type 2 Diabetes Mellitus,Sanofi,INDUSTRY,582,2,60,1,2022-07-07,2023-10-20,True,582,558,24,4.1,Withdrawal by Subject (17); Non-compliance with study schedule (3); Adverse Event (2); Other (2),Withdrawal by Subject,17.0,1
NCT03469349,Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB,cardiovascular disease,Peripheral Arterial Diseases,Takeda,INDUSTRY,366,2,20,3,2018-05-01,2019-08-28,True,366,351,15,4.1,Adverse Event (6); Withdrawal by Subject (4); Lost to Follow-up (4); Progressive Disease (1),Adverse Event,6.0,1
NCT02863328,Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,822,2,106,12,2016-08-10,2018-03-08,True,821,787,34,4.1,Withdrawal by Subject (19); Lost to Follow-up (14); Died (1),Withdrawal by Subject,19.0,1
NCT00862251,Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED),cardiovascular disease,Cardiovascular Disorder; Diabetes Mellitus,Organon and Co,INDUSTRY,808,3,0,0,2009-04,2011-03,True,808,775,33,4.1,Withdrawal by Subject (17); Adverse Event (12); Protocol Violation (3); Lost to Follow-up (1),Withdrawal by Subject,17.0,1
NCT01663233,Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine,cardiovascular disease,Essential Hypertension,Novartis Pharmaceuticals,INDUSTRY,266,2,28,6,2012-08,2013-05,True,266,255,11,4.1,Withdrawal by Subject (5); Protocol Deviation (5); Lost to Follow-up (1),Withdrawal by Subject,5.0,1
NCT04809220,A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders; Metabolic Disease; Endocrine System Diseases; Hypoglycemic Agents; Type 2 Diabetes Mellitus (T2DM)",Eli Lilly and Company,INDUSTRY,591,2,44,1,2021-04-13,2023-04-26,True,591,567,24,4.1,Withdrawal by Subject (14); Adverse Event (4); Lost to Follow-up (3); Death (1); Physician Decision (1); Due to long-term overseas business trips (1),Withdrawal by Subject,14.0,1
NCT02547935,"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD",diabetes type 2,"Type 2 Diabetes Mellitus, CKD and Albuminuria",AstraZeneca,INDUSTRY,459,3,112,9,2015-09-21,2018-05-18,True,448,430,18,4.0,Withdrawal by Subject (9); Lost to Follow-up (3); Screen Failure (2); Death (2); Other (1); Physician Decision (1),Withdrawal by Subject,9.0,1
NCT00987389,Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis,cardiovascular disease,Granulomatosis With Polyangiitis (Wegener's) (GPA); Microscopic Polyangiitis (MPA),University of Pennsylvania,OTHER,704,4,98,15,2010-05,2017-08,True,704,676,28,4.0,Withdrawal by Subject (10); Lost to Follow-up (9); Multiple different reasons (5); Ineligible (3); Withdrawn from Treatment (1),Withdrawal by Subject,10.0,1
NCT04109547,A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,521,4,66,6,2019-10-01,2021-10-27,True,521,500,21,4.0,Withdrawal by Subject (17); Physician Decision (3); Lost to Follow-up (1),Withdrawal by Subject,17.0,1
NCT05462756,A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections,diabetes type 2,Type 2 Diabetes; Type 2 Diabetes Treated With Insulin,Eli Lilly and Company,INDUSTRY,730,2,81,8,2022-08-11,2024-02-27,True,730,701,48,4.0,Withdrawal by Subject (21); Assigned Treatment by Mistake (7); Lost to Follow-up (7); Adverse Event (4); Non-Compliance with Study Drug (4); Death (2); Physician Decision (2); Protocol Violation (1),Withdrawal by Subject,21.0,2
NCT03296813,TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure,cardiovascular disease,Heart Failure,Duke University,OTHER,2973,2,60,1,2018-07-11,2022-07-29,True,2859,2746,0,4.0,,,,1
NCT01969708,Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2),cardiovascular disease,Central Retinal Vein Occlusion,"The Emmes Company, LLC",INDUSTRY,362,2,72,1,2014-09,2021-03,True,362,348,0,3.9,,,,1
NCT03066804,"A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients",cardiovascular disease,Heart Failure With Preserved Ejection Fraction,Novartis Pharmaceuticals,INDUSTRY,2572,2,380,32,2017-08-22,2019-10-28,True,2572,2471,101,3.9,Withdrawal by Subject (44); Death (40); Technical problems (6); Adverse Event (5); Physician Decision (4); Lost to Follow-up (2),Withdrawal by Subject,44.0,1
NCT02550288,A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383),dyslipidemia,Hypercholesterolemia,Organon and Co,INDUSTRY,309,5,0,0,2015-09-29,2016-05-30,True,309,297,12,3.9,Protocol Violation (8); Adverse Event (1); Physician Decision (1); Participant moved (1); Withdrawal by Subject (1),Protocol Violation,8.0,1
NCT01347710,A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.,cardiovascular disease,Coronary Artery Disease,Lantheus Medical Imaging,INDUSTRY,795,1,81,4,2011-06,2013-09,True,795,764,31,3.9,Angio or SPECT not completed (18); Adverse Event (4); Other (3); Withdrawal by Subject (2); Physician Decision (2); issue with vitals prior to dosing (1); Lost to Follow-up (1),Angio or SPECT not completed,18.0,1
NCT03552757,Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity,diabetes type 2,Obesity; Overweight,Novo Nordisk A/S,INDUSTRY,1210,3,147,13,2018-06-04,2020-05-01,True,1210,1164,46,3.8,Withdrawal by Subject (27); Lost to Follow-up (16); Death (3),Withdrawal by Subject,27.0,1
NCT00276484,To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090),dyslipidemia,Hypercholesterolemia,Organon and Co,INDUSTRY,579,2,0,0,2006-02,2008-03,True,579,557,22,3.8,Adverse Event (11); Withdrawal by Subject (7); Lost to Follow-up (2); Protocol Violation (1); Could not take time off work (1),Adverse Event,11.0,1
NCT01144338,Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,14752,2,629,35,2010-06-18,2017-04-24,True,14752,14187,0,3.8,,,,1
NCT01763866,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,dyslipidemia,Hyperlipidemia,Amgen,INDUSTRY,2067,24,244,21,2013-01-15,2013-12-04,True,1899,1826,73,3.8,Withdrawal by Subject (40); Decision by sponsor (26); Lost to Follow-up (6); Death (1),Withdrawal by Subject,40.0,1
NCT00550953,Filtered Trial for Telmisartan 40mg Non-responder,cardiovascular disease,Hypertension,Boehringer Ingelheim,INDUSTRY,314,0,5,1,2007-10,,True,314,302,12,3.8,Adverse Event (7); Not able to visit the site (5),Adverse Event,7.0,1
NCT01408303,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,cardiovascular disease,Hypertriglyceridemia; Cardiovascular Disease,AstraZeneca,INDUSTRY,646,3,89,1,2011-08,2012-06,True,647,623,24,3.7,Adverse Event (12); Withdrawal by Subject (6); Lost to Follow-up (3); Noncompliance (2); Protocol Violation (1),Adverse Event,12.0,1
NCT01015287,A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction,cardiovascular disease,Acute Coronary Syndromes,Eli Lilly and Company,INDUSTRY,4033,2,153,19,2009-12,2013-02,True,4033,3882,151,3.7,Physician Decision (40); Death (37); Withdrawal by Subject (33); Entry Criteria not Met (25); Sponsor Decision (10); Lost to Follow-up (3); Protocol Violation (2); Adverse Event (1),Physician Decision,40.0,1
NCT02009865,Epanova® for Lowering Very High Triglycerides II (EVOLVE II),dyslipidemia,Hypertriglyceridemia,AstraZeneca,INDUSTRY,379,2,40,7,2013-12-16,2014-12-23,True,162,156,6,3.7,Adverse Event (2); Protocol Violation (2); Withdrawal by Subject (2),Adverse Event,2.0,1
NCT00392678,Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D),diabetes type 2,Type 2 Diabetes,Joslin Diabetes Center,OTHER,277,4,16,1,2006-10,2010-12,True,108,104,0,3.7,,,,1
NCT02025621,Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass,cardiovascular disease,Coronary Artery Bypass Grafting; Mitral Valve Surgery; Low Cardiac Output Syndrome,"Tenax Therapeutics, Inc.",INDUSTRY,882,2,60,2,2014-07,2016-11,True,882,849,33,3.7,No longer eligible (25); Surgery initiated before infusion (6); Withdrawal by Subject (1); Death (1),No longer eligible,25.0,1
NCT02863419,Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,711,3,108,13,2016-08-10,2018-03-30,True,711,685,26,3.7,Withdrawal by Subject (13); Died (8); Lost to Follow-up (5),Withdrawal by Subject,13.0,1
NCT02207374,A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,601,3,43,1,2014-08-04,2016-02-27,True,601,579,22,3.7,Withdrawal by Subject (18); Death (2); Missing follow-up information (2),Withdrawal by Subject,18.0,1
NCT00345631,Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device,cardiovascular disease,"Angioplasty, Transluminal, Percutaneous Coronary; Coronary Arteriosclerosis; Peripheral Arteriosclerosis",Cordis US Corp.,INDUSTRY,488,2,17,1,2007-02,2007-09,True,488,470,18,3.7,Lost to Follow-up (14); Withdrawal by Subject (2); Adverse Event (1); Other reasons (1),Lost to Follow-up,14.0,1
NCT01813422,GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound,dyslipidemia,Hypercholesterolemia,Amgen,INDUSTRY,970,2,226,32,2013-04-18,2016-07-29,True,970,934,36,3.7,Withdrawal by Subject (22); Lost to Follow-up (6); Death (5); Sponsor Decision (3),Withdrawal by Subject,22.0,1
NCT00479713,A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED),cardiovascular disease,Hypercholesterolemia,Organon and Co,INDUSTRY,618,2,0,0,2007-02-01,2008-03-01,True,618,596,22,3.6,Adverse Event (14); Withdrawal by Subject (5); Death (1); Lost to Follow-up (1); Protocol Violation (1),Adverse Event,14.0,1
NCT02158806,Low Dose Aspirin for Venous Leg Ulcers,cardiovascular disease,Venous Leg Ulcer,"University of Auckland, New Zealand",OTHER,251,2,0,0,2015-03,2017-03-31,True,251,242,9,3.6,Lost to Follow-up (3); Death (2); Withdrawal by Subject (2); Moved out of area (1); Transferred to palliative care (1),Lost to Follow-up,3.0,1
NCT01350973,Efficacy of TAK-085 in Participants With Hypertriglyceridemia,dyslipidemia,Hypertriglyceridemia,Takeda,INDUSTRY,611,3,0,0,2009-11,2010-12,True,611,589,22,3.6,Adverse Event (18); Voluntary Withdrawal (4),Adverse Event,18.0,1
NCT04460885,"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before",diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,984,2,198,13,2020-11-25,2022-12-01,True,984,949,35,3.6,Withdrawal by Subject (14); Death (9); Lost to Follow-up (8); Physician Decision (3); Site closure (1),Withdrawal by Subject,14.0,1
NCT04788511,Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity,heart failure,Obesity,Novo Nordisk A/S,INDUSTRY,529,2,146,13,2021-03-16,2023-04-18,True,529,510,19,3.6,Lost to Follow-up (9); Death (7); Withdrawal by Subject (3),Lost to Follow-up,9.0,1
NCT05478252,A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,388,2,104,5,2022-08-03,2023-09-18,True,388,374,14,3.6,Lost to Follow-up (6); Withdrawal by Subject (5); Physician Decision (2); Death (1),Lost to Follow-up,6.0,1
NCT00658515,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,cardiovascular disease,Coronary Heart Disease,Hoffmann-La Roche,INDUSTRY,15871,2,1089,29,2008-04,2012-09,True,15871,15294,0,3.6,,,,1
NCT00782184,Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED),cardiovascular disease,Hypercholesterolemia,Organon and Co,INDUSTRY,250,2,0,0,2008-11,2010-09,True,250,241,9,3.6,Withdrawal by Subject (5); Adverse Event (3); Protocol Violation (1),Withdrawal by Subject,5.0,1
NCT01147250,Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide),diabetes type 2,Acute Coronary Syndrome,Sanofi,INDUSTRY,6068,2,829,49,2010-06,2015-02,True,6068,5853,215,3.5,Withdrawal by Subject (171); Lost to Follow-up (25); Site termination by sponsor (18); Other than specified (1),Withdrawal by Subject,171.0,1
NCT00618774,"An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination",cardiovascular disease,Hypertension,Boehringer Ingelheim,INDUSTRY,259,0,7,1,2008-01,,True,259,250,9,3.5,Adverse Event (8); Withdrawal by Subject (1),Adverse Event,8.0,1
NCT02597049,A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,424,3,41,9,2015-11,2017-02,True,424,409,15,3.5,Lost to Follow-up (5); Withdrawal by Subject (5); Adverse Event (2); Death (2); Noncompliant with Study Visits (1),Lost to Follow-up,5.0,1
NCT04964544,Technology-Assisted Cholesterol Trial in Consumers (TACTiC),dyslipidemia,High Cholesterol,AstraZeneca,INDUSTRY,1196,1,1,1,2021-07-08,2023-03-01,True,1196,1154,42,3.5,Withdrawal by Subject (18); Screen failure or other uncategorised (10); Lost to Follow-up (9); Physician Decision (4); Death (1),Withdrawal by Subject,18.0,1
NCT00799903,The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial,cardiovascular disease,Atherosclerosis,GlaxoSmithKline,INDUSTRY,15828,2,650,39,2008-12-01,2013-10-17,True,15828,15277,551,3.5,Withdrawal by Subject (354); Lost to Follow-up (149); Investigator Site Closed (48),Withdrawal by Subject,354.0,1
NCT05022004,A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension,hypertension,Primary Open Angle Glaucoma; Ocular Hypertension,Sun Pharmaceutical Industries Limited,INDUSTRY,599,2,40,2,2021-12-20,2023-01-06,True,597,576,0,3.5,,,,1
NCT02592824,Glutamate for Metabolic Intervention in Coronary Surgery II,cardiovascular disease,Coronary Artery Bypass Surgery; Postoperative Complications; Heart Failure,"University Hospital, Linkoeping",OTHER,321,2,4,1,2015-11-15,2020-10-30,True,314,303,11,3.5,Protocol Violation (8); Lost to Follow-up (3),Protocol Violation,8.0,1
NCT03877237,DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction,heart failure,Heart Failure With Reduced Ejection Fraction (HFrEF),AstraZeneca,INDUSTRY,313,2,76,9,2019-04-09,2020-03-07,True,313,302,11,3.5,Death (5); Adverse Event (3); Withdrawal by Subject (2); Physician Decision (1),Death,5.0,1
NCT02105272,Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension,hypertension,Glaucoma; Ocular Hypertension,"Otsuka Pharmaceutical Co., Ltd.",INDUSTRY,237,2,1,1,2014-04,2015-03,True,237,229,8,3.4,Adverse Event (3); Protocol Violation (2); Withdrawal by Subject (2); Physician Decision (1),Adverse Event,3.0,1
NCT02833844,"Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia",dyslipidemia,"Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection",Amgen,INDUSTRY,467,2,78,15,2017-05-22,2020-01-27,True,467,451,13,3.4,Withdrawal by Subject (6); Protocol Violation (4); Death (2); Lost to Follow-up (1),Withdrawal by Subject,6.0,2
NCT02413398,A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes Mellitus,AstraZeneca,INDUSTRY,321,2,87,8,2015-06-15,2017-11-07,True,321,310,11,3.4,Lost to Follow-up (6); Other Eligibility criteria (3); Withdrawal by Subject (2),Lost to Follow-up,6.0,1
NCT01959243,"Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants",cardiovascular disease,Hyperemia,Bausch & Lomb Incorporated,INDUSTRY,507,2,4,1,2014-02-22,2014-06-23,True,507,490,17,3.4,Adverse Event (7); Lost to Follow-up (4); Investigator Decision (3); Administrative reasons (3),Adverse Event,7.0,1
NCT02458287,"Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia",dyslipidemia,Hyperlipidemia,Pfizer,INDUSTRY,299,4,30,1,2015-06,2016-02,True,299,289,10,3.3,Withdrawal by Subject (5); Lost to Follow-up (2); Adverse Event (1); Protocol Violation (1); Relocated Out of State (1),Withdrawal by Subject,5.0,1
NCT03397121,Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH),dyslipidemia,Heterozygous Familial Hypercholesterolemia; Elevated Cholesterol,The Medicines Company,INDUSTRY,482,2,45,8,2017-11-28,2019-09-17,True,482,466,0,3.3,,,,1
NCT02911948,A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,210,2,38,1,2016-09-21,2017-11-22,True,210,203,7,3.3,Unclassified (3); Withdrawal by Subject (2); Protocol Violation (1); Lack of Efficacy (1),Unclassified,3.0,1
NCT03021343,Effect of Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surgery Patients,cardiovascular disease,Arrhythmia,Jordan Collaborating Cardiology Group,OTHER,360,2,0,0,2012-10,2015-02,True,360,348,0,3.3,,,,1
NCT03861052,A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes,diabetes type 2,Type 2 Diabetes,Eli Lilly and Company,INDUSTRY,636,4,46,1,2019-05-07,2021-03-31,True,636,615,21,3.3,Withdrawal by Subject (10); Adverse Event (8); Lost to Follow-up (1); Physician Decision (1); Relocation to other city (1),Withdrawal by Subject,10.0,1
NCT00415623,A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient,cardiovascular disease,Hypertension,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,305,2,14,1,2007-01,2007-10,True,305,295,10,3.3,Adverse Event (7); Withdrawal by Subject (2); Death (1),Adverse Event,7.0,1
NCT02773368,A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,420,2,88,11,2016-05-23,2017-10-23,True,420,406,14,3.3,Withdrawal by Subject (6); Lost to Follow-up (5); Unclassified (2); Missing (1),Withdrawal by Subject,6.0,1
NCT01318070,Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan,diabetes type 2,Type 2 Diabetes Mellitus,Takeda,INDUSTRY,339,3,0,0,2007-11,2008-10,True,339,328,11,3.2,Adverse Event (7); Withdrawal by Subject (2); Lack of Efficacy (1); Principal Investigator Discretion (1),Adverse Event,7.0,1
NCT00307047,SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System,cardiovascular disease,Coronary Artery Disease,Abbott Medical Devices,INDUSTRY,3687,2,65,1,2006-08,2012-05,True,3687,3569,118,3.2,"Lost to Follow-up (59); All death, all MI, all Revascularization (43); Withdrawal by Subject (12); Physician Decision (3); Lost to follow-up for other reasons (1)",Lost to Follow-up,59.0,1
NCT02304484,Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab,dyslipidemia,Hypercholesterolemia,Amgen,INDUSTRY,770,1,126,29,2014-11-24,2018-03-09,True,770,745,25,3.2,Withdrawal by Subject (14); Death (9); Lost to Follow-up (2),Withdrawal by Subject,14.0,1
NCT00918138,Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg,diabetes type 2,Type 2 Diabetes,AstraZeneca,INDUSTRY,219,2,21,4,2009-08,2010-05,True,93,90,3,3.2,Subject withdrew consent (2); Death (1),Subject withdrew consent,2.0,1
NCT01179048,Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,9341,2,428,33,2010-08-31,2015-12-17,True,9340,9042,298,3.2,Alive (269); Lost to Follow-up (17); Withdrawn - does not allow contact (12),Alive,269.0,1
NCT02827708,Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,324,2,117,8,2016-09-20,2018-05-15,True,324,314,10,3.1,Lost to Follow-up (4); Withdrawal by Subject (3); Death (3),Lost to Follow-up,4.0,1
NCT03574597,Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity,cardiovascular disease,Overweight; Obesity,Novo Nordisk A/S,INDUSTRY,17604,2,833,42,2018-10-24,2023-06-29,True,17604,17061,543,3.1,Lost to Follow-up (380); Withdrawal by Subject (163),Lost to Follow-up,380.0,1
NCT01131676,BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,7064,3,615,42,2010-07,2015-04,True,7028,6809,1999,3.1,"Adverse Event (843); Other than those specified (429); Refusal to continue, not due to AE (412); Consent withdrawn: Final VS available (83); Site closure: Final VS available (60); Non compliant with protocol (42); Lost to Follow-up (30); Site closure:Final VS not available (NA) (21); Consent withdrawn:Final VS not available (19); Lost to FU for 3PMACE:Final VS available (18); Study drug stopped, reason missing (12); Lack of Efficacy (12); Lost to FU for 3P-MACE:Final VS NA (10); Not treated (8)",Adverse Event,843.0,2
NCT00869206,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",cardiovascular disease,Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Alliance for Clinical Trials in Oncology,OTHER,1822,2,504,2,2009-03,2017-01,True,1822,1766,0,3.1,,,,1
NCT02226003,Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,291,3,0,0,2014-09-23,2016-02-23,True,291,282,9,3.1,Lost to Follow-up (6); Withdrawal by Subject (3),Lost to Follow-up,6.0,1
NCT02532855,A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,614,2,0,0,2015-10-20,2017-10-10,True,614,595,19,3.1,Withdrawal by Subject (12); Lost to Follow-up (7),Withdrawal by Subject,12.0,1
NCT01456000,HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF),cardiovascular disease,Paroxysmal Atrial Fibrillation,CardioFocus,INDUSTRY,405,2,21,1,2012-01,2016-01,True,353,342,0,3.1,,,,1
NCT01584232,A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus,diabetes type 2,Type 2 Diabetes Mellitus,Eli Lilly and Company,INDUSTRY,361,2,15,1,2012-04,2013-07,True,361,350,11,3.0,Adverse Event (4); Withdrawal by Subject (3); Physician Decision (3); Lost to Follow-up (1),Adverse Event,4.0,1
NCT00927862,Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin,cardiovascular disease,Thromboembolism,"Intermountain Health Care, Inc.",OTHER,2415,3,1,1,2008-08,2011-06,True,2415,2343,72,3.0,Missing data needed for endpt analyses (72),Missing data needed for endpt analyses,72.0,1
NCT00041938,Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial,cardiovascular disease,Heart Disease; Stroke; Ischemic Heart Disease; Myocardial Infarction,Columbia University,OTHER,2305,2,64,2,2002-10,2014-07,True,2305,2236,0,3.0,,,,1
NCT00848536,Efficacy Study of Travoprost APS Versus TRAVATAN,hypertension,Open Angle Glaucoma; Ocular Hypertension,Alcon Research,INDUSTRY,371,2,0,0,2009-03,2010-01,True,371,360,11,3.0,Adverse Event (4); Inadequate Control of IOP (2); Patient Moved (2); Withdrawal by Subject (1); Protocol Violation (1); Noncompliance (1),Adverse Event,4.0,1
NCT00391872,A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome,cardiovascular disease,Acute Coronary Syndrome,AstraZeneca,INDUSTRY,18624,2,672,44,2006-10,2009-03,True,18624,18062,562,3.0,Withdrawal by Subject (545); Protocol Violation (9); Reason unknown (6); Lost to Follow-up (2),Withdrawal by Subject,545.0,1
NCT03819153,A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease,diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,3533,2,413,28,2019-06-17,2024-01-09,True,3533,3432,101,2.9,Lost to Follow-up (53); Withdrawal by Subject (48),Lost to Follow-up,53.0,1
NCT05888103,Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.,cardiovascular disease,Primary Hypercholesterolemia or Mixed Dyslipidemia,Novartis Pharmaceuticals,INDUSTRY,207,2,28,1,2023-07-11,2024-10-24,True,207,201,6,2.9,Participant decision (6),Participant decision,6.0,1
NCT01369069,Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial,cardiovascular disease,Acute Ischemic Stroke; Diabetes; Hyperglycemia,University of Virginia,OTHER,1151,2,70,1,2012-04,2018-11-19,True,1151,1118,33,2.9,Lost to Follow-up (17); Withdrawal by Subject (16),Lost to Follow-up,17.0,1
NCT03989232,A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,961,2,129,11,2019-06-19,2020-11-09,True,961,933,28,2.9,Lost to Follow-up (13); Withdrawal by Subject (12); Death (3),Lost to Follow-up,13.0,1
NCT04620135,Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension,hypertension,Primary Open Angle Glaucoma; Ocular Hypertension,Aerie Pharmaceuticals,INDUSTRY,245,2,1,1,2020-11-30,2021-07-30,True,245,238,7,2.9,Adverse Event (5); Withdrawal by Subject (2),Adverse Event,5.0,4
NCT00180479,SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS),cardiovascular disease,Stents; Coronary Artery Disease; Total Coronary Occlusion; Coronary Artery Restenosis; Stent Thrombosis; Vascular Disease; Myocardial Ischemia; Coronary Artery Stenosis,Abbott Medical Devices,INDUSTRY,1002,2,65,1,2005-06,2011-11,True,1002,973,29,2.9,Lost to Follow-up (16); Death (6); Withdrawal by Subject (6); Informed consent not signed (1),Lost to Follow-up,16.0,1
NCT00090259,"Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)",cardiovascular disease,Heart Failure,Organon and Co,INDUSTRY,3834,2,0,0,2001-12-19,2009-05-13,True,3834,3724,110,2.9,Lost to Follow-up (56); Withdrawal by Subject (36); Investigator site closed (18),Lost to Follow-up,56.0,1
NCT01453855,Travoprost 3-Month Safety and Efficacy Study,hypertension,Open-Angle Glaucoma; Ocular Hypertension,Alcon Research,INDUSTRY,1099,2,0,0,2011-11,2012-08,True,864,840,24,2.8,Adverse Event (7); Patient Decision Unrel to Adverse Event (6); Inadequate Control of IOP (6); Lost to Follow-up (3); Noncompliance (1); Other (1),Adverse Event,7.0,1
NCT01665053,The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s),cardiovascular disease,Coronary Artery Disease,Boston Scientific Corporation,INDUSTRY,1684,2,126,16,2012-11,2018-12-22,True,1684,1637,0,2.8,,,,1
NCT01763827,Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2,dyslipidemia,Hyperlipidemia,Amgen,INDUSTRY,615,6,83,10,2013-01-21,2013-10-29,True,615,598,17,2.8,Decision by sponsor (8); Lost to Follow-up (6); Withdrawal by Subject (3),Decision by sponsor,8.0,1
NCT03470545,Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy,cardiovascular disease,Obstructive Hypertrophic Cardiomyopathy,"MyoKardia, Inc.",INDUSTRY,251,2,71,13,2018-05-29,2020-05-06,True,251,244,7,2.8,Adverse Event (2); Withdrawal by Subject (2); Death (1); Did not complete Week 30 assessments due to scheduling conflict (1); Week 30 not completed due to circumstances surrounding the COVID-19 pandemic (1),Adverse Event,2.0,1
NCT00430508,Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension,cardiovascular disease,Essential Hypertension,Daiichi Sankyo,INDUSTRY,972,4,55,7,2007-02,2008-05,True,971,944,27,2.8,Adverse Event (13); Other (5); conmed-BP-pulse-ABPM withdrawal criteria (4); Withdrawal by Subject (3); responder at visit 4 (2),Adverse Event,13.0,1
NCT01000727,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,cardiovascular disease,Acute Coronary Syndrome,GlaxoSmithKline,INDUSTRY,13026,2,914,36,2009-12-01,2014-04-24,True,13026,12675,351,2.7,Withdrawal by Subject (220); Lost to Follow-up (84); Study closed/terminated (47),Withdrawal by Subject,220.0,1
NCT03268005,"Research Study Comparing a New Medicine ""Fast-acting Insulin Aspart"" to Another Already Available Medicine ""NovoRapid""/""NovoLog"" in People With Type 2 Diabetes",diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,1264,2,167,18,2017-09-19,2019-01-29,True,1091,1062,29,2.7,Withdrawal by Subject (22); Lost to Follow-up (4); Death (3),Withdrawal by Subject,22.0,1
NCT00878644,Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial,cardiovascular disease,Cardiac Arrest,University of Michigan,OTHER,295,2,34,2,2009-09,2014-06,True,295,287,0,2.7,,,,1
NCT02207634,Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects,cardiovascular disease,Dyslipidemia,Amgen,INDUSTRY,1974,2,416,30,2014-09-10,2016-11-11,True,1974,1921,53,2.7,Withdrawal by Subject (52); Lost to Follow-up (1),Withdrawal by Subject,52.0,1
NCT04233801,A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin,diabetes type 2,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,INDUSTRY,219,3,24,1,2020-04-15,2022-03-10,True,219,213,6,2.7,Withdrawal by Subject (5); Other than listed (1),Withdrawal by Subject,5.0,1
NCT02239120,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),cardiovascular disease,Stroke; Secondary Prevention,Boehringer Ingelheim,INDUSTRY,5390,2,569,42,2014-11-27,2018-08-14,True,5390,5243,147,2.7,Death (114); Lost to Follow-up (33),Death,114.0,1
NCT04251156,Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.,diabetes type 2,"Overweight; Obesity; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,375,2,33,4,2020-12-08,2022-08-23,True,375,365,10,2.7,Withdrawal by Subject (8); Lost to Follow-up (2),Withdrawal by Subject,8.0,1
NCT00783263,A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139),dyslipidemia,Hypercholesterolemia,Organon and Co,INDUSTRY,440,4,0,0,2008-11,2010-05,True,440,428,12,2.7,Adverse Event (6); Withdrawal by Subject (4); Lost to Follow-up (2),Adverse Event,6.0,1
NCT05259033,"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)",diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,683,2,136,14,2022-04-11,2024-01-16,True,683,665,18,2.6,Withdrawal by Subject (15); Death (2); Lost to Follow-up (1),Withdrawal by Subject,15.0,1
NCT03086330,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,302,2,72,7,2017-03-15,2018-08-06,True,302,294,8,2.6,Withdrawal by Subject (5); Lost to Follow-up (3),Withdrawal by Subject,5.0,1
NCT00430950,Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension,cardiovascular disease,Essential Hypertension,Daiichi Sankyo,INDUSTRY,1011,2,41,4,2007-02,2008-10,True,1010,984,26,2.6,"Adverse Event (13); concomitant medication,etc. (12); Withdrawal by Subject (1)",Adverse Event,13.0,1
NCT01651780,"Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH",cardiovascular disease,Severe Aortic Stenosis; Transcatheter Aortic Valve Replacement; Aortic Valve Replacement,The Medicines Company,INDUSTRY,803,2,33,7,2012-10,2015-06,True,803,782,21,2.6,Physician decision: Day 30 visit <23 day (6); Reason Not Specified: No 30-day visit (4); Physician decision: No 30-day visit (3); Inclusion/Exclusion Criteria Not Met (3); Lost to Follow-up (3); Withdrawal by Subject (2),Physician decision: Day 30 visit <23 day,6.0,1
NCT02881957,Hypovitaminosis D in Neurocritical Patients,cardiovascular disease,Craniocerebral Trauma; Intracranial Aneurysm; Brain Neoplasms; Spinal Cord Injuries; Seizures; Meningitis; Stroke; Intracranial Hemorrhages; Critical Illness; Vitamin d Deficiency,University of Utah,OTHER,274,2,1,1,2016-10-10,2018-10-10,True,274,267,7,2.6,Withdrawal by Subject (3); Comfort care (1); Concurrent trial enrollment (1); Discharged within 48 hours (1); Protocol Violation (1),Withdrawal by Subject,3.0,1
NCT01890421,Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD),cardiovascular disease,Coronary Artery Disease,Bayer,INDUSTRY,426,1,23,7,2013-07-19,2017-08-31,True,426,415,11,2.6,Other reason (10); Adverse Event (1),Other reason,10.0,1
NCT03877224,DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction,heart failure,Heart Failure With Preserved Ejection Fraction (HFpEF),AstraZeneca,INDUSTRY,504,2,101,12,2019-04-04,2020-07-09,True,504,491,13,2.6,"Withdrawal by Subject (7); Death (5); Participant is alive, just unable to come for visits (1)",Withdrawal by Subject,7.0,1
NCT03018028,"Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes",diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,243,5,16,1,2017-01-10,2018-08-15,True,243,237,6,2.5,Withdrawal by Subject (6),Withdrawal by Subject,6.0,1
NCT00434967,Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo,cardiovascular disease,Hypertension,AstraZeneca,INDUSTRY,2207,4,27,6,2007-01,2008-01,True,1524,1486,38,2.5,Withdrawal by Subject (14); Adverse Event (12); Patient Disposition Challenges (5); Physician Decision (3); Protocol Violation (2); Lost to Follow-up (1); Randomized in error (1),Withdrawal by Subject,14.0,1
NCT01156012,Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients,hypertension,Glaucoma,Laboratoires Thea,INDUSTRY,404,2,1,1,2009-09,2010-12,True,402,392,10,2.5,Adverse Event (4); Non respect of one of inclusion criteria (3); Lost to Follow-up (1); Withdrawal by Subject (1); use of commercial drug instead of study (1),Adverse Event,4.0,1
NCT04298229,Efficacy and Safety of Dapagliflozin in Acute Heart Failure,diabetes type 2,"Heart Failure; Diabetes Mellitus, Type 2",Vanderbilt University Medical Center,OTHER,240,2,6,1,2020-04-01,2023-05-17,True,240,234,6,2.5,Physician Decision (2); Withdrawal by Subject (2); Did not receive IV loop diuretics (2),Physician Decision,2.0,1
NCT01340768,Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,870,2,0,0,2010-06-22,2011-09-21,True,870,848,22,2.5,Lost to Follow-up (14); Withdrawal by Subject (6); Other (2),Lost to Follow-up,14.0,1
NCT01302392,A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma,cardiovascular disease,Multiple Myeloma,Amgen,INDUSTRY,315,2,68,19,2010-09,2015-09,True,315,307,8,2.5,Withdrawal by Subject (7); Lost to Follow-up (1),Withdrawal by Subject,7.0,1
NCT04102189,A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity,obesity,Overweight; Obesity,Novo Nordisk A/S,INDUSTRY,201,2,51,8,2019-10-07,2022-03-28,True,201,196,5,2.5,Withdrawal by Subject (3); Withdrawal by parent/guardian (1); Lost to Follow-up (1),Withdrawal by Subject,3.0,1
NCT00335452,Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS,cardiovascular disease,Acute Coronary Disease; Angina Unstable,Sanofi,INDUSTRY,25086,4,38,38,2006-06,2009-09,True,25086,24491,595,2.4,Death (587); Lost to Follow-up (8),Death,587.0,1
NCT02791490,A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848),diabetes type 2,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,INDUSTRY,458,2,0,0,2016-06-16,2018-02-01,True,458,447,11,2.4,Withdrawal by Subject (8); Lost to Follow-up (3),Withdrawal by Subject,8.0,1
NCT01830140,A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension,hypertension,Glaucoma; Ocular Hypertension,Allergan,INDUSTRY,466,2,2,1,2013-07,2014-05,True,466,455,0,2.4,,,,1
NCT00383019,A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).,hypertension,Glaucoma; Ocular Hypertension,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,300,2,54,1,2006-11-14,2007-10-01,True,289,282,7,2.4,Adverse Event (6); Withdrawal by Subject (1),Adverse Event,6.0,1
NCT03389555,"Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial",metabolic syndrome,Sepsis; Septic Shock; Metabolic Disturbance,Beth Israel Deaconess Medical Center,OTHER,205,2,13,1,2018-02-09,2020-02-28,True,205,200,5,2.4,Protocol Violation (4); Death (1),Protocol Violation,4.0,1
NCT00006305,Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes,diabetes type 2,"Coronary Disease; Cardiovascular Diseases; Heart Diseases; Insulin Resistance; Diabetes Mellitus; Diabetes Mellitus, Non-Insulin-Dependent",University of Pittsburgh,OTHER,2368,4,0,0,2000-09,2009-03,True,2368,2312,56,2.4,Withdrawal by Subject (56),Withdrawal by Subject,56.0,1
NCT04795531,"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)",diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,588,2,93,12,2021-03-24,2022-06-23,True,588,574,14,2.4,Withdrawal by Subject (8); Death (3); Physician Decision (2); Lost to Follow-up (1),Withdrawal by Subject,8.0,1
NCT01877915,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",cardiovascular disease,Heart Failure; Coronary Artery Disease,"Janssen Research & Development, LLC",INDUSTRY,5081,2,563,32,2013-09-10,2018-04-19,True,5022,4900,122,2.4,Withdrawal by Subject (97); Lost to Follow-up (19); Other (6),Withdrawal by Subject,97.0,1
NCT02111564,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,cardiovascular disease,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Janssen Research & Development, LLC",INDUSTRY,12024,2,595,37,2014-01-07,2018-05-03,True,12019,11745,274,2.3,Death (229); Withdrawal by Subject (40); Lost to Follow-up (5),Death,229.0,1
NCT03015220,Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,458,4,34,1,2017-01-10,2018-07-12,True,458,448,10,2.2,Withdrawal by Subject (9); Lost to Follow-up (1),Withdrawal by Subject,9.0,1
NCT02741245,A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832),dyslipidemia,Hypercholesterolemia,Organon and Co,INDUSTRY,321,5,0,0,2016-06-09,2017-01-18,True,321,314,7,2.2,Adverse Event (4); Protocol Violation (2); Withdrawal by Subject (1),Adverse Event,4.0,1
NCT06005597,Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies,cardiovascular disease,Dyslipidemias; Hypercholesterolemia; Familial Hypercholesterolemia; ASCVD; High Cholesterol,NewAmsterdam Pharma,INDUSTRY,407,4,45,1,2024-03-01,2024-10-16,True,407,398,9,2.2,Lost to Follow-up (6); Death (3),Lost to Follow-up,6.0,1
NCT01880736,A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,458,4,40,1,2013-06,2014-04,True,458,448,10,2.2,Withdrawal Criteria (9); Adverse Event (1),Withdrawal Criteria,9.0,1
NCT01103960,"An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy",cardiovascular disease,Hypertension,Boehringer Ingelheim,INDUSTRY,324,2,16,3,2010-07,,True,324,317,7,2.2,Adverse Event (3); Withdrawal by Subject (3); Other (1),Adverse Event,3.0,1
NCT04024072,To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes,hypertension,"Glaucoma, Open-Angle; Ocular Hypertension",Padagis LLC,INDUSTRY,495,2,1,1,2019-06-24,2020-04-30,True,495,484,0,2.2,,,,1
NCT00526474,Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737),cardiovascular disease,Atherosclerosis; Ischemia; Myocardial Infarction; Cerebrovascular Accident; Peripheral Arterial Disease,Merck Sharp & Dohme LLC,INDUSTRY,26449,2,0,0,2007-09-01,2011-12-01,True,26449,25885,0,2.1,,,,1
NCT02059278,Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension,hypertension,Primary Open Angle Glaucoma; Ocular Hypertension,Nephron Pharmaceuticals Corporation,INDUSTRY,335,2,1,1,2014-01,2015-01,True,335,328,7,2.1,Withdrawal by Subject (3); Adverse Event (2); Lost to Follow-up (1); Ran out of IP and decided to discontinue (1),Withdrawal by Subject,3.0,1
NCT01565941,Heart And Lung Failure - Pediatric INsulin Titration Trial,cardiovascular disease,Heart Failure; Respiratory Failure,Boston Children's Hospital,OTHER,713,2,35,3,2012-04,2018-02,True,713,698,15,2.1,Randomized; did not receive intevention (10); Withdrawn by parent/guardian (5),Randomized; did not receive intevention,10.0,1
NCT01231373,Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence,cardiovascular disease,Varicose Veins,Boston Scientific Corporation,INDUSTRY,235,4,12,1,2010-11,2014-08,True,235,230,5,2.1,Withdrew consent prior to randomization (3); Lost to Follow-up (1); Withdrew Consent (1),Withdrew consent prior to randomization,3.0,1
NCT04462536,Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis,cardiovascular disease,"Stroke, Acute",NoNO Inc.,INDUSTRY,850,2,81,9,2020-12-06,2023-08-31,True,850,832,18,2.1,Withdrawal by Subject (12); Lost to Follow-up (6),Withdrawal by Subject,12.0,1
NCT01720446,Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,3297,4,253,21,2013-02-21,2016-03-15,True,3297,3232,65,2.0,Lost to Follow-up (50); Withdrawal by Subject (15),Lost to Follow-up,50.0,1
NCT01827046,Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III,cardiovascular disease,Intracerebral Hemorrhage,Johns Hopkins University,OTHER,499,2,84,9,2013-12-30,2018-09,True,499,489,10,2.0,Lost to Follow-up (6); Withdrawal by Subject (4),Lost to Follow-up,6.0,1
NCT02596126,Secondary Prevention of Cardiovascular Disease in the Elderly Trial,cardiovascular disease,Myocardial Infarction; Cardiovascular Disease,Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III,OTHER,2499,2,113,7,2016-07,2022-03-31,True,2499,2450,49,2.0,Lost to Follow-up (33); Protocol Violation (16),Lost to Follow-up,33.0,1
NCT00141453,ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial,diabetes type 2,Diabetic Nephropathy; Type 2 Diabetes Mellitus; Proteinuria,"Daiichi Sankyo Co., Ltd.",INDUSTRY,577,2,2,2,2003-04,2009-01,True,577,566,11,1.9,Protocol Violation (11),Protocol Violation,11.0,1
NCT01959529,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,7637,2,446,20,2013-10-29,2016-10-16,True,7637,7489,148,1.9,Other (138); Lost to Follow-up (5); Hypoglycaemia (2); Lack of glycaemic control (2); Adverse event (not hypoglycaemia) (1),Other,138.0,1
NCT06834490,Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia,cardiovascular disease,Chronic Cerebral Ischemia,Pharmasoft,INDUSTRY,318,2,14,2,2019-11-05,2020-12-08,True,318,312,0,1.9,,,,1
NCT01975246,Add-on to Micamlo BP Trial,cardiovascular disease,Hypertension,Boehringer Ingelheim,INDUSTRY,309,2,30,1,2013-11,2014-07,True,309,303,6,1.9,Adverse Event (3); Lack of Efficacy (1); Protocol Violation (1); Other than stated (1),Adverse Event,3.0,1
NCT02914509,Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT,hypertension,Open Angle Glaucoma; Ocular Hypertension,"Ocular Therapeutix, Inc.",INDUSTRY,565,2,10,1,2016-11-07,2019-03-30,True,565,554,0,1.9,,,,1
NCT00558064,Filtered Trial for Amlodipine Non-responder,cardiovascular disease,Hypertension,Boehringer Ingelheim,INDUSTRY,531,0,41,1,2007-10,,True,531,521,10,1.9,Adverse Event (5); Lack of Efficacy (1); Protocol Violation (1); Lost to Follow-up (1); Withdrawal by Subject (1); No visit within allowance period (1),Adverse Event,5.0,1
NCT00443053,Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis),cardiovascular disease,"Thrombosis, Venous",GlaxoSmithKline,INDUSTRY,3002,2,227,17,2007-03,2009-07,True,3002,2948,54,1.8,Withdrawal by Subject (27); Lost to Follow-up (9); Other (7); Physician Decision (4); Adverse Event (3); Noncompliance (3); Did Not Meet Eligibility Criteria (1),Withdrawal by Subject,27.0,1
NCT00135707,Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS),cardiovascular disease,Preeclampsia,The George Washington University Biostatistics Center,OTHER,10154,2,16,1,2003-06,2009-01,True,10154,9969,185,1.8,Lost to Follow-up (183); Withdrawal by Subject (1); Institutional review board request (1),Lost to Follow-up,183.0,1
NCT01535014,Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients,obesity,Obesity,Materia Medica Holding,INDUSTRY,493,4,17,1,2011-12-12,2013-06,True,493,484,0,1.8,,,,1
NCT00046228,A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse),cardiovascular disease,Myocardial Infarction,"Centocor, Inc.",INDUSTRY,2461,3,227,19,2002-08,2008-01,True,2452,2407,0,1.8,,,,2
NCT00843492,A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery,cardiovascular disease,"Thrombosis, Venous",GlaxoSmithKline,INDUSTRY,1351,2,122,6,2008-12,2010-06,True,1243,1221,22,1.8,Lost to Follow-up (8); Withdrawal by Subject (4); Adverse Event (3); Investigator/Orthopedic Surgeon Decision (2); Orthopedic Surgery (2); Immobilization Stopped (1); Visit Not Performed (1); Deep-vein Thrombosis (1),Lost to Follow-up,8.0,1
NCT02662569,Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia,dyslipidemia,"Diabetes, Hyperlipidemia, Mixed Dyslipidemia",Amgen,INDUSTRY,986,4,110,10,2016-04-14,2017-12-06,True,986,968,18,1.8,Withdrawal by Subject (17); Lost to Follow-up (1),Withdrawal by Subject,17.0,1
NCT01344447,Gadobutrol Enhanced MRA of the Supra-aortic Vessels,cardiovascular disease,Carotid Stenosis,Bayer,INDUSTRY,479,1,56,14,2011-05-12,2014-05-28,True,479,471,8,1.7,Adverse Event (1); Protocol Violation (1); Withdrawal by Subject (1); The contrast was not seen (1); Physician Decision (1); MRA unsuccessful (1); Bolus tracking failed (1); Error of power injector (1),Adverse Event,1.0,1
NCT02984384,PREVENTion of Clot in Orthopaedic Trauma,cardiovascular disease,Blood Clot; Trauma,Major Extremity Trauma Research Consortium,OTHER,12424,2,21,2,2017-04-24,2022-02-18,True,12424,12211,0,1.7,,,,1
NCT00081731,Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions,cardiovascular disease,"Atherosclerosis; Cardiovascular Diseases; Hypertension, Renovascular; Renal Artery Obstruction",Baim Institute for Clinical Research,OTHER,947,2,1,1,2004-04,2013-09,True,947,931,16,1.7,scientific integrity issue (16),scientific integrity issue,16.0,1
NCT01732822,A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease,cardiovascular disease,Peripheral Artery Disease,AstraZeneca,INDUSTRY,13885,2,776,28,2012-12-04,2016-09-26,True,13885,13649,236,1.7,Withdrawal by Subject (236),Withdrawal by Subject,236.0,1
NCT02739984,Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia,diabetes type 2,Hypercholesterolemia; Mixed Dyslipidemia; Type 2 Diabetes,Amgen,INDUSTRY,424,2,66,7,2016-05-17,2017-08-03,True,424,417,7,1.7,Lost to Follow-up (3); Withdrawal by Subject (2); Sponsor Decision (1); Death (1),Lost to Follow-up,3.0,1
NCT02964247,LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,303,2,82,7,2017-03-03,2018-05-08,True,303,298,5,1.7,Withdrawal by Subject (3); Lost to Follow-up (2),Withdrawal by Subject,3.0,1
NCT04401293,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,cardiovascular disease,Sars-CoV2; COVID,Northwell Health,OTHER,257,2,6,1,2020-04-26,2021-05-14,True,257,253,4,1.6,Withdrawal by Subject (4),Withdrawal by Subject,4.0,1
NCT02254291,A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,308,3,25,1,2014-10-02,2015-11-11,True,308,303,5,1.6,Withdrawal by Subject (4); Missing follow-up information (1),Withdrawal by Subject,4.0,1
NCT03914326,A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes,diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,9651,2,492,34,2019-06-17,2024-08-23,True,9651,9495,156,1.6,Lost to Follow-up (94); Withdrawal by Subject (61); Randomised more than once (1),Lost to Follow-up,94.0,1
NCT00162032,A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease,cardiovascular disease,Kawasaki Disease,Lantheus Medical Imaging,INDUSTRY,445,2,50,7,2005-08,2010-12,True,445,438,7,1.6,Lost to Follow-up (6); Reason not specified (1),Lost to Follow-up,6.0,1
NCT03811574,STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity,obesity,Overweight; Obesity,Novo Nordisk A/S,INDUSTRY,401,4,28,2,2019-01-21,2020-11-20,True,401,395,6,1.5,Withdrawal by Subject (6),Withdrawal by Subject,6.0,1
NCT04770532,"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin",diabetes type 2,"Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,526,2,88,9,2021-03-05,2022-03-01,True,526,518,8,1.5,Death (4); Withdrawal by Subject (3); Physician Decision (1),Death,4.0,1
NCT01730534,Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events,diabetes type 2,"Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event",AstraZeneca,INDUSTRY,17190,2,805,34,2013-04-25,2018-09-11,True,17160,16906,254,1.5,Withdrawal by Subject (224); Lost to Follow-up (30),Withdrawal by Subject,224.0,1
NCT00396877,Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation,cardiovascular disease,"Heart Defects, Congenital",Sanofi,INDUSTRY,906,2,31,31,2006-11,2010-02,True,906,892,14,1.5,Parent(s)/guardian(s)'s request (11); Lost to Follow-up (3),Parent(s)/guardian(s)'s request,11.0,1
NCT01413178,A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma,cardiovascular disease,Myeloma,M.D. Anderson Cancer Center,OTHER,205,2,1,1,2011-09-30,2019-03-10,True,205,202,3,1.5,Ineligible (2); Toxicity (1),Ineligible,2.0,1
NCT01087723,European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial,cardiovascular disease,Acute Coronary Syndrome,The Medicines Company,INDUSTRY,2198,2,145,9,2010-03,2014-08,True,2198,2164,34,1.5,Withdrawal by Subject (23); Lost to Follow-up (5); Reason Not Specified (3); Physician Decision (2); 1 Year Visit Too Early (<335 days) (1),Withdrawal by Subject,23.0,1
NCT02540993,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,diabetes type 2,Chronic Kidney Disease,Bayer,INDUSTRY,5734,2,978,48,2015-09-17,2020-04-14,True,5734,5656,78,1.4,GCP violations (60); Withdrawal by Subject (10); Lost to Follow-up (8),GCP violations,60.0,1
NCT01072877,Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence,cardiovascular disease,Varicose Veins,Boston Scientific Corporation,INDUSTRY,279,5,20,1,2010-12,2012-11,True,279,275,4,1.4,Lost to Follow-up (4),Lost to Follow-up,4.0,1
NCT03191396,Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,577,2,92,12,2017-06-27,2018-08-13,True,577,569,8,1.4,Withdrawal by Subject (5); Lost to Follow-up (3),Withdrawal by Subject,5.0,1
NCT02545049,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,diabetes type 2,Diabetic Kidney Disease,Bayer,INDUSTRY,7352,2,975,48,2015-09-17,2021-02-02,True,7437,7334,103,1.4,GCP violations (85); Lost to Follow-up (10); Withdrawal by Subject (8),GCP violations,85.0,1
NCT01991795,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes Mellitus, Type 2",AstraZeneca,INDUSTRY,19271,2,1237,43,2014-02-10,2019-01-25,True,19271,18999,272,1.4,Withdrawal by Subject (211); Site prematurely closed by sponsor (51); Lost to Follow-up (10),Withdrawal by Subject,211.0,1
NCT01318109,Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan,diabetes type 2,Type 2 Diabetes Mellitus,Takeda,INDUSTRY,288,3,0,0,2008-08,2009-04,True,288,284,4,1.4,Adverse Event (2); Withdrawal by Subject (1); Schedule Conflict (1),Adverse Event,2.0,1
NCT01080391,"Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma",cardiovascular disease,Relapsed Multiple Myeloma,Amgen,INDUSTRY,792,2,127,20,2010-07-14,2017-12-05,True,792,781,11,1.4,Randomized but not treated (11),Randomized but not treated,11.0,1
NCT02420262,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,506,2,117,12,2015-07-26,2016-10-05,True,506,499,7,1.4,Withdrawal by Subject (5); Adverse Event (1); Unclassified (1),Withdrawal by Subject,5.0,1
NCT00916370,SPIRIT PRIME Clinical Trial,cardiovascular disease,Myocardial Ischemia; Coronary Artery Stenosis; Coronary Disease; Coronary Artery Disease; Coronary Restenosis,Abbott Medical Devices,INDUSTRY,525,2,62,2,2009-06,2014-02,True,505,498,7,1.4,Death (4); Withdrawal by Subject (2); Physician Decision (1),Death,4.0,1
NCT01084239,Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography,cardiovascular disease,Acute Coronary Syndrome; Myocardial Infarction; Unstable Angina Pectoris,Massachusetts General Hospital,OTHER,1000,2,1,1,2010-04,2012-03,True,1000,987,13,1.3,Lost to Follow-up (13),Lost to Follow-up,13.0,2
NCT01603602,BOTOX® Treatment in Pediatric Upper Limb Spasticity,cardiovascular disease,Pediatrics; Muscle Spasticity; Cerebral Palsy; Stroke,Allergan,INDUSTRY,235,3,45,9,2012-07-12,2017-07-06,True,235,232,3,1.3,Personal Reasons (2); Adverse Event (1),Personal Reasons,2.0,1
NCT01286558,Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg),cardiovascular disease,Hypertension,Boehringer Ingelheim,INDUSTRY,225,2,8,1,2011-01,,True,225,222,3,1.3,Adverse Event (2); Withdrawal by Subject (1),Adverse Event,2.0,1
NCT01743001,Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome,cardiovascular disease,Pulmonary Arterial Hypertension,Actelion,INDUSTRY,226,2,55,21,2013-05-21,2016-12-01,True,226,223,3,1.3,Physician Decision (1); Pregnancy (1); Death (1),Physician Decision,1.0,1
NCT00049673,Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma,cardiovascular disease,Multiple Myeloma and Plasma Cell Neoplasm,NCIC Clinical Trials Group,NETWORK,332,2,18,1,2002-10-15,2013-09-19,True,332,328,4,1.2,No receive treatment/lost to follow-up (4),No receive treatment/lost to follow-up,4.0,1
NCT03057977,EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced),cardiovascular disease,Heart Failure,Boehringer Ingelheim,INDUSTRY,3730,2,520,20,2017-03-06,2020-05-28,True,3730,3688,1039,1.1,Adverse Event (680); Withdrawal by Subject (236); Lost to Follow-up (28); Lost to follow-up to primary endpoint (18); Patient decision to stop/interrupt medication (14); Not attending study visit (13); Protocol Violation (11); Patient moved away/being abroad (7); Other medical condition (no Adverse Event) (6); Unable to continue treatment (5); Due to Covid-19 Pandemic (5); Not treated (4); Limited follow-up agreed (4); Personal Reasons (2); Patient received Empagliflozin for Diabetes (2); Principle Investigator Decision (2); Reason Unknown (1); Unblinded medication (1),Adverse Event,680.0,2
NCT03473223,Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome,cardiovascular disease,Acute Coronary Syndrome,CSL Behring,INDUSTRY,18226,2,903,49,2018-03-21,2023-11-17,True,18226,18022,204,1.1,Withdrawal by Subject (89); Indirect contact (61); Other (Not specified) (52); Lost to Follow-up (2),Withdrawal by Subject,89.0,1
NCT02819284,Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease,cardiovascular disease,Dry Eye Syndromes; Keratoconjunctivitis Sicca,"Kala Pharmaceuticals, Inc.",INDUSTRY,909,2,62,1,2016-06,2017-09,True,905,895,0,1.1,,,,1
NCT01344460,Gadobutrol Enhanced MRA of the Renal Arteries,cardiovascular disease,Renal Artery Obstruction,Bayer,INDUSTRY,317,1,70,13,2011-05,2012-07,True,315,312,3,1.0,Lost to Follow-up (2); Withdrawal by Subject (1),Lost to Follow-up,2.0,1
NCT01342081,DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%,hypertension,Open Angle Glaucoma; Ocular Hypertension,"Santen Pharmaceutical Co., Ltd.",INDUSTRY,489,3,1,1,2011-05,,True,489,484,5,1.0,Withdrawal by Subject (2); Did not receive allocated intervention (1); Adverse Event (1); Physician Decision (1),Withdrawal by Subject,2.0,1
NCT02065791,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,diabetes type 2,"Diabetes Mellitus, Type 2; Diabetic Nephropathy","Janssen Research & Development, LLC",INDUSTRY,4401,2,575,34,2014-02-17,2018-10-30,True,4401,4361,40,0.9,Lost to Follow-up (22); Withdrawal by Subject (16); Closed Site (2),Lost to Follow-up,22.0,1
NCT00092677,An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED),cardiovascular disease,Aortic Stenosis,Organon and Co,INDUSTRY,1873,2,0,0,2001-01,2008-04,True,1873,1857,16,0.9,Adminstrative (14); Lost to Follow-up (2),Adminstrative,14.0,1
NCT00071032,Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease,cardiovascular disease,Anemia; Hematologic Diseases; Cardiovascular Diseases; Heart Diseases; Myocardial Infarction; Thromboembolism; Pneumonia; Cerebrovascular Accident,"Rutgers, The State University of New Jersey",OTHER,2016,2,1,1,2003-07,2009-05,True,2016,1999,17,0.8,Withdrawal by Subject (14); Lost to Follow-up (2); Missing Primary Outcome (1),Withdrawal by Subject,14.0,1
NCT00089895,EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED),cardiovascular disease,Myocardial Ischemia; Acute Coronary Syndrome,Organon and Co,INDUSTRY,9406,2,0,0,2004-11-01,2008-11-01,True,9406,9329,77,0.8,Consent Withdrawn (25); Exclusion criteria met (12); Not otherwise specified (12); Physician Decision (10); Technical reason (9); Missing (6); Bleeding (2); Surgery (1),Consent Withdrawn,25.0,1
NCT02813265,Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease,cardiovascular disease,Dry Eye Syndromes; Keratoconjunctivitis Sicca,"Kala Pharmaceuticals, Inc.",INDUSTRY,918,2,60,1,2016-06,2017-10,True,915,908,0,0.8,,,,1
NCT01225562,"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin",cardiovascular disease,Myocardial Infarction; Cardiovascular Death; Atherothrombosis; Stroke,AstraZeneca,INDUSTRY,21379,3,827,31,2010-10,2014-12,True,21162,20998,164,0.8,Withdrawal by Subject (154); Lost to Follow-up (10),Withdrawal by Subject,154.0,1
NCT01994720,[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES],cardiovascular disease,Acute Ischaemic Stroke; Transient Ischaemic Attack,AstraZeneca,INDUSTRY,13307,2,521,33,2014-01-07,2016-03-02,True,13199,13097,102,0.8,Withdrawal by Subject (102),Withdrawal by Subject,102.0,1
NCT01764633,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,cardiovascular disease,Dyslipidemia,Amgen,INDUSTRY,27564,2,1284,49,2013-02-08,2016-11-11,True,27564,27353,211,0.8,Withdrawal by Subject (193); Lost to Follow-up (18),Withdrawal by Subject,193.0,1
NCT01294163,Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery,cardiovascular disease,Coronary Artery Disease; General Anesthetic Drug Allergy; Coronary Artery Bypass Graft Surgery,Air Liquide Santé International,INDUSTRY,509,3,17,4,2011-04,2014-04,True,509,505,0,0.8,,,,1
NCT02930018,Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke,cardiovascular disease,"Stroke, Acute",NoNO Inc.,INDUSTRY,1105,2,50,8,2017-03-01,2019-11-20,True,1105,1096,9,0.8,Withdrawal by Subject (7); Lost to Follow-up (2),Withdrawal by Subject,7.0,1
NCT04435626,Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%,cardiovascular disease,Heart Failure,Bayer,INDUSTRY,6016,2,661,37,2020-09-14,2024-06-14,True,6016,5982,34,0.6,major GCP violations (15); Withdrawal by Subject (13); Lost to Follow-up (6),major GCP violations,15.0,1
NCT00489827,Glutamate for Metabolic Intervention in Coronary Surgery,cardiovascular disease,Coronary Artery Bypass; Myocardial Ischemia; Myocardial Infarction; Coronary Artery Disease,"University Hospital, Linkoeping",OTHER,865,2,3,1,2005-10,2022-08,True,865,861,4,0.5,Intraoperative exclusion criteria (4),Intraoperative exclusion criteria,4.0,1
NCT01082874,PeriOperative ISchemic Evaluation-2 Trial,cardiovascular disease,Cardiovascular Disease,Hamilton Health Sciences Corporation,OTHER,10010,4,23,23,2010-07,2015-01,True,10010,9963,47,0.5,Lost to Follow-up (36); Withdrawal by Subject (11),Lost to Follow-up,36.0,1
NCT02361944,Risk of Oxygen During Cardiac Surgery Trial,cardiovascular disease,Cardiac Surgery,Vanderbilt University,OTHER,213,2,1,1,2016-04-05,2021-01-08,True,201,200,1,0.5,surgery cancellation (1),surgery cancellation,1.0,1
NCT01953328,Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk,cardiovascular disease,Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events,Amgen,INDUSTRY,409,8,54,1,2013-10,2014-06,True,404,402,2,0.5,Withdrawal by Subject (1); Lost to Follow-up (1),Withdrawal by Subject,1.0,1
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",cardiovascular disease,Cardiac Arrest,University of Washington,OTHER,3024,3,9,2,2012-05,2016-01,True,3024,3009,15,0.5,Withdrawal by Subject (8); Lost to Follow-up (7),Withdrawal by Subject,8.0,1
NCT02504216,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,cardiovascular disease,Peripheral Artery Disease,Bayer,INDUSTRY,6564,2,532,34,2015-08-18,2020-01-09,True,6564,6538,26,0.4,Withdrawal by Subject (20); Lost to Follow-up (6),Withdrawal by Subject,20.0,1
NCT02145468,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),cardiovascular disease,Acute Coronary Syndrome,GlaxoSmithKline,INDUSTRY,3503,2,341,34,2014-06-03,2015-12-14,True,3489,3476,13,0.4,Withdrawal by Subject (13),Withdrawal by Subject,13.0,1
NCT01217307,Metformin to Reduce Heart Failure After Myocardial Infarction,cardiovascular disease,ST Elevation Myocardial Infarction (STEMI); Coronary Artery Disease; Heart Failure; Diabetes,University Medical Center Groningen,OTHER,380,2,1,1,2011-01,2015-10,True,380,379,1,0.3,Withdrawal by Subject (1),Withdrawal by Subject,1.0,1
NCT03036150,A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease,cardiovascular disease,Chronic Kidney Disease,AstraZeneca,INDUSTRY,4304,2,390,21,2017-02-02,2020-06-12,True,4304,4289,15,0.3,Withdrawal by Subject (11); Lost to Follow-up (4),Withdrawal by Subject,11.0,1
NCT01156571,A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX),cardiovascular disease,Atherosclerosis; Percutaneous Coronary Intervention; Acute Coronary Syndrome,The Medicines Company,INDUSTRY,11145,2,1,1,2010-09,2012-12,True,11145,11109,0,0.3,,,,1
NCT01870778,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",heart failure,Acute Heart Failure,Novartis Pharmaceuticals,INDUSTRY,6600,2,540,35,2013-10-02,2017-02-01,True,6545,6528,17,0.3,Withdrawal by Subject (15); Lost to Follow-up (2),Withdrawal by Subject,15.0,1
NCT02900378,randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure,cardiovascular disease,Chronic Heart Failure With Reduced Ejection Fraction,Novartis Pharmaceuticals,INDUSTRY,621,2,119,19,2016-12-20,2018-04-11,True,621,619,51,0.3,Adverse Event (25); Protocol Deviation (8); Withdrawal by Parent/Guardian (8); Death (5); Non-compliance with Study Drug (2); Withdrawal of Informed Consent (2); Lost to Follow-up (1),Adverse Event,25.0,2
NCT00059332,Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial,cardiovascular disease,Cerebrovascular Accident,Jeffrey L. Saver,OTHER,1700,2,1,1,2005-01,2013-03,True,1700,1695,5,0.3,Withdrawal by Subject (3); Lost to Follow-up (2),Withdrawal by Subject,3.0,1
NCT02692716,A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",Novo Nordisk A/S,INDUSTRY,3183,2,228,21,2017-01-17,2018-09-25,True,3183,3172,11,0.3,Lost to Follow-up (7); Withdrawal by Subject (4),Lost to Follow-up,7.0,1
NCT01394952,Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND),diabetes type 2,"Cardiovascular Disease; Diabetes Mellitus, Type 2",Eli Lilly and Company,INDUSTRY,9901,2,300,25,2011-07-22,2018-08-21,True,9901,9867,34,0.3,Withdrawal by Subject (15); Sponsor Decision (12); Lost to Follow-up (5); Physician Decision (2),Withdrawal by Subject,15.0,1
NCT03619213,Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.,heart failure,Heart Failure With Preserved Ejection Fraction,AstraZeneca,INDUSTRY,6263,2,348,20,2018-08-27,2022-03-27,True,6263,6242,21,0.3,Withdrawal by Subject (18); Lost to Follow-up (3),Withdrawal by Subject,18.0,1
NCT03036124,Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure,cardiovascular disease,Chronic Heart Failure With Reduced Ejection Fraction (HFrEF),AstraZeneca,INDUSTRY,4744,2,419,20,2017-02-08,2019-07-17,True,4744,4733,11,0.2,Withdrawal by Subject (9); Lost to Follow-up (2),Withdrawal by Subject,9.0,1
NCT04564742,Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.,cardiovascular disease,Acute Myocardial Infarction; Heart Failure,AstraZeneca,INDUSTRY,4017,2,103,2,2020-12-22,2023-07-05,True,4017,4008,9,0.2,Consent Withdrawal (8); Lost to Follow-up (1),Consent Withdrawal,8.0,1
NCT02981407,Myocardial Ischemia and Transfusion,cardiovascular disease,Myocardial Infarction; Anemia,"Rutgers, The State University of New Jersey",OTHER,3506,2,133,6,2017-04-25,2023-10-20,True,3506,3504,2,0.1,Withdrawal by Subject (2),Withdrawal by Subject,2.0,1
NCT03354429,THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death,cardiovascular disease,Acute Ischaemic Stroke; Transient Ischaemic Attack,AstraZeneca,INDUSTRY,11016,2,387,28,2018-01-22,2019-12-13,True,11016,11000,16,0.1,Withdrawal by Subject (15); Lost to Follow-up (1),Withdrawal by Subject,15.0,1
NCT00623623,STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction,cardiovascular disease,Myocardial Infarction,Boehringer Ingelheim,INDUSTRY,1899,2,201,16,2008-03-01,2012-09-01,True,1899,1897,2,0.1,Previous enrolment into this study (2),Previous enrolment into this study,2.0,1
NCT00177047,Autologous Transplant for Multiple Myeloma,cardiovascular disease,Multiple Myeloma,"Masonic Cancer Center, University of Minnesota",OTHER,363,1,1,1,2004-04-20,2020-08-01,True,363,363,0,0.0,,,,1
NCT00212992,Biphasic Defibrillation Study: Trial to Compare Fixed Versus Escalating Energy,cardiovascular disease,Cardiac Arrest,Ottawa Hospital Research Institute,OTHER,221,2,1,1,2001-03,2006-07,True,221,221,0,0.0,,,,1
NCT02271230,Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure,cardiovascular disease,Heart Failure,Brigham and Women's Hospital,OTHER,25871,4,1,1,2014-08,2019-12,True,25871,25871,0,0.0,,,,1
NCT03345771,Antimicrobial Barrier Dressing Versus Closed-incision Negative Pressure Therapy in the Obese Primary Total Joint Arthroplasty,obesity,Osteoarthritis,NYU Langone Health,OTHER,230,2,1,1,2017-11-13,2021-06-01,True,230,230,0,0.0,,,,1
NCT03381742,Efficacy and Safety of Low-dose Ticagrelor,cardiovascular disease,Coronary Artery Disease,First Affiliated Hospital of Harbin Medical University,OTHER,3043,4,1,1,2017-12-13,2019-02-13,True,3043,3043,0,0.0,,,,1
NCT00324350,Intensive Glycemic Control and Skeletal Health Study,cardiovascular disease,Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia; Hypertension; Diabetes Mellitus; Coronary Disease,"University of California, San Francisco",OTHER,7287,2,5,2,2003-10,2009-06,True,7287,7287,0,0.0,,,,1
NCT01109004,Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702),cardiovascular disease,Multiple Myeloma,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,758,3,54,1,2010-05,2018-03-03,True,758,758,0,0.0,,,,1
NCT00358579,Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest,cardiovascular disease,Cardiac Arrest,Singapore General Hospital,OTHER,727,2,4,1,2006-03,2010-01,True,727,727,0,0.0,,,,1
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,cardiovascular disease,Multiple Myeloma,University of Arkansas,OTHER,668,2,1,1,1998-08,2014-08,True,668,668,0,0.0,,,,1
NCT02322320,"Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)",cardiovascular disease,Multiple Myeloma,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,273,3,42,1,2015-03,2019-06-07,True,273,273,0,0.0,,,,1
NCT00516503,Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer,cardiovascular disease,"Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific",Alliance for Clinical Trials in Oncology,OTHER,208,2,165,1,2008-02,2010-01,True,203,203,0,0.0,,,,1
NCT01608100,Evaluation of a New Cardiac Biomarker Assay,cardiovascular disease,Acute Coronary Syndrome; Acute Myocardial Infarction,Abbott Diagnostics Division,INDUSTRY,1101,1,12,1,2012-06,2014-09,True,1101,1101,0,0.0,,,,1
NCT04552041,"Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.",cardiovascular disease,Vascular Dementia,Materia Medica Holding,INDUSTRY,406,2,33,1,2020-12-03,2022-09-22,True,399,399,0,0.0,,,,1
NCT00000479,Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer,cardiovascular disease,Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Heart Diseases; Myocardial Infarction; Myocardial Ischemia; Vascular Diseases,Brigham and Women's Hospital,OTHER,39876,4,0,0,1992-09,2005-02,True,39876,39876,0,0.0,,,,1
NCT01591005,SONOlysis in Prevention of Brain Infarctions dUring Carotid Stenting and caroTid EndaRterectomy,cardiovascular disease,Internal Carotid Artery Stenosis,University Hospital Ostrava,OTHER,242,4,1,1,2010-10,2015-06,True,242,242,0,0.0,,,,1
NCT03640949,Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest,cardiovascular disease,Heart Arrest,Lars Wiuff Andersen,OTHER,501,2,10,1,2018-09-17,2022-01-21,True,501,501,0,0.0,,,,1
NCT00075088,Tele-Electrocardiography in Emergency Cardiac Care,cardiovascular disease,Myocardial Infarction; Chest Pain,"University of California, San Francisco",OTHER,794,2,1,1,2003-09,2009-06,True,794,794,0,0.0,,,,1
NCT03452917,Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest,cardiovascular disease,Out-Of-Hospital Cardiac Arrest,University of Washington,OTHER,1502,2,1,1,2018-02-08,2020-04-30,True,1497,1497,0,0.0,,,,1
NCT02757872,Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives,cardiovascular disease,Hypertension; Kidney Diseases,Albert Einstein College of Medicine,OTHER,2232,4,1,1,2016-04,2022-03-31,True,2232,2232,0,0.0,,,,1
NCT01685567,Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure,cardiovascular disease,Carotid Artery Disease,Silk Road Medical,INDUSTRY,219,1,21,2,2012-11,2016-07,True,219,219,0,0.0,,,,1
NCT02301910,Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI,cardiovascular disease,Myocardial Infarction,"Supergene, LLC",INDUSTRY,382,2,17,1,2014-05-16,2016-12-01,True,382,382,0,0.0,,,,1
NCT01545232,"Pragmatic, Randomized Optimal Platelet and Plasma Ratios",cardiovascular disease,Trauma,"The University of Texas Health Science Center, Houston",OTHER,680,2,12,2,2012-08,2013-12,True,680,680,0,0.0,,,,1
NCT03151993,Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS,cardiovascular disease,Ischemic Stroke,"Supergene, LLC",INDUSTRY,336,2,18,1,2017-03-18,2019-06-20,True,336,336,0,0.0,,,,1
NCT00953212,Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery,cardiovascular disease,Atrial Fibrillation; Atrial Flutter,MaineHealth,OTHER,304,4,1,1,2009-08,2012-02,True,304,304,0,0.0,,,,1
NCT01031095,(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention),cardiovascular disease,Coronary Artery Disease,Bursa Postgraduate Hospital,OTHER,200,2,1,1,2009-06,2010-06,True,200,200,0,0.0,,,,1
NCT00003816,Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer,cardiovascular disease,"Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific",Roswell Park Cancer Institute,OTHER,361,9,1,1,1998-10-19,2019-07-12,True,361,361,0,0.0,,,,1
NCT04362085,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,cardiovascular disease,COVID-19,Unity Health Toronto,OTHER,465,2,1,1,2020-05-11,2021-10-14,True,465,465,0,0.0,,,,1
NCT00744848,Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy,cardiovascular disease,Hemorrhoids,"Pacira Pharmaceuticals, Inc",INDUSTRY,204,2,20,1,2008-08,2009-02,True,204,204,0,0.0,,,,1
NCT01570829,Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients,obesity,Obesity,Materia Medica Holding,INDUSTRY,331,2,17,1,2011-12,2013-06,True,331,331,0,0.0,,,,1
NCT00081328,Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY),diabetes type 2,"Diabetes Mellitus, Type II",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,699,3,16,1,2004-05,2014-02,True,699,699,0,0.0,,,,1
NCT03815292,Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke,cardiovascular disease,Mild Cognitive Impairment; Ischemic Stroke,Materia Medica Holding,INDUSTRY,276,2,28,1,2018-10-19,2020-01-27,True,275,275,0,0.0,,,,1
NCT01932112,Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial),cardiovascular disease,Atrial Fibrillation; Persistent Common Pulmonary Vein,Yong Seog Oh,OTHER,378,1,1,1,2012-11,2015-05,True,378,378,0,0.0,,,,1
NCT00391469,Induction of Mild Hypothermia Following Out-of-hospital Cardiac Arrest,cardiovascular disease,Out-of-hospital Cardiac Arrest,University of Washington,OTHER,1359,1,1,1,2007-12,2013-08,True,1359,1359,0,0.0,,,,1
NCT00577135,Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study),cardiovascular disease,Heart Failure,Duke University,OTHER,308,4,9,2,2008-02,2010-02,True,308,308,0,0.0,,,,1
NCT01176240,A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease,cardiovascular disease,Orthostatic Hypotension; Parkinson's Disease,Chelsea Therapeutics,INDUSTRY,225,2,60,1,2010-06,2012-11,True,51,131,49,-156.9,Adverse Event (15); Lack of Efficacy (11); Protocol Violation (6); Withdrawal by Subject (6); Physician Decision (3); Supine Hypertension (3); withdrew prior to dosing (3); Stop due to diverse problems (1); Lost to Follow-up (1),Adverse Event,15.0,2
NCT00385697,The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus,diabetes type 2,Type 1 Diabetes Mellitus,MacroGenics,INDUSTRY,554,5,115,16,2006-10,2011-08,True,38,497,57,-1207.9,Withdrawal by Subject (27); Lost to Follow-up (24); Adverse Event (4); Other (2),Withdrawal by Subject,27.0,3
NCT02678312,"Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure",heart failure,Pediatric Heart Failure,Novartis Pharmaceuticals,INDUSTRY,393,3,98,29,2016-11-03,2022-01-03,True,17,333,45,-1858.8,Death (20); Subject/guardian Decision (11); Technical Problems (6); Adverse Event (4); Lost to Follow-up (3); Physician Decision (1),Death,20.0,3
